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Abstract
Previous studies in this laboratory have demonstrated that exposure to 5-Bromo-2- 
deoxyuridine (BrdU) induces differentiation in the lung epithelial cancer cell lines 
DLKP and A549. This induction o f differentiation was accompanied by increased 
protein expression o f cytokeratins-8 and -18, a 2Pi integrin, cell-adhesion protein Ep- 
CAM, eukaryotic initiation factor eIF-4E and the transcription factors c-myc and YY1. 
Following exposure to BrdU, RT-PCR analysis identified large increases in the mRNA 
levels o f MRP1, MRP3, BCRP, BAXa, MRIT, COX-2 and eIF-2a, together with 
smaller gene expression increases for MRP2, a-catenin and E-cadherin, in the DLKP 
cell line. Survivin gene and protein expression was decreased. Increased gene 
expression of MRP 1 and BCRP, as well as decreased MRP2, MRP4 and mdr-1 gene 
expression was observed in A549. DNA microarray analysis o f BrdU-treated DLKP 
detected significantly increased gene expression of ETR103, p55CDC, Inil, NSEP, 
EB1, RPS19 and FNRB, and significantly decreased gene expression o f CREB2, c-myc, 
RPL6, TBP, CNBP, HIP116 and SOD1.
RT-PCR analysis o f the DLKP cells identified increased expression of the MRP1, 
MRP2 and BCRP genes following exposure to cisplatin, o f MRP2, a-catenin and E- 
cadherin following exposure to taxol and o f MRP1, MRP2 and a-catenin following 
exposure to VP 16. These results suggested that patterns o f gene induction following 
exposure to an inducing agent are specific for that agent.
Transfac™ transcription factor analysis o f the 5’ promoter regions o f MRPs 1-3, BCRP, 
MRIT, COX-2, eIF-2a, a-catenin and E-cadherin identified seven potentially shared 
factors. These factors were GATAs 1-3, MZF1, Ik-2, CdxA and AML-la. RT-PCR 
analysis revealed increased GATA-2 and GATA-3 expression in BrdU-treated DLKP, 
but no change in BrdU-treated A549. RT-PCR analysis also revealed increased GATA- 
2 expression in VP16-treated DLKP.
Luciferase reporter plasmids attached to truncated regions o f the MRP1 5’ promoter 
identified the major regulatory region in normal DLKP cells. This region encompassed 
-91 to +103 bases relative to the transcriptional start site. When the DLKP cells were 
treated with BrdU, luciferase production increased dramatically in another area o f the 
promoter (beween -91 and -411 bases, relative to the transcriptional start). This region 
of the MRP1 contains a single GATA-2 transcription factor recognition sequence. A 
similar result was observed following exposure to VP 16. However, no significant 
change in luciferase readings was observed between BrdU-treated and untreated cells 
over the whole 2kb promoter, indicating that the major transcriptional target for BrdU is 
outside this region o f the gene.
RT-PCR analysis on a number o f human lung, breast and oesophageal tumour samples 
was carried out to examine the expression o f MRPs 1-6, BCRP, mdr-1, mdr-3, COX-1, 
COX-2, MRIT, BAXa, B c I -x l, B c l-x s , Bcl-2a, Survivin, BAG, BAP, eIF-4E, eIF-2a 
and c,-myc.
A novel ribozyme to MRP1 was designed and was observed to cleave its intended target 
in an in vitro cleavage assay. The ribozyme was successfully transfected into MRP1- 
expressing DLKP-SQ cells. However, the transfections did not affect significantly 
neither MRP1 RNA or protein expression nor the drug resistance profiles o f the cells. 
RNaseH activity assays for antisense oligonucleotides analyses were also successfully 
set up using an mdr-1 antisense. However, the identification o f effective MRP1 
antisense oligonucleotides was not made by either in vitro or in vivo studies.
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Introduction
1.1 General Introduction
One of the central goals o f the gene expression field is understanding how a mammalian 
organism regulates transcription o f approximately 30,000 genes in the proper spatial 
and temporal patterns. Knowledge of how transcription factors function during this 
“differential” gene expression can be applied to fundamental issues in the fields of 
biology and medicine. To decipher these mechanisms, we need to understand the 
numerous processes influencing transcription and develop technical and strategic 
approaches for addressing them. A gene’s regulatory mechanisms may be o f interest for 
a wide variety o f reasons. The gene may be expressed with an interesting temporal or 
spatial pattern during the development of a cell or organism, suggesting that the gene’s 
regulatory factors play an important developmental role. Alternatively, aberrant 
regulation of the gene may contribute to a particular disease, or the gene may be 
specifically expressed in a cell type associated with disease. In these instances, the 
regulatory factors may contribute to an understanding o f  disease pathogenesis or may 
provide targets for therapeutic intervention.
Lung cancers are o f two principal types; Small Cell Lung Cancer (SCLC) and Non- 
Small Cell Lung Cancer (NSCLC). SCLC tends to spread rapidly, which normally 
discounts the use o f surgery as an effective treatment. As a result, treatment normally 
consists o f chemotherapy alone, or sometimes combined with radiation. NSCLC is 
normally refractory to chemotherapy, and so alternative combination treatments, such as 
surgery and radiotherapy, are usually employed. Strategies designed to treat lung 
cancers have been severely impaired by the lack of knowledge regarding the biological 
mechanisms controlling the differentiation and development o f both normal and disease 
states of the lung. Despite recent advances in modem medical science little has been 
achieved in increasing the life expectancy o f those diagnosed with lung cancer. Clearly, 
an alternative approach to the treatment o f the disease in the lung would be o f benefit, 
both to researchers and patients.
In the post-genome era it may soon be possible to associate a specific tumour type with 
a specific gene expression profile and to define each molecular lesion characteristic of 
any given cancer. It is intuitive that a successful therapeutic strategy for cancer should 
aim at elucidating the mechanisms underlying disease development and differentiation
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which ultimately lead to full-blown neoplastic transformation. This approach is now 
rendered possible by major advances along several lines o f  investigation;
1. The possibility o f analysing gene expression through high throughput methods
2. A more detailed knowledge of the regulatory regions and o f the transcription factors 
that control gene expression also facilitated in the future by a comprehensive whole 
genome comparative analysis of these regulatory sequences
3. The ability o f modulating gene expression at the single gene level through various 
approaches both pharmacological and biochemical
The purpose o f this study is to advance the understanding of an alternative regimen of 
cancer treatment currently referred to as “Differentiation Therapy” (Roth, 1992; Lotan,
1996). Little is currently known o f the transcriptional processes underlying 
differentiation in the lung. It is hoped from this analysis that a more detailed picture of 
transcriptional control in BrdU- and drug-induced lung cancer differentiation and gene 
expression may be postulated. This information may ultimately assist in identifying 
transcriptional targets for the therapeutic treatment o f lung cancer.
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1.2 Introduction to Cellular Differentiation and Stem Cell Theory
Cellular differentiation can be defined as the process leading to the expression o f the 
phenotype characteristic of the functionally mature cell in vivo. Ham and Veomott 
(1980) described the process as “a cell acquires or displays a new phenotype without 
changing its genotype”. As differentiation progresses, cell division is reduced and 
eventually lost (Davila et al., 1990).
The principal cells that differentiate are stem cells, which are capable o f rapid cell 
growth and division. These cells are multipotent and thus have the potential to 
differentiate into several different cell phenotypes. In general, they possess unlimited 
proliferative potential but they can remain quiescent under certain microenvironment 
conditions (Davila et al., 1990). Differentiated cells are thought to be produced, not 
directly from stem cells, but rather via a committed progenitor or transit amplifying 
population (Watt, 1991). These cells continue and commit to differentiated cell types, 
allowing continual regeneration of the stem-cell population. It is important to note that 
although stem cells are capable of differentiating into multiple cell lineages, this is not 
their defining characteristic.
1.2.1 Gene expression and differentiation
The destiny o f a cell during embryogenesis and development is regulated by gene 
expression which restricts the number o f lineages that stem cells have the potential to 
form. Previous studies (Ham and Veomott, 1980) have proposed that “determination” is 
a process whereby a cell becomes committed to differentiate into a specific lineage. A 
determined or committed cell initially may not appear phenotypically different; this 
only occurs after the genetic blueprint has been implemented (Maclean and Hall, 1987). 
A cell can differentiate in a manner that results in either the irreversible loss of its 
proliferative properties (terminally differentiated), or in the retention o f some of its 
proliferative capacity while the cell itself is fully differentiated (non-terminally 
differentiated). A number of other differentiation states are also well documented: 
dedifferentiation is the process by which a cell loses its differentiated phenotype and 
transdifferentiation occurs when a cell dedifferentiates and then redifferentiates into a
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new and distinct phenotype (Davila et al., 1990). It is apparent from this that as a cell 
undergoes differentiation, its gene expression profile will likewise change. This will be 
discussed in greater detail in later sections.
1.2.2 Differentiation mediated via tissue determined stem cells
A progenitor stem cell represents the progeny o f stem cells which possess more limited 
proliferation and differentiation potential. This cell is usually only involved in a single 
cell lineage. Although stem cells in adult organs are pluripotent, the differentiated 
descendants are not usually expressed beyond the relevant organ in which the stem cell 
occurs, i.e. these stem cells are tissue determined stem cells (TDS cells) and are thus 
considered separate from embryonic stem cells (ES cells) (Sell, 1994).
1.2.3 The cell cycle and differentiation
TDS cells are believed to undergo a slow cell cycle in order to reduce the risk of errors 
during DNA replication. As TDS cells are present throughout the life o f the organism, 
such errors could become amplified in the organism (Lajtha, 1982). Indeed it is 
proposed that most tumours contain TDS cell populations (Khan et al., 1991) and that 
the overlapping expression o f differentiation markers (Gazdar et al., 1988) within 
cancer cells is indicative o f a stem cell origin for most lung epithelial tumours.
1.2.4 Models o f cell differentiation
During the differentiation process o f TDS cells it is necessary that they maintain a 
constant cell number. One popular model for this is asymmetrical cell division. 
According to this model, when the stem cell divides one daughter cell remains a stem 
cell while the other becomes a transit cell and enters the differentiation process. This 
model suffers from a fundamental flaw in that it suggests that after receiving an 
appropriate stimulus it proceeds into a cell cycle that yields two different daughter cells 
(Lajtha, 1982). According to a model proposed by Holtzer et al. (1975), TDS cells are
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only capable of binary decisions, e.g. stem cell A is capable of generating cells B or C, 
and cell B may then differentiate to cells D or E. As the transit cells pass through this 
hierarchy they go through cell division.
Although proliferation and differentiation appear to be interlinked processes during 
stem cell maturation, they are quite separate events that occur concomitantly. This 
suggests the whole differentiation process may be understood in terms o f a spiral model 
(Potten and Lofiler, 1990). Some TDS cells appear to be highly pluripotent giving rise 
to several different cell lineages, e.g. the haematopoietic system. Given this 
pluripotency, it can be envisaged that depending on the signal, a stem cell will adopt 
one direction o f maturation over another.
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1.3 Differentiation in the Lung
The lung is an extremely complex organ consisting o f over 40 different cell types, 
allowing it to function as the principal gas exchange organ in the body. At least seven 
epithelial cell types lining the tracheobronchial airways have been identified. The lungs 
are organised into the intrapulmonary airways (bronchi and bronchioles) which account 
for 6-10% of the lungs volume, and the gas exchange area or parenchyma which 
accounts for approximately 80-90% of the lung volume.
1.3.1 Models o f Lung differentiation
While the processes behind differentiation o f epithelial and other cell systems are 
relatively well understood (Fuchs and Byrne, 1994), lung cell developmental biology 
lags behind. This is partly due to a failure to identify a stem cell o f the lung. The 
principle o f stem cells and their in vitro cultivation and manipulation is now well 
established for a number o f tissue types. The existence o f a stem cell in the lung is 
strongly suspected, given the ability o f the lung to regenerate when exposed to local 
damage by atmospheric components (e.g. smoke, carbon black particles) and by 
lipophilic chemicals absorbed (e.g. through the gut) into the blood stream. However, 
identification o f such a stem cell is hampered by the complexity of the respiratory 
system and the variety of cell types present (Plopper and Hyde, 1992; Paine and Simon, 
1996; Mariassy, 1992).
1.3.2 Theory of common stem cell origin in lung cancer:
The most predominant hypothesis for stem cells in vivo in lung is that a different set of 
progenitor cells exist (including basal cells) each destined to give rise to a discrete 
differentiated cell type (Evans et al., 1989; Jetten, 1991; Plopper et al., 1992). In the 
case of type II cells, these cells proliferate and then differentiate into type I cells 
(Adamson and Bowden, 1979) and Clara cells can differentiate into ciliated cells 
(Jetten, 1991).
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However, an alternative proposal is that there is a single pluripotent stem cell for 
generating ciliated cells, Clara cells and the other differentiated cell types (McDowell,
1987). This hypothesis suggests the existence of a monotypic stem cell, which is 
believed to be able to arise through dedifferentiation of any differentiated secretory cell 
type. There is some empirical evidence for this hypothesis as Clara cells are found to be 
positive for surfactant protein-A (SP-A) and surfactant protein-B (SP-B) which were 
originally described as specific products o f type II pneumocyte cells. This suggests that 
Clara cells and type II pneumocytes are derived from the same stem cell.
Further tentative indications come from studies o f fetal mouse lung where a definite 
population o f progenitor cells co-express SP-A (type II cells), cclO (Clara cells), and 
calcitonin gene-related protein (CGRP) (pulmonary neuroendocrine cells), each being a 
gene product used to indicate differentiated function in a different respiratory epithelial 
cell type (Wuenschell et al., 1996). The studies reviewed by Emura (1997) suggest the 
possibility o f a single population of pluripotent stem cells in the lung with the additional 
possibility o f de-differentiation o f ciliated, secretory and basal cells to provide the lung 
with regenerative capacity.
The presence o f common overlapping features between lung cancer cell types supports 
the theory o f a common stem cell origin for lung epithelial cancers. Gazdar et al. (1981) 
outlined how all the cells of the bronchial epithelium and the tumours which arise from 
them could have a common stem cell origin. The transforming events which lead to 
carcinogenesis affect undifferentiated or partially-differentiated cells. There are many 
reports in the literature o f evidence for the presence o f stem cell populations in tumour 
cell lines (Khan et al., 1991). Gazdar et al. (1981) also suggested that the overlapping 
expression of markers between different tumour types is indicative o f a common stem 
cell origin o f lung epithelial cancers.
In summary, very little data exists about stem cells in the lung, the pathways they 
follow, their distribution and mechanism o f action. No markers yet exist for lung stem 
cells. The idea o f dedifferentiation is in contrast to the stem cell models developed in 
skin, liver and intestine in which the stem cell pre-exist in the epithelium (Emura,
1997). The lung is susceptible to local damage from a number o f sources, as outlined. 
Therefore, it must possess some form of mechanism to regenerate itself, even if  limited.
In attempting to identify if  a cell is a stem cell, its native state is often altered during the 
investigation. This may result in loss o f the stem cell or only a limited spectrum of 
responses being observed from the cell. Thus, due to the variety o f cell types present 
and by the complexity o f the respiratory system, identification o f a lung stem cell is a 
difficult task.
1.3.3 Identification of a stem-like lung cell line, DLKP:
All o f this has interesting implications with the isolation of a poorly-differentiated lung 
cell line, DLKP, at the NCTCC (Law et al., 1992). Clones derived from this cell line 
exhibit the remarkable capacity to regenerate the mixed parental population over time. 
The DLKP novel cell line has been categorised as extremely poorly differentiated and 
consists o f at least three subpopulations, termed SQ (Squamous), I (Intermediate) and M 
(Mesenchymal) (McBride et al., 1998). These populations have shown the ability to 
interconvert and eventually, when cultured alone, replenish the parental phenotype. 
This, combined with the lack o f expression of a number o f differentiation-specific 
markers, has lead to the speculation that DLKP may represent a stem cell-like 
population. This has afforded a unique opportunity to study the process o f lung cancer 
differentiation in-vitro, particularly the early stages o f this process. Such studies will 
provide valuable insights into the mechanisms o f early lung development, both in 
diseased and normal tissues, possibly identifying targets for therapeutic intervention and 
aiding in the design of strategies to treat lung cancers more effectively.
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1.4 Cancer and Differentiation Therapy:
Cancer has been referred to as a “disease o f abnormal differentiation” (Spom and 
Roberts, 1983) and is theoretically a prime target for “Differentiation Therapy” (Roth, 
1992; Lotan, 1996). Induction o f differentiation has been considered as a possible 
component o f therapy for cancer (Waxman et al., 1988). The ultimate objective o f this 
strategy is not aimed at killing the tumour so much as to induce the cancer cells, whose 
growth rate and cell cycle have become deregulated, to commit to differentiate into 
more “normal” cells in an attempt to slow and even halt growth and progression of the 
cancer. It is hoped that if  differentiation-induced cancer cells lose their proliferative 
ability and cease to grow, then an examination o f the molecular processes underlying 
this change would be o f importance. It is this concept which formed the main objective 
o f this study.
In vivo and in vitro studies support the role for differentiation defects early in the 
process o f carcinogenesis. This may be due to the uncoupling o f the integrated control 
of differentiation and proliferation in cancer cells, where such developments can result 
in a relative insensitivity to differentiation signals and increased sensitivity to 
proliferation signals. Two scenarios thus exist for the possible origins o f cancer; from 
dedifferentiation o f mature cells which retain the capacity to divide or from maturation 
arrest of immature cells. With increasing tumour progression, the histology of the 
tumour often indicates poorer differentiation and from a prognostic standpoint, patients 
with poorly differentiated tumours will generally have a lower survival rate than those 
with differentiated tumours (Behrens, 1994).
1.4.1 Physiological inducers o f differentiation
A number o f physiological agents involved in the modulation o f lung differentiation in 
vivo have been identified, although their mechanisms o f action remain largely unknown.
A number o f studies using isolated lung cells (both adult and fetal) and cell lines have 
implicated a number o f candidate factors including glucocorticoid steroids (Palmiter,
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1972; Speirs et ah, 1991), chemokines (Sundell et ah, 1980; Lesur et al., 1992), cell- 
matrix and cell-cell interactions (McCormick et ah, 1995; Speirs et ah, 1991).
Brurserud et al. (2000), reviewed that acute myelogenous leukaemia (AML) cells could 
be differentiated into further subsets following exposure to all trans-retinoic acid 
(ATRA) and several cytokines, such as IL-3 and GM-SCF. Thalidomide was also 
observed to be an effective differentiating agent on human leukaemia K562 cells by 
Hatfill et ah (1991). A combination o f GM-CSF and 1,25-dihydroxy Vitamin D3 
induced differentiation in human monoblast U937 leukaemia cells. A further 
differentiation study on the U937 cell investigating the differentative properties o f low- 
dose ara-C line also included another leukaemic cell line, HL60 (Pinto et ah, 1988). 
Another study (Glazer et ah, 1986), observed induced differentiation in HL-60 cells 
following treatment with the cyclopentenyl analogue o f cytidine. 1,25-dihydroxy 
Vitamin D3 also induced differentiation in two studies (Taoka et ah, 1993; Muto et ah, 
1999). In the first study, Taoka et ah reported that interaction o f the vitamin with HL60 
cells induced differentiation o f that cell line into monocyte cells. In the second study, 
Muto et ah examined the differentiation of a novel retinoic acid-resistant APL cell line 
(UF-1) following exposure to the vitamin. The vitamin induced growth inhibition and 
G1 arrest which resulted in differentiation o f the cells towards granulocytes.
One of the first differentiation strategies to show promise in both in vitro and in vivo 
trials was that of the Vitamin A based differentiation-inducing compounds 
(Gendimenico and Mezich, 1993; Lotan, 1996). Natural retinoids have been found to 
play an important role in the maintenance o f the normal differentiated state o f the adult 
lung (Chytil, 1992). Retinoids thus play an important role in cancer differentiation and 
chemoprevention (Lotan, 1996). Retinoic acid (RA), has been implicated in the control 
of both cellular proliferation and differentiation, and has been shown to effect over 200 
different gene products (Chytil, 1992). For example, RA regulates elastin production by 
lung fibroblasts during alveolar formation (McGowan et ah, 1995). In clinical trials, 
topical application of Retinoic Acid (RA) was shown to reduce the formation o f skin 
papillomas (Tenenbaum et al., 1998). Retinoic Acid has shown very strong potential as 
a therapeutic in cases o f APL (Acute Promyelocytic Leukaemia) (Asou et al., 1998) and 
AML (Acute Myeloid Leukaemia) (Tallman, 1996) reducing the risk o f relapse and 
increasing the chance o f long-term survival (Takeshita et al., 1995; Degos, 1997).
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Alternative approaches, including the development o f novel RA metabolism blocking 
agents that increase endogenous levels o f RA by inhibiting its breakdown in cancer cells 
(Sciarra et al., 1998), are currently being applied to the treatment o f prostate cancer.
1.4.2 Artificially-induced differentiation and gene expression
The gene expression profiles o f cells change with the differentiation status o f the cell. 
As a result, the cellular expression o f certain genes and proteins may sometimes be used 
as markers to indicate the level or occurrence of differentiation in that cell. Although 
none of these gene changes may be defined as differentiation markers, there is enough 
evidence from differentiation studies to demonstrate the relevance o f gene expression to 
the process o f cellular differentiation.
c-fos mRNA expression was observed to be increased in a number o f cell lines 
following exposure to the D vitamin analogue 1,25-dihydroxy Vitamin D3 (Kim et al., 
1991; Taoka et al., 1993). c-myc gene expression was also decreased in both o f these 
studies, which were associated with an induced differentiated phenotype o f the cells. 
Pinto et al. (1988) also detected increased c-fos gene expression and decreased c-myc 
expression in the HL60 cell line following low-dose ara-C-induced differentiation. An 
increase in mRNA and protein expression levels o f  the cyclin-dependant kinase 
inhibitors p21 and p27 was observed by Muto et al. (1999) in the retinoic acid-resistant 
APL cell line (UF-1) following exposure to 1,25-dihydroxy Vitamin D3. An analogue 
o f the D3 vitamin, EB 1089, was also observed to enhance the toxicity effect of 
adriamycin in MCF-7 breast tumour cells and also to promote apoptotic cell death in 
these cells (Sundaram et al., 2000).
Retinoic acid (RA) also induces the differentiation of the murine P19 teratocarcinoma 
cell line (Scheibe et al., 1991). In the same study, an increase in expression of alkaline 
phosphatase (ALP) mRNA and protein was also observed. RA also induces 
differentiation in human cancer cell lines, with a concomitant increase in expression of 
certain genes. Liu and Rabbani, (1995) observed an increase in expression o f urinary 
plasminogen activator (uPA) mRNA and protein in the human prostate cancer cell line,
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PC-3, following exposure to RA. Exposure to the chemical also resulted in increased 
invasiveness of the cell line.
Park et al. (1999) observed induced expression of the CCAAT/enhancer binding protein 
8 (C/EBPs) in the acute promyelocytic leukaemia (APL) cell line following exposure to 
retinoic acid (RA). The group observed that C/EBPe, a nuclear transcription factor 
expressed predominantly in myeloid cells, is a downstream target gene responsible for 
RA-induced granulocytic differentiation o f APL cells.
Expression o f the mdr-1 gene has also been examined following treatment o f mdr-1 - 
expressing cells with differentiating agents. Mickley et al. (1989) found that expression 
of mdr-l/Pgp correlated with the degree o f differentiation in SW-620 and HCT-15 cell 
lines exposed to sodium butryate, dimethyl sulfoxide and dimethylformamide. 
However, the group also found that its induction was not always accompanied by 
expression of the multidrug-resistant phenotype. Zhou et al. (1993) induced a 
promyelocytic HL60/DNR cell line to differentiate using all-trans retinoic acid (ATRA) 
and dimethyl sulfoxide and observed that mdr-1 mRNA and protein expression levels 
remained unaffected.
1.4.3 Use o f Bromodeoxyuridine (BrdU) to induce differentiation in human cells
5-Bromo-2’-deoxyuridine (BrdU) has been used for twenty years as a tool for 
measuring DNA synthesis in isolated chromosomes and in cells and tissues. BrdU is a 
thymidine (Td) analogue which can compete with Td for incorporation into DNA. It 
appears to be capable o f modulating differentiation in a number o f cell lineages. Its 
activity is reversible if removed from the culture medium or if  thymidine is added to the 
growth medium in equimolar concentrations (Ashman and Davidson, 1980). This 
indicates that BrdU is not acting as a mutagen, but is reversibly blocking specific 
differentiation pathways.
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1.4.3.1 Examples of BrdU-induced differentiation
Low levels o f BrdU have been shown to alter the differentiation status o f different kinds 
o f cells. It is best referred to as a differentiation modulating agent since it has been 
shown to be a potent inducer of differentiation in some cell lines (Yen et al., 1987; 
Sugimoto et ah, 1988; Valyi-Nagy et al., 1993), while it can inhibit the differentiation 
o f others (Seecoff and Dewhurst, 1976, Tapscott et al., 1989). The exact mechanism by 
which BrdU exerts its differentiation-modulating effects is unclear but incorporation 
into DNA is seen as essential. This involves BrdU being converted to 
bromodeoxyuridine monophosphate, which competes with thymidine for incorporation 
into DNA (O’Neill and Stockdale, 1974). Experimental evidence for this hypothesis 
comes from a study by Keoffler et ah (1983) which showed that a thymidine kinase- 
deficient human myeloid cell line (HL-60) was unable to incorporate BrdU into its 
DNA and subsequently failed to respond to the ability o f BrdU to modulate its 
differentiation status.
BrdU has also been found to induce differentiation of melanoma cells, with a resultant 
change in morphology. Flattening of the cells, with a 20-fold increase in cell surface 
area and a 17-fold increase in nuclear area was observed (Valyi-Nagi et ah, 1993). 
Tumourigenicity o f these cells in nude mice was suppressed when the cell lines were 
treated with BrdU. Colony formation in soft agar o f these BrdU-treated cells was also 
decreased by more than 10% at a 1 OuM concentration compared to untreated cells 
(Valyi-Nagi et ah, 1993).
BrdU has been shown to induce terminal differentiation in HL60 leukaemic cells (Yen 
and Forbes, 1990). BrdU induces the early events, leading to precommitment to the 
onset of terminal differentiation along the myeloid or monocytic pathways. BrdU has 
also been found to induce differentiation in human myeloid leukaemia cells (Koeffler et 
ah, 1983).
BrdU has also been observed to induce Schwannian differentiation in neuroblastoma 
(Sugimoto et ah, 1988). BrdU treatment o f neuroblastoma cells has been shown to 
upregulate expression of human melanoma-associated antigen (Feyles et ah, 1991a).
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Feyles et al. (1991b) examined the effects o f BrdU on a SCLC cell line with features of 
neuroendocrine differentiation. Treatment resulted in induction o f substrate-adherent 
growth, along with an epithloid morphology and increased expression o f 
neuroendocrine markers.
1.4.3.2 Models o f BrdU-induced differentiation:
A number o f models exist to explain the ability o f BrdU to modulate differentiation. 
The first envisages that BrdU induces chromosomal breakages and incorporates into 
DNA in a non-random fashion at sequences termed “fragile sites” (Hecht et al., 1988; 
Sutherland, 1988; Sutherland, 1991). These fragile sites have recently been correlated 
with predisposition to colon cancer (Tunca et al., 2000). These breakages and the 
associated chromosomal aberrations can be associated with stepwise changes in the 
differentiation o f a cell. Some corroboration for this model comes from a study by 
Schwartz and Snead (1982) which found that BrdU seemed to concentrate within 
repetitive DNA nucleotide sequences rather than randomly throughout the nuclear 
DNA. However, such selective incorporation would suit the other models also. This 
explains the reproducibility of the effects observed with BrdU-induced differentiation. 
O ’Neill and Stockdale (1973) developed a model for BrdU-induced modulation of 
differentiation that assumes that BrdU “sensitivity” resides on a single pair of 
chromosomes, suggesting the presence of a “master gene” or target through which BrdU 
exerts its effects. In this model, inhibition o f differentiation occurs in a dominant 
fashion if  approximately 30% or more o f naturally occurring thymidine is replaced by 
BrdU in the readout strand o f either chromosome. This sort o f model agrees with the 
predicted mechanisms of action o f a number o f DNA-intercalating agents. BrdU 
substitution into DNA and intercalation o f such agents may have similar effects, thought 
to be through direct DNA bending at either major or minor grooves, thereby altering 
promoter structure and availability to transcription factors. BrdU has been demonstrated 
to decrease c-myc expression at the transcriptional level in the leukaemic cell line, HL60 
(Yen and Forbes, 1990) and in human melanoma lines (Valyi-Nagyi et al., 1993). This 
result would appear to suggest that the c-myc promoter regions are susceptible to 
modulation by agents that disrupt promoter structure through thymidine substitution. 
The incorporation o f BrdU into DNA may also affect the ability o f the cell to methylate
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guanine residues near genes. Such inhibition o f methylation could lead to increased 
transcription o f those genes. Kresnak and Davidson, (1993) observed an inverse 
relationship between the susceptibility o f various guanine residues to dimethylsulphate 
(DMS) methylation and the susceptibility o f  those residues to mutagenesis by BrdU.
Alternatively, BrdU may directly influence the ability o f proteins to associate 
with DNA. The second model proposes that BrdU alters the affinity o f DNA sequences 
for regulatory proteins. Studies on the lac operon with BrdU incorporated showed that 
the lac suppressor was bound with greater affinity (Lin and Riggs, 1972).
In the third model, BrdU has been found to exert its effects on differentiation by 
alteration o f a key regulatory gene(s) that alters transcription o f genes involved in 
differentiation (Arnold et al., 1988; Rauth and Davidson, 1993). In BrdU inhibition of 
myoblast differentiation, such an alteration occurs with the down-regulation or complete 
inhibition o f the key regulatory gene, MyoDl (Tapscott et al., 1989; Nanthakumar and 
Henning, 1995). It could be envisaged that BrdU-induced alteration o f differentiation in 
other tissues e.g. inhibition in mammary epithelial cells and pancreatic acinar cells, 
could be by a similar mechanism. This is strengthened by the homology o f MyoDl to 
the myc family o f  proteins, which have an important role in differentiation. Indeed, in 
BrdU-induced differentiation of neuroblastoma, a decrease o f both N -myc protein and 
mRNA levels occur (Ross et al., 1995).
Finally, it is possible that BrdU incorporation causes an alteration in the reading 
frame of the DNA template resulting in the formation o f an abnormal mRNA, which is 
incapable o f synthesising the correct differentiation products (Hill et al., 1974).
1.4.3.3 BrdU-induced differentiation and gene expression
While the effects o f BrdU on the differentative properties o f different cell lines has been 
demonstrated, less is known of the molecular bases underlying such changes. As the 
ability o f BrdU to modulate differentiation may be related to its incorporation into 
DNA, this may implicate the involvement o f inhibition o f expression of differentiation- 
specific genes (Harding et al., 1978). Induction or inhibition o f differentiation depends 
on the particular cell type and the target genes. Decreased c-myc gene expression levels 
as a result o f BrdU treatment has been demonstrated in terminally differentiated
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leukaemic cells (Yen and Forbes, 1990) and in differentiating melanoma cells (Valyi- 
Nagi et al., 1993).
Horii et al. (1989) observed decreased gene expression o f the N-myc and c-src 
transcription factors in human neuroblastoma cells following BrdU-induced 
differentiation. BrdU has also been shown to decrease expression o f the c-jun gene in 
human melanoma cells (Rieber and Rieber, 1994), as well as c-myb gene expression in 
HL60 cells (Yen et al., 1992). Additional studies have identified the ability o f BrdU to 
induce expression o f the following genes; prolactin (Wilson et al., 1983), numerous 
glycolipid antigens (Andrews et al., 1990), neuronal kinesin (Vignali et al., 1996) and 
endothelin A (Ohtani et al., 1997).
In addition, BrdU has also been shown to upregulate expression o f the actin gene and 
increase cell adhesiveness in B16 melanoma cells (Gomez et al., 1995). Actin may be 
an important gene in melanoma growth where actin expression appears to be inversely 
correlated with melanoma metastatic potential (Shimokawa-Kuroki et al., 1994).
1.4.3.4 BrdU: Differentiating agent or inducer o f pre-commitment?
BrdU is considered by some scientists to be an inducer o f pre-commitment to 
differentiation rather than an actual differentiation inducing agent. This was highlighted 
by the findings that BrdU treatment o f HL60s for 24 hours, followed by treatment with 
Retinoic Acid resulted in a faster response to Retinoic Acid (RA) than the single 
addition of RA alone (Yen et al., 1990). It would appear that BrdU can initiate some of 
the early changes induced by RA in HL60 differentiation, including early c-myc 
downregulation. However, the same author reported previously (Yen et al., 1987) that 
pre-commitment to differentiation involves an early increase in c-myc levels in the same 
leukaemic line, as induced by RA. This suggests that pre-commitment to differentiation 
in these cells involves increased expression o f c-myc. It therefore appears that the true 
mechanisms of induction and commitment to differentiation remain unclear, even in 
individual cell types.
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1.4.3.5 BrdU as an inhibitor o f differentiation:
BrdU has been found to suppress differentiation and promote invasiveness o f melanoma 
cells (Thomas et al., 1994). The integrin repertoire expressed by melanoma cells is 
relevant to their invasive phenotype. Expression of (X2 P1 , a 5Pi and a 6Pi integrins and 
metalloproteinases were found to be increased, while induction o f 0 C3 and a vp 3 integrins 
was shown in these cells. The production o f melanin was repressed by BrdU. BrdU- 
treated cells were found to cause extensive invasion of Matrigel (Thomas et al., 1994). 
BrdU has been found to block myogenesis and differentiation through a myogenic 
regulatory gene, M yoDl, in a mouse myoblast cell line (Tapscott et al., 1989). It 
appears that although BrdU was incorporated into the muscle structural genes, these 
genes were apparently transcribed normally.
1.4.3. 6  Use o f BrdU as an antitumour agent
As already outlined, BrdU competes with naturally occurring Thymidine for 
incorporation into DNA during replication and as such it, and other similar compounds, 
should be ideal candidates for anti-tumour agents, since they require cell division and 
DNA synthesis to exert their effects (Bick and Devine, 1977). While few clinical trials 
are based on the differentiation-modulating properties o f this drug (Freeman, 1969; 
Ameye et al., 1989), BrdU has been used widely as a radiosensitiser in an attempt to 
improve radiological treatments (Lawrence et al., 1992; McGinn and Kinsella, 1993). 
Radiosensitisation trials to date include the treatment o f malignant glioma (Vander et 
al., 1990), ulcerative herpetic keratitis (van Bijsterveld et al., 1989), malignant 
astrocytomas (Greenberg et al., 1988) and malignant brain tumours (Matsutani et al., 
1988). Administration o f BrdU is normally by controlled perfusion (Doirion et al., 
1999), and has been used in combination with radiolabelled monoclonal antibodies 
(Buchsbaum et al., 1994). While radiolabelled antibody approaches offer the potential 
of targeted chemotherapy, they are limited by low dose-relate deliverable. As such, the 
trials of Buchsbaum et al. (1994) may offer a means o f enhancing the efficacy of low 
dose radiolabelled monoclonal antibody approaches.
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1.4.3.7 BrdU-induced differentiation in the NCTCC
Recent work in the NCTCC has shown that BrdU induces differentiation in the poorly 
differentiated lung carcinoma cell line, DLKP, and in the lung adenocarcinoma cell line, 
A549 (P. Meleady, PhD. Thesis, 1997; F. O ’ Sullivan, PhD. Thesis, 1999; D. Walsh, 
PhD. Thesis, 1999). The morphological effects o f BrdU-induced differentiation 
included cell flattening and enlargement, accompanied by a decreased growth rate. 
Removal o f BrdU resulted in a gradual reversion towards the parental undifferentiated 
phenotype, indicating that the exposed cells were not terminally differentiated by the 
agent. This indicated that BrdU exposure did not result in fully differentiated cells but 
possibly that the agent induced a pre-commitment to differentiate in the DLKP cell line. 
BrdU has been suggested to induce pre-commitment to differentiation in a leukaemic 
cell line (Yen and Forbes, 1987). However, removal o f BrdU after seven days exposure 
to DLKP cells did not affect expression levels o f cytokeratin-8 three months later (D. 
Walsh, PhD. Thesis, 1999). This result indicated that BrdU is an “irreversible” 
mutational inducer o f DLKP, in agreement with findings reported by Feyles el al. 
(1991a), using a SCLC cell line, NCI-H69.
Previous work carried out in the NCTCC (P. Meleady, PhD. Thesis, 1997) examined the 
effect o f BrdU exposure on the DLKP cell line. Treatment o f the cells with BrdU 
resulted in the induction o f the cx,2 pi integrin and upregulation o f CC2 P1 integrin 
expression. Associated with this change in integrin expression was a functional change 
in the properties o f the cells themselves with BrdU treatment. The cells developed 
different adhesive properties showing more rapid attachment to the extracellular matrix 
proteins, collagen, laminin and fibronectin, and to basement membrane compared to 
untreated cells. Addition o f an anti-antigen blocking antibody to BrdU-treated cells 
reversed the changes in adhesive properties o f the cells. BrdU treatment also induced 
the expression of a number o f epithelial antigens, including Epithelial Specific Antigen 
(a cellular adhesion molecule) and keratin 19 (K19) filaments in DLKP. In order to 
demonstrate that these results were not due to a “cloning” effect o f BrdU, two o f the 
clonal populations described by McBride et al. (1998) were exposed to BrdU and 
assessed for keratin expression (D. Walsh, PhD. Thesis, 1999). Both DLKP-SQ and 
DLKP-I clonal cell lines proved to be inducible for the cytokeratins. A significant
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upregulation o f keratin 19 protein expression was also observed in the human 
adenocarcinoma cell line, A549, after BrdU treatment (P. Meleady, PhD. Thesis, 1997). 
Preliminary RT-PCR analysis, however, failed to show any effect on expression of 
keratin 19 mRNA.
Further work on the DLKP cell line (F. O ’ Sullivan, PhD. Thesis, 1999), identified that 
BrdU increased expression o f the non-calcium dependent, homophilic cell-adhesion 
protein, Ep-CAM as well as decreasing expression o f the focal adhesion proteins a - 
actinin and a-catenin. The Ca2+-dependent cell-cell adhesion protein, E-cadherin, is 
believed to be affected by BrdU exposure through the elevated expression o f these two 
genes. mRNA expression of the Ep-CAM homologue GA733-1 was also upregulated in 
DLKP, but not A549 cells, following BrdU exposure.
Protein expression studies (D. Walsh, PhD. Thesis, 1999) revealed increased expression 
o f cytokeratins K8 and K18 in BrdU-exposed DLKP. No change in mRNA expression 
was observed following treatment with the agent, which indicated that these proteins 
may be translationally regulated by BrdU. Expression o f the eukaryotic initiation factors 
eIF-4E and 2 a  as well as the transcription factor Yin-Yang 1 (YY1) and c-Mycl 
proteins were also observed to increase in BrdU-treated DLKP and A549 cells. A BrdU- 
induced translational cascade was posited from these results, utilising the c-myc and 
YY1 transcription factors as targets for BrdU action, through which all subsequent 
protein upregulation was mediated. This has been backed up by a previous finding that a 
major function o f transcription factors is to indirectly regulate the translational 
efficiency o f the cell (Grandori et al., 1996). This theory possibly explains the lack of 
transcriptional targets identified for c-myc to date.
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1.5 Selection of agents which may induce similar effects to BrdU in lung cell lines
From the results presented here, it was apparent that the differentiating agent, BrdU, 
was capable o f inducing a host of gene and protein expression changes in lung epithelial 
cell lines. It was therefore considered interesting to examine whether other agents were 
capable o f inducing a similar response. To this end, three chemotherapeutic drugs were 
chosen, cisplatin, taxol and VP 16 which may be capable o f mimicking the gene 
induction and differentiation-inducing effects o f BrdU.
1.5.1 Use o f chemotherapy in the treatment o f cancer
Surgery, radiotherapy and chemotherapy are all effective treatments for cancer and have 
been used alone and in combination. Surgery and radiotherapy can often eradicate 
primary or localised disease but may ultimately fail because the cancer has metastasised 
to other areas o f the body. In such instances, chemotherapy may control or eliminate 
metastatic disease and reduce mortality. Chemotherapy combined with surgery or 
radiotherapy or both, known as adjuvant therapy, has increased survival rates for a 
number o f solid tumours that were previously treated by only one therapeutic modality.
Chemotherapy remains the main form of drug treatment at all stages of cancer 
development. The chemicals involved are directed at disrupting the cell cycle, with 
RNA, DNA and protein molecules as the targets. Synthetic chemotherapeutic agents 
currently in use can be categorised according to whether they alkylate DNA (alkylating 
agents) or antagonise metabolites required for DNA synthesis (antimetabolites). A third 
group are natural products from plants and fungi.
The ultimate clinical effectiveness of any anticancer drug requires that it kill malignant 
tumour cells in vivo at doses that allow enough cells in the patient’s critical tissues (e.g. 
bone marrow, gastrointestinal tract) to survive so that recovery can occur. In general, 
anticancer drugs are most useful against malignant tumours with a high proportion of 
dividing cells. Thus, in practical terms, drugs alone are primarily effective against the 
leukaemias and lymphomas. The most common malignant tumours, however, are 
“solid” tumours, including those of the colon, rectum, lung and breast. These tumours
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usually have a low proportion o f dividing cells and therefore are less susceptible to 
treatment by drugs alone.
1.5.2 Introduction to chemotherapeutic drugs
A total o f six separate chemotherapeutic drugs were utilised in this study to examine the 
effect of various therapies on lung cancer cells. Details on each o f the drugs is provided 
in Section 2.3, although a general introduction to their mode of action will be included 
here. The six drugs utilised here are Adriamycin (Doxorubicin), Cisplatin, Taxol 
(Paclitaxel), VP16 (Etoposide), Vinblastine and Vincristine. In Section 3.3, reference is 
made to a separate study carried out by Dr. Yizheng Liang, in which additional drugs 
were used.
1.5.2.1 Adriamycin (Doxorubicin)
Adriamycin is a natural product drug, a multi-ring fungal anthracycline and a related 
compound to epirubicin. Both drugs have several effects on DNA (and RNA). They 
intercalate and cause partial unwinding o f the DNA helix but they also generate single- 
and double-strand breaks. Intercalation between adjacent pairs in the double helix 
results in the inhibition o f replication, transcription and replication. Adriamycin also 
binds to the enzyme DNA topoisomerase II. This enzyme is needed for the cleavage, 
unwinding and rejoining o f DNA strands during DNA synthesis. Adriamycin blocks the 
religation step but it can also generate free radicals, which may contribute to its strand- 
breaking action (Carter et al., 1981; Niedle and Waring, 1983). All the effects of 
adriamycin on DNA contribute to the drug being an S-phase-specific agent.
Adriamycin is widely used in the treatment o f leukaemias and solid cancers such as 
those o f the breast, lung and ovary (Carter et al., 1981; King, 2000; Schiller, 2001; 
Schuette, 2001). Its main side effect is on heart function and this is dose limiting. Drug 
resistance results from overproduction o f P-glycoprotein and decreased efficiency in 
repairing DNA strand breaks. Topoisomerase II mutations have been detected in
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experimentally induced adriamycin-resistant cell lines (King, 2000) but the clinical 
relevance o f this observation is uncertain.
1.5.2.2 Cisplatin
Cisplatin, and its analogue Carboplatin, are platinum-containing alkylating 
chemotherapeutic agents. Alkylating agents form adducts with DNA bases that disrupt 
DNA synthesis. Most alkylating agents have two functional groups, each o f which can 
react with a DNA base and form interstrand and intrastrand cross-links within the DNA 
double-helix. These links can be formed at any stage o f the cell cycle, so alkylating 
agents are not phase-specific. Cisplatin and its analogue are converted to alkylating 
species in the body, preferentially forming adducts at the N-7 position o f guanine and 
adenine. These adducts can interact with adjacent bases on the same strand (intrastrand 
adducts) or on separate strands (interstrand adducts). The order o f formation for adduct 
formation is G:G > A:G > others. Intrastrand adducts distort the DNA helix whilst 
interstrand links prevent strand separation so that replication is inhibited or abnormal. 
Cisplatin is particularly effective against ovarian and testicular cancers (Einhorn, 1997; 
Gregory et ah, 2000; Nardi et ah, 2001) although it is also a common choice for the 
chemotherapeutic treatment o f some lung cancers (Novello and Chevalier, 2001; 
Schiller, 2001; Schuette, 2001). It has an advantage over other chemotherapeutic agents 
in that it has minimal effect on the bone marrow. Its main toxicities are nausea, renal 
dysfunction (nephrotoxicity) and neural effects. Carboplatin has a similar anti-tumour 
profile to Cisplatin but it has greatly reduced side effects, especially nephrotoxicity 
(King, 2000).
Resistance to Cisplatin can result from its altered cellular transport, enhanced repair of 
damaged or inactivating reactions o f the cisplatin with sulphydryl groups in proteins 
and glutathione (King, 2000). Cisplatin derivatives are also substrates for glutathione-S- 
transferase, the detoxifying enzyme which conjugates the drug with reduced 
glutathione, leading to cisplatin-resistant cancers overexpressing the enzyme (Liu et ah, 
2001). The drug also upregulates metallothionine (Aubrecht et ah, 1999), whose 
sulphydryl groups interact with the drug by a reaction analogous to that o f glutathione.
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1.5.2.3 Taxol (Paclitaxel)
The importance o f  microtubules as a target for taxol was suggested by its ability to 
induce G2 /M cell cycle arrest under conditions that had minimal effect on DNA, RNA 
or protein synthesis (Pratt et al., 1994). However, in contrast to other known 
microtubule antagonists, taxol disrupts the equilibrium between free tubulin and 
microtubules by shifting it in the direction o f assembly, rather than disassembly. As a 
result, taxol treatment causes both the stabilisation o f ordinary cytoplasmic 
microtubules and the formation o f abnormal bundles o f microtubules (Schiff and 
Horwitz; 1979; Schiff and Horwitz; 1980). In a study o f human leukaemic cell lines, the 
reversibility o f bundle formation was correlated with resistance to taxol cytotoxicity 
(Rowinsky eta!., 1988).
Paclitaxel is a novel anticancer agent with activity in a broad range o f epithelial cancers, 
including carcinomas o f the ovary, breast, head, neck, bladder, lung and prostate 
(Schiller, 2001; Schuette, 2001). The efficacy o f the drug is limited by the development 
o f drug resistance in a population of malignant surviving cells. Defined molecular 
mechanisms for acquired tumour cell resistance to taxol include overexpression of mdr- 
1 (Chen et al., 1994; Lin et al., 1999) and differential expression of (3-tubulin isotypes 
or P-tubulin gene point mutations (Dumontet et al., 1996; Giannakakou et al., 1997). 
Recent data also suggest that p53 status and mitosis checkpoint control is important in 
determining the sensitivity o f the cells to Taxol (Li and Benezera, 1996). Further 
studies, reviewed in Blagosklonny and Fojo, (1999), have outlined numerous additional 
cellular and molecular effects, such as induction of cytokines and tumour-suppressor 
genes, indirect cytotoxicity due to secretion o f tumour necrosis factor, vast activation of 
signal-transduction pathways and selective activity against cells lacking functional p53. 
All o f these effects have been noted only with taxol concentrations 1,000-fold higher 
than that required for mitotic arrest and apoptosis.
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1.5.2.4 Vinca alkaloids (Vinblastine; Vincristine)
Vincristine and Vinblastine are complex plant alkaloids isolated from the periwinkle 
plant Catharanthus roseus. They are members o f a general class o f drugs that act as 
mitotic inhibitors which act by interfering with the function o f microtubules, a class o f 
long, tube-like cellular organelles approximately 250nm in diameter (Pratt and Ruddon, 
1979). Microtubules and microfilaments play an important role in the movement o f cells 
relative to each other and in the movement o f organelles within the cytoplasm of a 
single cell. The cytotoxicity o f vincristine and vinblastine is attributed to their ability to 
interrupt cell division in metaphase (Bruchovsky et al., 1965), but other effects could 
also contribute to cell death. Their action is M  phase specific.
The vinca alkaloids specifically exert their effect by binding to tubulin and prevent its 
polymerisation (King, 2000). As polymerised tubules form the spindles that retract 
chromosomes into daughter cells at mitosis, their disruption results in blocked mitosis. 
Exposure o f mitotic cells to the drugs is followed by the rapid disappearance of the 
spindle apparatus and the maintenance o f the chromosomes in the condensed state. 
Although the effects are seen at the time, the actual vincristine-tubulin interaction 
occurs during interphase. Although chemically unrelated, the terpene taxol (from yew 
trees) acts at the same locus but prevents tubulin depolymerisation.
Although vincristine and vinblastine have very similar chemical structures and behave 
in essentially the same way at the level o f drug-tubulin interaction, there are differences 
in the spectrum o f the antitumour activity o f the two drugs in both experimental animal 
tumours and clinical cancer. No reason for these differences is currently known. These 
compounds are effective against a broad spectrum o f cancers such as lung, ovarian and 
testicular cancer (Culine et al., 1994; Einhom, 1997; Schiller, 2001; Schuette, 2001). 
They have bone marrow and neural toxicities, and development o f drug resistance to 
both agents is via overproduction of P-glycoprotein (Bradley et al., 1989).
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1.5.2.5 VP16
Etoposide (VP 16) is a semisynthetic derivative o f  the mitotic inhibitor Podophyllotoxin, 
which acts by binding to tubulin. The end result o f such tubulin binding by 
Podophyllotoxin is microtubule dissolution and mitotic arrest (Pratt and Ruddon, 1979) 
and it was originally thought that VP 16 exerted its effect in a similar fashion. However, 
VP 16 does not induce micro tubule dissolution and the drug reduces the mitotic index 
rather than produce mitotic arrest. Instead, the drug appears to have its primary effect in 
G2  or perhaps late S phase, and prevents the entry o f the cell cycle into mitosis (Huang 
et al., 1973; Grieder et al., 1974). In various systems, VP16 has been shown to decrease 
nucleotide uptake into cells (Loike and Horwitz, 1976a) and to increase intracellular 
DNA degradation (Loike and Horwitz, 1976b). More recently, (Van Maanen et al.,
1988) it has been shown to be a inhibitor o f DNA topoisomerase II (Topo II). Topo II 
interacts with DNA in the process o f DNA unwinding and the sealing o f DNA strand 
breaks (Pratt et al,, 1994). VP 16 inhibits the ability o f Topo II to repair these strand 
breaks, leading to the generation o f unrepairable double-strand breaks at critical sites 
(Smith, 1994). Smith et al. (1994) also showed that etoposide can induce cell cycle 
delay and modulation o f topo II in small cell lung cancer (SCLC). However, the exact 
biological mechanism of action o f VP 16 remains unclear.
VP 16 and the other epiodophyllotoxin analogue, VM 26 are active against Hodgkins 
disease, non-Hodgkin’s lymphoma, acute leukaemias and small cell lung cancer 
(Fitoussi et al., 1999; Schiller, 2001; Schuette, 2001).
1.5.3 Differentiation induced by exposure to chemotherapeutic drugs
Murine erythroleukaemia cells (MELC) selected for resistance to vincristine were more 
easily induced to differentiate by hexamethylenebisacetamide (HMBA) (Richon et al., 
1991). This group observed that drug-selected cells differentiated far more quickly than 
non-drug-selected and that this change may be due to gene expression changes caused 
by the selection process. 5-fluorouracil was also found to induce differentiation in K562 
cells (Yang and Chang, 1995). Adriamycin (doxorubicin) has been shown to induce 
differentiation in human breast tumour MCF-7 cells (Fomari et al., 1994). This
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differentiated phenotype was also associated with a decrease in c-myc mRNA levels in 
the cell line. Doxorubicin also induced a senescence-like phenotype in colon carcinoma 
cell lines HCT116 and HT1080, which was accompanied by a knock-out o f expression 
ofp53 andp21 (Chang etal., 1999).
1.5.4 Gene induction response to chemotherapy
1.5.4.1 Gene induction response to Cisplatin:
Gately et al. (1994), observed increased expression o f the growth arrest and DNA 
damage-inducible gene GADD-153 in human ovarian 2008 carcinoma cells, when the 
tumour cells were grown both in vitro and in tumour xenografts in nude mice. Further 
work on this subject carried out by Delmastro et al. (1997), indicates that this response 
is more directly correlated with downstream biologic effects o f cisplatin damage than 
with actual Pt-DNA adduct levels. The induction o f expression of c-jun in the human 
melanoma cell line RPMI8322 following exposure to cisplatin was observed by Zhao et 
al. (1995). Cisplatin and VP-16 were used to study the induction o f apoptosis in Panc-1 
cells, and its outcome relative to the expression o f BAX and Bcl-2 (Lee et al., 1997). 
The group found upregulation o f BAX expression, but no change in the expression of 
Bcl-2 in the cells. Expression of p53 is the gene studied most often in cells following 
exposure to cisplatin (Lee et al., 1997; Siddik et al., 1998; Zamble et al., 1998; Jones et 
al., 1998; Hagopian et al., 1999). Lee et al. (1997) found that mutated p53 was required 
for the induction o f apoptosis in PANC-1 cells in the study already mentioned, although 
no upregulation in expression of the gene was observed following exposure to cisplatin. 
Siddik et al. (1998) observed increases in p53 expression which were found to be 
cisplatin dose-dependent in human A2780 ovarian cancer cells. Induction o f p53 and 
p21 in the cisplatin-resistant ovarian cancer cell line OVCA-429 by cisplatin and 
another platinum analogue, DACH-acetato-Pt was observed by Hagopian et al. (1999). 
Jones et al. (1998) found upregulated expression o f Bak and 21-kDa BAX in human 
A2780 cells following exposure to cisplatin. Exposure to taxol was also observed to 
increase expression of these genes in A2780, but it was also found to increase 
expression of Bak and 21-kDa BAX in a cisplatin-resistant, p53-null variant of the cell
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line. No change in expression levels of Bcl-2, B c 1 - x l ,  or 24-kDa BAX was observed in 
either of the cell lines during the experiment. This result indicated that functional p53 
may be required for the cisplatin effects and not for the taxol-related effects. p53 gene 
responses to cisplatin has also been examined in mouse testicular teratocarcinoma cells 
(Zamble et al., 1998). This group observed p53 protein accumulation through 
transcriptional mechanisms, followed by induction o f p53-target genes. Cisplatin 
exposure also caused prolonged cell cycle arrest followed accompanied by induction of 
the p21 gene. Cisplatin was also observed to induce expression o f the ERCC-1 gene, 
which is important in nucleotide excision repair, following exposure to the drug in 
human ovarian A2780 cells (Li et al., 1998).
1.5.4.2 Gene induction response to Taxol (Paclitaxel) :
The resistance mechanisms utilised by human MES-SA sarcoma cells in response to 
exposure to taxol were examined by Dumontet et al. (1996). The group found that taxol 
exposure resulted in activation o f expression o f the mdr-1 gene in this cell line, which 
yielded a broad resistance to vinblastine, adriamycin and etoposide (VP16). Taxol was 
also observed to increase expression of the growth arrest and DNA damage-inducible 
gene GADD-153 in the human ovarian 2008 carcinoma cell line (Gately et al., 1996), 
and to induce apoptosis in human ovarian carcinoma SKOV3 cells, (Ling et al., 1998), 
with an attendant induction of c-Mos gene expression. In the same study, Ling et al. 
also observed an induction o f c-Mos protein expression following exposure to 
vinblastine in the SKOV3 cell line, but no change following exposure to camptothecin, 
etoposide and cisplatin. Examination of gene expression in a taxol-selected SK.OV3 cell 
line using cDNA microarray technology revealed increased expression o f mdr-1 but not 
MRP1 (Duan et al., 1999). The taxol-resistant cell line was also observed to be cross- 
resistant to adriamycin and vincristine. Overall, twelve genes were observed to be 
overexpressed in the resistant subline; these included the cytokines interleukin 6, 
interleukin 8 and monocyte chemotactic protein 1. Induction o f expression of mdr-1 
mRNA was also observed in a number o f human ovarian cell lines by Yamamoto et al. 
(2000), following exposure of the cell lines to taxol.
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1.5.4.3 Gene induction response to V P-16 (Etoposide):
Jaffrezou et al. (1994) examined the effect o f VP-16 on human sarcoma MES-SA cells. 
They observed a significant decrease in the expression o f both topoisomerase II a  and (3 
mRNA (Topo II is the natural target enzyme for etoposide) in six out o f seven stably 
established mutant cell lines. No change in expression of MRP1 was observed. The 
effect o f VP 16 in mouse L fibroblasts was examined by Sacchi and Schiaffonati, 
(1996), in which the authors looked at expression levels o f three classes o f genes: stress- 
response, growth- and cycle-related and apoptosis-related. The group observed 
repression of the c-myc, c-fos and c-jun genes, as well as transient induction o f the 
apoptotic tTG gene. Etoposide-exposed A549 cells revealed an increase in expression of 
MRP1, a decrease in LRP expression and no change in expression levels o f the mdr-1 
gene (Trussardi et al., 1998). Gibson et al. (1999) examined the gene expression of 
BAXa and Bcl-2 in a number o f cell lines exposed to a combination dose o f VP-16 
followed by cyclophosphamide. Increased BA Xa expression was first observed in three 
breast cancer cell lines; MCF-7, MDA-MB-435S and MDA-MB-A231 following 
exposure to V P-16 alone. An additional dose o f cyclophosphamide induced higher 
levels o f BA Xa expression than were observed with just VP-16. This combination of 
chemotherapeutic agents also resulted in reduced Bcl-2 expression, whereas exposure to 
V P-16 alone had no effect.
1.5.4.4 Gene induction following exposure to other chemotherapeutic drugs
Exposure to the DNA-damaging agent 5-fluorouracil (5-FU) has been shown to induce 
an increase in thymidylate synthase (TS) gene expression in the human colon cancer 
H630 cell line when combined with interferon-gamma (Chu et al., 1993). 5-fluorouracil 
on its own was also found to induce differentiation in K562 cells (Yang and Chang, 
1995), although no change in c-myc mRNA or protein expression levels was observed. 
5-FU was also found to induce expression of the carcinoembryonic antigen (CEA) in 
the human colon carcinoma cell line HT-29 (Prete et al., 1996). Finally, p53 mRNA and 
protein expression in a number o f p53-expressing clonal cell lines was examined 
following exposure to the drug (Miijolet et al., 2000). The group found that p53 mRNA
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expression varied according to the clone under examination, but that in all clones, 5-FU 
altered transcriptional and translational regulation leading to up-regulation o f the p53 
protein.
Adriamycin (doxorubicin) has been shown to induce differentiation in human breast 
tumour MCF-7 cells (Fomari et al., 1994). This differentiated phenotype was also 
associated with a decrease in c-myc mRNA levels in the cell line. A single-step 
adriamycin selection was attempted by Chen et al. (1994), in which a number o f clones 
were isolated from the human sarcoma cell line MES-SA and analysed for mdr-1 
expression. Elevated levels o f mdr-1 mRNA were found in all clones tested as well as 
increased P-glycoprotein expression. Expression levels o f topoisomerase II a  and (3, 
MRP1, glutathione and p i 10 were unaffected. Doxorubicin also induced a senescence­
like phenotype in colon carcinoma cell lines HCT116 and HT1080, which was 
accompanied by a knock-out of expression of p53 and p21 (Chang et al., 1999). 
Exposure to related anthracyclines also resulted in induced gene expression. Nielsen et 
al. (1998) observed significant increases in P-glycoprotein expression in murine Ehrlich 
ascites tumour cells (EHR2) after exposure to daunorubicin, a related analogue. Two 
other analogues, 4-demethoxydaunorubicin and MX2, a morpholino-anthracycline, were 
also observed to induce mdr-1 expression in a low-level human multidrug-resistant 
leukaemia cell line, CEM/A7R (Hu et al., 1999).
The chemotherapeutic drug cytarabine (ara-C) induced LRP gene expression (Komarov 
et al., 1998) (although no consequent increase in LRP protein was reported), as well as 
inducing apoptosis in HL-60 cells (Bouffard and Momparler, 1995). Other 
chemotherapeutic drugs which have been found to induce gene expression include 
gemcitabine, which has been shown to induce c-jun and c-fos gene expression in the 
HL-60 cell line (Bouffard and Momparler, 1995), as well as inducing p53 and p21 
expression in the human lung cancer cell line H460 (Tolis et al., 1999). The 
chemotherapeutic drug Topotecan has also been shown to have the same effect in this 
latter study (Tolis et al., 1999). Mitoxantrone, a novel antineoplastic drug, has also been 
shown to induce apoptosis in human myeloid leukaemia HL-60 and KG-1 cells as well 
as increasing c-jun gene expression and repressing the expression o f c-myc and Bcl-2 
(Bhalla et al., 1993).
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Christodoulopoulos et al. (1999) found that chlorambucil induced expression of the 
human homologue of Rad51 (HsRad51) in lymphocytes from patients with B-cell 
chronic lymphocytic leukaemia (B-CLL). Chlorambucil is the standard alkylating agent 
used to treat patients with B-CLL, while HsRad51 may be implicated in recombination 
repair and induction of DNA repair enzymes.
Tamoxifen is a nonsteroidal antiestrogen which is widely used in breast cancer 
treatment and is currently under evaluation as a chemopreventative agent for individuals 
at high risk o f contracting the disease. Examination o f the effects o f Tamoxifen on the 
expression o f xenobiotic metabolising enzymes in F344 rat liver cells was also 
investigated (Nuwaysir et al., 1995). The group observed increases in expression of 
CYPTTB1, CYPIIB2, CYPIIBA and microsomal epoxide hydrolase mRNA and protein 
levels in both male and females.
1.5.4.5 Gene induction following exposure to other agents
Induced gene expression has been observed in a number o f cell types following 
exposure to different agents. The range of gene-altering substances is very wide, 
incorporating chemical agents which differ vastly in terms o f their mode o f activity and 
make-up (e.g. chemotherapeutic drugs), as well as physical agents which induce a more 
corporeal effect, such as UV irradiation, and heat shock.
Expression o f the mdr-1 and p53 genes are the two most studied genes following 
induction by various external agents. Mdr-1 gene expression has been found to be 
upregulated in the human renal adenocarcinoma cell line HTB-46 following exposure to 
heat-shock and arsenite (Chin et al., 1990). Further work on this area identified the 
presence o f heat-shock responsive elements in the promoter sequence o f the mdr-1 gene 
which were responsible for the heat-shock-mediated increase in expression (Kioka et 
al., 1992). Expression o f the mdr-1 gene has also been found to be induced in human 
cancer KB cells following exposure to UV light irradiation (Uchiumi et al., 1993). Two 
sequences in the mdr-1 promoter were found be essential for the stress induction of the 
mdr-1 gene promoter activity. Chaudhary and Roninson, (1993) also observed increases 
in expression o f the mdr-1 gene following treatment with a variety o f chemotherapeutic
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drags, a number o f which will be discussed later. Mdr-1 expression has also been 
induced in rat liver tumours following injection o f diethylnitrosamine (Fardel et al., 
1994), a treatment which also induced mdr-3 gene expression in two clones isolated 
from one o f the treated tumours. Sodium butyrate, a differentiating agent, induced mdr- 
1 gene expression in the human colon carcinoma cell lines Clone-A (Kramer et al., 
1993), as well as SW 620, HCT-15, DLD-1 and LS 180 (Frommel et al., 1993). Other 
genes found to be induced by chemical means in cancer cells include COX-2-induced 
protein expression in human colon carcinoma cell line HT-29 by carbachol, a stable 
receptor agonist (Yang and Frucht, 2000), as well as c-myc mRNA, induced in rat livers 
by aflatoxin B1 and age (Larson et al., 1993) and suppressed in MCF-7 human breast 
tumour cells by the anthracycline analogue, idarubicin (Gewirtz et al., 1998). Both 
mRNA and protein expression o f the breast cancer resistance gene BRCA-1 was 
inhibited in the human breast MCF-7 and ovary BG-1 cell lines by exposure to the 
polycyclic aromatic hydrocarbon Benzo[a]pyrene. This hydrocarbon has also been 
found to induce expression o f the p53 gene in A549 and NIH 3T3 cells (Pei et al., 
1999). p53 protein expression has also been induced in normal lymphocyte cells 
following exposure to the alkylating agent nitrogen mustard (Bhatia et al., 1995), while 
suppression of the gene has been observed in human chronic lymphocytic leukaemia 
(CLL) cells following exposure to the synthetic flavone Flavopiridol (Byrd et al., 1998).
A number o f other agents have been found to induce gene expression following 
exposure in certain cell lines. Oltipraz is a synthetic dithiolethione with 
chemopreventative activity against carcinogen-induced neoplasia o f liver, lung and 
colon in several animal model systems. Delivery of oltipraz to patients at high risk of 
colorectal cancer resulted in the induction of mRNA for the detoxifying enzymes y- 
glutamylcysteine synthase (y-GCS) and DT-diphorase taken from colon mucosal 
biopsies (O’Dwyer et al., 1996). Further work on this dithiolethione by this group 
identified the induction o f DT-diaphorase mRNA in the human colon adenocarcinoma 
cell line HT-29, following exposure to oltipraz (O’Dwyer et al., 1997). Asbestos has 
been found to induce c-fos and c-jun gene expression in rat pleural mesothelial cells 
(Heintz et al., 1993). Asbestos has also been shown to induce an extended lifespan in 
normal human mesothelial cells with a concomitant increase in expression o f the SV40 
T antigen (Xu et al., 1999). The phorbol ester TPA (phorbol 12-myristate 13-acetate)
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has been shown to induce c-fos and c-myc gene expression in mononuclear blood cells 
taken from patients with B-chronic lymphocytic leukaemia (B-CLL) (Drexler et al.,
1989), as well as inducing LRP gene expression in HL-60 and K562 cells (Komarov et 
al., 1998) and ERCC-1 protein in human ovarian A2780 cells (Li et al., 1998).
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1.6 Eukaryotic gene transcription
In eukaryotes, DNA is assembled into chromatin, which maintains genes in an inactive 
state by restricting access to RNA polymerases and its accessory factors. During the 
process o f development, genes are turned on and off in a pre-programmed fashion, a 
process which eventually generates cell specificity. This developmental program is 
orchestrated by transcription factors which bind to specific DNA recognition sites near 
the genes they control. A single transcription factor is not dedicated to each regulatory 
event. Instead, a mechanism called combinatorial control is employed (Carey and 
Smale, 2000). In combinatorial control, different combinations o f ubiquitous and cell- 
type-specific regulatory proteins are used to turn genes on and off in different regulatory 
contexts. The ability o f an organism to employ small numbers o f regulatory proteins to 
elicit a larger number o f regulatory decisions is one of the major strengths o f eukaryotic 
transcriptional control.
1.6.1 General overview o f gene structure and activation
In a typical gene, a DNA sequence called the core promoter is located immediately 
adjacent to and upstream of the gene. The core promoter binds RNA polymerase II (Pol 
II) and its accessory factors and directs Pol II to begin transcribing at the correct start 
site. In vivo, in the absence o f regulatory proteins, the core promoter is generally 
inactive and fails to interact with the general transcription machinery. Immediately 
upstream of the core promoter is a regulatory promoter, and farther away either 
upstream or downstream are enhancer sequences. Regulatory promoters and enhancers 
bind proteins called activators, which “turn on” or activate transcription o f the gene. 
Activation generally occurs by recruitment o f the general machinery to the core 
promoter via interactions between the activator bound to promoter DNA and the general 
machinery in solution. Some activators are ubiquitously expressed, whereas others are 
restricted to certain cell types, regulating genes necessary for a particular cell’s function.
To activate a gene, the chromatin encompassing that gene and its control regions must 
be altered or “remodelled” to permit transcription. The mechanisms o f remodelling are 
unclear, but they involve changes in the structure of chromatin and in modification of
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histones that somehow increase accessibility to transcription factors. Remodelling 
achieved at a local level affects only the chromatin close to a gene. In some instances, 
however, a single gene or locus of related genes may spread over lOOkb or more. In 
these cases, genes might be under the control o f not simply specific enhancers and 
regulatory promoters but also of locus control regions (LCRs), which remodel 
chromatin and control global access activators over an extended region (Carey and 
Smale, 2000).
Once enhancers are accessible, they can stimulate transcription o f a gene. However, 
because enhancers are known to activate transcription when they are positioned large 
distances from a gene, they could inadvertently activate other nearby genes in the 
absence of appropriate regulation. To focus the action o f the enhancer or LCR on the 
appropriate gene or set o f genes, the gene and its regulatory regions are thought to be 
assembled into a domain. Domain formation appears to involve boundary elements and 
matrix attachment regions (MARs). Boundary or insulator elements are thought to flank 
both sides of an individual gene or gene locus. These elements bind proteins that 
prevent the enhancer from communicating with genes on the opposite side of the 
insulator. MARs also flank some active genes and tether them as loops to the nuclear 
periphery or matrix although a gene function has not been established (Carey and 
Smale, 2000).
The current view is that once the enhancer and promoter are acccesible, they bind to 
combinations o f activators. Binding of activators is generally cooperative, where one 
protein binds weakly, but multiple activators engage in protein-protein interactions that 
increase each o f their affinities for the regulatory region. The nucleoprotein structures 
comprising these combinatorial microarrays o f activators are called enhanceosomes 
(Carey and Smale, 2000). The enhanceosome interacts with the general transcription 
machinery and recruits it to a core promoter to form “the Pre-Initiation Complex” or 
PIC (see Section 1.6.1.1). The enhanceosome, the general machinery and the core 
promoter form a complicated network o f protein-protein and DNA-protein interactions 
that dictate the frequency o f transcription intiiation. The interactions between the 
enhanceosome and components o f the general machinery are rarely direct but are 
bridged or linked by proteins called coactivators.
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1.6.2 Transcription Initiation
Eukaryotic gene transcription occurs in three stages; initiation, promoter clearance, 
elongation and termination. The main target for regulation appears to be the process of 
RNA polymerase binding and transcription initiation. RNA polymerase is the enzyme 
that reads the DNA code and convert it into an RNA “message”. This is then 
transported from the nucleus to the cytoplasm where it can be translated into protein. 
The three RNA polymerases lack the intrinsic ability to interact specifically with DNA 
sequences but they acquire specificity through interaction with cellular proteins called 
transcription factors. These place the RNA polymerase enzyme in the correct position 
on the DNA to begin transcription. There are three different RNA polymerase enzymes 
which carry out distinct functions: RNA polymerase I (Pol I) transcribes ribosomal 
RNA (rRNA), RNA polymerase II (Pol II) transcribes protein-encoding messenger 
RNAs (mRNAs) and RNA polymerase III (Pol III) transcribes genes coding for amino 
acid transfer RNAs (tRNAs) (Geiduschek and Kassavetis, 2001; Landick, 2001). As a 
result, Pol n  is the focus o f most of the discussion which will take place here.
1.6.2.1 Initiation and the formation o f the Pre-Initiation Complex (PIC)
The promoter region o f eukaryotic protein-coding genes is arbitrarily divided into two 
segments: a core promoter region o f encompassing DNA sequences between 
approximately -4 0  and +50 bases relative to a transcriptional start site and an enhancer 
region consisting o f either positive or negative regulatory elements (Fig. 1.6.1) (Carey 
and Smale, 2000). The two key genetic elements within the core promoter are the 
TATA box and the initiator (Inr) element. Core promoter structures contain 
combinations o f these elements, termed TATA+ Inr', TATA+ Inr+ and TATA' Inr+ 
(Novina and Roy, 1996). The majority o f cellular promoters contain a TATA box. 
Recently, a number o f genes have been identified that do not contain a TATA m otif and 
appear to be predominantly housekeeping genes.
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Fig. 1.6.1 Model of typical gene and components involved in gene activation
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1. Bind to and control assembly o f the preinitiation complex containing Pol II, the 
general transcription factor, and coactivators
2. Position the transcription start site and control the directionality o f transcription
3. Respond to nearby or distal activators and repressors in a cell 
(Carey and Smale, 2000).
In most cases, the core promoter elements do not play a direct role in regulated 
transcription. The core promoter alone is generally inactive in vivo, but in vitro it can 
bind to the general machinery and support low levels o f transcription. This amount o f 
basal transcription is dictated by the DNA sequences in the core promoter. Activators 
greatly stimulate transcription levels, and the effect is called activated transcription 
(Carey and Smale, 2000).
The basic process o f transcription initiation involves the recruitment o f  RNA 
polymerase II to the transcriptional start site via tethering to various General 
Transcription Factors (GTFs) that recognise the promoter region and begin assembly o f 
the “pre-intiation complex” (PIC). This is a giant complex estimated to consist o f 
approximately 50 components adding up to a molecular weight o f more than 3 MDa 
(Halle and Meisteremst, 1996). The PIC that binds the core promoter consists o f  two 
classes o f factors; the GTFs including Pol II, TFIIA (Transcription Factor IIA), TFIIB, 
TFIID, TFIIE, TFIIF and TFIIH and coactivators and corepressors that mediate 
response to regulatory signals (Myer and Young 1998).
T.1
1.6.3 Transcriptional Enhancers
Transcriptional regulation is controlled by the binding o f sequence-specific DNA- 
binding proteins to regulatory promoters and enhancers (reviewed in Blackwood and 
Kadonaga, 1998). The regulatory promoter is normally defined as the region 
surrounding the core promoter and within a few hundred base pairs of the transcription 
start site, either upstream or downstream of the gene or within an intron. The 
distinctions between regulatory promoters and enhancers have even become blurred 
over time because control elements found in an enhancer can often function in the 
context of a promoter (Blackwood and Kadonaga, 1998). Conversely, individual 
promoter elements can often impart enhancer activity if  multimers of that element are 
inserted at a more distant location.
Currently, the specific properties that permit an enhancer to function from a great 
distance have not been determined. Current models for enhancer action have been 
reviewed recently (Kadonaga, 1998). The current view is that enhancers bind activators 
and other sequence-specific proteins that are involved in chromatin remodelling. Once 
bound, these activators loop out the intervening DNA to interact with proteins bound to 
the regulatory or core promoters. These interactions are believed to stabilise 
transcription factor assembly.
1.6.4 Regulation o f Gene Transcription from TATA-less promoters
In recent years there have been a growing number o f reports of promoter elements that 
lack any discernible TATA box motif, originally thought to be a critical control point in 
the initiation process. Surprisingly, many of these, including creatine kinase, 
dihydrofolate reductase, cytochrome c oxidase and a number of ribosomal proteins 
(Azizkhan et al., 1993; Basu et al., 1993), are “housekeeping” genes. In the case of 
cytochrome c oxidase (COX-1, COX-2), the -1 7  to +20 region o f the promoter contains 
fused binding sites for two enhancer proteins, NF-E1 (also called YY1) and SP1 (Basu 
et al., 1993). The transcription start site at position — 8  to +9 is flanked by a 17 base 
initiator element (Inr). Mutation studies showed that basal transcription from this Inr 
element did not involve SP1 binding but was completely dependent on YY1 binding.
3 8
The importance o f SP1 sites in the regulation of TATA-less promoter initiation may 
actually depend more upon the presence of immediately adjacent YY1 binding. This is 
highlighted by the findings o f Basu et al. (1993) above, together with the demonstration 
that SP1 and YY1 physically interact to form a protein complex (Lee et al., 1993) 
suggesting a synergistic effect on TATA-less promoter activity in the presence o f  both 
factors. The role o f this interaction with SP1 is still unclear, however, since SP1 actually 
counters YY1-mediated transcriptional activation o f the TATA-less dihidrofolate 
reductase gene in Drosophila (Azizkhan et al., 1993).
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1.7 Gene expression profiles examined in this study
From the results already obtained by other researchers, as well as the previous findings 
in this laboratory (Section 1.4.3.7), the cell systems o f DLKP and A549 were chosen to 
study the effects o f BrdU-induced differentiation in lung epithelial cell lines. As has 
been already shown, a significant level o f induced protein expression in response to 
BrdU has already been demonstrated in these cell lines (Section 1.4.3.7). It was 
considered interesting to examine the expression levels o f a number o f functionally 
diverse genes during BrdU-induced differentiation in these cells. The rest o f this 
Introduction deals with a discussion o f these genes, the expression of which was 
examined in the BrdU-treated lung cell lines using RT-PCR analysis.
Broadly, there were six classes of genes examined;
1. Genes associated with mediating multidrug resistance (MDR); this group was the 
most populous, incorporating mdr-1, mdr-3, MRPs 1-6, and BCRP
2. Apoptotic genes; the pro-apoptotic MRIT, BAXa, Bcl-xs and BAP and the anti- 
apoptotic B c1-xl , Bcl-2a, Survivin and BAG genes
3. Eukaryotic initiation factor genes, eIF-2a and eIF-4E
4. Genes involved in tumour progression; COXs-1 and COX-2
5. Cell adhesion genes; E-cadherin, a-catenin and P-catenin
6 . The transcription factor gene; c-myc
Each of these genes are discussed in greater detail in the following subsections, which 
will provide the main reasons these genes were selected for analysis in this study.
1.7.1 Introduction to multidrug resistance (MDR)
Multidrug Resistance (MDR) severely compromises the efficacy o f cancer 
chemotherapy in the clinic. It occurs when tumours that may initially have been 
sensitive, become resistant to a variety o f therapeutically important anticancer drugs that 
are structurally unrelated and have diverse cellular targets. MDR may be observed in 
primary therapy (inherent resistance) or be acquired during or after treatment (acquired 
resistance) (Yu et at, 1999). Although the majority o f tumours do show an initial
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response to chemotherapy, a relapse that neither responds to the drugs initially used nor 
to other anticancer drugs often follows. In-vitro studies have shown that MDR is 
accompanied by reduced intracellular drug accumulation due to increased drug efflux 
by energy-dependant trans-membrane drug transport proteins (Endicott and Ling, 1989).
One major mechanism o f resistance to such drugs is linked to decreased cellular 
accumulation o f anticancer drugs through enhanced cellular efflux o f the anti-tumour 
compounds. Such multidrug resistance can be conferred in vivo and in vitro, by a 
number o f proteins. The most important genes mediating drug resistance in vivo are the 
Mr 170,000 P-glycoprotein (encoded by the MDRl gene) (Gottesman and Pastan, 1993), 
and the more recently identified 190kDa MRP1 (Cole et al., 1992) and its homologues 
(Kool et al., 1997). All of these proteins are members o f the ABC (ATP-binding 
cassette) transporter family and function as ATP-dependent active transporters.
1.7.1.1 P-glycoprotein (Pgp)
Pgp is a plasma membrane efflux pump with ATPase activity and a molecular weight of 
170 kDa. It is composed o f two similar halves, each containing six putative 
transmembrane domains and one nucleotide-binding site consensus sequence. This 
unique structural characteristic o f Pgp has been conserved in a large number of 
membrane associated transporters from bacteria to higher eukaryotes, forming a novel 
superfamily of proteins called the ATP binding cassettes (ABC) transporters (Higgins, 
1992). The ATP-binding cassette (ABC) transporters, present in organisms ranging 
from bacteria to man, are involved in the ATP-dependent transport o f a wide variety o f 
compounds, ranging from inorganic ions to large polypeptides (Tusnady et al., 1997), 
and are involved in the tolerance to a wide diversity o f cytotoxic agents in both 
prokaryotes and eukaryotes (Higgins, 1992).
Pgp acts to promote the efflux o f a variety o f drugs with resultant reduction in 
intracellular drug concentration (Clynes, 1993). The physiological function of Pgp is 
not, however, completely understood. Detoxification o f naturally occurring compounds 
and excretion o f endogenous metabolites, e.g. steroid hormones, are possibilities, while
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there is evidence that it is an essential component o f a volume-regulated chloride 
channel (Gottesmann and Pastan, 1993).
1.7.1.2 Multidrug resistance-associated Protein 1 (MRP1) and MRP homologues
Studies o f a Pgp negative multidrug resistant cell line led to the identification o f another 
transmembrane protein, the p-190 multidrug resistance-associated protein (MRP) (Cole 
et al., 1992). MRP is a 1531 amino acid protein that was predicted to be a member o f 
the ABC transporter superfamily (Loe et al., 1996). This protein is now recognised as 
MRP1 (Hipfner et al., 1999). Despite their similar function, MRP1 and Pgp show little 
sequence homology, which is restricted to the ATP binding site. Drug cross-resistance 
profiles are similar but not identical for MRP1 and Pgp overexpressing cells (Lautier et 
al., 1996) and agents that reverse Pgp are usually less effective on MRP1.
1.7.1.2.1 MRP1 Protein structure
Most ABC transporters are comprised o f two polytopic MSDs (Membrane Spanning 
Domain) and two NBDs (Nucleotide Binding Domain) (Higgins, 1992). The predicted 
topology o f MRP 1 is inconsistent with the typical four-domain structure. A schematic 
outline o f the protein topology of MRP1 is provided in Fig. 1.7.1.
Fig. 1.7.1 Predicted MRP1 protein structure
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1.7.1.2.2 Investigation o f important regions o f MRP 1 protein structure
Gao et al. (1998), investigated the possible role o f the third MSD o f MRP1 and its 
related transporters and their results demonstrated that two truncated molecules 
(MRP229-1531 and MRP281-1531) lacking M SDl can be expressed in Sf21 cells as 
efficiently as the full length protein. They then examined the ability o f  various MRP1 
fragments, expressed individually and in combination, to transport the MRP substrate, 
Leukotriene C4 (LTC4). It was found that elimination o f the entire NH2 terminal MSD, 
or just the first putative transmembrane helix, or substitution o f the MSD with the 
comparable region of the functionally and structurally related transporter, the canalicular 
multispecific organic anion transporter (cMOAT/MRP2), had little effect on protein 
accumulation in the membrane. However, all three modifications decreased LTC4 
transport activity by at least 90%. Transport activity could be reconstituted by co­
expression o f the NH2-terminal MSD with a fragment corresponding to the remainder of 
the MRP molecule, but this required both the region encoding the transmembrane 
helices o f the NH2 terminal MSD and the cytoplasmic region (L0) linking it to the next 
MSD. In contrast, a major part o f the cytoplasmic region linking the NH2-proximal 
nucleotide binding domain of the protein to the COOH-proximal MSD was not required 
for active transport o f L T C 4 .
In most ABC transporters, the binding and the subsequent hydrolysis o f ATP by the 
NBDs is believed to be coupled to, and provide the energy for substrate transport 
(Hipfher et al., 1999). These domains are highly conserved, typically showing 30-40% 
identity among different superfamily members in a core region o f about 2 0 0  amino 
acids. The NBDs of ABC superfamily members share two sequence motifs, designated 
“Walker A” and “Walker B”, with many other nucleotide binding proteins (Walker et 
al., 1982). Mutational analysis o f a number o f ABC proteins indicates that these two 
regions are critical for ATPase function (Hipfher et al., 1999). Another feature that 
distinguishes MRP 1-like transporters from other ABC superfamily members is a 
difference in the structure of the NH2-proximal NBD (NBD1). Alignment o f the primary 
sequences o f MRP 1, LtPgpA, and CFTR with the human Pgp encoded by the MDR1 
gene revealed that, in comparison to P-glycoprotein, these transporters all contain a 
“deletion” o f 13 amino acids located between the Walker A and B motifs o f NBD1.
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1.7.1.2.3 Identification of homologues of MRP 1
The first transport protein to be recognised as a member o f the MRP family was 
cMOAT (Taniguchi et al., 1996). A full length human cMOAT cDNA was isolated 
which was highly homologous to rat cMOAT. Sequencing o f cMOAT revealed an open 
reading frame coding for 1545 amino acids that showed 46% similarity to that o f human 
MRP1. Taniguchi et al. (1996), estimated the size o f cMOAT to be approx. 4.5kb, 
similar to that of MRP 1 mRNA but larger than the human mdr-1 mRNA.
To date five human MRP 1-related proteins, designated MRP2, MRP3, MRP4, MRP5 
and MRP6  have been discribed (Kool et al, 1997; Taniguchi et al., 1996; Konig et al, 
1999; Kool et al, 1999a and 1999b and Kiuchi et al., 1998). A search o f the human 
Expressed Sequence Tag (EST) database by Allikmets et al. (1996), yielded 21 new 
ABC genes, including genes for transporters related to MRP1. In an independent search, 
Kool et al (1997), found four transporters related to MRP1 and cMOAT and analysed 
the expression of these genes, called MRP3-6, in normal tissues and tumour cell lines. A 
fifth homologue of MRP1 was also identified as the human SUR (sulfonyl urea 
receptor) gene. The percentages of homology for the COOH-terminal 124 amino acids 
are shown in Table 1.6.1. Percentages o f identity were determined using the GAP 
program of GCG (Kool et al., 1997). The highest homology is found between MRP1 
and MRP3 (83% similarity) and the lowest between SUR and any o f the MRPs (59% 
similarity).
Table 1.7.1: Homology between the COOH terminal 124 amino acids of the six 
human MRP homologues and human SUR
MRP1 MRP2 MRP3 MRP4 MRP5 MRP6 HSUR
MRP1 1 0 0
cMOAT 73 1 0 0
MRP3 83 73 1 0 0
MRP4 69 65 64 1 0 0
MRP5 6 6 65 62 6 6 1 0 0
MRP6 69 64 67 62 57 1 0 0
HSUR 59 57 57 58 57 46 1 0 0
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The existence o f a seventh family member, MRP7, has only been inferred from a 
database search and so far there is no other information available (Borst et al., 1999). 
The sMRP has been reported by Suzuki et al. (2000), to be a spliced variant of the 
MRP5 gene, expressed in various human tissues. ARA represents the 3 ’end of the 
MRP6  gene that is incidentally co-amplified with MRP1 in cells selected for adriamycin 
resistance (Kool et al., 1999). Within the group o f mammalian ABC transporters the 
MRPs form a cluster that is clearly demarcated from the other known groups, such as 
Pgp, CFTR and the sulphonylurea receptors.
1.7.1.2.4 Function /Transport by MRP 1 and MRP homologues
In 1994 two groups independently demonstrated that MRP1 is able to transport 
glutathione (GSH) conjugates o f drugs (Leier et al., 1994 and Jedlitschly et al., 1994). 
Leier et al. (1994), demonstrated that the MRP1 gene encodes a primary-active ATP 
dependent export pump that can transport the cysteinyl leukotriene, LTC4 and 
glutathione conjugates such as glutathione disulphate (GSSG). Elevated levels o f ATP- 
dependent transport o f LTC4 and certain other GSH conjugates were also demonstrated 
by Jedlitschly et al. (1994). The findings that MRP1 can transport cysteinyl leukotrienes 
(e.g. LTC4) as well as other GSH conjugates suggest that this protein may be a GSH 
conjugate/organic anion transporter, a GSH-X pump. Therefore, it appears that MRP1 is 
a transporter o f multivalent organic anions, preferably glutathione S-conjugates (Loe et 
al., 1996b; Jedlitsky et al., 1996; Muller et al., 1994), but also o f sulphate conjugates 
(Jedlitsky et al., 1996).
The mechanism of MRP 1-mediated transport o f chemotherapeutic drugs is presently 
unclear. Although MRP1 has been shown to reduce cellular accumulation o f at least 
some o f the drugs to which it confers resistance, such as adriamycin, daunorubicin, 
vincristine and VP-16, it has previously not been possible to demonstrate direct 
transport o f these compounds or other unmodified chemotherapeutic drugs by MRP1- 
enriched membrane vesicles (Cole et al., 1998; Jedlitschky et al., 1996; Loe et al., 1996 
and Muller et al., 1994), and contrary reports claiming to have shown direct transport of 
these compounds have recently been retracted (Cole et al., 1998). A  number o f authors 
have also reported the ability o f the MRP1 protein to mediate the active transport of
45
neutral (etoposide (VP-16)) and cationic (adriamycin, vincristine, daunorubicin and 
rhodamine 123) lipophilic drugs as well as anions (e.g. dinitrophenyl-S-glutathione and 
calcein) (Broxterman et al., 1996).
Jedlitschy et al. (1997), demonstrated that bilirubin glucuronides were better substrates 
for MRP2 than MRP1, which are transported by both proteins in an ATP dependent 
manner. MRP2 is also reported to be the predominant export pump responsible for 
hepatobiliary excretion of the amphiphilic anion Fluo-3 (Keppler et al., 1999 and Konig 
et al., 1999). MRP3 expression has been correlated with doxorubicin resistance and a 
weaker, but still highly significant connection with resistance to vincristine, etoposide 
and cisplatin (Young et al., 1999). Bakos et al. (1998), reported that MRP4 expressed 
the basic structure required for GS-X pump activity as does MRP1, however 
characterisation of MRP4 substrates remains to be elucidated. Suzuki et al. (2000), 
reported that MRP5 mRNA was detected in a large number o f human tissues. Kool et al. 
(1999b), reported that their analysis o f a number o f MDR and cisplatin resistant cell 
lines provided no evidence for the involvement o f MRP6  in drug resistance.
1.7.1.2.5 MRP 1 and MRP homologue expression in cell lines and human tissues
Since the discovery of MRP1 in the small cell lung cancer cell line, H69AR (Cole et al., 
1992), MRP1 has been identified in non-Pgp multidrug resistant cell lines from a 
variety o f tumour types, including leukemias, fibrosarcoma, non-small cell lung, human 
small cell lung, breast, cervix, prostate, and bladder carcinomas (Izquierdo et al., 1996). 
MRP1 has also been detected either at the protein or mRNA level in normal human 
tissues including lung, stomach, colon, peripheral blood macrophages, thyroid, testis, 
nerve, bladder, adrenal, ovary, pancreas, gall-bladder, duodenum, heart, muscle, 
placenta, brain, kidney, liver and spleen (Loe et al., 1996a; Zaman et al., 1993; Cole et 
al., 1992 and Kool et al., 1997).
MRP2 (cMOAT) is found predominantly in the liver, duodenum and, in low levels, in 
the kidney (Kool et al., 1997; Schaub et al., 1997). Kool et al. (1997) and Kiuchi et al. 
(1998), reported that MRP3 mRNA is mainly expressed in the liver, colon, intestine and 
adrenal gland, and to a lesser extent in several other tissues. Kool et al. (1997), reported
46
that MRP4 was found only in a small number o f tissues at very low levels. However, 
Lee et al. (1998), demonstrated, using RNA blot analysis, the expression o f MRP4 in a 
wide range o f tissues, with particularly high levels in prostate, but almost undetectable 
levels in the liver. MRP5, like MRP1, is readily detected in several tissues with highest 
levels in skeletal muscle, intermediate levels in kidney, testis, heart and brain and low 
levels in most other tissues, including lung, liver, spleen, thymus, prostate, ovary and 
placenta (Belinsky et al., 1998). Recent investigations have shown that MRP6  is 
predominantly expressed in liver and kidney cells and to a lesser extent in other tissues 
(Kool et al., 1999b).
1.7.1.2.6 MRP1 and clinical multidrug resistance
The expression of MRP1 protein and/or mRNA has been detected in almost every 
tumour type examined, including both solid tumours (lung, gastrointestinal and 
urothelial carcinomas, neuroblastoma, glioma, retinoblastoma, melanoma, cancers of the 
breast, endometrium, ovary, prostate and thyroid) (Ito et al., 1998; Canitrot et al., 1998; 
Chan et al., 1997; Nanashima et al., 1999; Hipfher et al., 1999; Oshika et al., 1998; Loe 
et al., 1996), and hematological malignancies (Filipits et al., 1997; Abbaszadegan et al., 
1994; Loe et al., 1996b). Among the common tumour types, expression o f high levels of 
MRP1 is particularly frequent in the major histologic forms o f non-small cell lung 
cancer (Nooter et al., 1996; Giaconne et al., 1996; Hipfner et al., 1999).
A number o f authors have reported that the expression levels o f MRP 1 are o f prognostic 
significance. Chan et al. (1997), reported that MRP1 expression in retinoblastoma (RB) 
was associated with the rare failures o f chemotherapy in RB. Canitrot et al. (1998), and 
Campling et al. (1997), reported that the expression o f MRP1 mRNA was a negative 
determinant o f the chemotherapeutic response of untreated Small Cell Lung Cancer 
(SCLC). MRP1 was also reported by Ito et al. (1999), to have prognostic value in 
primary breast cancer and might be used as one of the markers for poor prognosis in 
patients with this disease (Huang et al., 1998). Oda et al. (1996), also suggested a link 
between MRP1 expression and poor prognosis in Ewings sarcoma and malignant 
peripheral neuroectodermal tumour o f bone (MPNT).
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1.7.1.2.7 Additional genes thought to be associated with MDR
BCRP was first identified in the human MCF-7 breast cancer cell line which displayed 
an ATP-dependant reduction in intracellular anthracycline accumulation (Doyle et al.,
1998). Since then, it has been characterised and identified in a number o f human tissues 
(Maliepaard et al., 2001a). BCRP mRNA encodes a protein o f 663 amino acids which 
was also identified as a member o f the ABC family o f transporters that encompass the 
MRP homologues. A previous study by Ma et al. (1998) had identified a novel 
mechanism of multidrug resistance in the ovarian cancer cell line IGROV1 selected in 
topotecan. Further research (Maliepaard et al., 1999; Scheffer et al., 2000; Yang et al., 
2000) confirmed the expression o f the BCRP gene in the IGROV1 and MCF-7 cell lines 
following selection in topotecan. Scheffer et al. (2000) also localised the protein in the 
plasma membrane o f the IGROV1 cell line. BCRP expression has also been observed in 
cell lines following exposure to mitoxantrone (Maliepaard et al., 1999; Ross et al.,
1999), and the BCRP gene is sometimes referred to as the Mitoxantrone resistance gene 
(MXR). Further studies identified expression of BCRP in a flavopiridol-resistant MCF- 
7 subline (Robey et al., 2001).
Expression o f BCRP has been linked with resistance to mitoxantrone, methotrexate 
(MTX), adriamycin, daunorubicin bisantrene and topotecan (Doyle et al., 1998; Volk et 
al., 2000; Litman et al., 2000). A clinical study (Ross et al., 2000), observed a 
sufficiently high level o f BCRP gene expression in patients with AML to warrant 
additional investigation. Little is currently known o f how BCRP mediates cross­
resistance to these drugs.
Despite its close sequence similarity to mdr-1 (75%) (reviewed in Klein et al., 1999), 
mdr-3 is not implicated in multidrug resistance. However, the absence of mdr-3 protein 
expression has been identified as the cause o f progressive familiar intrahepatic 
cholestasis in both rats and humans (PFIC2 and 3, respectively) (reviewed in Klein et 
al., 1999). Mdr-3 is a phospholipid (phosphatidyl choline) translocator (van Helvoort et 
al., 1996), with a highly specific expression pattern in the canalicular membrane of the 
liver (Smith et al., 1994).
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1.7.2 COX-1 and COX-2
As outlined in Section 1.7.1, COX-1 and COX-2 refer to two isoforms of the enzyme 
prostaglandin endoperoxide synthase (PGE). This enzyme transforms arachidonic acid, 
liberated by phospholipase A2, to prostaglandins. PGE is a dual function enzyme, 
incorporating both a cyclooxygenase and a peroxidase activity (Vane et al., 1996).
Human COX-1, a 22kb gene, is a membrane bound hemo-and glyco-protein with a 
molecular weight o f 71kD. It is found in greatest amounts in the endoplasmic reticulum of 
prostanoid-forming cells. The three-dimensional structure, determined by Picot et al. 
(1994), shows that COX-1 comprises three independent folding units: an epidermal growth 
factor like domain, a membrane binding motif and an enzymatic domain. COX-1 is 
constitutively produced and is believed to be involved in regulating normal cellular 
processes, such as gastro intestinal (GI) cytoprotection, vascular homeostasis, and renal 
function. The concentration of the enzyme remains largely stable, but small increases of 
expression of two-to four-fold can occur in response to stimulation with hormones or 
growth factors (DeWitt et al., 1991).
In contrast, COX-2, identified by Fu et al. (1990), as an inducible synthase and a distinct 
isoform of cyclooxygenase encoded by a different gene from COX-1, is undetectable in 
most normal tissue. However, the expression of COX-2 can be increased dramatically after 
exposure of fibroblasts, vascular smooth muscle or endothelial cells to growth factors, 
hypoxia, phorbol esters or cytokines and by lipopolysaccharides (LPS) in 
monocytes/macrophages (Bolten, 1998, Vane et al., 1996). The human COX-2 gene is 
8.3kb in size, smaller than COX-1 but with a similar molecular weight. The amino acid 
sequence of its cDNA shows only a 60% homology with COX-1. COX-2 and COX-1 also 
have similar active sites for the attachment of arachidonic acid or NSAIDs, although the 
active site of COX-2 is larger than that of COX-1 and can accept a wider range of 
structures as substrates (Meade et al., 1993). Both enzymes have similar Km and Vmax 
values for the metabolism of arachidonic acid. (Meade et al., 1993).
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1.7.3 Introduction to translation initiation
Initiation is the primary target for the control o f translation, with the binding o f the 
ribosomal pre-initiation complex to the mRNA and the scanning process being 
controlled through a number o f mechanisms including RNA-binding repressors, 
modulation o f the Initiation Factors involved, and the effects o f secondary structure 
adopted by a particular mRNAs 5’-UTR.
The basic process o f translation initiation involves the binding o f the 40S Ribosomal 
subunit complexed with a charged initiator tRNA (tMet) to the 5’ Cap from where it 
scans the 5 ’ UTR in search o f an in-frame AUG start codon. tRNAs (transfer RNAs~) 
carry the Amino Acids to the actively translating ribosome during protein synthesis. The 
Eukaryotic signal to begin translation is an AUG codon in a particular context, and as 
such, all proteins begin with a Methionine (encoded by AUG and recognised by t-Met) 
that is later cleaved. The 40S ribosomal subunit is guided onto the correct region o f the 
mRNA to begin translation by numerous Initiation Factors, known as elFs (eukaryotic 
translation Initiation Factors), that catalyse various stages o f the binding, scanning and 
initiation processes (Kleijn, 1998).
1.7.3.1 Eukaryotic Initiation Factor 2 (eIF-2)
With their individual roles the eukaryotic translation Initiation Factors (elFs) act in 
concert to assemble the ribosome on the 5 ’ end o f the mRNA and begin the scanning 
process in search o f the initiator AUG codon. eIF-2 recruits the initiator tRNA (Met- 
tRNA) and conducts it as a M et tRNA-eIF2-GTP complex to the 40S Ribosomal 
subunit, to form the 43S pre-initiation complex (Colhurst el al., 1987; Altman and 
Trachsel, 1993).
eIF-2 is a multimeric protein comprising of three dissimilar polypeptide chains, a , p and 
y, which are thought to remain associated throughout the process o f initiation (Proud et 
al., 1991). The a-subunit is the site for regulation of eIF-2 activity, via phosphorylation. 
The P-subunit is involved in the interaction of eIF-2 with eIF-2B, which recycles eIF-2
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via GDP-nucleotide exchange, and with eIF-5, which catalyses GTP-hydrolysis to 
release the tRNA during initiation. The y-subunit is the actual “carrier” o f the GTP/GDP 
molecule (Asano and Hinnesbuch, 1998).
1.7.3.2 Eukaryotic Initiation Factor 4E (eIF-4E)
eIF4E, otherwise known as eIF4a or the small cap binding protein, binds directly to the 
5' 7-Methyl-Gppp cap in an ATP-dependent manner, and is thought to be the first factor 
to interact with the mRNA to initiate translation. eIF-4E is a 25 kDa phospho-protein 
responsible for Cap-binding specificity in eIF-4F complexes during eukaryotic 
translation initiation events. eIF-4E consists o f a single a,p domain which contains 8  
antiparallel p strands forming a curved P sheet (Sonenberg and Gingras, 1998). 
Phosphorylation o f eIF-4E occurs as part o f the eIF-4F complex (Tauzon et al., 1990) 
greatly enhancing and stabilising its association with the cap (Minich et al., 1994).
eIF-4E is widely accepted as the limiting factor in translation initiation, particularly for 
mRNAs with complex 5’ UTRs (Hentze, 1997). It is present in molar levels 
significantly lower than that o f other initiation factors (Sonenberg, 1996). It is the most 
specifically targeted mRNA-binding elF and is an essential component of the 
cytoplasmic cap-binding complex. The cap-binding activity o f the elF-4E peptide is 
thought to reside in a highly evolutionarily conserved placement o f tryptophan residues 
in both yeast and mammals (Altmann et al., 1988). This factor therefore plays a critical 
role in the regulation o f translation, particularly o f specific mRNA species, and the 
levels and activity o f eIF-4E are critical to the control o f cellular proliferation and 
differentiation (Jaramillo et al., 1991). A rather novel and as-yet to be proven additional 
function for eIF-4E has been suggested, namely that it may play some part in the 
transport o f mRNAs from the nucleus (Rom et al., 1998).
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1.7.4 Introduction to transcription factors
1.7.4.1 c-myc
c-myc is a member o f a multigene family consisting o f two other members, L -myc 
(identified in SCLC) and N -myc (expressed in neuroblastomas) (Erisman and Astrin, 
1988). It is one of the immediate early growth response genes and is rapidly, but 
transiently, induced in quiescent cells upon mitogenic stimulation; mRNA and protein 
levels are sustained throughout the cell cycle in proliferating cells (Evan et al., 1992). 
The gene is frequently seen translocated to the heavy chain locus o f the 
immunoglobulin gene in Burkitt’s lymphoma suggesting that c-myc has a primary role 
in the transformation of some human haematopoietic cells (Watt et al., 1983).
The c-Myc protein is a member o f the nuclear oncoproteins and acts as a transcription 
factor to promote cell proliferation and has an elusive role to play in control o f the cell 
cycle (Pardee, 1989). C-Myc usually stimulates proliferation, but if  growth is inhibited 
by other factors, Myc-induced apoptosis will occur. Myc therefore has a dual role to 
play in the cell: myc stimulates growth in the presence o f survival factors and induces 
apoptosis in the presence o f growth inhibiting factors (Mihich and Schimke, 1994).
Expression of the c-myc gene occurs in most cell types and is detectable in almost all 
proliferating cells and is vital for normal cell development. Deregulated c-myc 
expression in found in a wide variety of malignancies. Overexpression of both the gene 
and protein has been associated with early relapse and poor prognosis in clinical breast 
tumours (Kreipe et al., 1993).
1.7.5 Introduction to cell adhesion and cell adhesion molecules (CAMs)
Cell adhesion is crucial for the assembly o f individual cells into the three-dimensional 
tissues o f animals. Cells do not simply “stick together” to form tissues, but rather are 
organised into very diverse and highly distinctive patterns. A variety o f cell adhesion 
mechanisms are responsible for assembling cells together and, along with their
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connections to the internal cytoskeleton, determine the overall architecture o f the tissue. 
Thus, cell adhesion systems should be regarded as mechanisms that help translate basic 
genetic information into the complex three-dimensional patterns o f cells in tissues 
(Gumbiner, 1999). The expression on the surface o f cells o f various types o f cell 
adhesion molecules influences cell-cell sorting, tissue architecture and cellular 
differentiation. Cell adhesion molecules carry out these functions by binding other cell 
adhesion molecules or by binding to the extra-cellular matrix (ECM).
The ability to recognise similar (homotypic) or dissimilar (heterotypic) cell types or 
ECM proteins is mediated by four classes o f membrane receptor; integrins, selectins, 
cadherins and the immunogloblulin cell adhesion molecules. All these CAMs are in 
effect membrane receptors whose extracellular domains bind ligands that generate 
conformational change in the cytoplasmic tail, enabling it to bind cytoplasmic proteins 
(Gumbiner, 1999). These adaptor molecules link with various signalling pathways that 
influence cell proliferation, migration, differentiation and apoptosis. Cell-cell adhesion 
seems to be a static process but dynamic rearrangements o f adhesion should occur 
during the various cellular processes, such as epithelial cell scattering (metastasis), 
dispersal of cancer cells, or differentiation (Kaibuchi et al., 1999).
1.7.5.1 E-cadherin
There are at least twelve known members o f the cadherin family, which are divided into 
subclasses, sharing a common basic structure. The three main subclasses are E-Cadherin 
(found on many types o f epithelial cells), P-Cadherin (found in the placenta and 
epidermis), and N-Cadherin (found on nerve, heart and lens cells) (Takeichi, 1991). 
Cadherins are the “glue” by which adjacent epithelial cells are attached to each other; 
they are important in determining the pattern o f cells in a tissue. They function as Ca2+- 
dependent homophilic cell-cell binding proteins (Nose et al., 1990). They are believed 
to modulate differentiation by co-signalling with other cell adhesion molecules e.g. E- 
cadherin and the integrins act together to modulate glandular differentiation in 
colorectal cells (Pignatelli et al., 1992)
5 3
The cadherin molecules interact with the actin cytoskeleton via the catenins (a, P, and 
y) located in the focal adhesion complexes (Ozawa et al., 1990). The cytoplasmic 
domain o f E-cadherin interacts with P-catenin or y-catenin directly, which then interact 
with oc-catenin, which has been thought to directly or indirectly link the complex 
composed of E-cadherin, P-catenin and oc-catenin with the actin cytoskeleton. Through 
these interactions with the catenins to the cytoskeleton, the cadherins form cell junctions 
in epithelial cells (Ranscht, 1994). A disruption o f these catenins leads to a disruption o f 
cadherin function (Ozawa et al., 1990).
Down-regulation o f the E-cadherin/catenin complex has been implicated in oesophageal 
cancer (Kadowaki et al., 1994), gastric cancer (Streit et al., 1996) and colon cancer 
(Vermeulen et al., 1995). At present, little is known about cadherin expression in SCLC 
(Shimoyama et al., 1989). E-cadherin suppression is also associated with various stages 
o f differentiation and development (Christofori and Semb, 1999).
1.7.5. 2  a-catenin
The interaction of cadherin-catenin complex with the actin-based cytoskeleton through 
a-catenin is indispensable for cadherin-based cell adhesion activity (Imamura et al.,
1999). Fusion studies involving the COOH portion o f a-catenin and mutant non­
functional E-cadherin as expressed in mouse L cells (Nagafuchi et al., 1994), indicated 
that a-catenin, especially the COOH-terminal half, is crucial for the full cadherin-based 
cell adhesion activity as well as cadherin-cytoskeleton interaction.
1.7.5.3 p-catenin
P-catenin, the vertebrate homologue of armadillo protein in Drosophila, is a 
multifactorial protein involved in two apparently independent processes; cell-cell 
adhesion and signal transduction via transcriptional activation. The role o f P-catenin in 
adhesion has already been outlined; in the adherens junctions o f epithelial cells, the 
cytoplasmic domain o f E-cadherin organises a peripheral protein complex, including a -
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catenin, P-catenin and y-catenin that is necessary for adhesion to occur. Recently, 
studies have implicated mutations in the P-catenin gene with a characteristic phenotype 
in ovarian malignant transformation; endometroid ovarian carcinoma (Palacios and 
Gamallo, 1998).
1.7.6 Introduction to apoptosis
Apoptosis is a mechanism of cell death whereby a cell actively participates in its own 
destruction. “Apoptosis” was a term used by Kerr et al. (1972), to describe a series of 
morphological changes shared by dying cells in various biological systems. These 
morphological changes include cell shrinkage, membrane blebbing, chromatin 
condensation and endonucleolytic cleavage o f DNA into nucleosomal-length fragments, 
and finally the production o f budding “apoptotic-bodies” . The process does not induce 
an inflammatory response.
Apoptosis is regulated by many genes in normal tissues, some o f which are normal 
cellular counterparts o f genes influential in the transformation o f normal to malignant 
cells. The protein products o f these genes can influence cell viability either by 
promoting or inhibiting cell death and it is the balance or interplay o f this myriad of 
proteins which influences a cell’s susceptibility to death.
1.7.6.1 The Bcl-2 Gene family:
The study o f the Bcl-2 family as genes that influence cell viability and death 
independent o f cell division represents a vast area o f research in the whole field of 
cancer biology. Analysis by Tsujimoto and Croce (1986) indicated that the Bcl-2 gene 
consists of at least two exons that produce three transcripts o f 8.5kb, 5.5kb and 3.5kb 
long mRNAs. The Bcl-2 cDNA sequence was analysed, from which two protein 
products were postulated; Bcl-2a (239 amino acids) and Bcl-2p (205aas), that differ 
only at their carboxy terminus. The Bcl-2a mRNA encodes a 26kDa protein that is 
homologous to the hypothetical Epstein-Barr virus protein BHFR1 (Cleary et al., 1986).
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The anti-apoptotic activity of the Bcl-2 gene has been reviewed by Reed (1994). 
Evidence has been found to suggest that Bcl-2 functions as an apoptosis-repressing gene 
primarily by inhibiting the cell death function o f pro-apoptotic proteins such as BAX 
(Hunter and Parslow, 1996). Craig (1995) also indicated that Bcl-2 may inhibit 
apoptosis by altering Ca2+ fluxes through intracellular organelles. As calcium can 
function as a second messenger in intracellular signalling, this may be how Bcl-2 exerts 
its effect on cell death signal transduction pathways.
A number o f other genes have been discovered recently as members o f this group; 
among them, Bcl-x (Boise et al., 1993), BAX and BAG (Takayama et al., 1995). These 
proteins can homo- or hetero-dimerise and the balance o f the pro- or anti-apoptotic 
effect determines whether a cell should live or die.
Bcl-2 has been found to associate in vivo with a Bcl-2-associated X protein (BAX). 
BAX was identified as a 21kDa protein with extreme amino acid homology with Bcl-2, 
and which forms homo- or hetero-dimers with Bcl-2 in vivo. When BAX predominates, 
apoptosis is increased and the repressive activity o f Bcl-2 is countered. Three alternative 
transcripts o f the gene have been identified - a , (3 and y. BA Xa codes for the 21kDa 
protein product o f the gene. RNA splicing may act as a differential regulator o f BAX 
activity and localisation with BAX(3 providing an additional level o f  regulation. No 
function for BAXy has yet been elucidated. BAX was first reported to act as a tumour 
suppressor (Yin et al., 1997). The group observed that p53-induced expression of BAX 
stimulated apoptosis in slow-growing mouse tumours. An antisense oligonucleotide 
directed against the gene in a rat sympathetic neuron cell line promoted growth of the 
cell line (Gillardon et al., 1996). Expression o f BAX has also been correlated with 
intracellular accumulation o f taxol in SW626 ovarian cancer cells (Strobel et al., 1998). 
Expression o f the gene has also been correlated with differential regulation in tumours 
o f the central and peripheral nervous system (Krajewski et al., 1997) and in uterine 
cancer (Saitoh et al., 1999).
Boise et al. (1993), isolated the Bcl-x gene from libraries by hybridisation with a Bcl-2 
probe. Two distinct Bcl-x mRNAs can form as a result o f alternative splicing -  the long 
form Bcl-xL, (233 amino acids) and the short form, Bcl-xs (170 amino acids). The
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shorter form lacks two domains, BH1 and BH2, commonly found in most proteins of 
the Bcl-2 family. Bcl-x can function as a Bcl-2-independent regulator o f apoptosis but 
both transcripts work in a reciprocal fashion to one another, i.e. Bc1-xl confers 
resistance to apoptosis (anti-apoptotic) whereas Bcl-xs, in a dominant manner, prevents 
increased levels o f Bcl-2 from inducing apoptosis. Both Bc1-xl and Bcl-xs can form 
heterodimers and/or multidimers with Bcl-2 (Sato et al., 1994). A heteromeric complex 
between Bcl-xs and Bcl-2 is normally inactive, whereas Bcl-xL normally mediates 
apoptosis by binding to the same downstream regulators o f apoptosis as Bcl-2. To date, 
Bcl-x expression has been detected in a number o f clinical studies, including primary 
colorectal cancers (Krajewska et al., 1996) and esophageal squamous cell carcinoma 
(Takayama et al., 2 0 0 1 ).
BAG (or Bag-1) was identified by Takayama et al. (1995). The group found that the 
BAG-1 protein shares no significant homology with Bcl-2 or other Bcl-2 family 
proteins, which can form homo- and heterodimers. In gene transfer experiments using a 
human lymphoid cell line, Jurkat, coexpression o f BAG-1 and Bcl-2 provided 
markedly increased protection from cell death induced by several stimuli, including 
staurosporine, anti-Fas antibody, and cytolytic T cells, relative to cells that contained 
gene transfer-mediated elevations in either BAG-1 or Bcl-2 protein alone. BAG- 
transfected 3T3 fibroblasts also exhibited prolonged cell survival in response to an 
apoptotic stimulus. These findings indicated that Bag-1 represented a novel type o f anti­
cell death gene and suggest that some routes of apoptosis induction previously ascribed 
to Bcl-2-independent pathways may instead reflect a need for the combination o f Bcl-2 
and BAG-1. Further studies Takayama et al. (1997) showed that the protein inhibits 
expression o f the heat-shock protein Hsp70/Hsc70 and thus may provide a link between 
cell signalling, cell death and the stress response. BAG-1 protein was also observed to 
inhibit retinoic acid (RA)-induced apoptosis in MCF-7 breast cancer cells (Liu et al.,
1998), and expression of the gene was correlated with cell survival and enhancement o f 
Bcl-2 activity in hydridoma cells (Terada et al., 1997).
5 7
1.7.6.2 Introduction to other genes involved in modulating apoptosis
1.7.6.2.1 Survivin
Survivin is the most recently discovered, and also the smallest member o f a group of 
anti-apoptotic genes (IAPs). It consists o f 12 amino acids and has a molecular weight of
16.4 kDa. In contrast to the other described IAPs, Survivin displays regulation at the 
transcriptional level. It is abundant during development in proliferating tissues and in 
tissues in which apoptosis is evident, but is low or absent in terminally differentiated 
adult tissues (Kobayashi et al., 1999). Most importantly, Survivin is upregulated in a 
number o f common cancers and transformed cell lines (Ambrosini et al., 1997). 
Additional evidence suggesting that Survivin may play an important anti-apoptotic role 
in cell proliferation and cancer progression comes from the findings that Survivin is 
upregulated in G2/M (Li et al., 1998; Kobayashi et al., 1999) and that it is associated 
with spindle microtubules and seems to require this association for anti-apoptotic 
activity at least with respect to the apoptosis inducer taxol (Li et al., 1998). Also, 
overexpression o f the gene encoding Survivin blocks cell death in response to a number 
o f different stimuli (Li et al., 1998; Kobayashi et al., 1999) and Survivin binds, 
although not well, to processed forms o f caspase-3 and caspase-7 (Kobayashi el al.,
1999). An antisense oligonucleotide directed at Survivin promoted caspase activation 
and cell death in HeLa cells (Ambrosini et al., 1998).
1.7.6.2.2 MRIT
There is a paucity o f information on the pro-apoptotic MRIT gene. MRIT or “MACH- 
related inducer o f toxicity” has been observed to interact with B c1-xl and FLICE 
(MACH) simultaneously and independently (Han et al., 1997). MACH is a large 
prodomain caspase that links the aggregated complex of the death domain receptors of 
the tumor necrosis factor receptor family to downstream caspases which trigger 
apoptosis. However, unlike FLICE, the C-terminal domain of MRIT lacks the caspase 
catalytic consensus sequence (Han et al., 1997). This group also showed that MRIT 
associates with caspases possessing large and small prodomains (FLICE, and
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CPP32/YAMA), as well as with the adaptor molecule FADD. Thus, MRIT is a 
mammalian protein that interacts simultaneously with both caspases and a Bcl-2 family 
member. Thus the gene may function as a crucial link between cell survival and cell 
death pathways in mammalian cells.
1.7 .6 .2.3 B A P
BAP (or Bap31) has been defined as a human Bcl-2-interacting protein (Ng et al.,
1997). It is a 28-kD (p28) polytopic integral protein o f the endoplasmic reticulum 
whose COOH-terminal cytosolic region contains overlapping predicted leucine zipper 
and weak death effector homology domains (anti-apoptotic), flanked on either side by 
identical caspase recognition sites. Ng et al. (1997) also showed that Bap is part o f a 
complex that includes Bcl-2/Bcl-XL and procaspase-8 . Bax, a pro-apoptotic member of 
the Bcl-2 family, does not associate with the complex; however, it prevents Bcl-2 from 
doing so. In the absence of elevated Bcl-2 levels, apoptotic signaling by adenovirus 
E l A oncoproteins promote cleavage of p28 at the two caspase recognition sites. The 
resulting NH2-terminal p20 fragment induces apoptosis when expressed ectopically in 
otherwise normal cells. Taken together, the results suggest that Bap is part o f a complex 
in the endoplasmic reticulum that mechanically bridges an apoptosis-initiating caspase, 
like procaspase-8 , with the anti-apoptotic regulator Bcl-2 or B c1-xl (Ng and Shore,
1998).
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1.8 DNA microarrays
Nucleic acid microarrays provide a powerful methodology for studying biological 
systems on a genomic scale. Microarray technology has enabled the modem science of 
gene expression profiling in which the expression state o f hundreds to thousands of 
genes may be summarised in a single experiment. This high throughput analysis o f gene 
expression has revolutionised traditional methods o f basic science research, disease 
investigation, drug discovery and toxicity testing.
A standard microarray consists o f hundreds o f long oligonucleotides immobilised by 
UV irradiation on a plastic, glass or membrane support. Each gene on a microarray is 
represented by one o f these oligos. Standard oligos are 80 bases in length. This length is 
chosen to combine the high hybridisation efficiency of a lengthy cDNA fragment with a 
short oligo's ability to distinguish between different genes. These microarrays are 
probed with radiolabelled cDNA generated from the target RNA samples o f interest. 
Once hybridised, excess label is rinsed away and the microarray is examined using 
specific instruments and software. Computer analysis specially designated for a selected 
microarray then decides if alterations in gene expression have been observed, and if  so, 
by how much. With an optimised system, the examination o f expression o f thousands of 
genes may be examined in any system.
Although the technology is relatively novel, it has been extensively utilised already in a 
large number o f studies. It has recently been used in lung cancer cell lines to examine 
expression of apoptotic gene expression (Kannan et al., 2001) as well as general genetic 
profiling o f squamous lung cell carcinomas (Wang et al., 2000) and in bronchial 
epithelial cells (Hellmann et al., 2001). However, this is just a small number o f the 
instances o f usage o f the technology; a current literature search revealed over 3500 
published articles featuring microarray analysis.
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1.9 Aims o f thesis
Previous work by a number o f researchers in this laboratory had identified that exposure 
o f the lung epithelial cell lines DLKP and A549 to the differentiating agent 5 ’-Bromo-2- 
deoxyuridine (BrdU) induced expression of a number o f diverse proteins including 
cytokeratins- 8  and -18, a 2Pi integrin, cell-adhesion protein Ep-CAM, eukaryotic 
initiation factor eIF-4E and the transcription factors c-myc and YY1. The mRNA levels 
for ot2 integrin was increased in the DLKP cells following exposure to BrdU, However, 
mRNA expression levels for the other proteins remained unaffected by exposure to 
BrdU (P. Meleady, PhD. Thesis, 1997).
As BrdU has been postulated to integrate into the DNA of exposed cells, it was 
expected that the agent exerted at least part o f  its differentiation and gene-inducing 
effects transcriptionally. In order to investigate this hypothesis, it was necessary to 
elucidate the effects o f BrdU on gene expression levels in differentiating cells. As there 
is a significant dearth o f evidence for transcriptional regulation o f gene expression by 
BrdU, it was decided to examine the expression o f several genes in BrdU-differentiated 
DLKP and A549 cells. Performing these experiments formed the starting point for the 
project described in this thesis.
A transcriptional model o f BrdU-induced gene expression does not currently exist. In 
order to create a potential model, a numbers o f questions needed to be answered;
1. What genes are induced by BrdU in differentiated cells?
2. Are there any common factors which may mediate BrdU-induced transcriptional 
upregulation in these cells?
To address the first question, RT-PCR was chosen as the initial method of analysis, 
although DNA microarray analysis was included at a later stage. This latter method 
would be the preferred initial gene identification procedure for future studies, due to the 
wide number o f genes which may be assayed for expression rapidly and easily. The type 
o f genes chosen for examination were selected from functionally diverse groups, some 
of whom have already been shown to be induced during differentiation. Several genes 
were identified as being affected, the bulk of these in the DLKP cell line.
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Once several genes identified affected by BrdU had been identified, it was hypothesised 
that BrdU may mediate induction of gene expression in DLKP by utilising a common 
transcription factor, or group of factors. 5’ promoter analysis o f several o f these affected 
genes was carried out and which identified a number o f common transcription 
recognition sites shared by all genes. RT-PCR analysis on these common factors was 
then carried out to investigate if  expression o f these factors was affected in BrdU- 
treated DLKP.
The DLKP cell line was also exposed to a variety o f chemotherapeutic drugs both in 
short-term assays (two weeks or less) and in the selecting-out of drug-resistant DLKP 
sublines. The gene expression profiles o f these cells was then examined by RT-PCR.
Gene expression studies by RT-PCR was also carried out on a number o f human lung 
tumour tissue samples to identify potential clinically relevant gene expression markers 
in lung cancer.
Finally, the use o f gene therapy techniques to modify expression o f the MRP1 gene in a 
subline o f DLKP, DLKP-SQ was carried. This was attempted using both antisense and 
ribozymes to downregulate MRP1 gene and protein expression. This was carried out to 
investigate if  expression o f this potentially clinically important gene could be decreased 
in lung cancer cell lines by such methods.
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Section 2.0
2.1 Preparation for cell culture
2.1.1 Water
Ultrapure water was used in the preparation o f all media and lx  solutions. Pre­
treatment, involving activated carbon, pre-filtration and anti-scaling was first carried 
out. The water was then purified by a reverse osmosis system (Millipore Milli-RO 10 
Plus, Elgastat UHP). This system is designed to produce purified water from a suitable 
municipal water supply. The system utilises a semi-permeable reverse osmosis 
membrane to remove contaminants from the feed water. This results in water which is 
low in organic salts, organic matter, colloids and bacteria with a standard o f 12-18 
MQ/cm resistance.
2.1.2 Glassware
Solutions pertaining to cell culture and maintenance were prepared and stored in sterile 
glass bottles. Bottles (and lids) and all other glassware used for any cell-related work 
were prepared as follows; all glassware and lids were soaked in a 2 % (v/v) solution of 
RBS-25 (AGB Scientific) for at least 1 hour. This is a deproteinising agent which 
removes proteinaceous material from the bottles. Following scrubbing and several 
rinses in tap water, the bottles were washed twice by machine (Miele G7783 
washer/disinfecter) using Neodisher GK detergent and sterilised by autoclaving. Waste 
bottles containing spent medium from cells were autoclaved, rinsed in tap water and 
treated as above. Glassware used for large-scale cell production were treated specially, 
as outlined in Section 2.2.4.1.
2.1.3 Sterilisation
Water, glassware and all thermostable solutions were sterilised by autoclaving at 121 °C 
for 20 min under 15 p.s.i. pressure. Thermolabile solutions were filtered through a
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0.22|am sterile filter (Millipore, millex-gv, SLGV-025BS). Low protein-binding filters 
were used for all protein-containing solutions. Acrodisc (Pall Gelman Laboratory, 
C4187) 0 .8 /0 .2 [im filters were used for non-serum/protein solutions.
2.1.4 Media Preparation
The basal media used during routine cell culture were prepared according to the 
formulations shown in Table 2.1.1. lOx media were added to sterile ultrapure water, 
buffered with HEPES (Sigma, H-9136) and NaHCC>3 (BDH, 30151) and adjusted to a 
pH of 7.45 - 7.55 using sterile 1.5M NaOH and 1.5M HC1. The media were filtered 
through sterile 0.22 (am bell filters (Gelman, 121-58) and stored in 500ml sterile bottles 
at 4°C. Sterility checks were carried out on each 500ml bottle o f medium as described 
in Section 2.2.8.
The basal media were stored at 4°C up to their expiry dates as specified on each 
individual lOx medium container. Prior to use, 100ml aliquots o f basal media were 
supplemented with 2mM L-glutamine (Gibco, 25030-024) and 5% foetal calf serum 
(PAA laboratories, A15-042) and this was used as routine culture medium. This was 
stored for up to 2 weeks at 4°C.
Table 2.1.1 Preparation of basal media
DMEM (Dulbecco's 
Modified Eagle Medium) 
(mis)
(Sigma, D-5648)
Hams FI 2 (mis) 
(Sigma, N-6760)
1 OX Medium 500 Powder
Ultrapure H20  (UHP) 4300 4700
1M HEPES1 1 0 0 1 0 0
7.5% N aH C03 45 45
1 The w eight equivalent o f  1M N - (2-H ydroxyethyl) piperazine-N '- (2-ethanesulfonic acid) (HEPES) was 
dissolved in  an 80%  volum e o f  ultra-pure water and autoclaved. The pH  was adjusted to 7.5 w ith 5M  
NaOH.
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Ham’s F12 medium was supplemented with 5% FCS. For most cell lines, (DLKP, 
DLKP-A2B, DLKP-SQ, A549 and A549 C9) ATCC (Ham’s F12/ DMEM (1:1)) 
supplemented with 5% FCS and 2mM L-glutamine was routinely used. For the COR 
L23S/R cell lines, RPMI 1640 media (Gibco, 52400-025), was routinely used. This was 
supplied as a IX  stock and supplemented with 10% FCS and 2mM L-glutamine. Also, 
in order to maintain the strongly MRP 1-overexpressing character o f COR L23R, this 
cell line was fed once every two-three weeks with media containing Adriamycin at a 
concentration o f 0.2 (j,g/ml. For these cells, Adriamycin was dissolved in sterile distilled 
water at 500 fig/ml and aliquoted into 500 jj,1 aliquots. These could be stored for up to 
one year at -20°C. The working concentration o f Adriamycin in media was taken to be
0 . 2  (j,g/ml.
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2.2 Routine management o f cell lines
2.2.1 Safety Precautions
All routine cell culture work was carried out in a class II down-flow re-circulating 
laminar flow cabinet (Nuaire Biological Cabinet). Any work which involved toxic 
compounds was carried out in a cytoguard (Gelman). Strict aseptic techniques were 
adhered to at all times. Both laminar flow cabinets and cytoguards were swabbed with 
70% industrial methylated spirits (IMS) before and after use, as were all items used in 
the experiment. Each cell line was assigned specific media and waste bottles and only 
one cell line was worked with at a time in the cabinet which was allowed to clear for 
15min between different cell lines. The cabinet itself was cleaned each week with 
industrial detergents (Virkon, Antec. International; TEGO, T.H.Goldschmidt Ltd.), as 
were the incubators. A separate Laboratory coat was kept for aseptic work and gloves 
were worn at all times during cell work.
2.2.2 Cell Lines
The cell lines used during the course o f this study, their sources and their basal media
* . . .  2 requirements are listed in Table 2.2.1. Lines were maintained in 25cm flasks (Costar,
3050), 75cm2 flasks (Costar, 3075) or 175cm2 flasks (Nulge Nunc, 156502) at 37°C and
fed every two to three days.
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Table 2.2.1 Cell Lines used in study
Cell Line Source of Cell Line Media Cell Type
DLKP NCTCC ATCC* Poorly differentiated human 
Lung squamous carcinoma
DLKP-SQ NCTCC ATCC* Squamous clonal sub-population 
o f DLKP
A549 ATCC'1' ATCC* Human Lung adenocarcinoma
A549 C9 NCTCC ATCC* Clonal sub-population of A549
CORL23S Dr. P. Twentyman R P M I1640 Large cell lung cancer cell line
COR L23R Dr. P. Twentyman R P M I1640 Adr-resistant variant o f  CORL23 
(S)
ATCC* = Basal media consists o f a 1:1 mixture o f DMEM and Hams F12.
ATCC'1' = American Tissue Culture Collection.
NCTCC = National Cell and Tissue Culture Centre.
2.2.3 Subculture o f Adherent Lines
During routine subculturing or harvesting o f adherent lines, cells were removed from 
their flasks by enzymatic detachment.
Cell culture flasks were emptied o f waste medium and rinsed with a pre-warmed (37°C) 
trypsin/EDTA (Trypsin Versene - TV) solution (0.25% trypsin (Gibco, 25090-028),
0.01% EDTA (Sigma, E-5134) solution in PBS (Oxoid, BR14a)). The purpose o f this 
was to inhibit any naturally occurring trypsin inhibitor which would be present in 
residual serum. Fresh TV was then placed on the cells (4ml/25cm flask, 7ml/75cm 
flask or 10ml/175 cm2 flask) and the flasks incubated at 37°C until the cells were seen 
to have detached (5-10 min). The flasks were struck once, roughly, to ensure total cell 
detachment. The trypsin was deactivated by addition o f an equal volume of growth 
medium (i.e. containing 5% serum). The entire solution was transferred to a 20ml 
sterile universal tube (Greiner, 201151) and centrifuged at 1,200 rpm for 3 min. The 
resulting cell pellet was resuspended in pre-warmed (37°C) fresh growth medium,
6 8
counted (Section 2.2.5) and used to re-seed a flask at the required cell density or to set 
up an assay.
2.2.4 Subculture o f suspension cells
Large amounts o f cells (e.g. DLKP-SQ) were sometimes required for certain assays, 
such as for the Inside-Out Vesicle (IOV) assays described in Section 2.3.2. Although 
these cells are normally adherent, they are grown in suspension in order to maximise
o
cell growth in large numbers (e.g.l x 1 0  cells).
Cell lines growing in suspension did not require enzymatic detachment. Sometimes it 
was necessary to detach some o f the cells, which had become loosely adhered to the 
flask surface by gently tapping the flask. The cell suspension was removed to a sterile 
universal centrifuged at 1200rpm for 3 min and used to re-seed fresh flasks or set up 
assays. 500ml glass spinner flasks from Techne (Cambridge, UK) were used for the 
majority o f the Inside-Out Vesicle (IOV) culture experiments, although 500ml spinner 
flasks from Bellco (New Jersey, USA) were also used. Before glass spinner flasks 
could be used for any cell work they needed to be siliconised to prevent cells adhering 
to the glass.
2.2.4.1 Siliconisation o f spinner flasks
1. Spinner flasks were soaked in a warm solution o f 2% RBS-25 for one hour and then 
scrubbed vigorously with a scrubbing brush.
2. After treatment with RBS, the flasks were soaked in 0.1 M NaOH overnight. This is 
a depyrogenation step, which removes excess dimethyldichlorosilane from previous 
treatments and also any contaminating proteins.
3. Flasks were rinsed three times in tap water and three times in UHP water and were 
allowed to dry overnight @ 37°C.
4. A small amount (approximately 10-15mls) o f 2% dimethyldichlorosilane in 1,1,1 
trichloroethane (BDH, 33164) was added to the flasks. They were then rotated by 
hand to ensure even coating o f all surfaces (including the agitator and inside the
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lids). This procedure was carried out with care in a fume hood. The flasks were 
allowed to air-dry overnight, after which time they were rinsed three times in 
ultrapure (UHP) water. A small amount o f UHP water was left in the flask after the 
final rinse and the two side arm caps left a little open to allow steam ventilation 
during autoclaving.
5. Flasks were loosely covered with tin foil and sterilised at 121°C at 15 p.s.i. absolute 
pressure for 2 0  minutes.
2.2.4.2 Culturing in spinner flasks
1. After sterilisation, flasks were rinsed with pre-warmed medium and incubated at 
37°C ready for use.
2. Cells in the exponential phase o f growth were trypsinised in the normal manner. 
250ml o f medium containing cells harvested from a 175cm flask (Nulge Nunc, 
156502) were inoculated into the spinner.
3. Flasks were incubated at 37°C on a magnetic spinner unit (Techne, MCS-104L) at 
an average speed o f 25rpm. After a period o f 24 hours, the agitation rate was 
increased to 35rpm.
4. After three days o f growth in the spinner flasks, the cells were fed with 100 mis 
media. Cells were harvested after seven days at which time the cell number was 
approximately 1.5 x 108 cells per flask.
2.2.4.3 Sampling from spinner flasks
Sampling was carried out in the laminar flow cabinet making sure to keep the agitator 
rotating to ensure a representative sample from the spinner flask was being obtained. 
Usually, a 1ml sample was taken and centrifuged at 1200rpm for 3 minutes. The 
supernatant was then carefully removed and 1 ml of pre-warmed trypsin was added to 
the cells and incubated at 37°C for 5-10 minutes. The cells were pipetted gently to 
obtain a single cell suspension and counted as described in Section 2.2.5. Trypsin was 
added to try to break up cell aggregates.
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2.2.5 Cell Counting
Cell counting and viability determinations were carried out using a trypan blue (Gibco,
15250-012) dye exclusion technique.
1. An aliquot o f trypan blue was added to a sample from a single cell suspension in 
a ratio o f 1:5.
2. After 3 min incubation at room temperature, a sample o f this mixture was 
applied to the chamber o f a haemocytometer over which a glass coverslip had 
been placed.
3. Cells in the 16 squares o f the four outer comer grids o f the chamber were 
counted microscopically. An average number per comer was calculated with the 
dilution factor being taken into account and final cell numbers were multiplied 
by 104 to determine the number of cells per ml. The volume occupied by sample 
in chamber is 0 .1 cm x 0 .1 cm x 0 .0 1 cm i.e. 0 .0 0 0 1 cm3 (therefore cell number x 
104 is equivalent to cells per ml). Non-viable cells were those which stained 
blue while viable cells excluded the trypan blue dye and remained unstained.
2.2.6 Cell Freezing
To allow long term storage o f cell stocks, cells were frozen and cryo-preserved in liquid
nitrogen at temperatures below -180°C. Once frozen properly, such stocks should last
indefinitely.
1. Cells to be frozen were harvested in the log phase o f growth (i.e. actively
growing and approximately 50 - 70% confluent) and counted as described in 
Sections 2.2.5.
2. Pelleted cells were re-suspended in serum and an equal volume o f a
DMSO/semm (1:9, v/v) (Sigma, D-5879). This solution was slowly added 
dropwise to the cell suspension to give a final concentration o f at least 5x l0 6 
cells/ml. This step was very important, as DMSO is toxic to cells. When added 
slowly, the cells had a period o f time to adapt to the presence o f the DMSO, 
otherwise cells may have lysed.
3. The suspension was aliquoted into cryovials (Greiner, 122 278) which were
quickly placed in the vapour phase o f liquid nitrogen containers (approximately
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-80°C). After 2.5 to 3.5 hours, the cryovials were lowered down into the liquid 
nitrogen where they were stored until required.
2.2.7 Cell Thawing
1. Immediately prior to the removal o f a cryovial from the liquid nitrogen stores for 
thawing, a sterile universal tube containing growth medium was prepared for the 
rapid transfer and dilution o f thawed cells to reduce their exposure time to the 
DMSO freezing solution which is toxic at room temperature.
2. The cryovial was removed and thawed quickly under hot running water.
3. When almost fully thawed, the DMSO-cell suspension was quickly transferred 
to the media-containing universal.
4. The suspension was centrifuged at 1,200 rpm. for 3 min, the DMSO-containing 
supernatant removed, and the pellet re-suspended in fresh growth medium.
5. A viability count was carried out (Section 2.2.5) to determine the efficacy of the 
freezing/thawing procedures.
6 . Thawed cells were then placed into 25cm2 tissue culture flasks with 7mls o f the 
appropriate type o f medium and allowed to attach overnight.
7. After 24 hours, the cells were re-fed with fresh medium to remove any residual 
traces o f DMSO.
2.2.8 Sterility Checks
Sterility checks were routinely carried out on all media, supplements and trypsin used 
for cell culture. Samples o f basal media were inoculated either into TSB (Oxoid 
CM129) (incubated at 20-25°C) or thioglycollate broth (Oxoid, CM173) (and incubated 
at 30-35°C). Both sets were incubated at their specific temperature for up to 2 weeks 
checking for turbidity and sedimentation. TSB supports the growth of yeasts, moulds 
and aerobes, while thioglycollate supports the growth o f anaerobes and aerobes. Growth 
media (i. e. supplemented with serum and L-glutamine) were sterility checked at least 2 
days prior to use by incubating samples at 37°C and checking as before.
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2.2.9 Mycoplasma Analysis
Mycoplasma examinations were carried out routinely (at least every 3 months) on all 
cell lines used in this study.
2.2.9.1 Indirect Staining Procedure
In this procedure, Mycoplasma-negative NRK cells (a normal rat kidney fibroblast line) 
were used as indicator cells. These cells were incubated with supernatant from test cell 
lines and examined for Mycoplasma contamination. NRK cells were used for this 
procedure because cell integrity is well maintained during fixation. A fluorescent 
Hoechst stain was utilised which binds specifically to DNA and so will stain the nucleus 
o f the cell in addition to any Mycoplasma DNA present. A  Mycoplasma infection 
would thus be seen as small fluorescent bodies in the cytoplasm of the NRK cells and 
sometimes outside the cells.
1. NRK cells were seeded onto sterile coverslips in sterile Petri dishes (Greiner, 
633185) at a cell density o f 2x l0 3 cells per ml and allowed to attach overnight at 
37°C in a 5% CO2 humidified incubator.
2. 1ml o f cell-free (cleared by centrifugation at 1,200 rpm for 3 min) supernatant
from each test cell line was inoculated onto an NRK Petri dish and incubated as 
before until the cells reached 20 - 50% confluency ( 4 - 5  days).
3. After this time, the waste medium was removed from the Petri dishes, the
coverslips washed twice with sterile PBS, once with a cold PBS/Camoys (50/50) 
solution and fixed with 2ml o f Camoys solution (acetic acid:methanol-l:3) for 
1 0  mins.
4. The fixative was removed and after air drying, the coverslips were washed twice 
in deionised water and stained with 2 mis o f Hoechst 33258 stain (BDH) 
(50ng/ml) for 10 mins.
From this point on, work proceeded in the dark to limit quenching o f the fluorescent 
stain.
1. The coverslips were rinsed three times in PBS.
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2. They were then mounted in 50% (v/v) glycerol in 0.05M citric acid and 0.1M 
disodium phosphate.
3. Examination was carried out using a fluorescent microscope with a UV filter. 
Prior to removing a sample for mycoplasma analysis, cells should be passaged a min. of 3 
times after thawing to facilitate the detection of low level infection.
• Cells should be subcultured for 3 passages in antibiotic free medium (as antibiotics 
may mask the levels o f infection).
•  Cell lines routinely cultured in the presence o f drugs should be sub-cultured at least 
once in drug free medium before analysis (some drugs such as adriamycin lead to 
background level of autofluorescence).
• Optimum conditions for harvesting supernatant for analysis occur when the culture is 
in log-phase near confluency and the medium has not been renewed in 2-3 days.
2.2.9.2 Direct Staining
The direct stain for Mycoplasma involved a culture method where test samples were 
inoculated onto an enriched Mycoplasma culture broth (Oxoid, CM403) - supplemented 
with 20% serum, 10% yeast extract (Oxoid L21, 15% w/v) and 10% stock solution 
(12.5g D-glucose, 2.5g L-arginine and 250mls sterile-filtered UHP). This medium 
optimised growth of any contaminants and incubated at 37°C for 48 hours. Sample o f 
this broth were streaked onto plates o f Mycoplasma agar base (Oxoid, CM401) which 
had also been supplemented as above and the plates were incubated for 3 weeks at 37°C 
in a CO2 environment. The plates were viewed microscopically at least every 7 days and 
the appearance o f small, “fried egg” -shaped colonies would be indicative of a 
mycoplasma infection.
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2.3 Specialised techniques in cell culture
2.3.1 Miniaturised in vitro toxicity assays
2.3.1.1 In vitro toxicity assay experimental procedure
Due to the nature o f the compounds tested in the assays, precautions were taken to limit 
the risks involved in their handling and disposal. All work involving toxic compounds 
was carried out in a Gelman “Cytoguard” laminar air flow cabinet (CG Series). All 
chemotherapeutic drugs used by this researcher were stored and disposed o f as 
described in Table 2.3.1. A number o f additional drugs were used by Dr. Yizheng Liang 
in the selecting-out o f drug-resistant DLKP cell lines (Section 3.3).
Table 2.3.1 Chemotherapeutic drugs used in study
Cytotoxic drug Supplier Inactivation Storage
Vinblastine David Bull 
Laboratories Ltd.
Autoclave Store at 4UC
Vincristine David Bull 
Laboratories Ltd.
Autoclave Store at 4°C
Adriamycin Farmitalia Hyperchlorite inactivation 
followed by autoclaving
Store at 4°C
VP16 Bristol-Meyers squib, Incineration Store at RT
(Etoposide) Pharm. Ltd.
Cisplatin David Bull 
Laboratories Ltd.
Incineration Store at RT
Taxol Bristol-Meyers squib, 
Pharm. Ltd.
Incineration Store at 4°C
1. Cells in the exponential phase o f growth were harvested by trypsinisation as 
described in Section 2.2.3.
2. Cell suspensions containing lxlO 4 cells/ml were prepared in cell culture medium. 
Volumes of 100 (_ils o f these cell suspensions were added in to 96 well plates
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(Costar, 3599) using a multichannel pipette. The plates were divided so that each 
variable was set up with 8  repeats and 12 variables per plate. A control lane, one to 
which no drug would be added, was included on all plates. Plates were agitated 
gently in order to ensure even dispersion o f cells over a given well. Cells were 
incubated overnight at 37°C in an atmosphere containing 5% CO2 .
3. Cytotoxic drug dilutions were prepared at their final concentration in cell culture
medium. The plates were emptied o f media and 100 pi volumes o f the drug dilutions 
were added to each well using a multichannel pipette. Plates were mixed gently as 
above.
4. Cells were incubated for 6  days at 37°C and 5% CO2 . At this point the control wells 
would have reached approximately 80% confluency.
5. Assessment o f cell survival in the presence of drug was determined by acid 
phosphatase assay (Section 2.3.1.4). The concentration o f drug which caused 50% 
cell kill (IC50 o f the drug) was determined from a plot o f the % survival (relative to 
the control cells) versus cytotoxic drug concentration.
2.3.1.2 NSAID mediated drug toxicity combination assays
1. Cells were trypsinised from the flask in the exponential phase o f growth as 
described in Section 2.2.3.
2. Cell suspensions containing 1 x 104 cells /ml were prepared in cell culture medium. 
Volumes o f lOOpl o f this cell suspension were added into 96-well plates (Costar, 
3599) using a multichannel pipette. Plates were agitated gently in order to ensure 
even dispersion of cells over a given well. Cells were incubated overnight at 37°C 
in an atmosphere containing 5% CO2 .
3. Cytotoxic drug dilutions and Indomethacin NSAID dilutions were prepared at 4X 
their final concentration in media. Volumes o f 50 fils o f the drug dilution and 50 
jals o f the NSAID dilution were added to each relevant well so that a total final 
volume o f 200 pis was present in each well. Stock Indomethacin solutions were 
prepared at approximately 15mg/10ml media, filter sterilised with a 0 .2 2 pm filter 
(Millipore, millex-gv, SLGV-025BS) and were then used for all subsequent 
dilutions. All potential toxicity-enhancing agents were dissolved in DMSO, ethanol
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or media as appropriate. Solvent control experiments showed that no toxicity 
enhancement effects were due to the presence o f  DMSO or ethanol.
4. Cells were incubated for 6  days at 37°C in an atmosphere containing 5% CO2. At 
this point the control wells would have reached approximately 80% confluency.
5. Cell number was assessed using the acid phosphatase assay (Section 2.3.1.4) and 
the relevant efficiency of each NSAID tested was elucidated.
2.3.1.3 In-vitro Antisense Toxicity assays
1. Cells were trypsinised from the flask in the exponential phase o f growth as 
described in Section 2.2.3.
2. Cell suspensions containing 1 x 104 cells /ml were prepared in cell culture 
medium. Volumes o f 100 j j .1 o f this cell suspension were added into 96-well 
plates (Costar, 3599) using a multichannel pipette. Plates were agitated gently in 
order to ensure even dispersion o f cells over a given well. Cells were incubated 
overnight at 37°C in an atmosphere containing 5% CO2.
3. Antisense oligonucleotides at different concentrations were combined with a 
transfection agent (as outlined in Section 2.4.4.4) and added to media. 100 (ils of 
this oligo:media mix was added to each well and the plates were incubated 
overnight at 37°C and 5% CO2.
4. After 24 hours, this media was removed from the plates and fresh media 
containing antisense oligos and transfection reagents were added. The cells were 
re-incubated for 48 hours at 37°C and 5% CO2 .
5. After 48 hours, the media was removed from the plates, the wells were rinsed 
once with fresh media and re-incubated with 100 (ils fresh media per well for 4 
hours.
6 . Cytotoxic drug dilutions were prepared at their final concentration in cell culture 
medium. The plates were emptied o f media and 100 p.1 volumes o f the drug 
dilutions were added to each well using a multichannel pipette.
7. Cells were incubated for 4 days at 37°C and 5% CO2. At this point, the plates 
were taken down and assayed for confluency using the acid phosphatase assay 
(Section 2.3.1.4).
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2.3.1.4 Assessment o f cell number - Acid Phosphatase assay
1. Following the incubation period o f 6  days, media was removed from the plates.
2. Each well on the plate was washed with 100 (ils PBS. This was removed and 
100 (ils o f freshly prepared phosphatase substrate (lOmM p-nitrophenol 
phosphate (Sigma 104-0) in 0.1M sodium acetate (Sigma, S8625), 0.1% triton 
X-100 (BDH, 30632), pH 5.5) was added to each well. The plates were wrapped 
in tinfoil and incubated in the dark at 37°C for 2 hours.
3. The enzymatic reaction was stopped by the addition o f 50 jils o f 1M NaOH to 
each well.
4. The plate was read in a dual beam plate reader at 405 nm with a reference 
wavelength o f 620 nm.
2.3.2 Inside-out Vesicle (IOV) assays
2.3.2.1 Isolation of IOVs
The isolation o f IOVs from various cell lines was performed as described by Ishikawa
et al. (1994) and was carried out as follows;
1. Approximately 7 x 108 cells were pelleted at 5,000 rpm (1,200 x g) for 10 mins. at 
4°C in a Sorvall refrigerated centrifuge.
2. The supernatant was decanted and the pellets resuspended in 50ml ice cold PBS. 
The combined pellets were transferred to a 50 ml tube (Coming, 430921) and spun 
at 4,000 rpm for 5 mins.
3. The resulting cell pellet was resuspended in 230 mis hypotonic buffer (Table 2.3.2). 
The PMSF was added to the buffer immediately before use.
4. Cells were lysed by gentle agitation at 4°C for 1.5 hours.
5. The cell lysate was centrifuged at 28,000 rpm (100,000 x g) for 35 mins. at 4°C in a 
Beckman SW28 rotor in a Beckman XL-80 ultracentrifuge.
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6 . The resulting pellets were resuspended in 10 mis o f  hypotonic buffer and 
homogenised for 15 mins at 4°C with a Braun Potter S8 8 6  homogeniser.
7. The homogenised cell extract was diluted to a final volume o f 20 mis with 
incubation buffer which was prepared as shown in Table 2.3.3.
8 . This crude membrane fraction (roughly 10 mis) was layered over 28.5 mis 38% 
sucrose/lOmM Tris-HCl pH 7.4, (38g sucrose in 100ml lOmM Tris-HCl pH 7.4) 
and centrifuged at 28,000 rpm (100,000 x g) for 35 mins. at 4°C in an SW28 rotor. 
The interface was marked to specify the location o f the plasma membrane band 
which developed after the sucrose centrifugation step.
9. A thin white band became localised at the interface after centrifugation and this was 
removed with a pasteur pipette and diluted to a total volume o f 2 0  mis with 
incubation buffer.
10. The suspension was centrifuged at 38,200 rpm (100,000 x g) for 35 mins. at 4°C 
using a Beckman 70/70.1 Ti rotor.
11. The pellets were resuspended in 0.2 mis incubation buffer. Vesicles were formed by 
passing resuspended pellets through a 27-guage needle 20 times using a 1ml 
syringe.
12. To determine the protein concentration, a Bradford assay was carried out (Section 
2.4.1.2) and the IOV preparation was diluted to a concentration o f 5mg protein/ml 
with incubation buffer. Volumes o f 50 (j.ls IOVs were frozen at -80°C.
Table 2.3.2_________ Hypotonic buffer for IOV isolation
Buffer Constituent Preparation Instructions
0.5mM Sodium Phosphate (pH 7.0) 30 mg NaP in 500 ml UHP
0.1 mM EGTA 19.2 mg EGTA added to NaP solution
0.1 mM PM SF 100 mM stock prepared in EtOH
Table 2.3.3 Incubation buffer for IOV isolation
Buffer Constituent Preparation instructions
10 mM Tris-HCl (pH 7.4) 1.21 lg  Tris in 1L UHP water
250 mM Sucrose 42.79g Sucrose in 500 ml 10 mM Tris-HCl (pH 7.4)
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2.3.2.2 Transport assays with 10Vs
Transport assays with IOVs were performed as described by Ishikawa et al. (1994). The 
protocol used is described below;
1. A number o f  solutions were prepared in advance o f the assay. The protocol used for 
the preparation o f the incubation buffer has already been described in Table 2.3.3. 
An ATP/creatine phosphate/MgCl2/10mM Tris-HCl (pH 7.4) solution is prepared as 
outlined in Table 2.3.4. Volumes of200|j,ls were frozen at -80°C.
Table 2.3.4 ATP/Creatine p h osp h ate/M gC V lO m M  Tris-HCl preparation protocol
Buffer constituent Preparation instructions
MgCl2 6H20 203.3mg in 30 mis Incubation buffer
ATP (Disodium salt) 6.05 mg ATP in 3 mis MgCl2 6H20 solution
Creatine phosphate 32.7 mg in 3mls ATP solution
2. For the AMP solution, 4.99mg AMP (Sigma, A1752) was substituted for the ATP 
(Sigma A7699). Once prepared, 100 pi volumes were frozen at -80°C.
3. A creatine kinase solution (2mg/ml), (Sigma, C5755) was prepared in incubation 
buffer and 50|il aliquots frozen at -80 °C.
4. Prior to performing the assay, filters (Millipore, GSWP-02500) were soaked in the 
incubation buffer for 1 hour at 4°C. Once soaked, the filters were applied to the filter 
apparatus (Millipore, 12-25 Sampling Manifold) and vacuum was applied to the 
system.
5. An eppendorf thermomixer (Eppendorf, 5436) was allowed to equilibrate at 37°C and 
once at temperature, the ATP, AMP, creatine kinase and IOV solutions were thawed 
rapidly at 37°C. After thawing, solutions were immediately placed on ice.
6 . An eppendorf was placed in the thermomixer and the following added sequentially: 60 
|jls incubation buffer, 30 fils ATP, 5 jals creatine kinase, 5 (ils [3HJ-LTC4 (DuPont 
NEN, NET-1018, 0.01 mCi/ml) and 10 (ils IOVs. After every sequential addition the 
thermomixer was adjusted to half speed mixing to allow agitation of the various 
components o f the mixture.
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7. Aliquots of 20 (ils were removed at appropriate timepoints and added in to 1ml o f ice 
cold incubation buffer.
8 . These were then washed through the filter apparatus. The eppendorf was washed out 
with 1 ml o f ice cold incubation buffer. The filter was finally washed with 2 mis o f ice 
cold incubation buffer.
9. Filters were removed and placed in 8  mis scintillation cocktail (ICN, 882475) in a 
scintillation vial. After allowing 12 hours for the filters to fully dissolve, the vials were 
counted for [3H] content using a Beckman LS-6500 scintillation counter using a 1 
minute count time.
10. For an AMP negative control, the above procedure was repeated with ATP replaced by 
AMP. For a total negative control, neither ATP nor AMP were included but were 
instead replaced with 30 |fis incubation buffer.
11. For assessment o f a compound’s ability to inhibit LtC4 transport ability, the compound 
of interest was dissolved in incubation buffer at the desired concentration. 5 jals o f this 
was added to an eppendorf in the thermomixer. 55 (als o f incubation buffer was then 
added. The standard volumes of ATP, AMP, creatine kinase, LtC4 and IOV were 
added to a total final volume of 1 1 0  (ils.
2.3.3 Differentiation Studies
Differentiation studies were carried out using 5-bromodeoxyuridine (BrdU) (Sigma, 
B5002). BrdU powder was reconstituted in UHP water to a stock concentration of 
lOmM and the resultant solution was filter sterilised through a sterile 0.22pm filter, 
aliquoted into sterile Eppendorfs and stored at -20°C for up to 1 year.
2.3.3.1 Differentiation assays
All differentiation assays were carried out on adherent A549 and DLKP cells. In all
* 3experiments, cells were plated onto 6 -well plates (Costar, 3516) at densities o f 5x10 
per well. 1.5ml of medium was sufficient for each well. The cells were allowed to attach 
and form colonies by incubating at 37°C, 5% C 0 2 for 48 hours. The plates were covered
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with parafilm to prevent contamination. The medium was removed and replaced with 
BrdU-containing medium at 10f.iM concentration. The length o f time the flasks were 
exposed to BrdU is as outlined here;
2 -day exposure flask 
5-day exposure flask 
7-day exposure flask 
15-day exposure flask
Plates were wrapped in aluminium foil because of the light-sensitive nature o f BrdU and 
incubated for up to 21 days. Medium was replaced every 2-3 days over the course of 
the assay. All waste medium was retained for disposal by incineration.
2.3.3 Exposure o f DLKP cells to chemotherapeutic drugs
24 x 175cm2 flasks were set up with DLKP cells at a concentration of 9 x 105 cells per 
flask (30 mis per flask, 3 x 104 cells/ml) and incubated o/night at 37°C. There were 
eight flasks per drug type per experiment, making up the total number o f flasks; one 
flask each for RT-PCR analysis, Western blotting and in-vitro toxicity testing, 
respectively. The length o f exposure times for each flask was as follows:
3 x 2-day exposure flask 
3 x 5-day exposure flask 
3 x 7-day exposure flask 
3 x 15-day exposure flask
The cells were separately exposed to three drugs, cisplatin, taxol and VP 16. The 
concentrations were calculated from preliminary in vitro toxicity assays and RT-PCRs 
on exposed cells. These concentrations are listed in Table 3.2.1.
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2.4 Analytical Techniques
2.4.1 Western Blot analysis
2.4.1.1 Sample preparation
Cells were grown in flasks until they reached 80-90% confluency. They were then 
trypsinised and centrifuged at 1,200 rpm. for 5 min. The pellet was washed in PBS and re­
pelleted twice. The tube was inverted and drained of supernatant. Further treatment of the 
cell pellet depended on the type of extract required; lysed or sonicated.
2.4.1.1.1 Lysis o f cell pellet
lm l o f lysis buffer (PBS, 1% NP-40 (Sigma; N-3516), IX  protease inhibitors and
0.2mg/ml PMSF (Sigma, P7626)) was added to the pellet and left on ice for 20 min. A 
100X stock solution o f protease inhibitors consisted o f 400mM DTT (Sigma, D5545), 
lmg/ml aprotonin (Sigma, A l l 53), lmg/ml leupeptin (Sigma, L2884), lmg/ml soybean 
trypsin inhibitor (Sigma, T9003), lmg/ml pepstatin A (Sigma, P6425) and lmg/ml 
benzamidine (Sigma, B6506). If cell lysis had not occurred after 20 min the cells were 
subjected to sonication. Whole cell extracts were aliquoted and stored at -80°C.
2.4.1.1.2 Sonication of cell pellet
One protease inhibitor tablet from Complete™ Protease Inhibitor (Boehringer Mannheim, 
1 697 498) was added to 2 mis UHP. This was then diluted 1/25 and 200 j-tls of this 
diluted solution was added to the pellet. The mix was sonicated in a Labsonic U (Braun) 
2-3 times at a repeating duty cycle o f 0.5s, while checking under a microscope to make 
sure all the cells had been lysed. Before loading on to an SDS-PAGE gel, 2 fils o f the 
sonicated sample was removed and diluted to 10 jils with UHP for protein quantification.
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Sonicated cell extracts were either used immediately in Westerns or were stored at -80°C.
2.4.1.2 Quantification o f Protein
Protein levels were determined using the Bio-Rad protein assay kit (Bio-Rad; 500-0006) 
with a series o f bovine serum albumin (BSA) (Sigma, A9543) solutions as standards. A 
stock solution o f 25 mg/ml BSA was used to make a standard curve. 10 f_tl samples were 
diluted into eppendorfs in a stepwise fashion from 0 - 2  mg/ml BSA. The Biorad was first 
filtered through 3MM filter paper (Schleicher and Schuell, 311647) and then diluted 1/5 
with UHP as it was supplied as a 5-fold concentrate. The diluted dye reagent (490 (J.ls) 
was added to each standard and sample eppendorf and the mixtures vortexed. The 500 pi 
samples were diluted out in 100 pi aliquots onto a 96-well plate (Costar, 3599). After a 
period of 5 min to lh, the OD570 was measured, against a reagent blank. From the plot of 
the OD570 o f BSA standards versus their concentrations, the concentration o f protein in 
the test samples was determined. From this, a relative volume for each protein sample was 
determined for loading onto the gels. Usually 10-20 pg protein per lane was loaded.
2.4.1.3 Gel electrophoresis
Proteins for western blot analysis were separated by SDS-polyacylamide gel 
electrophoresis (SDS-PAGE). Resolving and stacking gels were prepared as outlined in 
Table 2.4.1 and poured into clean 10cm x 8 cm gel cassettes which consisted of 1 glass 
and 1 aluminium plate, separated by 0.75cm plastic spacers. The plates were cleaned by 
first rinsing in RBS, followed by tap water and finally UHP. After drying, the plates 
were wiped down in one direction using tissue paper soaked in 70% Industrial 
Methylated Spirits (IMS). The spacers and comb used were also cleaned in this way. 
After these had dried, the resolving gel was poured first and allowed to set for 1 hour at 
room temperature. The stacking gel was then poured and a comb was placed into the 
stacking gel in order to create wells for sample loading. Once set, the gels could be used 
immediately or wrapped in aluminium foil and stored at 4°C for 24 hours.
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IX running buffer (14.4g Glycine, 3.03g Tris and lg  SDS in 1L) was added to the 
running apparatus before samples were loaded. The samples were loaded onto the 
stacking gels, in equal amounts relative to the protein concentration o f the sample. The 
loading buffer (New England Biolabs, 7709) was prepared by adding 1/10 volume 30X 
Reducing agent to 1 volume 3X loading buffer, and this mix was added at Vi volume to 
each of the test samples. The samples were loaded including l\i\ o f molecular weight 
colour protein markers (New England Biolabs, 7708S). The gels were run at 250V, 
45mA for approximately 1.5 hours. When the bromophenol blue dye front was seen to 
have reached the end o f the gels, electrophoresis was stopped.
Table 2.4.1 Preparation of electrophoresis gels
Components Resolving gel 
(7.5%)
Resolving gel 
(12%)
Stacking gel
Acrylamide stock*2 3.8 mis 5.25 mis 0.8 mis
Ultrapure water 8.0 mis 6.45 mis 3.6 mis
1.875M-Tris/HCl, pH 8.8 3.0 mis 3.0 mis -
1.25M-Tris/HCl, pH 6.8 - - 0.5 mis
10% SDS (Sigma, L-4509) 150 (ils 150 |uls 50 fils
10% Ammonium persulphate 
(Sigma, A-1433)
60 p,ls 60 fils 17 j*ils
TEMED 
(Sigma, T-8133)
10 jals 10 fils 6 fjls
2 Acrylamide stock solution consists o f  29 .lg  acrylamide (Sigma, A8887) and 0.9g N N ’-methylene bis- 
acrylamide (Sigma, 7256) dissolved in 60ml UHP w ater and m ade up to 100ml final volume. The solution 
was stored in  the dark at 4°C for up to 1 month. A ll com ponents were purchased from  Sigma, SDS (L-4509), 
N H 4-persulphate (A-1433) and TEM ED, N ,N ,N ,N ’-tetram ethylethylenediam ine (T-8133).
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2.4.1.4 Western blotting
Following electrophoresis, the acrylamide gels were equilibrated in transfer buffer 
(25mM Tris, 192mM glycine (Sigma, G-7126) pH 8.3-8.5 without adjusting) for 10 
min. Protein in gels were transferred onto PVDF membranes (Boehringer Mannheim, 
1722026) by semi-dry electroblotting. Eight sheets o f Whatman 3mm filter paper 
(Whatman, 1001824) were soaked in transfer buffer and placed on the cathode plate of a 
semi-dry blotting apparatus (Biorad). Excess air was removed from between the filters 
by rolling a universal over the filter paper. A piece o f PVDF membrane, cut to the same 
size o f the gel, was prepared for transfer (soaked for 30 secs, in methanol, 2 mins. in 
UHP and finally 5 mins. in transfer buffer) and placed over the filter paper, making sure 
there were no air bubbles. The acrylamide gel was placed over the PVDF membrane 
and eight more sheets o f presoaked filter paper were placed on top o f the gel. Excess air 
was again removed by rolling the universal over the filter paper. The proteins were 
transferred from the gel to the nitrocellulose at a current o f 34mA at 15V for 24-25 
mms.
All incubation steps from now on, including the blocking step, were carried out on a 
revolving apparatus (Stovall, Bellydancer) to ensure even exposure o f the blot to all 
reagents. The PVDF membranes were blocked for 2 hours at room temperature with 
fresh filtered 5% non-fat dried milk (Cadburys, Marvel skimmed milk) in Tris-buffered 
saline (TBS) with 0.5% Tween (Sigma, P-1379) pH 7.5. After blocking, the membranes 
were rinsed once in IX  TBS and incubated with 10 mis primary antibody. The specific 
conditions for the MRP1 antibody are outlined in Section 2.4.1.4.1, below. Bound 
antibody was detected using enhanced chemiluminescence (ECL).
2.4.1.4.1 MRP1
Protein samples assayed for the presence o f MRP 1 were treated with a 1/50 dilution of 
anti-human MRP1 Rat Mab (MRP1 R l)  (TCS, ZUMC-201). The MRP1 antibody was 
diluted 1:50 in IX  TBS with 0.1% Tween and the membranes were incubated shaking 
overnight at 4°C. The primary antibody was removed and the membranes rinsed 3 
times with TBS/0.5% Tween. The secondary antibody was a 1/10,000 dilution of rabbit
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anti-rat-HRP immunoglobulin (Dako, P450). The membranes were washed 3 times in 
TBS/0.5% Tween and developed as outlined in Section 2.4.1.5.
2.4.1.5 Enhanced chemiluminescence detection
Protein bands were developed using the Enhanced Chemiluminescence Kit (ECL) 
(Amersham, RPN2109) according to the manufacturer’s instructions.
The blot was removed to a darkroom for all subsequent manipulations. A sheet of 
parafilm was flattened over a smooth surface, e.g. a glass plate, making sure all air 
bubbles were removed. The membrane was placed on the parafilm, and excess fluid 
removed. 1.5mls o f ECL detection reagent 1 and 1.5mls o f reagent 2 were mixed and 
covered over the membrane. Charges on the parafilm ensured the fluid stayed on the 
membrane. The reagent was removed after one minute and the membrane wrapped in 
cling film. The membrane was exposed to autoradiographic film (Boehringer 
Mannheim, 1666916) in an autoradiographic cassette for various times, depending on 
the signal (30s -  5 mins.). The autoradiographic film was then developed.
The exposed film was developed for 5min in developer (Kodak, LX24, diluted 1:6.5 in 
water). The film was briefly immersed in water and fixed (Kodak, FX-40, diluted 1:5 
in water), for 5min, The film was transferred to water for 5 min and then air-dried.
2.4.2 RNA Analysis
2.4.2.1 Preparation for RNA Analysis
Due to the labile nature o f RNA and the high abundance o f RNase enzymes in the 
environment a number of precautionary steps were followed when analysing RNA 
throughout the course o f these studies.
• All solutions (which could be autoclaved) that came into contact with RNA were all
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prepared from sterile ultra-pure water and treated with 0.1% diethyl pyrocarbonate 
(DEPC) (Sigma, D5758) before autoclaving (autoclaving inactivates DEPC), with 
the exception o f Tris-containing solutions (DEPC reacts with amines and so is 
inactivated by Tris). The Tris-containing solutions were made with DEPC-treated 
ultra-pure water.
• Disposable gloves were worn at all times to protect both the operator and the 
experiment (hands are an abundant source o f RNase enzymes). This prevented the 
introduction of RNases and foreign RNA/DNA into the reactions. Gloves were 
changed frequently.
2.4.2.2 RNA Isolation
Total RNA was extracted from cultured cell lines, antisense-, ribozyme- and plasmid- 
transfected cell lines, as well as BrdU-treated cell lines. Human tumour and normal 
specimens throughout the course o f these studies were also analysed using the technique 
outlined below. The size o f the flasks varied, but the method remained the same.
A standard method o f extracting RNA from cells was as follows: cells were seeded into 
175cm2 flasks (Nulge Nunc, 156502) at a density o f approximately 2 x l0 6 per flask and 
allowed to attach and form colonies for 48-72 hours at 37°C. The cells were trypsinised 
and the pellet was washed once with PBS. The cells were pelleted and lysed using 1ml 
of TRI REAGENT™ (Sigma, T-9424). The following procedure is that outlined in the 
protocol for TRI REAGENT™. The samples were allowed to stand for 5 mins. at room 
temperature to allow complete dissociation o f nucleoprotein complexes. 0.2 mis of 
chloroform was added per ml of TRI REAGENT™ used and the sample was shaken 
vigorously for 15 sec and allowed to stand for 15 min at room temperature. The sample 
was centrifuged at 13000rpm for 15 mins. at 4°C in a microfuge. This step separated 
the mixture into 3 phases with the RNA contained in the colourless upper aqueous layer. 
The DNA and protein fractions resulting from the total RNA isolation were retained in 
case they were required at some future date. The aqueous layer was transferred to a new 
Eppendorf and 0.5 mis of 100% isopropanol was added per ml o f TRI REAGENT™ 
originally used. The sample was mixed and allowed to stand at room temperature for
10-15 mins. before being centrifuged again at 13000rpm for 10 min at 4°C. The RNA 
formed a precipitate at the bottom of the tube. The supernatant was removed and the
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pellet was washed with 1ml of 75% ethanol per ml o f TRI REAGENT used and 
centrifuged at 4°C for 5 mins. at 13000rpm. The supernatant was removed and the 
pellet was allowed to air-dry for 10-15 mins. 20-30 p,ls o f  DEPC water was added to the 
RNA to resuspend the pellet.
2.4.2.3 RNA Quantitation
RNA was quantified spectrophotometrically at 260nm using the following formula:
OD260nm x Dilution factor x 40 = (J,g/ml RNA 
An A260/A280 ratio o f 1.8-2 is indicative o f pure RNA, although RNA with ratios from 1.7 
- 2 . 1  were routinely observed and used in subsequent experiments. Partially solubilised 
RNA has a ratio o f <1.6 (Ausubel et ah, 1991). The yield o f RNA from most lines of 
cultured cells is 100-200|jg/90mm plate (Sambrook et al., 1989). In these studies 200 |ig 
RNA per 175cm2 flask was retrieved. RNA samples were diluted to 500 ng/pl and stored 
at -80°C.
2.4.2.4 Micropipette Accuracy Tests
Accuracy and precision tests were carried out routinely on all micropipettes used in all 
steps of the RT-PCR reactions. The accuracy and precision o f the pipettes was determined 
by standard methods involving repeatedly pipetting specific volumes o f water and 
weighing them on an analytical balance. The specifications for these tests were supplied 
by Gilson.
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2.4.2.5 Reverse-Transcription Polymerase Chain Reaction (RT-PCR) analysis o f isolated 
RNA
2.4.2.5.1 Reverse Transcription of isolated RNA
Reverse transcriptase (RT) reactions were set up on benches using micropipettes, which 
were specifically allocated to this work.
To form the cDNA, the following reagents were mixed in a 0.5ml eppendorf 
(Eppendorf, 0030 121 023), heated to 72°C for 5 min and then chilled on ice.
2(4.1 o f a 5x buffer (lOOmM-Tris/HCl, pH 9.0, 50mM-KCl, 1% Triton X-100) (Sigma, P- 
2317)
1.2jj,1 25mM-MgCl2 (Sigma, M-8787) 
ljil oligo (dT) primers (1 f_ig/ul)
1 (0.1 RNasin (40U/(J.1) (Sigma, R-2520)
0.4(j.l dNTPs (lOmM of each dNTP) (Sigma, DNTP-100)
2\x\ total RNA (500ng/jal) 
lA\x\ DEPC water
To this, 4p.l water and 1 |il Moloney murine leukaemia virus-reverse transcriptase 
(MMLV-RT) (40,000U/|J,1) (Sigma, M-1302) were added. The solutions were mixed 
and the RT reaction was carried out by incubating the Eppendorfs at 37°C for 1 hour. 
The MMLV-RT enzyme was inactivated by heating to 95°C for 3 mins. The cDNA 
was stored at -20°C until required for use in PCR reactions as outlined in Section 
2.4.2.6.2.
2.4.2.5.2 Polymerase Chain Reaction (PCR) amplification of cDNA
The cDNA formed in the above reaction was used for subsequent analysis by PCR
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A standardised polymerase chain reaction (PCR) procedure was followed in this study. 
Standard Eppendorf tubes were used, as for the RT reactions. All reagents had been 
aliquoted and were stored at -20°C and all reactions were carried out in a laminar flow 
cabinet. A complete list o f all PCR primers and reaction conditions are included in 
Appendix A.
A typical PCR reaction contained the following:
9pl UHP
5(il 5x buffer (lOOmM-Tris/HCl, pH 9.0, 50mM-KCl, 1% Triton X-100)
2\il 25mM-MgCl2
lfil each of first and second strand target primers3 (250ng/ml)
1(.U each of first and second strand endogenous control primer (250ng/ml) ((3-actin)
10f.il cDNA
Ta^/dNTP mixture 1(0,1 dNTPs (lOmM each o f dATP, dCTP, dGTP and dTTP)
0.5/j.I o f 5U/(il Taq DNA polymerase enzyme (Sigma, D-4545) 
18.5(0,1 UHP
The samples were mixed by pipetting two or three times. A typical reaction would be:
95°C for 3 min - denaturation
Taq/dNTP mixture added here
30 cycles: 95°C for 30 sec. - denaturation
X4oC for 30 sec. - annealing
72°C for 30 sec. - extension
And finally,
72°C for 7 min. extension
Following amplification, the PCR products were stored at 4°C for analysis by gel 
electrophoresis
3 A ll oligonucleotide primers used throughout the course o f  this thesis were m ade to order on an “Applied 
BioSystems 394 DNA/RNA Synthesiser” by  Oswel D N A  service, Lab 5005, M edical and Biological 
Services building, U niversity o f  Southampton, Boldrewood, Bassett Cresent East, Southampton, SOI 6 7PX.
4 Tem perature dependent on prim er type
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2.4.2.6 Electrophoresis ofPC R  products
A 2% agarose gel (Sigma, A-9539) was prepared in IX  TBE (10.8g Tris base, 5.5g 
Boric acid, 4 mis 0.5M EDTA, 996mls UHP) and melted in a microwave oven. After 
allowing to cool, 4 fils o f a lOmg/ml ethidium bromide solution was added per lOOmls 
o f gel which was then poured into an electrophoresis apparatus (BioRad). Combs were 
placed in the gel to form wells and the gel was allowed to set.
4jal o f 6X loading buffer loading buffer (50% glycerol, lm g/m l bromophenol blue, 
ImM EDTA) was added to 20jjl PCR of each sample and this was run on the gel at 80- 
90mV for approximately 2 hours. When the dye front was seen to have migrated the 
required distance, the gel was removed from the apparatus and examined on a 
transilluminator and photographed.
2.4.2.7 Densitometric analysis
Densitometric analysis was carried out using the MS Windows 3.1 compatible 
Molecular Analyst software/PC image analysis software available for use on the 670 
Imaging Densitometer (Bio-Rad. CA) Version 1.3. Developed negatives o f gels were 
scanned using transmission light and the image transferred to the computer. The amount 
o f light blocked by the DNA band is in direct proportion to the intensity o f the DNA 
present. A standard area was set and scanned and a value was taken for the Optical 
Density (O.D.) o f each individual pixel on the screen. The average value o f this O.D. 
(within a set area, usually cm2) is normalised for background o f an identical set area. 
The normalised reading is taken as the densitometric value used in analysis. As a result, 
these O.D. readings were unitless.
2.4.3 Northern Analysis
The RNA samples to be analysed were first separated by Formaldehyde-Agarose 
Electrophoresis.
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2.4.3.1 Formaldehyde-Agarose gel Electrophoresis
A 100ml 1% agarose gel was prepared by dissolving lg  o f agarose in 73.4 ml UHP. The 
gel was cooled to around 60°C and 10ml of 10X MOPS buffer (0.25M MOPS, 0.05M 
Na acetate, 0.01 EDTA, pH 7.0) was added along with 16.6 ml formaldehyde and mixed 
well before pouring. The running buffer for the gel was IX  MOPS containing 12.9 ml 
formaldehyde/300ml. 1 or 2|ig o f mRNA was freeze-dried overnight in a 500 fil 
eppendorf and dissolved in 5jol o f UHP, to allow equal loading volumes. The RNA 
samples were mixed with RNA loading buffer (2.9jj.1 10X MOPS, 5fol formaldehyde,
14.3 (0,1 formamide, 1.43jxl tracking buffer and heated to 65°C for 15min, placed on ice 
and loaded onto the gel. The RNA samples were run on the gels at 10 V/cm for 2 hours 
alongside RNA size markers (Promega, G3191). The gels were washed in 3 changes of 
UHP over 30 minutes.
2.4.3.2 Northern Blotting
A sheet o f Hybond-N (Amersham, RPN 303N) was cut to the same size as the RNA gel. 
A tray or glass dish was half filled with the transfer buffer (20X SSC (8.823 % (w/v) tri­
sodium citrate, 17.532 % (w/v) NaCl, pH 7-8)). A platform was made to stand in the 
tray above the level o f the transfer buffer and a wick (3MM filter paper) was placed 
over the platform into the transfer buffer. The RNA gel was placed loading side down 
on the wick platform without trapping air bubbles. The Hybond-N was placed on top of 
the RNA gel and three sheets o f 3MM filter paper placed upon the Hybond-N. A stack 
o f absorbent tissue paper over 5cm high was placed on top o f the filter paper and was 
covered with a glass plate. Finally, a glass plate with a 750g weight was placed on top 
of the paper stack and the transfer was carried out overnight. After blotting, the transfer 
apparatus was dismantled and the wells were marked on the Hybond-N to allow 
identification by hand. The nucleic acid was fixed to the membrane by baking at 80°C 
for 2 hours and stored until use between two sheets of dry filter paper.
After blotting, the gel was soaked in a 1 pg/ml EtBr solution with agitation and was 
then viewed under a UV lamp. The efficiency o f RNA transfer to the membrane could
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then be assessed by looking for remaining traces o f 28S and 16S ribosomal bands. The 
lane on the gel containing the RNA markers was removed from the gel before blotting 
and stained with EtBr alongside the blotted gel. The position o f the RNA markers were 
photographed and used as a reference to size bands on the developed Northern Blots.
2.4.3.3 Preparation o f MRP1 Hybridisation probe
The MRP1 probe was prepared from a MRP1 cDNA plasmid (pH(3-Apr-neo) kindly 
donated by Dr. Susan Cole. A lkb fragment o f the MRP1 cDNA was cut from the 
plasmid using two restriction enzymes. The fragment was electrophoresed on a 1% low- 
melting point agarose gel containing ethidium bromide at 75mV for 1 to 2 hours along 
with the molecular weight size markers DC and III (Boehringer Mannheim, 558 552 and 
1 449 460) to check for the correct fragment size. The gel was viewed under a UV 
illuminator and the fragment band cut out o f the gel with a scalpel. The 1 kb fragment 
was extracted from the agarose using the Qiaex II Agarose Gel Extraction kit according 
to the manufacturer's protocol (Qiagen, 20021).
2.4.3.4 Radioactive Labelling of Probes
All DNA probes were random prime labelled with [a -32P]dCTP (Amersham) using the 
Prime-a-gene labelling kit (Promega : U1100) according to the supplied protocol. 
Riboprobes (RNA) were generated with [a-32P]CTP (Amersham) using the Riboprobe 
In Vitro Transcription Systems kit (Promega: P I440) according to the supplied protocol. 
The T7 promoter and RNA polymerase were used in this labelling reaction. 20 to 40 ng 
of cDNA fragment and 5(0.1 o f [a-32P]dCTP or [a-32P]rCTP was used to make each 
probe.
To test the percentage incorporation o f nucleotides into the DNA probes, TCA 
precipitation was performed. 1 pi out o f the 50jol reaction mix was diluted 1 in 100 with 
water. 1 pi o f the diluted probe was blotted onto four 1cm2 pieces o f filter paper and air- 
dried. Two of these pieces o f filter paper were washed twice for 10 minutes in 10% Tri-
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chloro Acetic Acid (Riedel-del Haen: UN-No-1839), rinsed in 100% ethanol and air- 
dried. The counts on the two washed and unwashed pieces o f filter were measured using 
a scintillation counter. The filter paper was placed in scintillation counter tubes with 
10ml of scintillation fluid (Ecolite) (ICN, 882475) and the Counts per minute (CPM) 
read. The CPM o f the washed pieces o f filter paper as a percentage o f the unwashed 
pieces o f filter paper gave the percentage incorporation o f the probe. Probes with less 
than 50% incorporation were purified using NAP10 columns (Amersham, 17-0854-01) 
according to the manufacturer’s protocol.
2.4.3.5 Hybridisation of labelled probes to RNA membranes
The Northern membranes were prehybridised overnight at 65°C in 10ml of 
hybridisation buffer (In 100ml : 43ml 1 M Sodium phosphate pH 7.2, 33 ml 20% 
Sodium Dodecyl Sulphate (SDS), 20 ml 5% BSA, 4ml 0.5 M EDTA) per membrane. 
The hybridisation was carried out in glass hybridisation tubes in a hybridisation oven. 
The appropriate probe was heated to 100°C for 5 min before addition to 10ml of 
preheated (65°C) hybridisation buffer. Sufficient probe was used to give 3 x l0 6 CPM/ml 
hybridisation buffer. The pre-hybridisation buffer was discarded from the hybridisation 
tubes and replaced with the fresh hybridisation buffer containing the denatured probe. 
Hybridisation was carried out at 65°C overnight. The membranes were then washed at 
65°C for 5 min in 2X SSC, followed by 2 x 15 min washes in 0.5X SSC, 0.1% SDS and 
2 x 1 5  min washes in 0.1X SSC, 0.1% SDS. The membranes were wrapped in cling film 
and exposed to X-ray film at -80°C for the desired length o f time (typically 24h to 5 
days).
2.4.4 Plasmid DNA manipulation
2.4.4.1 Plasmids and oligonucleotides used
The MRP1 ribozyme was cloned into the pH^Apr-l-neo expression plasmid and was a
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generous gift from Dr. Kevin Scanlon. All standard5 antisense molecules used were 
phosphorothioate oligonucleotides, all other antisense were Second-Generation™ 
chimera6 oligos. A list o f all phosphorothioate antisense sequences is included in 
Appendix A (Table 7.5A), while the designed Second-Generation™ chimera sequences 
are listed in Table 3.10.1.
2.4.4.2 Production of unique plasmid DNA samples
In certain cases, as in the event o f the in-vitro ribozyme cleavage experiment (Section 
2.4.7), plasmid DNA expressing the correct sequence o f interest in the right orientation 
was manufactured in the lab. In these cases, the target DNA fragment (e.g. the ribozyme 
in-vitro cleavage (IVC) target fragment) experiment was amplified in a standard RT-PCR 
reaction (Section 2.4.2.5), cloned into a suitable vector (Section 2.4.4.2.1) and analysed 
using restriction digest (Section 2.4.4.5) and sequencing reactions (Section 2.4.4.6). The 
protocols following on from this Section can be regarded as examples o f the actual 
protocols used.
2.4.4.2.1 Ligation o f target DNA into a suitable vector
The procedure followed for ligating the all vectors with their corresponding target DNA 
was that as outlined in the pTarget™ Mammalian Expression Vector System (Promega, 
A1410) and all manipulations carried out were as outlined in the pTarget™ Mammalian 
Expression Vector System Technical Manual (Promega, TM044). All necessary 
ingredients were supplied with the kit.
1. The vector ratio calculation was carried out for the insertrvector involved as 
follows:
5 M ade to order on an “A pplied BioSystems 394 D N A /RN A  Synthesiser” by  O sw el D N A  service, Lab 
5005, M edical and Biological Services building, University o f  Southampton, Boldrewood, Bassett Cresent 
East, Southampton, SO 16 7PX.
6 M anufactured by  O ligos Etc. Inc., 172 M ain St., P.O. B ox 309, Bethel, M E, 04217, U SA
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60ng Vector X 0.476 kb Insert X __2 = 10 r\g insert
5.67kb vector 1
2. The pTarget™ vector and Control insert tubes were first centrifuged to collect 
the contents at the bottom of the tube.
3. Ligation reactions were set up as described in Table 2.4.2.
Table 2.4.2 List of standard components for ligation reaction
Standard Reaction Positive Reaction
T4 DNA Ligase 10X 1 (il 1 |il
Buffer
Vector (60ng) 1 (il 1 (il
Target PCR product 1 (il -
Control Insert DNA - 2 fil
T4 DNA Ligase 1 |il 1 (il
UHP 6 (il 5 (il
4. The tubes were incubated overnight at 4°C.
5. The DNA was stored at -20°C after ligation. The DNA is now ready for 
transformation into bacteria (Section 2.4.4.3).
2.4.4.3 Transformation of Bacteria
lOOpl of competent JM109 bacterial cell suspension (Promega, L2001) was mixed with 
20ng DNA and placed on ice for 40min after which the mixture was heat-shocked at 
42°C for 90sec and then placed on ice for 3min. 1ml o f LB broth ((10g Tryptone 
(Oxoid, L42), 5g Yeast Extract (Oxoid, L21) 5g NaCl (Merck, K1880814))/litre LB, 
autoclaved before use) was added to the competent cell suspension and incubated at 
37°C for 40min. 400(il o f this suspension was spread on a selecting agar plate (LB agar 
containing appropriate antibiotic conc.) and incubated overnight at 37°C. Single 
colonies, which grew on these selecting plates, were further streaked onto another 
selecting plate and allowed to grow overnight at 37°C.
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2.4.4.4 DNA miniprep of plasmid DNA
This was carried out in order to determine the orientation o f the inserted DNA sequence
in the transformed plasmid. Only plasmids with the insert in the correct orientation
could be used in the in-vitro cleavage (IVC) experiment.
1. Single colonies were selected off the plates and incubated in universals 
containing 5 mis LB/Amp shaking at 180rpm at 37°C overnight. White colonies 
generally contain inserts, but inserts may also be present in blue colonies. For 
this reason, a number o f white colonies, blue colonies and white-blue colonies 
(white colonies with a blue centre) were selected for incubation. The positive 
control reaction yielded all blue colonies, which were too numerous to count.
2. After 16-24 hours incubation, 1.5 mis o f culture was removed from each of the 
incubated samples and spun down at 8500rpm in a microfuge. The supernatant 
was decanted and another 1.5 mis o f culture was added and again spun down.
3. The samples were subjected to a plasmid miniprep, as outlined in the Stratagene 
Clearcut™ Miniprep kit (Stratagene, 400732). The cell preps were each 
resuspended in three 105 jols o f Solution 1.
4. 125 fils o f  Solution 2 was added, and the eppendorf was mixed gently by 
inversion.
5. 125 fils o f Solution 3 was added, and the eppendorf was mixed gently by 
inversion. The eppendorf was then placed on ice for 5 mins.
6. The eppendorf tubes were then spun down in a microfuge at 8500rpm and the 
supernatants were carefully transferred to fresh tubes, leaving cell debris behind.
7. The kit-supplied DNA binding resin was mixed by vortexing until resuspended. 
15 fils o f this resin was added to each collected supernatant. The tubes were then 
mixed by inversion.
8. The samples were loaded into kit-supplied spin cups. The cups were spun down 
in a microfuge at 13,000rpm for 30 secs., which retained the resin and plasmid 
DNA.
9. A kit-supplied wash buffer was prepared for each sample by diluting 200 fils of 
2X wash buffer with 200 fils o f 100% (v/v) ethanol. 400 fils o f this wash buffer 
was added to the spin cup and the cups spun at 13,000rpm again for 30 secs. 
This step was repeated for all samples.
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10. The spin cups were transferred to fresh eppendorfs. 50 (als o f UHP was loaded 
into each spin cup to elute the DNA and the samples spun down at 13,000rpm 
again for 30 secs. The plasmid DNA was stored at -20°C in the eppendorfs.
2.4.4.5 Restriction enzyme digestion o f  plasmid DNA
5 fils o f each isolated plasmid sample was run out on a 2% agarose gel to check for 
degradation. Restriction digestion was then carried out to confirm orientation o f the 
insert. All digestions were carried out using the recipe as outlined in Table 2.4.3.
Table 2.4.3 Standard DNA digestion mix
Component Volum e (fils)
DNA sample 1 0
undiluted enzyme 1
10X Multi-core reaction buffer (Promega, R9991) 1.5
UHP 2.5
All 15 pis were run out on a 1% agarose gel, together with 3 |ils loading dye. From the 
banding patterns observed, the orientation o f the insert was correctly discerned. From 
this information, samples were selected for large-scale plasmid preparation.
2.4.4 .6  Plasmid DNA Sequencing
In order to fully confirm the orientation o f the inserted DNA in the plasmid, certain 
samples which had been indicated as being o f desired orientation from the restriction 
digest were sequenced using the following procedures.
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2.4.4.6.1 Preparation/Purification o f plasmid DNA prior to Sequencing
1. From the appropriate culture universal from Section 2.4.4.3, 50pls o f culture 
was removed and spread on LB/Ampicillin plates. The plates were incubated at 
37°C overnight.
2. The following day, single colonies were selected and were incubated shaking in 
universals containing 10 mis LB/Ampicillin media at 37°C overnight.
3. Plasmid DNA was isolated using the Wizard™ Plus Minipreps DNA 
Purification System (Promega, A7100). 3 mis o f the culture was pelleted at 
1,400 x g for 10 mins. The pellet was resuspended in 400 pis cell resuspension 
solution and then in 400 pis Cell Lysis solution in an eppendorf. The tube was 
mixed and 400 pis Cell Neutralisation solution was added. The lysate was 
centrifuged at 13,000rpm in a microfuge for 30 mins. The plasmid was then 
purified without using a vacuum manifold.
4. A Wizard™ minicolumn was set up in the usual way and the cleared lysate from 
the cleaned plasmid samples was added to the barrel o f the minicolumn/syringe 
assembly. The lysate was pushed into the column using the plunger. The lysate 
was then washed in 2  mis column wash solution and centrifuged at 13,000rpm in 
a microfuge for 2 mins. The plasmid DNA was eluted by the addition o f 50 pis 
UHP followed by centrifugation at 13,000rpm in a microfuge for 2 mins.
2.4.4.6.2 Sequencing o f plasmid DNA
The plasmid DNA was sequenced using the ^Sequencing™  Kit (Pharmacia Biotech,
27-1682-01). The sequencing gel was poured as outlined in Section 2.4.7.8 .
1. 10 pis o f template DNA, 2 pis o f diluted (2.5 pM) T7 primer, and 2 pis o f annealing 
buffer were added together in an eppendorf, mixed, centrifuged and incubated at 
60°C for 10 mins. These were then left at room temperature for 10 mins. and 
centrifuged again.
2. To this mix was added 3 pis o f labelling mix (dATP), 1 pi o f labelled dATP (S35) 
and 2 pis o f diluted T7 DNA polymerase. These were mixed and left at room 
temperature for 5 mins.
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3. Four eppendorfs were labelled A,C,G,T for each template, 2.5 (als o f each o f the 
“read short mixes” were added to their corresponding tube and incubated for 1 min. 
at 37°C.
4. To each o f the pre-warmed sequencing mixes, 4.5 jals o f the labelling reaction was 
added, mixed by gentle pipetting and incubated at 37°C for 5 mins.
5. 5 (ols o f stop solution was added and mixed gently.
4 fils o f each reaction was added to a fresh tube and incubated at 75-80°C for 2 mins. 
And immediately loaded on the sequencing gel. The remainder o f the sequencing 
reactions was stored at -20°C.
Once orientation had been confirmed by sequencing, large-scale preparation was carried 
out.
2.4.4.7 Large scale plasmid preparation
A single colony (Section 2.4.4.3) was inoculated into 10ml o f LB Amp 50(j,g/ml and 
grown overnight; 2ml of this suspension (1% inoculum) was added to 200ml o f TB (2.4g 
Tryptone, 4.8g Yeast Extract, 0.8 mis Glycerol, 0.17M KH2PO4 and 0.72M K2HPO4) 
Amp 50(j.g/ml and left to grow overnight at 37°C for large scale isolation o f plasmid from 
JM109 cells. The following day the cells were pelleted and lysed in 20ml o f an ice-cold 
solution containing 50mM glucose, 25mM Tris-Cl, lOmM EDTA, pH8.0 and 5mg/ml 
lysozyme (Sigma, L6876) at room temperature for 10-15min. 40ml o f a 0.2N NaOH and 
1.0% SDS solution was gently mixed with the lysate until the suspension became clear 
and incubated on ice for lOmin. 30ml of 3M K-Acetate, pH5.2 was added to the above 
and mixed gently until a flocculent precipitate appeared at which stage the mixture was 
stored on ice for at least lOmin. The sample was centrifuged at 35,000xg. for lh  at 4°C. 
The supernatant was then recovered and added to 0.6 volume o f 100% Isopropanol, 
mixed gently and left at room temperature for 20-3 Omin. The suspension was then 
centrifuged at 35,000xg. for 30min at 20°C after which the supernatant was discarded. 
The pellet was washed in ice-cold 70% ethanol and resuspended in 5ml o f TE, pH8.0. To 
remove any contaminating RNA, the plasmid solution was treated with RNase Plus (5 
Prime —» 3 Prime Inc.; 5-461036) (to a final dilution of 1:250) for 30min at 37°C followed
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by phenol:chloroform:isoamyl alcohol extractions (25:24:1). 10M ammonium acetate was 
added to the aqueous phase to a final concentration o f 2.0M. 0.6 volume of 100% 
Isopropanol was added to the sample, mixed and stored at room temperature for 20- 
30min. The sample was centrifuged at 13,000rpm and the DNA pellet was washed in 70% 
ethanol and resuspended in 3.6ml of lOmM Tris-Cl, ImM EDTA, and 1.0M NaCl, pH8.0. 
1.8ml of this sample was loaded into one o f two pZ523 columns (following the 
manufacturer’s instructions) and the column effluent was precipitated with 0.6 volume 
100% Isopropanol, as described previously. The DNA was pelleted at 13,000rpm in an 
epifuge, washed in 70% ethanol and resuspended in TE. The DNA concentration was 
determined by measuring the OD260nm-
2.4.5 Transfection of mammalian cells with exogenous DNA
2.4.5.1 Optimisation of plasmid/antisense transfection protocol
Before full transfections involving the various DNA fragments into the different cell 
lines could proceed, transfection protocols were first optimised for each o f the 
parameters involved. The DNA used was the pCH llO  plasmid which codes for beta- 
galactosidase activity.
The target cell line was trypsinised in the usual fashion (Section 2.2.3) and set up in the 
container o f interest (i.e. 24/6-well plate, 25-75 cm2 flask) at several different cell 
concentrations, which were arbitrarily chosen. Following incubation overnight at 37°C, 
the cells were transfected according to the transfection protocol for the transfectant 
used. Only the volumes of transfectant and conc. o f DNA were altered to ascertain the 
most efficient combination. Cells were transfected either in the presence of serum 
overnight or for four hours in the absence of serum, both at 37°C. After transfection, the 
cells were washed 2X with PBS and fixed by the addition o f fix solution (0.4mls 25% 
glutaraldehyde (Sigma, G-7526), lOmls 0.5M Sodium Phosphate buffer (pH 7.3), 
2.5mls 0.1 EGTA (pH 8.0)(Sigma, E-0396), O.lmls 1.0M MgCl2 (Sigma, M-8266), 
37mls UHP) for 10 mins. The cells were then washed for 10 mins. in wash solution 
(40mls 0.5M Phosphate buffer (pH 7.3), lOmls 1.0M MgCl2 (Sigma, M-8266), 20mg
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Sodium deoxycholate (Sigma, D-4297), 40(j.ls Nonidet P-40 (Sigma 1-3021), 160mls 
UHP). Staining was carried out on the cells using 2.5mls o f stain solution (lOmls rinse 
solution, 0.4mls X-gal (Sigma, B-4252) (25mg/ml in dimethylformamide), 16.5mg 
potassium ferricyanide (Sigma, P-8131), 16.5mg potassium ferrocyanide (Sigma, P- 
9387)) overnight at 37°C. After staining, the cells were washed with lOmls rinse 
solution and examined microscopically. Positive cells were those stained blue - the 
combination resulting in the most blue colonies was adjudged to be the most efficient 
association and was thereafter used for that cell line.
2.4.5.2 Transfection o f DNA using lipofection reagents
On the day prior to transfections, the cells to be transfected were plated from a single
9 c
cell suspension (Section 2.2.3) and seeded into 25cm flasks at 3x10 cells per flask. On
the day o f the transfection, the plasmids to be transfected were prepared along with the
lipid transfection reagents according to the manufacturers protocols (DOTAP -
Boehringer Mannheim, 1 202 375; Lipofectin -  GibcoBRL, 18292-011; Lipofectamine,
GibcoBRL, 10964-013; Fugene6  - Boehringer Mannheim, 1 814 443). The cells were
either transfected for four hours in the absence o f serum after which the media was
replaced with serum containing media, or for 24h to 48h in the presence o f 10% FCS.
For all transfections the cells were incubated at 37°C. This procedure is the same for
plasmids coding for ribozyme expression as well as normal gene expression. For
• ■ 2transfection o f antisense oligonucleotides, cells were set up in duplicate 25cm flasks 
and treated on days one and two in exactly the same way as for ribozyme transfections. 
However, on the third day, cells were again transfected with fresh media supplemented 
with transfection mix. The cells were then reincubated at 37°C. After 24 hours, one set 
of cells was taken down for analysis by RT-PCR (Section 2.4.1), and the second set was 
removed after 48 hours for analysis by Western blotting (Section 2.1.4.6). Cells were 
also transfected with antisense in 96-well plates for the purpose o f determining the 
effect on their drug resistance profiles (Section 2.3.1.2).
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2.4.5.3 Estimation o f transfection effect
Examining the effect o f  transfections took different forms regarding the type o f DNA 
used. Ribozyme transfections involved the selection and establishment o f stably- 
transfected clonal cell lines, where RNA, protein and drug profiles were only assayed 
once the new cell line(s) were obtained. Antisense transfections differed in that they were 
treated as transient transfections and results were obtained from the transfected cells 
immediately, without the cloning out of transfected cells.
For expression plasmids, (pCHllO), as has already been explained, effect 
detection was achieved by staining for the plasmid, in which transfected colonies stained 
blue. These could then be counted and the relative efficiency o f the transfection calculated 
from the number of transfected vs. untransfected cells. Other expression plasmids used 
were pTarget™ and pGL3.
In the case of ribozyme transfections, single colonies o f stably transfected cells 
were selected and isolated. The selection process was carried out by feeding the 
“transfected” cells with media containing geneticin (Sigma; G9516) - the plasmids used 
had a geneticin-resistant gene, therefore, only those cells containing the plasmid will 
survive treatment with geneticin. 2  days after transfection, the flask o f cells was fed with 
3-4 times the levels o f geneticin normally required to kill 50% of the cells transfected 
(e.g. IC50 for DLKP-SQ cells is 65|ig/ml; cells were fed with media containing 200(ig/ml 
geneticin). In complete media, when the cells grew readily in this concentration of 
selecting agent, the concentration was increased step-wise to a final concentration of 
600|_ig/ml. At this stage the cells were plated out in 96-well plates (Costar, 3596) at a 
clonal density o f one cell/well. Clonal populations were propagated from these wells, as 
transfected cells were periodically challenged with geneticin to maintain stability of 
transfectants and prevent cross-contamination with non-transfected cells.
Cells treated with antisense were taken down as outlined in Section 2.4.4.4. RT- 
PCR analysis, Western blotting was carried out to determine the effect, if  any, o f the 
transfection on a given gene. In-vitro Toxicity assays were also carried out (Section
2 .3.1 .2 ) to determine effect on drug resistance.
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2.4.6 Isolation o f RNA from Tumour/Normal Samples
1. Breast and Lung samples (both Tumour (T) and Normal (N)) were obtained 
from Drs. Enda McDermott and Vincent Lynch, respectively. Both work at St. 
Vincent’s hospital, Mount Merrion.
2. Samples arrived within 4 hours o f the operation via courier. They were 
transported in a 50ml tube in a sealed clear plastic bag to prevent contamination 
contained inside a padded envelope. Tubes were filled with RNAlater (Ambion, 
7021) to prevent degradation by RNases. Upon arrival, tubes were stored at -  
80°C until RNA isolation.
3. All manipulations o f the human material was carried out inside a class II down- 
flow re-circulating laminar flow cabinet (Nuaire Biological Cabinet) to prevent 
contamination. The floor o f the cabinet was lined with two sheets o f tin foil and 
then covered with two large plastic autoclavable sheets.
4. All implements (e.g. scissors, forceps, tin foil, etc.) used in the RNA isolation 
were baked @ 200°C overnight prior to use.
5. The Tumour/Normal sample was removed from the 50ml tube and squeezed 
using the forceps to remove any excess RNAlater solution. This is carried out as 
the presence o f excess RNAlater alters the pH o f the solution, which affects the 
subsequent yi eld o f RNA.
6 . A piece o f tin foil was folded into a cup shape and ~20mls of liquid N2 was 
added. The liquid N 2 was allowed to boil off, allowing it time to permeate to the 
centre o f the tissue sample.
7. The tin foil was folded over and the frozen tumour was struck roughly several 
times with a hammer. Extra liquid N 2 was added if  sample began to thaw.
8 . Broken pieces o f tissue were removed with a forceps to a Braun potter S8 8 6  
homogenisation chamber. 2 mis o f Tri Reagent was added, the pestle was 
inserted and the cells were homogenised on ice for ~5 mins. at medium speed.
9. After homogenisation, the cell homogenate was removed to two eppendorfs. 
These were spun @ 1300 rpm for 2 mins. in a bench-top microcentrifuge to 
remove large cell debris.
10. The samples then underwent the TRI REAGENT™ protocol for RNA isolation 
(Section 2.4.2.2).
105
2.4.7 RNase H assay
1. An antisense sequence was chosen from the literature or designed from the coding 
strand o f the gene o f interest. This sequence is included in the Appendix.
2. Two primers were selected which were complementary to each other. One o f these 
primers was attached to a T7 RNA polymerase promoter and Leader sequence and 
when amplified, yielded a DNA product complementary to the chosen antisense 
sequence. These primer sequences are also included in the Appendix.
3. The two primers were amplified together in a typical PCR reaction (Section
2.4.2.6 .2), except that there was no template DNA. The mix used was therefore as 
outlined in Table 2.4.4.
Table 2.4.4 List o f components for IVC-PCR
Item Volume (p,ls)
MgCl2 (Sigma, M-8787) 3
10X Buffer (Sigma, P-2317) 5
Primer A 2
Primer B 2
h 2o 36.5
dNTPs (lOmM) (Sigma, DNTP-100) 1
Taq (Sigma, D-4545) 0.5 ( 2  units)
The PCR was cycled for 35 cycles at an appropriate Tm (°C).
4. The PCR product was run out on a 1% agarose gel (Section 2.4.2.6 .3). The 
visualised gel was excised from the gel using a sharp blade and purified using a 
QIAEX II gel extraction kit (Qiagen, 20021) according to the manufacturers 
instructions.
5. Using a T7 Riboprobe kit (Promega, Cat. # P I440), the target DNA was converted 
to RNA, which was used to bind to the Antisense. The kit utilises the T7 RNA 
polymerase promoter to transcribe RNA from the DNA. Transcription takes place in 
the presence of a limiting amount of unlabelled rCTP and an excess o f radioactively 
labelled rCTP ([a-32P]rCTP (Amersham)) which ensures the incorporation o f this 
label into the RNA product. The transcription mix was as outlined in Table 2.4.5.
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Table 2.4.5 List of components for T7-riboprobe [g-32P]rCTP transcription
Item Volume ((ils)
Transcription Optimised 5X Buffer 4
DTT, lOOmM 2
Rnasin 1
ATP, GTP and UTP (2.5mM each) 4
100|i.M CTP 2.4
Template DNA 1
[oT32P]CTP (400Ci /mmol, lOmCi / ml) 5
T7 RNA Polymerase 1
6 . The transcription mix was incubated @ 37°C for 60 mins. After transcription, the 
tubes were spun down to gather all o f the reaction mix at the bottom. 1^1 o f RQ1 
DNase (Promega, M6101, supplied with kit) was then added and the mix was re­
incubated @ 37°C for 15 mins.
7. The transcription mix was extracted once with 24:24:1 Phenol:Chloroform: 
Isolamylalcohol and once with 24:1 Chloroform:Isoamylalcohol, before 0.5 
volumes o f 7.5M Sodium Acetate and 2.5 volumes 100% Ethanol were added. The 
RNA was left to precipitate for 60 mins. at -80°C.
8 . The RNA pellet was spun down at 13,000rpm in a bench-top microfuge and air- 
dried for 10 -  15 mins. The pellet was resuspended in 20 -  30 pis UHP.
9. This RNA product was added to an RNA Quick-Spin Column (Boehringer, 
1273990) which had been prepared according to the manufacturer’s instructions and 
the purified product was collected after centrifugation at 2600rpm for 4mins. in an 
SW28 bucket rotor.
10. A cleavage mix was set up as outlined in Table 2.4.6.
1 0 7
Table 2.4.6 List of components for RNase H-mediated cleavage of RNA
Item Volume (pis)
20mM HEPES-KOH, pH 8.0 1
50mM KCl (Promega, L4591) 1
4mM MgCl2 1
ImM DTT (Promega, PI 171) 1
Radioactively Labelled Target RNA 5
Antisense 5
50 (ig/ml BSA (Promega, R9461) 1
Ribonuclease H (Promega, M4281) 1
Prior to addition o f RNase H, the labelled target and antisense were incubated 
together @ 95°C for 3 mins. before incubation on ice for 1 min. The enzyme was 
then added and the tubes are placed @ 37°C for 20 mins. The reaction was stopped 
by addition of l|a,l o f 0.5 M EDTA (Sigma, E-5134).
11. This reaction mix was run on a 12% Polyacrylamide Gel. The mix for the gel is as 
outlined in Section 2.4.8 .5. Before loading onto the gel, the samples were incubated 
@ 95°C for 3 mins. before incubation on ice for 1 min. The gel was run @ 40V/cm 
for 45 mins. The gel was then removed and covered in clingfilm. X-OMAT AR film 
(Kodak, 1651512) was exposed to the gel overnight and developed as usual.
2.4.8 In-vitro cleavage o f MRP 1 Ribozyme
2.4.8.1 Generation and purification o f the Ribozyme and target DNA templates:
1. Two primers were chosen which would anneal to each other and amplify up a 
DNA copy o f the Ribozyme together with a T7 RNA polymerase Promoter and 
Leader sequence. Another pair o f MRP1 primers were selected which amplified 
up a stretch o f the MRP1 cDNA that contained the Rz cleavage site. The 
sequence o f the primers is included in the Appendix.
2. A standard PCR protocol was carried out using both sets o f primers separately as 
outlined in Section 2.4.2.6 .2.
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3. The PCR samples containing the Ribozyme were freeze-dried for two hours 
until completely desiccated. The dried samples were resuspended in a smaller 
volume o f UHP and purified using a Qiagen kit (Qiagen, 20021).
4. The PCR samples containing the target DNA for cleavage were purified directly 
using the Qiagen kit.
2.4.8.2 Isolation o f cell extract
MRP1 ribozyme-expressing clones were harvested in the usual manner (Section 2.2.3) 
and then resuspended in 1ml 5% SDS solution per 75cm2 flask o f confluent cells. This 
cell extract, or lysate, was agitated for 30 mins. at 4°C. The cell extract was stored at - 
20°C and used at roughly ten times the volumes o f the purified ribozyme RNA in the 
IVC reaction (Section 2.4.8.5).
2.4.8 .3 Ribozyme in-vitro Cleavage assay (IVC):
All radiolabelled RNA sequences were generated using the T7 Riboprobe® system 
(Promega, P I440).
1. The plasmid DNA was first linearised using a standard Sma I restriction enzyme 
which cut only once in the vector and not at all in the insert.
2. The DNA was cleaned up using the Wizard™ Plus Minipreps DNA Purification 
System (Promega, A7100).
3. The mix for the transcription protocol was made up as outlined in Table 2.4.7
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Table 2.4.7 Components for transcription of [a-32P]rCTP-IabeIled ribozyme
Component Volume (pis)
Transcription optimised 5X Buffer 4
DTT, lOOmM 2
Recombinant RNasin® Ribonuclease 0.5
Inhibitor
rATP, rGTP and rUTP7 (2.5 mM each) 4
100 pM rCTP 2.4
Linearised target plasmid DNA8 1
[a '32P] rCTP (50 pCi at 10 pCi/pl) 5
T7 RNA Polymerase 1
4. The eppendorf was incubated for 1 hour at 37°C.
5. 1 pi o f RQ1 DNase (Promega, M6101) was added to the tube and incubated for 15
mins. at 37°C.
2.4.8 .4 Purification of target DNA for Ribozyme cleavage
1. 25 pis TE-saturated pheno 1:chioroform was added to the tube. The tube was 
vortexed and spun down at 13,000rpm in a microfuge.
2. The yellow upper aqueous phase was then transferred to a fresh tube and 25 pis o f 
chloroform:isoamylalcohol (24:1) was added. The tube was vortexed, spun down 
and the upper phase transferred to a fresh tube as before.
3. 12.5 pis of 7.5M ammonium acetate and 75 pis o f  100% ethanol were added. The 
tube was mixed and placed at -70°C for 30 mins.
4. The tube was then centrifuged at 13,000rpm for 20 mins.
5. The supernatant was removed and the pellet was washed with 0.5 mis 70% ethanol.
The pellet was dried at room temperature for 10-15 mins. and finally resuspended in 
20 pis UHP.
7 Prepared by adding 1 (j.1 o f  each o f lOmM rATP, rGTP, rUTP and UHP.
8 Plasmid DNA must have a conc. o f at least 0.5 (a.g/(xl.
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6 . A Quick Spin™ column (Boehringer Mannheim, 1273990) was removed from 
packaging and prepared as instructed. The contents o f the tube were added to the 
column, which was placed in a collection tube.
7. The column was spun down in a Beckman SW28 rotor at 2600rpm for 2 mins.
8 . The eluate was stored at -20°C and the column was discarded.
2.4.8 .5 In-vitro Cleavage reactions with Ribozyme and Target DNA:
1. Cleavage reactions were set up in four eppendorfs as outlined in Table 2.4.8
Table 2.4.8 List o f components for ribozyme in-vitro cleavage (IVC) reactions
Component Volum e (pis)
Target RNA 1
50mM Tris pH 8.0 1
Ribozyme 4
MgCl2 1
Recombinant RNasin® Ribonuclease 1
Inhibitor
UHP 2
2. The UHP, 50mM Tris, target RNA and Ribozyme were added together first. The 
tubes were heated to 90°C for 3 mins. and placed on ice for 1 min.
3. MgCl2 and RNasin® were added to the tubes, and the samples were incubated at 
37°C.
4. The tubes were taken off the heating block at different time points and 10 pis o f 
sample loading dye was added to them to stop the reaction. The time points chosen 
were (mins.) 0, 30, 60,180. All samples were stored at -20°C.
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2.4.8 . 6  Polyacrylamide gel analysis for Sequencing/RNase Win vitro Cleavage
reactions:
The products o f the Ribozyme in-vitro cleavage reactions were run out on 12% 
Acrylamide gels as outlined here.
2.4.8 .6 .1 Preparation o f gel apparatus
Before pouring, the plates were washed in RBS to remove all traces o f gel, rinsed firstly 
with tap water and then UHP. These were then dried with tissue, treated with 10% SDS, 
followed by more UHP and wiped again. The plates were then wiped in one direction 
using 70% Industrial Methylated Spirits (IMS). The plastic seal (for RNase H/in vitro 
cleavage gels) and comb were also rinsed in tap water, UHP and then 70% IMS.
2.4.8 .6 .2 Gel composition (for all gels):
63g Urea (Sigma, U-5378) was dissolved in 15 mis 10X TBE in a microwave, together 
with 10 mis UHP and heated to 60°C. Once in solution, 30 mis 40% Acrylamide (Gibco 
BRL, 35722-024) was added and this was made up to 150 mis with UHP. Once gel cast 
had been assembled, to 50 mis gel o f this gel mix was added 250 pis o f freshly made 
10% APS (Reidel de Haen, 11222) and 50 pis TEMED. The gel mix was then ready to 
pour.
2.4.8 .6 .3 Assembly, Pouring and running o f gels:
For sequencing gels, a plastic sealing strip was lined on both sides o f the casting tray. 
The gel tray was laid flat, and the gel mix was poured onto it, starting from the bottom. 
The front plate was gently pushed forward from the bottom, while continuously adding 
the gel mix, until both plates were laid exactly on top o f each other. The gel cast was 
then fully assembled, with the gel sealed in using clips on both sides. The comb was
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then inserted and the gel was left to set for 30 mins. 21 o f IX  TBE was heated to 60°C 
and added to the gel apparatus. The comb was removed after the gel had set and a 
syringe was used to wash the wells o f residual urea. Sample running buffer (Section
2.4.3.1) was added to a number o f the wells and the gel was pre-run at 1700 volts for 1-
1.5 hours or until the temperature o f the gel reached 40-50°C, after which it was ready 
for loading o f sequencing samples. The samples were heated to 90°C for 3 mins. before 
being loaded on the gel. The gel was run for 2hrs, or until the loading dye (bromophenol 
blue/xylene cyanol) had reached the bottom of the gel.
For RNase Win-vitro cleavage gels, the base plate was laid flat and the outside was 
lined with the plastic seal. The front plate was placed directly over the base plate. The 
cast was kept in place with the use o f bullclips. The seal was tested by the addition o f 
UHP into the cast to check for leaks. Once no leaks were detected, the gel was poured, 
the comb was inserted and left to set. Once set, the bullclips were removed and the gel 
was placed upright in the running apparatus. IX  TBE was used as the gel running 
buffer, the comb was removed and a syringe was used to wash the wells o f residual 
urea. The sample running buffer was added to a number o f the wells and the gel was 
pre-run at 1700 volts for 20 mins., after which it was ready for loading o f cleavage 
reaction samples. The samples were heated to 90°C for 3 mins. before being transferred 
to ice for 1 min., after which they were loaded on the gel. The gel was run at 1700 volts 
for 1 hour, or until the loading dye had approached (within 2  cm of) the bottom of the
2.4.8.6.4 Disassembly and Developing o f acrylamide gels:
For sequencing gels, the plates were separated and 3MM filter paper (cut to size) was 
placed on top o f the gel, avoiding bubbles. The paper was lifted gently, taking the gel 
with the paper. This was then covered with cling film and placed on top o f another sheet 
o f 3MM filter paper in the gel drier, with the cling film facing up. The gel was dried at 
80°C for 2 hours. When dry, the gel was placed in a cassette and in the darkroom the 
cling film was removed and a sheet of X-ray film was placed on the gel (Kodak, X- 
OMAT S, 500 9907). The cassette was sealed shut and the gel was exposed to the film 
for 48 hours. The film was removed from the cassette in the darkroom, placed (and 
agitated) in developer (Kodak, 5070933) for 5 mins., UHP (1 min.), fixer (3 mins.)
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(Kodak, 5211412) and finally UHP again for 1 min. before being left to drip-dry 
overnight.
For RNase H¡in-vitro cleavage gels, the plates were separated and a sheet o f cling film 
was placed over the gel. The gel was placed behind a perspex screen and put inside a 
cupboard in the darkroom. A sheet o f X-ray film (Kodak, 5211412) was placed over the 
cling film and exposed for 48 hours. After exposure, the film was developed in the same 
way as for the sequencing gels.
2.4.9 DNA microarray analysis on BrdU-treated DLKP cells
RNA isolated from DLKP cells which had been exposed to BrdU for one week (Section 
2.3.3) and untreated control DLKP cells was used in the DNA microarray analysis. The 
procedure followed was as outlined by the manufacturer, “Atlas Human Cancer 1.2 
Array Gene” (Clontech, 7851-1). In brief, the procedure involved the generation o f a 
radioactively-labelled complementary DNA (cDNA) copy o f the isolated RNA samples. 
These labelled cDNA samples were each hybridised to a separate DNA array membrane 
(Clontech, PT3547-3) and the membranes were rinsed o f excess label. These hybridised 
membranes were then read using a Cyclone™ Phosphorimager and analysed with 
Atlaslmage™ 2.01 software. Altered expression o f genes observed between the two 
membranes were identified and quantified by computer analysis.
2.4.10 Luciferase transfections and monitoring of expression results
Plasmids containing the luciferase gene attached to truncated forms o f the MRP1 
promoter and a full-length CMV promoter were transfected overnight into DLKP cells 
as outlined in Section 2.4.5. A at lpg/pl working concentration of the plasmids was 
used, o f which l|ug was used per 5X105 cells (except the Positive plasmid, o f which 
10r|g was used per 5X105 cells). The following procedure for analysing luciferase levels 
in transfected cells was the same as that outlined in the Luciferase Assay System™ 
(Promega, E l500). After 24hrs, the cells were washed twice with IX  PBS and then left
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to lyse in IX lysis buffer (5X supplied with kit, diluted to IX with UHP) at 4°C for 
20mins. The lysis buffer, containing lysed cells, was removed to an eppendorf, vortexed 
for 30s and immediately placed in liquid N2. The eppendorf was then quickly thawed 
and the cells were spun at 13,000rpm in a bench-top microfuge (Hereaus). The 
supernatant was removed to a fresh eppendorf and the cell debris discarded. 1 Ojals o f 
this supernatant was then added to 50(.;ls IX luciferase substrate (5X supplied with kit, 
diluted to IX with UHP) and the luciferase levels analysed using a standard 
luminometer.
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Section 3.0
Results
3.1 Analysis o f cells exposed to BrdU
A549 and DLKP cells were cultured as outlined in Section 2.2.3, and set up for BrdU 
treatment (Section 2.3.3). Cells were continuously exposed to BrdU over different 
intervals as outlined in Table 3.1.1
Table 3.1.1 Breakdown of timepoints for drug-exposed DLKP cells
Time Point Sample Assay conditions
(Days) Name
0 C7 No BrdU exposure, Control sample
2 Br2 BrdU exposure for 2 days
5 Br5 BrdU exposure for 5 days
7 Br7 BrdU exposure for 7 days
15 B ri 5 BrdU exposure for 15 days
Initially, RT-PCR was used to analyse whether exposure to the differentiating agent 
resulted in any differences in RNA expression. In-vitro toxicity assays were also used to 
examine if exposure to the differentiating agent resulted in a change in the drug 
resistance profile o f the cell line.
3.1.1 Analysis o f BrdU-exposed A549 and DLKP cells using RT-PCR
Cells were taken down after the course of exposure to the differentiating agent and RNA 
was extracted using the TRI Reagent™ method as outlined in Section 2.4.2.2. Initially, 
RT-PCR was utilised to examine differences in the expression of various genes at the 
RNA level following exposure to BrdU.
All PCRs were duplicated in order to maximise accuracy o f the results. Initially PCRs 
were carried out on two separate isolations of BrdU-exposed cell samples. If the 
expression pattern o f a particular gene was observed to be significantly altered in both 
isolations, the process was repeated on a third, separate isolate for confirmation, again 
in duplicate. If this third result confirmed the earlier two, it was deemed significant and 
repeatable and only results which conformed to this criterion were examined
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individually in the following Sections. The results obtained for the other genes have 
been summarised in Table 3.1.3.
Expression levels o f a total o f twenty-five genes were successfully examined over the 
course o f the study (Table 3.1.2). Positive controls were unavailable for many of these 
samples and even when available, the resultant product was often o f unsatisfactory 
quality. In order to provide positive samples to validate the PCRs, PCR products which 
were deemed to be o f the correct size for the relevant gene (and therefore the correctly 
amplified product), were purified using a Qiagen kit (Qiagen, 20021) and used as 
positive samples. In some cases, these samples did not work as planned and in those gel 
photos the positive and negative lanes are not shown. The negative control used in all 
cases was filter-sterilised water.
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Table 3.1.2 List of genes examined for expression in BrdU-exposed cells
Gene 
M RPl 
MRP2 (cMOAT) 
MRP3 
MRP4 
MRP 5 
MRP6 
Mdr-1 
Mdr-3 
BCRP 
COX-1 
COX-2 
BAXa 
MR IT 
Survivin 
BAG 
BAP 
Bcl-2a 
B c 1 -X l 
Bcl-xs 
eIF-4E 
eIF-2a 
c-myc 
a-catenin 
P-catenin 
E-cadherin
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3.1.1.1 MRP1
MRP1 expression in A549 was found to increase with increasing days o f exposure to 
BrdU up until Day 7, whereafter expression returned to its normal resting state (Fig.
3.1.1). The approximate increase was 74% at day seven.
In DLKP, BrdU also induced MRP1 upregulation. A twelve-fold increase in MRP1 
expression is observed after seven days (Fig. 3.1.1).
3.1.1.2 MRP2 (cMOAT)
MRP2 expression was observed to decrease in BrdU-treated cell line A549 over all 
fifteen days o f treatment (Fig. 3.1.2). This expression decrease was not felt to be of 
significance in this cell line.
By contrast, MRP2 expression was upregulated in DLKP cells after treatment with 
BrdU (Fig. 3.1.2). DLKP expresses very low levels o f MRP2 normally, and the increase 
in expression was could only accurately be determined by densitometry. However, 
while the increase in expression appeared significant, MRP2 expression increasing 29- 
fold after BrdU treatment, the overall increase was not large.
3.1.1.3 MRP3
As can be seen from Fig. 3.1.3, MRP3 expression is almost undetectable in the control 
DLKP sample. However, after exposure to BrdU, expression levels are observed to rise 
to over 300-fold excess after fifteen days. No data exists for MRP 3 expression levels 
after fifteen days.
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Fig. 3.1.1: MRP 1 RT-PCR on BrdU-treated cells
Fig. 3.1.1a:
IX A549 DLKP NEG.
C Br Br Br Br C Br Br Br Br POS.
7 2  5 7 15 7 2  5 7 15
Fig. 3.1.1b:
A549 A549 A549 A549 A549 DLKP DLKP DLKP DLKP DLKP 
C7 Br 2 Br 5 Br 7 Br 15 C7 Br 2 Br 5 Br 7 Br 15
Fig. 3.1.1a: Gel electrophoresis photograph o f MRP 1 RT-PCR results on BrdU-treated
A549 & DLKP cells; Fig. 3.1.1b: Densitometrie analysis o f RT-PCR results.
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Fig. 3. L2:_____ MRP2 RT-PCR on BrdU-treated cells
Fig. 3.1.2a:
IX A549 DLKP Pos. Neg.
C Br Br Br Br C Br Br Br Br
7 2  5 7 15 7 2  5 7 15
cMOAT
ß-actin
Fig. 3.1.2b:
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A549 A549 A549 A549 A549 DLKP DLKP DLKP DLKP DLKP
C7 Br 2 Br 5 Br 7 Br 15 C7 Br 2 Br 5 Br 7 Br 15
Fig. 3.1.2a: Gel electrophoresis photograph o f MRP2 (cMOAT) RT-PCR results on
BrdU-treated A549 & DLKP cells; Fig. 3.1.2b: Densitometrie analysis o f RT-PCR
results.
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Fig. 3.1.3: MRP3 RT-PCR on BrdU-treated DLKP cells
Fig. 3.1.3a:
IX DLKP
C7 Br 2 Br 5 Br7
POS. NEG
Br
15
MRP 3
(3-actin
Fig. 3.1.3b:
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
DLKPC7 DLKP Br 2 DLKP Br 5 DLKP Br 7 DLKP Br 15
Fig. 3.1.3a: Gel electrophoresis photograph of MRP3 RT-PCR results on BrdU-treated
DLKP cells; Fig. 3.1.3b: Densitometric analysis o f RT-PCR results.
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3.1.1.4 MRP4
MRP4 expression was observed to decrease in a logarithmic fashion following BrdU 
treatment in the A549 cell line (Fig. 3.1.4). Like cMOAT and MRP3, MRP4 is 
expressed in A549 at relatively high levels in its normal state. The decrease in 
expression was largest after fifteen days, when expression levels were observed to be at 
12% that o f normal. In DLKP, MRP4 increased in expression over the course o f BrdU 
treatment, peaking at day seven with an increase o f  over 250-fold, before returning to 
near-normal levels.
3.1.1.5 mdr-1
mdr-1 expression was observe to decrease dramatically in A549 cells only after just one 
day o f BrdU treatment, after which levels did not rise significantly over the course of 
treatment (Fig. 3.1.5).
3.1.1.6 BCRP
BCRP expression in A549 was observed to increase gradually with increasing BrdU 
exposure over the whole course o f treatment (Fig. 3.1.6). As with mdr-1, BCRP is 
normally expressed at very low levels in DLKP. However, increasing expression of 
BCRP was observed in this cell line with increasing BrdU exposure up to seven days, at 
which an overall 44-fold increase was observed. Thereafter, expression decreased 
slightly.
3.1.1.7 COX-2
Initially, COX-2 expression in DLKP increased rapidly, reaching a 65-fold increase 
after only five days exposure to BrdU (Fig. 3.1.7). Expression peaked at seven days 
after which it was seen to subside slightly (roughly 44-fold). The gene was found to be 
expressed at very low levels in untreated DLKP cells (by contrast normal A549
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Fig. 3.1.4: MRP4 RT-PCR on BrdU-treated cells
Fig. 3.1.4a: 
IX A549 DLKP
C Br Br Br Br C Br Br Br Br
7 2  5 7 15 7 2  5 7 15
POS. NEG
ß-actin
MRP 4
Fig. 3.1.4b:
C7 Br 2 Br 5 Br 7 Br 15 C7 Br 2 Br 5 Br 7 Br 15
Fig. 3.1.4a: Gel electrophoresis photograph o f MRP4 RT-PCR results on BrdU-treated
A549 & DLKP cells; Fig. 3.1.4b: Densitometrie analysis o f RT-PCR results.
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Fig. 3.1.5: mdr-1 RT-PCR on BrdU-treated A549 cells
Fig. 3.1.5a:
IX A549
C l  Br 2 Br 5 Br 7 Br 15
POS. NEG
P-actin
mdr-1
Fig. 3.1.5b:
A549 C7 A549 Br 2 A 5 4 9 B r5  A 5 4 9 B r7  A 5 4 9B r15
Fig. 3.1.5a: Gel electrophoresis photograph of mdr-1 RT-PCR results on BrdU-treated
A549 cells; Fig. 3.1.5b: Densitometric analysis o f RT-PCR results.
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Fig. 3.1.6: BCRP RT-PCR on BrdU-treated cells
Fig. 3.1.6a:
IX A549
C Br Br Br Br C 
7 2 5 7 15 7
DLKP 
Br Br Br Br 
2 5 7 15
POS. NEG
BCRP
ß-actin
Fig. 3.1.6b:
C7 Br 2 Br 5 Br 7 Br 15 C7 Br 2 Br 5 Br 7 Br 15
A549 A549 A549 A549 A549 DLKP DLKP DLKP DLKP DLKP
Fig. 3.1.6a: Gel electrophoresis photograph o f BCRP RT-PCR results on BrdU-treated
A549 & DLKP cells; Fig. 3.1.6b: Densitometrie analysis o f RT-PCR results.
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Fig. 3.1.7: COX-2 RT-PCR on BrdU-treated DLKP cells
Fig. 3.1.7a:
IX DLKP
C7 Br 2 Br 5 B r7  Br 15
Fig. 3.1.7b:
DLKPC7 DLKP Br 2 DLKP Br 5 DLKP Br 7 DLKP Br 15
Fig. 3.1.7a: Gel electrophoresis photograph o f COX-2 RT-PCR results on BrdU-treated
DLKP cells; Fig. 3.1.7b: Densitometrie analysis o f RT-PCR results.
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expressed over 30 times this amount), so the increase in this gene was found to be 
among the most significant o f all the genes surveyed.
3.1.1.8 eIF-2a
elf-2a expression was found to increase in DLKP cells over the course of BrdU 
treatment (Fig. 3.1.8). Expression was observed to peak after five days exposure to the 
agent, with a three-fold upregulation. Thereafter, expression o f the gene did not alter 
much for the following ten days of treatment.
3.1.1.9 BAX a
A six-fold increase in BAX a  gene expression after five days exposure to BrdU was 
observed in the DLKP cell line (Fig. 3.1.9). This level o f expression remained constant 
until after seven days o f exposure, when it decreased dramatically to 10% that o f normal 
levels. Expression levels o f the gene in untreated cells are normally at a low level.
3.1.1.10 MRIT
As can be seen in Fig. 3.1.10, exposure to BrdU resulted in an increase in expression of 
the MRIT gene in the DLKP cell line. Initially, expression increased rapidly and was 
observed to increase over three-fold after two days o f exposure. This level o f increased 
expression persisted until after five days o f exposure, after which levels decreased to 
near-normal amounts. This expression pattern for MRIT was markedly dissimilar to the 
other patterns, as the expression increase was most noted after only two days exposure 
to the differentiating agent.
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Fig. 3.1.8: elf-2a RT-PCR on BrdU-treated DLKP cells
Fig. 3.1.8a:
IX DLKP NEG POS
C7 Br 2 Br 5 B r7  Br 15
Fig. 3.1.8b:
DLKPC7 DLKP Br 2 DLKP Br 5 DLKP Br 7 DLKP Br 15
Fig. 3.1.8a: Gel electrophoresis photograph of eIF-2a RT-PCR results on BrdU-treated
DLKP cells; Fig. 3.1.8b: Densitometric analysis o f RT-PCR results.
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Fig. 3.1.9: BAXa RT-PCR on BrdU-treated DLKP cells
Fig. 3.1.9a:
IX DLKP POS. NEG
C7 Br 2 Br 5 Br 7 Br 15
Fig. 3.1.9b:
DLKPC7 DLKP Br 2 DLKP Br 5 DLKP Br 7 DLKP Br 15
Fig. 3.1.9a: Gel electrophoresis photograph o f BA Xa RT-PCR results on BrdU-treated
DLKP cells; Fig. 3.1.9b: Densitometrie analysis o f RT-PCR results.
Fig. 3.1.10: MRIT RT-PCR on BrdU-treated DLKP cells
Fig. 3.1.10a:
IX DLKP
C7 Br 2 Br 5 Br 7 Br 15
MRIT
ß-actin
Fig. 3.1.10b:
DLKPC7 DLKP Br 2 DLKP Br 5 DLKP Br 7 DLKP Br 15
Fig. 3.1.10a: Gel electrophoresis photograph o f MRIT RT-PCR results on BrdU-treated
DLKP cells; Fig. 3.1.10b: Densitometrie analysis o f RT-PCR results.
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3.1.1.11 Survivin
Expression o f the Survivin gene was observed to decrease in the DLKP cell line 
following exposure to the differentiating agent, BrdU (Fig. 3.1.11). This was the only 
gene studied in DLKP whose expression was observed to consistently and significantly 
decrease in the cell line.
3.1.1.12 a-catenin
a-catenin expression in DLKP cells was observed to increase slightly in the cells tested 
following exposure to the differentiating agent BrdU. As can be seen in Fig. 3.1.12, the 
degree o f increase was not very large, as the maximum increase was roughly 66% of 
normal basal levels.
3.1.1.13 E-cadherin
The expression o f the E-cadherin gene was observed to increase in BrdU-exposed 
DLKP cells (Fig. 3.1.13). The expansion in expression was at its optimum at day five, 
with a roughly 2.5 fold increase, after which expression levels decreased to near-normal 
amounts after fifteen days o f treatment.
3.1.1.14 Summary of RT-PCR results for BrdU-exposed cells: significant and
non-significant
For purposes o f clarity, the RT-PCR results for the expression profiles of genes 
considered affected significantly by BrdU exposure in DLKP and A549 cells have been 
summarised in Table 3.1.3. The expression of a number o f other genes in these cells 
was also examined using RT-PCR. The results o f these PCRs were not included in the 
earlier Section due to either a lack o f consistency or a lack of significance. The results 
of these PCRs are summarised in Table 3.1.4.
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Fig. 3.1.11: Survivin RT-PCR on BrdU-treated DLKP cells
Br 15
-act in
Fig. 3.1.11b:
DLKPC7 DLKP Br 2 DLKP Br 5 DLKP Br 7 DLKP Br 15
Fig. 3.1.1 la: Gel electrophoresis photograph o f Survivin RT-PCR results on BrdU-
treated DLKP cells; Fig. 3.1.11b: Densitometrie analysis of RT-PCR results.
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Fig. 3.1.12: q-catenin RT-PCR on BrdU-treated DLKP cells
Fig. 3.1.12a:
IX DLKP 1 DLKP 2 Neg Pos
C7 Br Br 5 Br Br C7 Br Br Br Br
2 7 15 2 5 7 15
,-catenin
ß-actin
Fig
2.5 
2
1.5 
1
0.5
0
Fig. 3.1.12a: Gel electrophoresis photograph of a-catenin RT-PCR results on BrdU-
treated DLKP cells; Fig. 3.1.12b: Densitometrie analysis o f RT-PCR results.
.3.1.12b:
DLKP DLKP DLKP DLKP DLKP DLKP DLKP DLKP DLKP DLKP
C7 Br 2 Br 5 Br 7 Br 15 C7 Br 2 Br 5 Br 7 Br 15
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Fig. 3.1.13: E-cadherin RT-PCR on BrdU-treated DLKP cells
Fig. 3.1.13a:
IX DLKP
C7 Br 2 Br 5 Br 7 Br 15
Fig. 3.1.13b:
DLKPC7 DLKP Br 2 DLKP Br 5 DLKP Br 7 DLKP Br 15
Fig. 3.1.13a: Gel electrophoresis photograph o f E-cadherin RT-PCR results on BrdU-
treated DLKP cells; Fig. 3.1.13b: Densitometrie analysis o f RT-PCR results.
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Table 3.1.3 Summary of significant BrdU RT-PCR results
Gene Cell Line Effect o f BrdU on gene expression
MRP1 A549 Slight increase in expression (<two-fold)
DLKP Significant increase in expression (>twelve-fold after seven 
days
MRP2 A549 Slight decrease in expression
DLKP Significant increase in expression (>29-fold after seven days
MRP 3 DLKP Significant increase in expression (>300-fold after seven 
days
MRP4 A549 Significant decrease in expression up to fifteen days
DLKP Overall slight increase in expression
Mdr-1 A549 Significant decrease in expression
BCRP A549 Slight increase in expression (two-fold)
DLKP Significant increase in expression (44-fold after seven days)
COX-2 DLKP Significant increase in expression (67-fold after seven days)
EIF-2a DLKP Significant increase in expression (three-fold after five days)
BAXa DLKP Significant increase in expression (six-fold after five days)
MRIT DLKP Significant increase in expression (three-fold after five days)
Survivin DLKP Significant decrease in expression
a-catenin DLKP Slight increase in expression (<two-fold)
E-
eadherin
DLKP Slight increase in expression (>two-fold)
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Table 3.1.4 Summary oJr 11011-significant BrdU RT-PCR results
Gene Cell Line Effect o f BrdU on gene expression
MRP3 A549 Slight decrease in expression, result not significance
MRP5 DLKP No change in already low level o f gene expression
MRP6 A549 No consistent trend, up- and down-regulation observed 
over the course of the experiment
DLKP Overall decrease in expression, however bands were too 
faint to be certain o f an accurate result
Mdr-1 DLKP BrdU had very little effect on the expression o f this gene
Mdr-3 A549 No mdr-3 expression observed in any o f the samples
DLKP No mdr-3 expression observed in any o f the samples
COX-1 A549 No COX-1 expression observed in any of the samples
DLKP No COX-1 expression observed in any o f the samples
COX-2 A549 Inconsistent pattern o f upregulation, not repeatable
BAX a A549 Slight decrease in expression, result not felt to be of 
significance
BAG A549 Slight increase in expression, result not felt to be of 
significance
DLKP Slight decrease in expression, result not felt to be of 
significance
BAP A549 Slight decrease in expression, result not felt to be of 
significance
DLKP Slight decrease in expression, result not felt to be of 
significance
Survivin A549 Inconsistency in results; one isolate revealed a strong 
decrease in expression, the other a strong increase
MRIT A549 Overall slight increase in expression, however 
expression pattern was inconsistent over different 
isolates
Bel-2a A549 No gene expression observed in BrdU-treated cells
DLKP No gene expression observed in BrdU-treated cells
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Table 3.1.3 Cont’d.
Gene Cell Line Effect o f BrdU on gene expression
B c1-xl/s A549 Inconsistent and unrepeatable expression trends 
observed
DLKP Inconsistent and unrepeatable expression trends 
observed
c-myc A549 Slight increase observed overall, however, this result 
was not felt to be o f significance
DLKP Slight decrease observed in expression, however the 
result is not repeatable
eIF-4E A549 No clear pattern, change in expression varies for each 
isolate
DLKP Overall increase in expression, not consistently 
repeatable
eIF-2a A549 Slight decrease in expression, however not consistently 
repeatable
a-catenin A549 Slight rise in expression levels, unrepeatable
P-catenin A549 Slight decrease in expression, not significant
DLKP Slight increase in expression, not significant
E-cadherin A549 No significant alteration in gene expression
3.1.2 Analysis o f BrdU-exposed DLKP cells using in vitro toxicity testing
In the previous Section, RT-PCR analysis was used to examine the roles played by a 
number of genes in the BrdU-differentiated cell lines A549 and DLKP. The expression 
o f a number o f genes thought to be important in cancer progression and resistance to 
chemotherapy were observed to be altered in both o f these cell lines following exposure 
to BrdU. The greater number o f gene expression changes, however, were seen in the 
DLKP cell line. As a result, this cell line was chosen for further analysis.
In order to examine the effect o f up- and down-regulation o f a number o f these genes in 
the BrdU-treated cells, these treated cells were exposed in-vitro to a selection of
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chemotherapeutic drugs. The chemotherapeutic drugs chosen for in-vitro toxicity testing 
were drugs which are routinely used in the treatment o f lung cancer in the clinical 
setting and which have been used in the characterisation o f numerous lung cancer cell 
lines in our own laboratory. The four drugs chosen were
• Adriamycin (Doxorubicin),
• Cisplatin,
• Taxol
• VP16 (VP16).
The cells were set up for drug treatment as outlined in Section 2.3.1. A second assay 
was also set up exactly one week after the first, in order to provide a duplicate set of 
results. Five time points were then chosen1 for the analysis and treated with BrdU as 
outlined in Section 3.1.
Once the cells had been exposed for the required amount o f time, they were harvested 
and set up for in-vitro toxicity testing as outlined in Section 2.3.1.2. Four separate 
standard toxicity assays involving the four chosen individual chemotherapeutic drugs 
were set up in 96-well tissue culture plates, with one plate for each time point examined, 
giving a total o f 20 plates per experiment.
The cells were then exposed to the various drugs over a range o f concentrations, which 
encompassed the IC50 values for each drug for the DLKP cell line. At the end of the 
seven-day toxicity assay, the cells were taken down and analysed using the acid- 
phosphatase assay (Section 2.3.1.4). The results for the first set o f toxicity experiments 
were then compared with those obtained for the duplicate set for accuracy. If  any 
discrepancies were observed at this stage, the experiment was repeated. The results 
presented here are from one individual experiment which were successfully repeated.
1 These are the same time points which were selected for analysis in the BrdU RT-PCR 
analyses (Section 3.1.1).
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3.1.2.1 Effect o f BrdU-exposure on the drug-resistance o f DLKP cells
As can be seen from Figs. 3 .1 .14 -3 .1 .17 , exposure to the differentiating agent BrdU 
over several o f the selected timepoints does not affect greatly the resistance profile o f 
the DLKP cells. A very slight decrease in drug resistance is revealed with increasing 
length o f exposure to BrdU. However, this decrease is extremely small and is not 
considered significant.
After seven days exposure to BrdU, the growth rate o f the cells was observed to be 
severely interrupted, which facilitated the elimination o f the cells at a far lower drug 
concentration than that previously determined by toxicity analysis. This result was 
observed to be generally the same over the range o f drugs studied. By day fifteen, the 
growth rate o f the cells had returned to normal.
These results indicate that, in spite o f changes in gene expression (at the mRNA level) 
o f several genes which may be expected to confer drug resistance, no significant change 
in resistance to the drugs is observed. However, at day seven, exposure to BrdU resulted 
in a significant interruption of cell survival which was not observed at any o f the other 
time points.
3.1.3 Analysis o f BrdU-treated DLKP cells using Western blotting
These western blots were carried out by Rasha Linehan. The BrdU-exposed DLKP cells 
were also analysed using Western blotting. Analysis with this technique was limited to 
the number o f antibodies currently available for analysis in the NCTCC. Western blot 
analysis on whole-cell protein preparations was carried out on the cells for Survivin and 
MRP1. No expression o f the MRP1 protein was detected in these preparations of 
DLKP. However, expression o f the Survivin protein was observed to decrease slightly 
in the DLKP cells following treatment with BrdU. Fig. 3.1.18 shows the results o f the 
Survivin western blot as well as an a-tubulin western blot which was used to normalise 
the Survivin results. From the data presented in the densitometry, it can be seen that 
Survivin expression levels decrease slightly after two days exposure to the agent before 
increasing again up to seven days. After fifteen days exposure, expression levels have 
again decreased to less than half that of normal cells.
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Fig. 3.1.14 Effect of BrdU exposure on Adriamycin resistance in DLKP cells
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Fig. 3.1.15 Effect of BrdU exposure on Cisplatin resistance in DLKP cells
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Fig, 3.1.16 Effect of BrdU exposure on Taxol resistance in DLKP cells
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Fig. 3.1.17 Effect of BrdU exposure on VP16 resistance in DLKP cells
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Fig. 3.1.18: Survivin Western on BrdU-treated DLKP cells
Fig. 3.1.18a: 
DLKP Br 2 Br 5 Br 7 Br 15
Fig. 3.1.18b: 
DLKP Br 2 Br 5 Br 7 Br 15
Fig. 3.1.18c:
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Fig. 3.1.18a: Survivin W estern blot analysis o f  BrdU-treated D L K P  cells; F ig. 3 .1.18b: 
a-tubulin W estern blot on BrdU-treated D L K P  cells; F ig. 3 .1.18 c: Densitometrie 
analysis o f  W estern blot results.
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Fig. 3.1.18: Survivin Western on BrdU-treated DLKP cells
Fig. 3.1.18a:
DLKP Br 2 Br5 Br 7 Br 15
Fig. 3.1.18b:
DLKP Br 2 Br5 Br 7 Br 15
Fig. 3.1.18c:
DLKP Br 2 Br 5 Br 7 Br 15
Fig. 3.1.18a: Survivin Western blot analysis o f BrdU-treated DLKP cells; Fig. 3.1.18b: 
a-tubulin Western blot on BrdU-treated DLKP cells; Fig. 3.1.18c: Densitometric 
analysis o f Western blot results.
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3.2 Analysis o f cells continuously exposed to chemotherapeutic drugs
DLKP was exposed to a variety o f chemotherapeutic drugs to ascertain if  these drugs 
could, like BrdU, cause significant alterations in gene expression. The drugs selected for 
exposure, VP 16, Taxol and Cisplatin, are commonly used in the treatment o f lung 
cancer. As outlined in Section 1.5.4 o f the introduction, exposure o f cells to these drugs 
as well as drug-selection has resulted in increased expression o f several cancer-related 
genes. The cells were exposed to a sub-lethal concentration o f each drug which was 
chosen to ensure maximum cell survival while not affecting the inducible gene response 
already observed. The concentration of each drug used is listed in Table 3.2.1. The 
procedure for setting up this assay has already been outlined in Section 2.3.4. The cells 
were exposed to the relevant concentration o f each drug at the same specified intervals 
as those for the BrdU assays and were finally taken down two weeks after the exposure 
has commenced and subjected to analysis by RT-PCR and in-vitro toxicity testing. Two 
separate control cell lines were used in the analyses in order to increase the accuracy of 
the assay.
Drug Type Stock Concentration (rig/pl) Working Concentration (r|g/ml)
Cisplatin 1000 125
Taxol 6000 0.15
VP 16 20000 30
3.2.1 Analysis o f drug-exposed DLKP cells using RT-PCR analysis
Cells were taken down after the course o f exposure to each chemotherapeutic drug and 
RNA was extracted using the TRI Reagent™ method as outlined in Section 2.4.2.2. 
Each time course corresponded to a time point already examined in the BrdU exposure 
assays (Section 3.1) and are represented on the graphical plots here by those 
chronological divisions (i.e. VP 16 2 -  two days exposure to VP 16, VP 16 5 -  five days, 
etc.). Standard RT-PCR analysis was carried out on all RNA samples isolated as 
outlined (Section 2.4.2.5). All PCRs were duplicated in order to maximise accuracy of
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the results. Duplicate untreated DLKP control samples were also included to check 
reproducibility.
AH twenty-five genes whose expression was studied by RT-PCR in the BrdU-treated 
cells were also examined for altered expression in the drug-exposed DLKP cells. The 
negative control used in all cases was filter-sterilised water. Only results which were 
considered significant will be examined in detail in this Section.
3.2.1.1 MRP1
MRP1 expression was observed to be strongly upregulated following short-term 
exposure to the drugs cisplatin and VP16 (Figs. 3.2.1 and 3.2.2). Exposure o f the DLKP 
cells to taxol did not result in increased MRP1 expression (data not shown).
3.2.1.2 MRP2 (cMOAT)
MRP2 expression was observed increased in the DLKP cell line following exposure to 
all three selected chemotherapeutic drugs (Figs. 3.2.3 -  3.2.5).
3.2.1.3 BCRP
BCRP expression was observed increased in the DLKP cell line following exposure to 
cisplatin (Fig. 3.2.6). However, the expression increase was not exactly the same for 
both sets o f samples. In the first set, a strong difference in expression levels o f the gene 
was observed between the two control samples. Also, in this set, BCRP expression 
increased roughly two-fold by day seven only to decrease to near-normal levels by day 
fifteen. In the second set, expression o f the gene followed the same pattern, although 
increasing by a higher amount and ending at over two-fold the normal expression levels 
by day fifteen. However, it was felt that, in both cases, the increase in expression was 
repeatable and consistent with exposure to the chemotherapeutic agent, cisplatin.
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Fig. 3.2.1: MRP 1 RT-PCR on Cisplatin-treated DLKP^ells
Fig. 3.2.1a:
IX OLK DLK 2 
p p
15 Pos. Neg
MRP1
ß-actin
Fig. 3.2.1b:
Fig. 3.2.1a: Gel electrophoresis photograph o f MRP1 RT-PCR results on Cisplatin-
exposed DLKP cells; Fig. 3.2.1b: Densitometrie analysis o f  RT-PCR results.
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Fig. 3.2.2: MRP1 RT-PCR on VP16-treated DLKP cells
Fig. 3.2.2a:
Di DLK DLK 2 
P P
15 DLK DLK 
P P
7 15 Neg Pos.
ß-actin
Fig. 3.2.2b:
DLKP DLKP VP16 VP16 VP16 VP16 DLKP DLKP VP16 VP16 VP16 VP16 
2 5 7 15 2 5 7 15
Fig. 3.2.2a: Gel electrophoresis photograph o f MRP1 RT-PCR results on Etoposide-
exposed DLKP cells; Fig. 3.2.2b: Densitometrie analysis o f RT-PCR results.
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Fig. 3.2.3: MRP2 RT-PCR on Cisplatin-treated DLKP cells
Fig. 3.2.3a:
IX DLK DLK 2 5 7 15 DLK DLK 2 5 7 15 Neg Pos.
P P  P P
\/T D D 2
Fig. 3.2.3b:
Fig. 3.2.3a: Gel electrophoresis photograph o f MRP2 RT-PCR results on Cisplatin-
exposed DLKP cells; Fig. 3.2.3b: Densitometrie analysis o f RT-PCR results.
Fig. 3.2.4: MRP2 RT-PCR on Taxol-treated DLKP cells
Fig. 3.2.4a:
IX DLK DLK 2 5 7 15 DLK DLK 2 5 7 15 Neg Pos.
P P  P P
Fig. 3.2.4b:
Fig. 3.2.4a: Gel electrophoresis photograph o f MRP2 RT-PCR results on Taxol-exposed
DLKP cells; Fig. 3.2.4b: Densitometrie analysis o f RT-PCR results.
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Fig. 3.2.5: MRP2 RT-PCR on VP16-treated DLKP cells
Fig. 3.2.5a:
DC DLK DLK 2 5 7 15 DLK DLK 2 5 7 15 Neg Pos.
P P  P P
Fig. 3.2.5b:
Fig. 3.2.5a: Gel electrophoresis photograph of MRP2 RT-PCR results on VP16-exposed
DLKP cells; Fig. 3.2.5b: Densitometrie analysis o f RT-PCR results.
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Fig. 3.2.6: BCRP RT-PCR on Cisplatin-treated DLKP cells
Fig. 3.2.6a:
DC DLK DLK 2 5 7 15 DLK DLK 2 5 7 15 Neg Pos.
P P  P P
Fig. 3.2.6b:
Fig. 3.2.6a: Gel electrophoresis photograph o f BCRP RT-PCR results on Cisplatin-
exposed DLKP cells; Fig. 3.2.6b: Densitometrie analysis o f  RT-PCR results.
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Exposure o f the DLKP cells to taxol and VP 16 did result in some slight expression 
changes o f BCRP. However, these were not felt to be o f significance (data not shown).
3.2.1.4 a-catenin
Exposure o f DLKP cells to two of the chemotherapeutic drugs tested (taxol and VP 16) 
increased a-catenin expression (Figs. 3.2.7 and 3.2.8). In the case o f the VP16-treated 
cells, the expression increase was highly significant, with an overall increase o f over 
seven-fold after five days exposure to the drug. For the taxol-exposed cells, the result 
was far less impressive. Treatment with cisplatin was also observed to increase 
expression o f a-catenin in one o f the sample sets but not in the duplicate (data not 
shown).
3.2.1.5 E-cadherin
Exposure o f the DLKP cell line to taxol was observed to result in a small increase in 
expression of the E-cadherin gene (Fig. 3.2.9). Although the pattern o f expression 
increase was not identical in both sample sets, the increase in both was deemed 
significant at day fifteen.
3.2.1.6 Summary of RT-PCR results for drug-exposed DLKP cells: significant
and non-significant
For purposes o f clarity, the RT-PCR results for the expression profiles of genes 
considered affected significantly by drug exposure in DLKP cells have been 
summarised in Table 3.2.2.
1 5 5
Fig. 3.2.7: a-catenin RT-PCR on Taxol-treated DLKP cells
Fig. 3.2.7a:
IX DLK DLK 2 5 7 15 DLK DLK 2 5 7 15 Neg Pos.
P P  P P
Fig. 3.2.7b:
Fig. 3.2.7a: Gel electrophoresis photograph o f a-catenin RT-PCR results on Taxol-
exposed DLKP cells; Fig. 3.2.7b: Densitometrie analysis o f RT-PCR results.
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Fig. 3.2.8: a-catenin RT-PCR on VP16-treated DLKP cells
Fig. 3.2.8a:
IX DLK DLK 2 5 7 15 DLK DLK 2 5 7 15 Neg Pos.
i> P P P
Fig. 3.2.8b:
4
3.5 
3
2.5 
2
1.5 
1
0.5- 
0
Fig. 3.2.8a: Gel electrophoresis photograph o f a-catenin RT-PCR results on VP16-
exposed DLKP cells; Fig. 3.2.8b: Densitometrie analysis o f RT-PCR results.
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Fig. 3.2.9: E-cadherin RT-PCR on Taxol-treated DLKP cells
Fig. 3.2.9a:
IX DLK DLK 2 5 7 15 DLK DLK 2 5 7 15 Neg Pos.
P P  P P
Fig. 3.2.9b: 
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Fig. 3.2.9a: Gel electrophoresis photograph o f E-cadherin RT-PCR results on Taxol-
exposed DLKP cells; Fig. 3.2.9b: Densitometrie analysis o f RT-PCR results.
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Table 3.2.2 Summary of significant RT-PCR results for drug-exposed DLKP
Gene Drug Used Effect o f drug exposure on gene expression
MRP1 Cisplatin Significant increase in expression (>three-fold)
VP16 Significant increase in expression (>three-fold)
MRP2 Cisplatin Significant increase in expression (>thirty-fold)
Taxol Significant increase in expression (>six-fold)
VP16 Significant increase in expression (>four-fold)
BCRP Cisplatin Small increase in expression (two-fold)
a-catenin Taxol Small increase in expression (two-fold)
VP16 Significant increase in expression (>seven-fold)
E-cadherin Taxol Small increase in expression (two-fold)
O f the thirteen expression RT-PCRs carried out on the drug-exposed DLKP cells 
however, only five were observed to yield significant increases in gene expression 
following exposure to the chemotherapeutic agents. In no sample set was a significant 
decrease in gene expression observed. The results o f the non-significant PCR results are 
summarised in Table 3.2.3.
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Table 3.2.3 Summary of non-significant RT-PCR results for drug-exposed DLKP
Gene Drug type Result
MRP1 Taxol No change in expression profile
MRP3 Cisplatin No change in expression profile
Taxol No change in expression profile
VP16 No change in expression profile
MRP4 Cisplatin Slight increase in expression, unrepeatable
Taxol No change in expression profile
VP16 No change in expression profile
MRP 5 Cisplatin Slight decrease in expression
Taxol No change in expression profile
VP 16 No change in expression profile
MRP6 Cisplatin No gene expression detected
Taxol No gene expression detected
VP 16 No gene expression detected
Mdr-1 Cisplatin Little change in expression
Taxol Slight decrease in expression
VP16 No change in expression profile
Mdr-3 Cisplatin No gene expression detected
Taxol No gene expression detected
VP16 No gene expression detected
BCRP Taxol Variation in expression profile, very inconsistent
VP16 Same as for taxol-exposed DLKP
COX-1 Cisplatin No change in expression profile
Taxol No change in expression profile
VP16 No change in expression profile
COX-2 Cisplatin No change in expression profile
Taxol No change in expression profile
VP16 No change in expression profile
BAXa Cisplatin No change in expression profile
Taxol No change in expression profile
VP16 No change in expression profile
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Table 3.2.3 Cont’d.
Gene Drug type Result
MRIT Cisplatin No change in expression profile
Taxol No change in expression profile
VP16 No change in expression profile
Survivin Cisplatin No change in expression profile
Taxol No change in expression profile
VP16 No change in expression profile
BAG Cisplatin No change in expression profile
Taxol No change in expression profile
VP16 No change in expression profile
BAP Cisplatin No change in expression profile
Taxol No change in expression profile
VP16 No change in expression profile
Bcl-2a Cisplatin No change in expression profile
Taxol No change in expression profile
VP16 No change in expression profile
B c1-x l Cisplatin No change in expression profile
Taxol No change in expression profile
VP16 No change in expression profile
Bcl-xs Cisplatin No change in expression profile
Taxol No change in expression profile
VP16 No change in expression profile
eIF-4E Cisplatin No change in expression profile
Taxol No change in expression profile
VP16 No change in expression profile
eIF-2a Cisplatin No change in expression profile
Taxol No change in expression profile
VP16 No change in expression profile
e-myc Cisplatin No change in expression profile
Taxol No change in expression profile
VP16 No change in expression profile
a-catenin Cisplatin Slight increase in one sample
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Table 3.2.3 Cont’d.
Gene Drug type Result
P-catenin Cisplatin No change in expression profile
Taxol No change in expression profile
VP16 No change in expression profile
E-cadherin Cisplatin Slight increases in some samples
VP16 Same as for cisplatin-exposed DLKP
3.2.2 Analysis o f drug-exposed DLKP cells using in vitro toxicity testing
3.2.2.1 Effect o f Cisplatin exposure on DLKP drug-resistance profiles
As can be seen from Figs. 3.2.10 -  3.2.13, continuous exposure (as described in Section
3.2.1) to a selected sub-lethal concentration o f cisplatin did not elicit any great change 
in the toxicity profile o f the DLKP cells, nor the resultant IC 5 0  values. O f the four drug 
types chosen for examination, cisplatin did not affect very much the expected dose- 
response curve. However, in all cases, the level o f growth for the day five-treated 
sample was slightly higher than for all the other treatments, including the untreated 
controls. This increase ranged from 20-40% of the initial level o f growth for the control 
cells. Overall, the toxicity profiles did not appear to match those o f the BrdU samples, 
as the dose-response curve obtained for the day seven sample resembled for the greater 
part those o f the other treatments.
3.2.2.2 Effect o f Taxol exposure on the drug-resistance profiles o f DLKP cells
The results from these toxicity assays can be seen in Figs. 3.2.14 -  3.2.17. The drug 
profile results for the taxol-exposed DLKP cells did not differ greatly from those 
obtained for the cisplatin-exposed cells. As seen for the cisplatin-treated DLKP, the 
exposure o f the cells to low continuous-doses o f Taxol did not appear to alter the dose- 
response curves for any o f the treated samples. As can be seen from the dose-response 
curves, the pattern o f response does not differ much from treatment to treatment. Also,
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Fig. 3.2.10: Effect of Cisplatin exposure on Adriamycin resistance in DLKP cells
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Fig. 3.2.11: Effect of Cisplatin exposure on Cisplatin resistance in DLKP cells
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Fig. 3.2.12: Effect of Cisplatin exposure on Taxol resistance in DLKP cells
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Fig 3.2.13: Effect of Cisplatin exposure on VP16 resistance in DLKP cells
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Fig. 3.2.14: Effect of Taxol exposure on Adriamycin resistance in DLKP cells
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Fig. 3.2.15: Effect of Taxol exposure on Cisplatin resistance in DLKP cells
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Fig. 3.2.16: Effect of Taxol exposure on Taxol resistance in DLKP cells
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Fig. 3.2.17: Effect of Taxol exposure on VP16 resistance in DLKP cells
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as observed for the cisplatin-exposed cells, the dose-response curve for the day five 
sample was consistently higher than for the other samples, varying between 2 0  and 60% 
more than that o f the nearest untreated control growth sample. A comparison of the 
relevant IC 5 0 values, however, reveals no significant change in the drug-resistance 
profiles o f the cells. The profiles also did not match those obtained for the BrdU-treated 
samples, as the day seven-treated sample did not exhibit a lowered dose-response curve 
than those obtained for the other treatments.
3.2.2.3 Effect o f VP16 exposure on DLKP drug-resistance profiles
The drug-resistance profiles o f the VP16-exposed DLKP cells differed significantly 
from their control samples (Figs. 3.2.18 -  3.2.21), and also from the samples observed 
already. In each o f the four toxicity assays, the dose-response curves o f the VP16- 
treated cells were significantly lower than those obtained for the untreated control cells. 
It would appear from the plots that exposure to the drug caused a general disruptive 
effect on the growth of the cell which hinders the cell’s ability to respond to a toxicity 
assay with other, structurally unrelated, drugs. Furthermore, the debilitating effect on 
the growth o f the cell appears to worsen with increasing length of exposure to VP 16, 
and as such the dose-response pattern differs very significantly both from the patterns 
observed for the other treatments, as well as for the BrdU-exposed cells. While the 
general debilitative effect o f VP 16 on the growth o f  DLKP resembled slightly that 
obtained for the day seven BrdU-treated sample, none o f the other BrdU treatments 
resulted in this effect. An examination of the relative IC50s also reveals no significant 
change for the VP16-exposed samples relative to the control cells for each of the 
different drugs.
171
Fig. 3.2.18: Effect of VP 16 exposure on Adriamycin resistance in DLKP cells
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Fig. 3.2.19: Effect of VP16 exposure on Cisplatin resistance in DLKP cells
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Fig. 3.2.20: Effect of VP16 exposure on Taxol resistance in DLKP cells
Taxol Cone, (ng/ml)
Fig. 3.2.21: Effect of VP16 exposure on VP16 resistance in DLKP cells
VP16 Cone, (ug/ml)
3.3 Analysis of drug-selected DLKP cell lines using RT-PCR
The DLKP cell line was continuously pulse-selected (four to ten times) in a number of 
sub-lethal drug concentrations over a number o f weeks by Dr.Yizheng Liang. This 
procedure resulted in the selection out o f a number o f cell lines which displayed an 
increased resistance profile to the drug o f selection relative to the parent DLKP.
It was thought that an analysis o f the gene expression profiles o f these drug-selected cell 
lines would be useful in that it may provide certain correlations between the expression 
of certain genes relevant to continuous long- and short-term exposures to 
chemotherapeutic drugs. The effect of short-term exposure o f DLKP cells to a smaller 
number o f drugs has already been examined (Section 3.2.1); this Section will deal with 
the effect o f long-term selection o f the DLKP cell line in the presence o f a larger 
number o f chemotherapeutic agents.
The cells were set up and harvested as for a standard drug-exposure assay (Section 
2.3.3) by Dr. Liang and RNA was harvested and quantified in the usual manner (Section
2.4.2). This RNA was then used in RT-PCR reactions using all the available primers for 
multidrug resistance-related genes, as well as the a -  and (3-catenins as well as E- 
cadherin. Expression levels of the apoptotic genes were not examined for the drug- 
selected DLKP. The PCR products were run out on 2% agarose gels and photographed 
using film negatives for densitometric analysis. A total o f ten chemotherapeutic drugs 
were used in the selection process; these are listed, along with their abbreviations and 
method o f action in Table 3.3.1.
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Table 3.3.1 List of all drugs used in long-term selection from DLKP
Name of Drug Abbreviation Method o f action
Vincristine VCR Inhibitor o f chromatin function
VP16 VP 16 Inhibitor o f chromatin function
Taxotere Taxot Inhibitor o f chromatin function
Mitoxantrone Mitox Inhibitor o f chromatin function
Lomustine CCNU Covalent DNA binding drug
Carmustine BCNU Covalent DNA binding drug
Chlorambucil Chlor Covalent DNA binding drug
Cisplatin Cispl Non-covalent DNA binding drug
5-fluorouracil 5-FU Anti-metabolic drug
Methotrexate MTX Anti-metabolic drug
3.3.1 MRP 1
MRP1 expression was increased in most o f the drug-selected cell lines (Fig. 3.3.1). No 
change in expression was observed after selection in 5-fluorouracil and expression was 
slightly lowered in the Mitoxantrone-selected cell line. All other selections showed a 
slight increase in MRP1 gene expression following selection, most significant o f which 
was observed in the Vincristine- and VP16-selected cell lines (roughly two-fold). Short­
term exposures to cisplatin and VP 16 (Section 3.2.1) also revealed increased MRP1 
expression following exposure to VP 16.
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Fig. 3.3.1: MRP1 RT-PCR results on drug-selected cell lines
Fig. 3.3.1a:
Fig. 3.3.1b:
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Fig. 3.3.1a: Gel electrophoresis photograph of MRP 1 RT-PCR results on drug-selected
DLKP cells; Fig 3.3.1b: Densitometrie analysis of RT-PCR results.
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3.3.2 MRP 2 (cMOAT)
Only continuous selection in Vincristine resulted in an increased level o f expression of 
the MRP2 gene in these cell lines (>two-fold) (Fig. 3.3.2). All other selections resulted 
in slight decreases in the level o f cMOAT gene expression. This is in marked contrast to 
the short-term exposure results, where exposure to all three drugs resulted in significant 
upregulation o f cMOAT gene expression (Section 3.2.1).
3.3.3 MRP3
MRP3 expression was decreased in most of the drug-selected DLKP cell lines studied 
(Fig. 3.3.3). Expression o f the gene was observed increased in only two o f the drug- 
selected cell lines; those selected in Taxotere and Methotrexate. Short-term exposure o f 
DLKP to cisplatin, taxol and VP 16 also revealed no change in MRP3 expression 
(Section 3.2.1).
3.3.4 MRP4
MRP4 expression either decreased or remained unaffected in most o f the drug-selected 
cell lines studied (Fig. 3.3.4). MRP4 expression increased 2-fold in response to 
selection to the drugs CCNU, Cisplatin and Methotrexate. Expression of the gene was 
increased in excess o f three-fold in response to selection in BCNU. Gene expression 
had decreased following selection in Chlorambucil, Vincristine and VP 16. All other 
results were deemed insignificant. Short-term exposure o f DLKP to cisplatin, taxol and 
VP16 also revealed no change in MRP4 expression (Section 3.2.1).
3.3.5 MRP5
MRP 5 expression was increased in the majority of the drug-selected cell lines (Fig. 
3.3.5). Only selection in Vincristine and CCNU appeared to result in decreased or
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Fig. 3.3.2: MRP2 RT-PCR results from drug-selected cell lines 
Fig. 3.3.2a:
IX DLK DLK. VCR VP Taxo Mito CC BC Ch Cispl 5- MT Ne Pos.
P P 16 -tere x NU NU lor FU X g.
M R P 2
Fig. 3.3.2b:
0.6
DLKP DLKP VCR VP16 Taxot Mitox CCNU BCNU Chlor Cispl 5-FU MTX
Fig. 3.3.2a: Gel electrophoresis photograph of MRP2 RT-PCR results on drug-selected
DLKP cells; Fig 3.3.2b: Densitometrie analysis of RT-PCR results.
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Fig. 3.3.3: MRP3 RT-PCR results from drug-selected cell lines
Fig. 3.3.3a:
IX DLK DLK Taxo VP VCR Mi CCN BCN Chlo Ci 5-FU MT Neg. Pos.
P P tere 16 tox U U r spl X
MRP3
ß-actin
Fig. 3.3.3b:
DLKP DLKP Taxot VP16 VCR Mitox CCNU BCNU Chlor Cispl 5-FU MTX
Fig. 3.3.3a: Gel electrophoresis photograph of MRP3 RT-PCR results on drug-selected
DLKP cells; Fig 3.3.3b: Densitometrie analysis of RT-PCR results.
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Fig. 3.3.4: MRP4 RT-PCR results from drug-selected cell lines
Fig. 3.3.4a:
IX DLK DLK CCN BCN Ch Cispl VCR VP Taxo Mi 5-FU MT Neg. Pos.
p p U U lor 16 -tere tox X
ß-actin
MRP4
Fig. 3.3.4b:
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Fig. 3.3.4a: Gel electrophoresis photograph of MRP4 RT-PCR repeat results on drug-
selected DLKP cells; Fig 3.3.4b: Densitometrie analysis of RT-PCR results.
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Fig. 3.3.5: MRP5 RT-PCRresults from drug-selected cell lines
Fig. 3.3.5a:
IX DLK DLK VCR VP Taxo Mi BCN CCN Chlo Ci 5- MT Neg. Pos.
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Fig. 3.3.5b:
2.5
1.5
0.5
DLKP DLKP VCR VP16 Taxot Mitox BCNU CCNU Chlor Cispl 5-FU MTX
Fig. 3.3.5a: Gel electrophoresis photograph of MRP5 RT-PCR results on drug-selected
DLKP cells; Fig 3.3.5b: Densitometric analysis of RT-PCR results.
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unaffected expression. Short-term exposure to cisplatin, taxol and VP 16 did not result in 
increased MRP5 expression (Section 3.2.1).
3.3.6 mdr-1
DLKP expresses very low levels o f mdr-1 basally, and this is borne out by the control 
samples. Overall, mdr-1 expression was not altered significantly in most o f the drug- 
selected cell lines (Fig. 3.3.6). Only selection in Vincristine and Taxotere resulted in an 
increased expression level of the gene. Vincristine increased expression levels roughly 
four-fold, whereas selection in Taxotere increased levels almost 35-fold. No change in 
mdr-1 expression in DLKP was observed using short-term exposure to cisplatin, taxol, 
or VP 16.
3.3.7 BCRP
BCRP expression was observed to be decreased in most o f  the drug-selected cell lines 
(Fig. 3.3.7). The only significant increase was observed in the Mitoxantrone-selected 
cell line, which yielded a BCRP expression increase over eight-fold that o f normal 
DLKP cells. In contrast to the short-term exposure result (Section 3.2.1), in which 
BCRP expression was observed increased following exposure to cisplatin, selection in 
the drug resulted in decreased expression o f the gene.
3.3.8 Summary o f genes showing increased expression following selection in drug
As already outlined, this study had a dual purpose; to reveal if  selection of DLKP in 
different drugs revealed similar gene expression results to short-term exposure of the 
cell line to those drugs and also to indicate potential drug substrates for the multidrug 
resistance-associated genes currently under examination. The results for this second 
purpose are listed in Table 3.3.2.
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Fig. 3.3.6: mdr-1 RT-PCR results from drug-selected cell lines
Fig. 3.3.6a:
IX DLK DLK VCR VP Taxo Mi CCN BCN Ch Cispl 5-FU MT Neg.
P P 16 -tere tox U U lor X
Pos.
ß-actin
mdr-1
Fig. 3.3.6b:
Fig. 3.3.6a: Gel electrophoresis photograph of mdr-1 RT-PCR results on drug-selected
DLKP cells; Fig 3.3.6b: Densitometrie analysis of RT-PCR results.
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Fig. 3.3.7: BCRP RT-PCR results from drug-selected cell lines
Fig. 3.3.7a:
Fig. 3.3.7b:
DLKP DLKP VCR VP16 Taxot Mitox CCNU BCNU Chlor Cispl 5-FU MTX
Fig. 3.3.7a: Gel electrophoresis photograph of BCRP RT-PCR results on drug-selected
DLKP cells; Fig 3.3.7b: Densitometrie analysis of RT-PCR results.
Table 3.3.2 List of genes with increased expression following selection in drug
Drug Name Genes Upregulated Amount o f increase
Vincristine MRP1 2-fold
MRP2 >2-fold
Mdr-1 4-fold
VP16 (VP16) MRP1 2-fold
MRP5 4-fold
Taxotere MRP3 4-fold
MRP5 5-fold
mdr-1 35-fold
Miloxantrone MRP 5 4-fold
BCRP >8-fold
CCNU MRP1 1.5-fold
MRP4 2-fold
BCNU MRP1 1.5-fold
MRP4 >3-fold
MRP5 5-fold
Chlorambucil MRP5 3-fold
Cisplatin MRP4 2-fold
MRP5 4-fold
5-fluorouraciI MRP 5 5-fold
Methotrexate MRP3 >2-fold
MRP4 2-fold
MRP5 4-fold
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3.4 Analysis of promoter regions of genes affected by BrdU exposure
3.4.1 Transcription factor analysis o f promoter regions
From the results presented in Section 3.1.1, it was seen that exposing actively growing 
cells to the differentiating agent BrdU alters the mRNA expression levels o f a number 
o f specific genes. It was hypothesised from this observation that BrdU may affect 
expression of these genes at the transcriptional level, although the possibility that 
alterations in mRNA stability may be responsible could not be disregarded. It was also 
hypothesised that if  BrdU were affecting expression o f these genes transcriptionally, it 
may mediate this effect through a common transcription factor.
In order to test the BrdU-regulated common-transcription factor hypothesis, a sequence 
analysis o f the 5’ promoter regions of genes whose expression increased in BrdU- 
treated DLKP cells was carried out using a specific computer package which searches 
these sequences for known transcription factor binding sites. Once found and collated, 
the obtained transcription factors for each gene could be compared to each other in 
order to identify common transcription factors.
As the bulk o f the upregulated gene results were observed in DLKP, it was felt that 
analysis o f results in this cell line would be the most productive, although, as shall be 
demonstrated, the analysis was also extended to the A549 cell line as well. From the 
results presented in Section 3.1.1, a total o f twelve genes were observed to display 
increased expression in the DLKP cell line following exposure to BrdU. Nine o f these 
genes, MRPs 1-3, BCRP, COX-2, eIF-2a, MRIT, a-catenin and E-cadherin were 
chosen as the genes which would be subjected to the transcription factor analysis which 
will be outlined here.
Up to 3kb of sequence data from the promoter regions o f these six genes was obtained 
from GENBANK (http://www.ncbi.nlm.nih. gov/80/~) using BLAST searches and 
entered into the Transfac™ (http://www.transfac.gbf.de) database. The choice of 3kb of 
promoter sequence was an arbitrary one; previous characterisations o f the promoter
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regions o f the MRP genes 1, 2 and 3 (Zhu and Center, 1994; Stockel et ah, 2000, 
Fromm et ah, 1999) used between lkb and 2kb of promoter sequence for analysis. (This 
3kb o f promoter sequence denotes 3kb o f data in reverse from the translational start site 
of the gene). The database is web-based and analyses sequence for known transcription 
factor recognition sequences (motifs). The recognition sequences for these factors often 
vary by a few bases even within the same gene sequence. For this reason, a sample 
sequence m otif only is shown in Table 3.4.1 for each transcription recognition site, as to 
include all possible sequences would be impractical.
Once the promoter regions of the six genes had been analysed, a total o f one hundred 
and forty-seven different potential transcription factor recognition sequences were 
identified on a combination of all six promoter regions. These recognition sequences, as 
well as their attendant classification numbers and an example o f each o f their 
recognition sequences are shown in Table. 3.4.1. Obviously, these sites are merely 
putative, the database has identified recognition sequences which could possibly be 
utilised; most o f these potential sites will not be utilised by any transcription factor. 
Also, the level o f suitability o f factors to their relevant recognition sequences had to be 
arbitrarily chosen. For this experiment, a suitability percentage o f 85% was considered 
to allow for a level o f variation in the recognition motifs while also providing a large 
enough margin o f error to encapsulate all possible putative transcription factors.
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Table 3.4.1 List of Transfac™ transcription factor recognition motifs
Classification No. Name Sample Sequence
M00001 MyoD GGTCAGGTGGGG
M00002 E47 GCGGCCACCCGCCGG
M00003 v-Myb TTCAGTTATA
M00005 AP-4 CTGCCCGCCGCTGGGTCC
M00008 Spl ACCACGGCCG
M00009 Ttk 69K GTTCCTGC
M00011 Evi-1 ATTCTCTTGT
M00019 Dfd AATTCAATTACAGTTC
M00020 Ftz CTTACTTGCTTT
M00021 Kr ATAATCCGGT
M00022 Hb TTTTTTTTTG
M00025 Elk-1 GCGCTTCCGGAAGG
M00027 AbaA CCTTCCTCCTTCCCTCGCT
M00028 HSF TTTCT
M00029 HSF GGAAT
M00030 MATal TGATGAACAT
M00031 MATalpha2 GATTACATGC
M00032 c-Ets-l(p54) GGCCTCCGGC
M00033 p300 CCCAGGAGTTGGAG
M00037 NF-E2 GGCT GAGT C AC
M00039 CREB TGAGGTCA
M00040 CRE-BP1 CGGGCTTACGC
M00041 CRE-BPl/c-Jun TGAGGTCA
M00042 Sox-5 TTATTGTTAG
M00046 GCR1 GACTTCCTG
M00048 ADR1 TGGAGA
M00050 E2F GGGCCAAA
M00051 NF-kappaB (p50) GGGTCTCCCC
M00052 NF-kappaB (p65) GGGGATTCCC
M00053 c-Rel GGGGATTCCC
M00054 NF-kappaB GGGACTACCC
M00055 N-Myc GGACACGTGTGC
M00059 YY1 ATTAAAAAATGGAATCA
M00060 Sn AAGTTCCTTTGA
M00063 IRF-2 GGGTTCCCTTTTC
M00066 Tal-lalpha/E47 GTCAACAGCT
M00071 E47 GTCAACAGCT
M00072 CP2 TTGGCATGTGC
M00073 DeltaEFl ATT AGGT GTT A
M00074 c-Ets-l(p54) AAGTTCCTTTGA
M00075 GATA-1 CGTGATACGC
M00076 GATA-2 ACGGATACTG
M00077 GATA-3 CCTGATAGC
M00079 Evi-1 TTATCTTGTTC
M00080 Evi-1 AATTTTCTTA
M00081 Evi-1 TTATCTACTGA
M00082 Evi-1 TTATCATGTCT
M00083 MZF1 TCCCCTCC
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Table 3.4.1 Cont’d
Classification No. Name Sample Sequence
M00084 MZF1 TGGGGAGGGGCCA
M00087 Ik-2 AGCTGGGACTAC
M00091 BR-C ZI T AATTTTTTTT ATT ATT A
M00092 BR-C Z2 TTATTATTATTTTTT
M00093 BR-C Z3 TCTTTTAATTTATTT
M00094 BR-C Z4 TTTTCTTTTTTTT
M00096 Pbx-1 TTGATTTTT
M00098 Pax-2 CGTCGTCTTGCATTATTCA
M00099 S8 GC A ATT C A ATT AC AGT
M00100 CdxA TTTATTGCAC
M00101 CdxA TTTATTGCAC
M00104 CDP CRI AATGGATCGC
M00105 CDP CR3 CAATAAATATTTGTT
M00106 CDP CR3+HD AATGGATCGC
M00108 NRF-2 CTCTTCTGGTG
M00109 C/EBPbeta TTGTTAGGAAAGA
M00111 CF1 /U SP GGGTTCACG
M00112 CF1 /U SP GGGTTCACG
M00113 CREB GGGGTGACGCGG
M00116 C/EBPalpha CTTT AAGC AACTT G
M00117 C/EBPbeta AAGTTCTGCAACTC
M00120 D1 AATTTTT CTCT
M00121 USF AGGACACGTGTGCG
M00122 USF TAGTCACATGTCCA
M00123 c-Myc/Max AAGCACCTGTGA
M00126 GATA-1 AACCTCATCTCTCT
M00127 GATA-1 AACCTCATCTCTCT
M00128 GATA-1 AACCTCATCTCTC
M00129 HFH-1 TCTTGTTTATCT
M00130 HFH-2 GTTGTTTTTTT
M00131 HNF-3beta TTCTATTTGTTC
M00132 HNF-1 GGTT A ACGATT AAAT
M00133 Tst-1 ATTCAATTACAGTTC
M00136 Oct-1 T G AAT GC AT ATT AAT
M00137 Oct-1 TTTT GATT ACTT A
M00140 Bcd GGGATTAC
M00141 Lyf-1 TCTCTCAAA
M00142 N1T2 TATCTA
M00145 Bm-2 TCATATTTACAATGCC
M00146 HSF1 GGAAGGTTCT
M00147 HSF2 TTGATTTTTCT
M00148 SRY AAACTTA
M00154 STRE GCCCCTGC
M00156 RORalphal TTGACCTTATATT
M00157 RORalpha2 AG AAGT ATGTC AG
M00158 COUP-TF / HNF-4 TGAACTTTAAAACT
M00159 C/EBP TCTTT GGAAA AGT
M00160 SRY TCTCTTGTTTAT
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Table 3.4.1 Cont’d
Classification No. Name Sample Sequence
MOO 162 Oct-1 CCAATTTACATTTC
M00163 HSF TTTCTTTTCTTTTTT
M00164 HSF CTGAGATTTCTTTTCT
MOO 167 HSF TTTCTTTTCTTTTTT
MOO 172 AP-1 GCTGAGTCACT
M00173 AP-1 TTTT AGT C AC A
M00174 AP-1 GCTGAGTCACT
MOO 175 AP-4 TGCAGCTGTT
MOO 176 AP-4 TTCCTGCTGA
M00183 c-Myb AGCAGTTTGG
M00184 MyoD CACAGCTGAC
M00187 USF GTCACTTGGC
M00188 AP-1 GCTGAGTCACT
MOO 190 C/EBP CTTTAAGCAACTTG
MOO 192 GR ACAGAACAGAGCGTTGCCG
M00199 AP-1 CTGAGTCAC
M00203 GATA-X CAAACTTATCT
M00204 GCN4 TGAGTCACTC
M00209 NF-Y CGACTAACCGACTC
M00211 PolyA downstream 
element
CGTGATCTC
M00216 TATA ATTTTATACT
M00217 USF GCAGGTGG
M00220 SREBP-1 CTCAAGTGATC
M00221 SREBP-1 GTGGCGTGATC
M00222 Thl/E47 ACAGCCAGACGCCCTC
M00223 STATx TTCTCAGAA
M00226 P TCCTACCAC
M00227 v-Myb TCTAACTGT
M00228 VBP TTTACATCAT
M00230 Skn-1 ATGATGGAGAAACTGC
M00231 MEF-2 TCTTGTACTAAAAATACAAAAT
M00232 MEF-2 TCTTGTACTAAAAATACAAAAT
M00235 AhR/Amt TGAGGGGAGCGTGCCC
M00236 Amt CAGGACACGTGTGCGC
M00239 v-ErbA CCATGAGGTCAAGGCT
M00240 Nkx-2.5 TCAAGTG
M00241 Nkx-2.5 CTTACTTG
M00247 PacC C AGT GCC AAGAGAAGTA
M00248 Oct-1 ACTATGGTAATA
M00249 CHOP-C/EBPa GAGGATGCACAA
M00250 Gfi-1 CTGGTTCCTGCTGAGATTTCTT
M00252 TATA GTTGGCCATTTATAT
M00253 Cap TCATCCCC
M00254 CCAAT box CCGGGCCAATAA
M00257 RREB-1 GGGT GT GGTT GGGG
M00258 ISRE AGCAGAAGCGAAACTG
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!Table 3.4.1 Cont’d
Classification No. Name Sample Sequence
M00263
M00266
M00267
M00268
M00269
M00271
StuAp 
Croc 
XFD-1 
XFD-2 
XFD-3 
AM L-la
CACCGCGCCC
T AATTT ATTT ATT AAA 
CAT CT AAAT AAT CC 
TTTATGTGTATACT 
TTTTTGATTACTTA
TGGGGT
3.4.2 Identification o f common potential transcription factors
The number o f sequences outlined in Table 3.4.1 was obtained from o f a total o f two 
hundred and seventy-one known vertebrate transcription recognition factor sequences, a 
complete list o f which may be obtained at the following web address, 
(http://pdap 1 . trc.rwcp.or.jp/htbin/show tfmatrixY The Transfac™ sequence analysis for 
each promoter was then compared by hand to the complete list o f known transcription 
factor motifs in order to identify any common transcription factors that may exist 
between the six sequences. This was carried out as follows; if  the Transfac™ sequence 
analysis o f MRP 1, for example, indicated that the recognition sequence for a particular 
transcription factor was contained within the promoter sequence o f the MRP1 gene, a 
note was made by hand beside that transcription factor on the above-mentioned list. 
This was carried out for all six genes, at the end of which the recognition motifs o f a 
number o f common transcription factors had been identified as being present on the 
promoter sequences o f these six genes. Several motifs were repeated many times in 
different sequences, indicating that these factors may be important in regulating separate 
genes. Also, as evinced by Table 3.4.1, a far larger number o f potential transcription 
factors were identified on the promoter sequences o f the genes. Obviously, the more 
gene promoter sequences which were analysed for common transcription factors 
increased, the probability o f finding common sequence motifs decreased. This, 
however, does not mitigate against the identification o f other transcription factors as 
being important or even essential in the regulation o f those genes. This study was 
designed only to identify common transcription recognition sites.
As a result, only seven recognition sequences were identified as being common to all 
nine genes. These are summarised in Table 3.4.2.
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Table 3.4.2 Common transcription factors for genes induced by BrdU
Classification No. Name
M00075 GATA-1
M00076 GATA-2
M00077 GATA-3
M00083 MZF1
M00087 Ik-2
M00101 CdxA
M00271 A M L-la
3.4.3 RT-PCR analysis o f expression of transcription factors in BrdU-treated cells
The analysis was begun by examining whether the agent affected mRNA expression 
levels o f any o f the various transcription factors. From the literature, PCR primers were 
chosen to amplify each o f these nine transcription factors. A list of these primer 
sequences can be found in Appendix A (Table 7.2A). RT-PCR was carried out on the 
nine transcription factors using the BrdU-treated DLKP and A549 RNA samples (as 
outlined in Section 2.2.2.5). The amplified fragments were visualised using agarose gel 
electrophoresis.
Seven o f the nine transcription factor primer sets (C/EBP, GATA-1, IK-2, AM L-la, 
CdxA, Nkx-2.5 and MZF1) yielded either very weak signal or no signal at all for both 
cell lines and were discarded. This result does not, however, indicate that these 
transcription factors were not utilised in these cells. It is possible that the PCR primers 
or regimens selected were not optimal for gene amplification. The GATA-2 and GATA- 
3 PCRs however, yielded a clean reproducible product for both the A549 and DLKP 
cell lines. The results for these RT-PCRs are presented here.
3.4.3.1 GATA-2 gene expression in BrdU-treated A549 and DLKP cell lines
The results o f the duplicate GATA-2 RT-PCRs on DLKP and A549 cells are shown in 
Figs. 3.4.1 and 3.4.2. As can be seen, GATA-2 gene expression is strongly increased in
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the DLKP cell line following exposure to BrdU (Fig. 3.4.1). The pattern o f upregulation 
o f expression appeared to differ slightly, however, between the two preparations of 
DLKP cells. In the first sample set, expression of the gene was increased up to a 
maximum of over eight-fold that o f normal DLKP after seven days exposure to BrdU. It 
is interesting to note that all o f the genes used in the identification o f the GATA-2 and - 
3 transcription factors also reached a maximum level o f gene expression after seven 
days exposure to BrdU. Thereafter, expression of the gene decreased to roughly three 
times that of normal cells after fifteen days. In the second sample set, a higher level of 
basal GATA-2 expression was observed in the control DLKP sample. The subsequent 
increases in GATA-2 gene expression following BrdU treatment were, as a result, 
slightly lower with respect to this control sample. However, the expression increases 
were roughly similar when compared to the first sample set control, for all samples up 
to, and including, day seven. A final difference between the two was the observation of 
a very high level o f expression o f GATA-2 after fifteen days exposure to BrdU.
In the BrdU-treated A549 cells (Fig. 3.4.2), expression o f the GATA-2 gene was 
observed to increase in both preparations, although in an irregular fashion. A significant 
increase in expression of the gene (~fifty-fold) after two days treatment was observed in 
one set o f A549 cells examined. However, the increase was only significant against the 
very low level o f expression of the gene in the control sample. Also, GATA-2 
expression was observed to decrease after this date, although it remained higher than 
untreated expression levels. The second sample set yielded a different pattern of 
expression increase, this time yielding a maximum expression increase o f three-fold at 
day fifteen. Again, expression levels o f GATA-2 remained slightly higher throughout 
than for untreated A549.
3.4.3.2 GATA-3 gene expression in BrdU-treated A549 and DLKP cell lines
Similar to the results obtained for GATA-2 expression in the BrdU-treated DLKP cells, 
GATA-3 expression was also observed upregulated in the DLKP cell line following 
exposure to the agent (Fig. 3.4.3). In both sample preparations, the highest level of 
GATA-3 expression occurred after seven days o f exposure to BrdU, which was also the
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Fig. 3.4.1: GATA-2 RT-PCR on BrdU-treated DLKP cells
Fig. 3.4.1a:
IX DLKP DLKP
C7 Br 2 Br Br 7 Br C7 Br 2 Br 5 Br 7 Br 
5 15 15
ß-actin
Fig. 3.4.1b:
Fig. 3.4.1a: Gel electrophoresis photograph of GATA-2 RT-PCR results on BrdU-
treated DLKP cells; Fig. 3.4.1b: Densitometrie analysis of RT-PCR results.
Fig. 3.4.2: GATA-2 RT-PCR on BrdU-treated A54^cells
Fig. 3.4.2a:
IX A549
C7 Br Br 5 Br 7 Br 15 
2
A549
C7 Br Br 5 Br 7 Br 
2 15
GATA-2
ß-actin
Fig. 3.4.2b:
C7 Br 2 Br 5 Br 7 Br 15 C7 Br 2 Br 5 Br 7 Br 15
Fig. 3.4.2a: Gel electrophoresis photograph of GATA-2 RT-PCR results on BrdU-
treated A549 cells; Fig. 3.4.2b: Densitometrie analysis of RT-PCR results.
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Fig. 3.4.3: GATA-3 RT-PCR on BrdU-treated DLKP cells
Fig. 3.4.3a:
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C7 Br Br Br Br C7 Br Br Br Br
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Fig. 3.4.3b:
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Fig. 3.4.3a: Gel electrophoresis photograph of GATA-3 RT-PCR results on BrdU-
treated DLKP cells; Fig. 3.4.3b: Densitometrie analysis of RT-PCR results.
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time point at which most o f the genes upregulated in expression by BrdU reached their 
maximum expression potential. The level of expression for the first sample set was also 
observed to be far higher than the second, although, as already outlined, the pattern of 
expression remained identical.
The picture was significantly different for the BrdU-exposed A549 cells. Expression of 
the GATA-3 gene in both sample preparations was significantly decreased following 
exposure to the differentiating agent (Fig. 3.4.4).
3.4.3.3 Summary of GATA-2 and GATA-3 RT-PCR results
From these results, it is apparent that exposure o f  the DLKP cell line to the 
differentiating agent BrdU results in increased expression o f the transcription factors 
GATA-2 and GATA-3. These two transcription factors are potential transcriptionally 
regulating elements o f the six genes chosen for analysis due to their increased 
expression following exposure to BrdU. It is therefore possible that BrdU positively 
affects the expression of these six genes by increasing the expression o f one or more of 
the transcription factors responsible for the positive regulation of these genes.
By contrast, the expression patterns o f both GATA-2 and GATA-3 factors in the BrdU- 
treated A549 cells were far more irregular. GATA-2 expression does increase in A549 
following BrdU treatment, although this increase does not follow a linear pattern, and so 
may be directly correlated with increases observed for BrdU-upregulated genes in this 
cell line. For GATA-3, overall expression is observed to decrease in A549 cells 
following exposure to BrdU.
3.4.4 RT-PCR analysis o f expression o f transcription factors in drug-exposed DLKP
Following on from the analysis of the short-term drug-exposure assays carried out on 
DLKP cell line, it was thought relevant to investigate the gene expression profiles in the 
drug-treated DLKP cells, of the GATA-2 and GATA-3 transcription factors already 
examined in the BrdU-exposed cells. Standard RT-PCRs, as outlined in Section 2.4.2.5,
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Fig. 3.4.4: GATA-3 RT-PCR on BrdU-treated A549 cells
Fig. 3.4.4a:
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Fig. 3.4.4b:
Fig. 3.4.4a: Gel electrophoresis photograph of GATA-3 RT-PCR results on BrdU-
treated A549 cells; Fig. 3.4.4b: Densitometrie analysis of RT-PCR results.
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were carried out on the isolated RNA samples and the resulting PCR products eluted on 
a 2% agarose gel.
GATA-2 expression was significantly increased in the DLKP cells exposed to VP 16 
(Fig. 3.4.5), with an overall three-fold increase in expression o f the gene following 
exposure to the drug. However, no significant effect on GATA-2 expression was 
observed following exposure to cisplatin or taxol (Figs. 3.4.6 and 3.4.7, respectively). 
By contrast, GATA-3 expression was not significantly altered in DLKP cells exposed to 
any of the three chemotherapeutic drugs (Figs. 3.4.8 -  3.4.10).
3.4.5 Transcription factor analysis o f the 5’ promoter regions o f genes with increased 
expression following exposure to chemotherapeutic drugs
Exposure of the DLKP and A549 cell lines to the differentiating agent BrdU had helped 
identify a number o f genes whose expression was positively regulated by the agent 
(Section 3.1.1). This, in turn led to the identification o f the GATA-2 and -3 transcription 
factors, which may be involved in the BrdU-mediated regulation o f those genes (Section
3.4.2). It was considered that a similar approach to the analysis o f the promoter regions 
o f genes whose expression was observed increased following exposure to 
chemotherapeutic drugs may yield a similar discovery. DLKP cells were exposed to 
three chemotherapeutic drugs (cisplatin, taxol and VP 16) (Section 3.2.) and a number of 
genes were observed to be increased in expression following exposure to the different 
drugs (Section 3.2.1). As the method of drug action differs from one to another, it was 
considered prudent to analyse the promoter regions o f genes influenced by each drug in 
turn, i.e. the promoter regions o f the MRP genes 1 and 2, and the BCRP gene, all 
increased in expression in DLKP cells following exposure to cisplatin, would be 
compared to each other to identify common transcription factors. Likewise, the 
promoter regions o f MRP2, a-catenin and E-cadherin (expression increase following 
exposure to taxol) and M RPsl and 2 and a-catenin (induced by VP 16) would be 
compared for the same reason. The analysis and comparison o f the promoter regions 
was carried out as outlined in Section 3.4.1.
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Fig. 3.4.5: GATA-2 RT-PCR on VP16-treated DLKP cells
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Fig. 3.4.5a: Gel electrophoresis photograph of GATA-2 RT-PCR results on VP16-
exposed DLKP cells; Fig. 3.4.5b: Densitometrie analysis of RT-PCR results.
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Fig. 3.4.6: GATA-2 RT-PCR on Cisplatin-treated DLKP cells
Fig. 3.4.6a:
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Fig. 3.4.6b:
Fig. 3.4.6a: Gel electrophoresis photograph of GATA-2 RT-PCR results on Cisplatin-
exposed DLKP cells; Fig. 3.4.6b: Densitometrie analysis of RT-PCR results.
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Fig. 3.4.7: GATA-2 RT-PCR on Taxol-treated DLKP cells
Fig. 3.4.7a:
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Fig. 3.4.7b:
Fig. 3.4.7a: Gel electrophoresis photograph of GATA-2 RT-PCR results on Taxol-
exposed DLKP cells; Fig. 3.4.7b: Densitometrie analysis of RT-PCR results.
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Fig. 3.4.8: GATA-3 RT-PCR on Cisplatin-treated DLKP cells
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Fig. 3.4.8a: Gel electrophoresis photograph of GATA-3 RT-PCR results on Cisplatin-
treated DLKP cells; Fig. 3.4.8b: Densitometrie analysis of RT-PCR results.
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Fig. 3.4.9: GATA-3 RT-PCR on Taxol-treated DLKP cells
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Fig. 3.4.9a: Gel electrophoresis photograph of GATA-3 RT-PCR results on Taxol-
treated DLKP cells; Fig. 3.4.9b: Densitometrie analysis of RT-PCR results.
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Fig. 3.4.10: GATA-3 RT-PCR on VP16-treated DLKP cells
Fig. 3.4.10a:
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Fig. 3.4.10a: Gel electrophoresis photograph of GATA-3 RT-PCR results on Taxol-
treated DLKP cells; Fig. 3.4.10b: Densitometrie analysis of RT-PCR results.
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3.4.5.1 Transcription factor analysis o f the promoter regions o f Cisplatin-
induced genes
As already outlined (Section 3.4.1), the expression o f MRP1, MRP2 and BCRP of the 
examined genes was upregulated following exposure to the chemotherapeutic drug, 
cisplatin. Transcription factor analysis as outlined in Section 3.4.1 was carried out 
which identified a total o f one hundred and thirty potential transcription factors which 
were located on the 5 ’ promoter regions o f the three induced genes. These transcription 
factors are listed among the 147 transcription factors shown in Table 3.4.1. A  list o f the 
common potential transcription factors was subsequently drawn up from this total list o f 
130. These twenty-three common factors, together with a sample recognition sequence 
and the classification number o f each, are listed in Table 3.4.3.
Table 3.4.3. Common transcription factors for genes induced by Cisplatin
Classification No. Name Sample Sequence
M00033 P300 CCCAGGAGTTGGAG
M00075 GATA-1 CGTGATCCGC
M00076 GATA-2 CAGCATCTCC
M00077 GATA-3 CCTTATCTC
M00083 MZF1 TCCCCTCC
M00087 Ik-2 AGCTGGGACTAC
M00099 S8 GC AATT C AATT AC AGT
M00100 CdxA ATTTCTG
M00101 CdxA AATT AC A
M00106 CDP CR3+HD AATGGATCGC
MOO 122 USF TAGTCACATGTCCA
MOO 127 GATA-1 AACCTCATCTCTCT
M00141 Lyf-1 TCTCTCAAA
MOO 148 SRY AAACTTA
M00159 C/EBP TCTTTGGAAAAGT
MOO 162 Oct-1 CCAATTTACATTTC
M00173 AP-1 TTTTAGTCACA
MOO 174 AP-1 GCTGAGTCACT
M00203 GATA-X CAAACTTATCT
M00217 USF GCAGGTGG
M00240 Nkx-2.5 TCAAGTG
M00241 Nkx-2.5 CTTACTTG
M00271 AM L-la TGTGGT
As can be seen, all nine common potential transcription factors identified from the six 
BrdU-upregulated genes are observed here, along with fourteen other factors potentially 
utilisable by cisplatin in upregulating expression of the three genes under examination.
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3.4.5.2 Transcription factor analysis of the promoter regions of Taxol-induced genes
As already outlined (Section 3.4.1), the expression o f MRP2, a-catenin and E-cadherin 
o f the examined genes was upregulated following exposure to taxol. Transcription 
factor analysis as outlined in Section 3.4.1 was carried out which identified a total of 
one hundred and twenty-two potential transcription factors which were located on the 5’ 
promoter regions o f the three induced genes. These transcription factors are listed 
among the 147 transcription factors shown in Table 3.4.1. A list o f the common 
potential transcription factors was subsequently drawn up from this total list o f 122. 
These eighteen common factors, together with a sample recognition sequence and the 
classification number o f each, are listed in Table 3.4.4.
Table 3.4.4. Common transcription factors for genes induced by Taxol
Classification No. Name Sample Sequence
M00001 MyoD GGTCAGGTGGGG
M00008 Spl ACCACGGCCG
M00033 P300 CCCAGGAGTTGGAG
M00073 DeltaEFl ATT AGGTGTT A
M00075 GATA-1 CGTGATCCGC
M00076 GATA-2 CAGCATCTCC
M00077 GATA-3 CCTTATCTC
M00083 MZF1 TCCCCTCC
M00087 Ik-2 AGCTGGGACTAC
MOO 100 CdxA ATTTCTG
M00101 CdxA AATTACA
M00130 HFH-2 GTTGTTTTTTT
M00131 HNF-3beta TTCTATTTGTTC
M00141 Lyf-1 TCTCTCAAA
MOO 148 SRY AAACTTA
MOO 160 SRY TCT CTT GTTT AT
M00217 USF GCAGGTGG
M00271 AM L-la TGTGGT
3.4.5.3 Transcription factor analysis of the promoter regions o f VP16-induced genes
As already outlined (Section 3.4.1), the expression o f MRP1, MRP2 and a-catenin o f 
the examined genes was observed upregulated following exposure to VP 16. 
Transcription factor analysis as outlined in Section 3.4.1 was carried out which 
identified a total of one hundred and thirty-five potential transcription factors which
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were located on the 5’ promoter regions o f the three induced genes. These transcription 
factors are listed among the 147 transcription factors shown in Table 3.4.1. A list o f the 
common potential transcription factors was subsequently drawn up from this total list o f 
122. These twenty-seven common factors, together with a sample recognition sequence 
and the classification number o f each, are listed in Table 3.4.5.
Table 3.4.5. Common transcription factors for genes induced by VP16
Classification No. Name Sample Sequence
M00001 MyoD GGTCAGGTGGGG
M00008 Spl ACCACGGCCG
M00033 P300 CCCAGGAGTTGGAG
M00037 NF-E2 GGCT GAGTC AC
M00073 DeltaEFl ATTAGGT GTT A
M00075 GATA-1 CGTGATCCGC
M00076 GATA-2 CAGCATCTCC
M00077 GATA-3 CCTTATCTC
M00083 MZF1 TCCCCTCC
M00087 Ik-2 AGCTGGGACTAC
M00100 CdxA ATTTCTG
M00101 CdxA AATTACA
MOO 106 CDP CR3+HD AATGGATCGC
MOO 109 C/EBPbeta TT GTT AGGAAAG A
MOO 127 GATA-1 AACCTCATCTCTCT
M00130 HFH-2 GTTGTTTTTTT
M00131 HNF-3beta TTCTATTTGTTC
MOO 137 Oct-1 TTTTGATTACTTA
M00141 Lyf-1 TCTCTCAAA
MOO 148 SRY AAACTTA
M00159 C/EBP TCTTTGGAAAAGT
M00160 SRY TCTCTTGTTTAT
MOO 173 AP-1 TTTT AGT CACA
M00199 AP-1 CTGAGTCAC
M00203 GATA-X C AAACTT AT CT
M00217 USF GCAGGTGG
M00271 A M L-la TGTGGT
3.4.6 Analysis o f promoter regions o f the MRP1 gene in the DLKP cell line
MRP1 expression was observed increased by the action o f the differentiating agent 
BrdU, in both the DLKP and A549 cell lines; the only gene studied here to do so 
(Section 3.1.1). MRP1 expression was also increased in the short-term cisplatin- and 
VP16-exposed DLKP cells (Section 3.2.1) as well as in the vincristine- and VP16-
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selected cell lines (Section 3.3.1). As a result, it was considered useful to examine more 
closely the effect on the 5 ’ promoter region o f the gene o f the agents examined here 
(e.g. BrdU, Cisplatin, Taxol, VP16).
Computer-aided transcription factor analysis carried out here (Section 3.4.1), has 
already identified a number o f common transcription factors as being potentially 
involved in the BrdU-mediated regulation of the MRP1 gene in the DLKP cell line, 
while RT-PCR of those factors has identified two factors observed to be upregulated 
following exposure to BrdU (Section 3.4.2). Further transcription factor analysis 
examining the upregulation of MRP 1 by the chemotherapeutic drugs cisplatin and VP 16 
has also identified additional common potential transcription factors which may be 
utilised by these agents in the positive regulation o f MRP 1 (Section 3.4.5).
A complementary approach to examining the effect o f these agents on specific regions 
o f the 5 ’ promoter o f the MRP1 gene in the DLKP cell line would be useful in 
identifying which regions of the MRP1 promoter region were utilised by the various 
agents employed to produce the upregulated MRP1 gene response. As a result, it was 
considered necessary to examine the action o f these agents on the promoter region of 
the MRP1 gene specifically.
A number o f pGL2 (Promega, E1621) plasmid constructs containing truncated Sections 
o f the 5’ MRP1 promoter region attached to the luciferase gene were obtained from Dr. 
William Beck (Wang and Beck, 1998). The 5’ promoter region o f the human MRP1 
gene was cloned from drug-resistant HL-60 cells and the 2.1 kb (-2008 to +103bp, 
relative to the transcription start site) promoter fragment was fused to the luciferase 
gene in the pGL2-Basic (Promega, E1611) plasmid. Deletion mutants were generated 
by restriction digestion o f p-2008 with Bsu36l (at - 1 123bp), PvuU (at -660bp), BstER 
(at -41 lbp), Smal (at -91bp) and at 3’ o f the promoter with HindU I (at +103bp). The 
promoter fragments were then cloned into pGL2-Basic to generate p-1123, p-660, p-411 
and p-91, respectively. A schematic linear map of each o f the pGL2 plasmids used is 
shown in Fig. 3.4.11.
The five constructs were then transiently transfected in DLKP cells as outlined in 
Section 2.4.5. The cells were then either taken down at the prescribed day or treated
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Fig. 3.4.11: MRP^ gene promoter-luciferase reporter plasmids
p-2008
-2008 V Luciferase
p-1123
p-660
p-411
p-91
+103
Fig. 3.4.11: Schematic linear map o f pGL2 plasmids containing various lengths o f the 
human MRP1 gene promoter 5’ to the luciferase gene. Numbered DNA sequences in 
the above maps correspond to those in the published sequence (Zhu & Center, 1994), 
relative to the transcriptional start (arrow).
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with one o f four agents; BrdU, Cisplatin, Taxol or VP 16 before being taken down and 
assayed for luciferase expression.
The experiment took the form of six separate transfection experiments. The first 
(Untreated 0 hrs) was the standard luciferase transfection protocol; the cells were 
transfected overnight with the various plasmids, taken down and the luciferase readings 
obtained. This was intended as a dual control; one to indicate which parts o f the MRP1 
promoter were normally utilised in normal DLKP cells and two, to provide a basal level 
o f luciferase expression against which all other treatments could be compared. The 
(Untreated 24 hrs) sample refers to a second control where after the overnight 
transfection with the MRP1 promoter plasmids, the cells were re-fed with ordinary 
media and then left for a further 24 hrs. This was carried out to indicate any alterations 
in luciferase expression following removal o f the transfecting agent and plasmids. The 
BrdU and three drug treatments illustrated in Figs. 3.4.13 to 3.4.16 refer to DLKP cells 
transfected overnight with the MRP1 promoter plasmids, then exposed to one o f four 
agents (BrdU, Cisplatin, Taxol and VP 16) for a further 24 hrs. This was carried out to 
investigate which area o f the MRP1 promoter, if  any, is affected by these chemicals in 
upregulating expression o f the MRP1 gene as has already been demonstrated in this cell 
line. Although Taxol was not observed to influence MRP1 expression in DLKP cells, 
previous work carried out in this laboratory had indicated that it may induce expression 
o f the gene at near-fatal doses to the cells and so it was considered prudent to include 
the drug in our analysis.
The transfections displayed in Figs. 3.4.12 to 3.4.16 are identified by the region of the 
truncated MRP1 promoter each plasmid contains. Four additional internal transfection 
controls were also included in the experiment. These are listed as “DLKP”, “DLKP-F”, 
“BASIC” and “Positive” and refer to, respectively, untransfected DLKP cell line, 
untranfected DLKP in the presence of the transfecting agent, Fugene, DLKP transfected 
with the empty, or basic, pGL2 plasmid and DLKP transfected with the Positive pGL2 
plasmid, which is the luciferase gene attached to a full-length cytomegalovirus (CMV) 
promoter. Cells were transfected overnight and luciferase readings obtained as outined 
in Section 2.4.10.
213
While the “Untreated 0 hrs” transfection was carried out in duplicate, all other 
transfections were only carried out once. As such these results are, as yet, purely an 
indication o f the action o f the agents examined on the promoter region of the MRP1 
gene. The actual luciferase readings obtained for each transfection, including the 
average obtained for the duplicate untreated Ohrs transfections, and the results for the 
positive PGL2 transfection controls are shown in Table 3.4.6.
Table 3.4.6 List of luciferase readings obtained from plasmid transfections
U  Ohrs U 24hrs BrdU Cispl Taxol VP16
DLKP 4.325 0 0 5.112 0 0
DLKP-F 0 3.32 1.178 7.899 4.444 0
PBasic 2.803 0 6.2 3.4 0 4
p-2008 1060 1021 998 406 451 1196
p-1123 899 625 462 642 396 865
p-660 755 309 288 332 263 754
p-411 574 479 1944 264 357 1894
p-91 2490 1484 380 295 141 767
Positive 35300 23700 19170 13800 12300 14700
3.4.6.1 Basal expression o f the MRP1 gene in the DLKP cell line
Overnight transient transfection o f the MRP1 promoter-containing plasmids identified 
the -91 region o f the MRP1 promoter as being the primary region of the gene normally 
utilised in DLKP cells (Fig. 3.4.12). This region contains a large number o f 
transcriptional regulators, the most numerous being the Spl transcriptional promoter 
and was also the region identified by Zhu and Center (1994) as containing the major 
promoter o f the MRP1 gene in the Chinese hamster ovary (CHO) cell line. In this 
experiment, luciferase expression readings for the plasmid incorporating this fragment 
was roughly 2.5 times that o f the plasmid encoding the next highest fragment, that o f 
the complete -2008 promoter segment. Also, it may be noted that luciferase expression 
decreases to one fifth that obtained for the -91 plasmid if  the region o f promoter 
examined is increased to -411 bases. These results indicate that in the DLKP cell line, 
the main promoter for the MRP1 gene lies in the first ninety bases back from the
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Fig. 3.4.12: Examination of MRP1 promoter regulation in the DLKP cell line using
luciferase expression
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transcriptional start site o f the MRP1 gene and that there is potentially a major 
transcriptional repressor coded between the -91 and -411 bases o f the promoter 
sequence.
The following Figs. (Figs. 3.4.13 -  3.4.16) all include the luciferase results from the 
Untreated Ohrs (BLUE) and Untreated 24hrs (RED) controls which were obtained as 
controls for the other treatments as already outlined (Section 3.4.6). As was seen for the 
normal, untreated DLKP (Untreated Ohrs) (see above), the -91 bases of the MRP1 
promoter was also the most productive region o f the promoter used in positively- 
regulating expression o f the MRP1 gene after a further 24hrs in ordinary media 
(Untreated 24hrs), although expression levels are observed to decrease slightly for most 
plasmids. For instance, the decrease is roughly 3% for p-2008, but almost 60% for p- 
660. These two control transfections will be referred to in all treatments for comparative 
purposes. The gene-inducing agent in all subsequent plots (Figs. 3.4.13 -  Fig. 3.4.16) is 
represented by the yellow plot.
3.4.6.2 Expression o f the MRP1 gene in DLKP following exposure to BrdU
Fig. 3.4.13 shows the effect o f exposure to BrdU on the expression o f luciferase in the 
transfected cells. BrdU was exposed to the cells at a lOfiM concentration overnight -  
this is also the concentration at which BrdU has previously increased expression of 
several genes (Section 3.1). As can be seen, exposure to BrdU increases expression o f 
luciferase four-fold in the -411 transfected DLKP, while expression levels are markedly 
decreased in the -91 transfected cells. This result would appear to indicate that BrdU 
targets this area o f the MRP1 promoter in positively regulating expression o f the gene, 
with the subsequent decrease in transcriptional utilisation o f the recognition site within 
the -91 region of the promoter sequence. No significant changes were observed for the 
other fragments.
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Fig. 3.4.13: Effect of BrdU exposure on lucifrase expression in MRP1 Promoter-
transfected DLKP cells
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3.4.6.3 Expression of the MRP1 gene in DLKP following exposure to Cisplatin
The effect o f cisplatin on the expression of luciferase in the transfected cells is shown in 
Fig. 3.4.14. Cisplatin was exposed to the cells at a 125r)g/ml concentration overnight -  
this is also the concentration at which cisplatin has previously increased expression o f 
several genes (Section 3.2). As can be seen, the expression o f luciferase was lowered 
following exposure to the drug. No clear increase in expression was observed for any o f 
the plasmid transfections, and it would appear, from this transfection at least, that 
cisplatin is not a potential agent for the transcriptional induction o f MRP1 gene 
expression.
This result is quite surprising, as exposure to cisplatin has previously been demonstrated 
here to induce expression o f MRP1 in DLKP (Section 3.2). It is possible that this in 
vitro assay does not mimic exactly the effects o f the drug in vivo. Also, this difference 
in expression levels could be due to the fact that these cells were taken down and 
expression was analysed after only 24hrs o f exposure. In the previous results 
demonstrating MRP1 induction following cisplatin exposure, the earliest assay time 
point was 48hrs.
3.4.6.4 Expression o f the MRP1 gene in DLKP following exposure to Taxol
The effect o f taxol on the expression o f luciferase in the transfected cells was observed 
to be almost identical to the effect obtained following exposure to cisplatin, the results 
of which may be seen in Fig. 3,4.15. Taxol was exposed to the cells at a 0.15r|g/ml 
concentration overnight -  this is also the concentration at which taxol has previously 
increased expression of several genes (Section 3.2). Again, the expression of luciferase 
was observed to be lowered for all transfections following exposure to the drug. No 
clear increase in expression was observed for any o f the plasmid transfections, and it 
would appear again, from this transfection, that taxol is not a potential agent for the 
transcriptional induction of MRP 1 gene expression.
218
Fig. 3.4.14: Effect of Cisplatin exposure on luciferase expression in MRP1
Promoter-transfected DLKP cells
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Fig. 3.4.15: Effect of Taxol exposure on luciferase expression in MRP1 Promoter-
transfected DLKP cells
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3.4.6.5 Expression of the MRP1 gene in DLKP following exposure to VP16
Fig. 3.4.16 shows the effect o f exposure to VP 16 on the expression o f luciferase in the 
transfected DLKP cells. VP16 was exposed to the cells at a 30r|g/ml concentration 
overnight -  this is also the concentration at which VP 16 has previously increased 
expression of several genes (Section 3.2). As for the BrdU-treated cells, expression of 
luciferase increased four-fold in the -411 transfected DLKP, while expression levels 
were markedly decreased in the -91 transfected cells. This result would appear to 
indicate that VP 16 also targets this area of the MRP1 promoter in positively regulating 
expression o f the gene, again accompanied by the attendant decrease in luciferase 
production from the -91 promoter plasmid. No significant changes were observed for 
the other fragments.
3.4.7 Correlation o f Transfac™ data, MRP1 promoter transfections and RT-PCR 
results
From the results shown in this Section on the BrdU-affected genes, it was hypothesised 
that BrdU may be exerting an upregulation effect on the expression of GATA-2 or 
GATA-3 leading to an increase in expression of, among others, the MRP1 gene. The 
MRP1 promoter transfections localised the most likely site targetted by the BrdU to a 
region o f the MRP1 promoter between -91 and —411 bases back from the transcriptional 
start site. A re-examination o f the Transfac™ recognition site data for this 320 base 
region revealed a solitary potential recognition site for the GATA-2 transcription factor 
(M00076), as well as other potential binding sites for the common factors MZF1 
(M00083), CdxA (M00101) and A M L-la (M00271). A schematic map of this area o f 
the 5’ MRP1 promoter showing the location and orientation o f the potential relevant 
binding sites for transcription factors is displayed in Fig. 3.4.17.
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Fig. 3.4.16: Effect of VP16 exposure on luciferase expression in MRP1 Promoter-
transfected DLKP cells
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FigJ3AH: MRP1 5’ Promoter sequence
:44'
ATTAGCCAGG TGACCCTGGG
CTCTGCACCT GGGTTTCTTC
TACAGGATGA AATGAGGGCA
CTCCAGGCAG GTAGGCTCCG
TGACGGATAC TGTCCTTAAA
CAGGGTGTGT GGCCCCAAAG
GCGAGCCAAC GCTCCCCAGG
CTAAGCCTTG GAGGATCTGG
CAGGCCCGGG
CAGAGGGAAT CACTCAACCT
CTTCATGAAC GTGGAGACTT
CAGTTAAGGC GCCCGGTACA
TTCACGTTAT TTTCCCCTGG
CAGCATTTGA AAAGTGGT£G
ATCCCAGGCG CTTCCGGAAG
CCCGTCCGCG AGCGGTGGGC
GCyXjGGGGTG ACGCGGGGTC
Fig. 3.4.17: Sequence o f MRP1 5’ promoter from bases -91 to —411 (relative to the 
transcriptional start) containing transcription recognition sequences for A M L-la (RED), 
CdxA (PINK) and the solitary GATA-2 recognition factor (BLUE).
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3.5 Analysis of BrdU-treated DLKP cells by DNA microarray
From the results presented here (Section 3.1), it is apparent that exposure o f cell lines, 
most notably DLKP, to the differentiating agent BrdU, results in fluctuation o f 
expression o f a number o f genes normally expressed in that cell line. All o f these results 
were obtained from first optimising PCRs for the different genes, and then carrying out 
these RT-PCRs on RNA extracted from the BrdU-exposed cells. The choice of genes 
surveyed was based on “educated guesses” for the identification o f genes which may be 
relevant to drug resistance or differentiation.
The emergence recently, o f DNA array technology (see Section 1.8), has made possible 
the examination o f gene expression for a wide variety o f genes and proteins with a 
standardised labour-saving protocol. It was felt that this new technology would be the 
next logical approach to extend the analysis o f the BrdU-treated cell lines in our 
possession. By using DNA arrays to examine gene expression levels in BrdU-exposed 
cells, a much larger number o f genes could be identified as being either up- or 
downregulated following treatment with the agent. These results would then be 
complemented by RT-PCR analysis to confirm gene up- or downregulation. It was felt 
that this step would be necessary to confirm the efficacy o f any results received from 
the array.
A standard DNA array kit (Clontech, 7851-1) was obtained and used to examine 
changes in gene expression between normal control DLKP cells and DLKP cells which 
had been exposed to BrdU for seven days. The seven day sample was chosen for 
comparison with untreated DLKP cells. The same isolated RNA samples used in the 
RT-PCRs were used in the DNA array experiment, which was carried out as outlined in 
Section 2.4.9.
A schematic map o f the array and its organisation is provided in Fig. 3.5.1. The type o f 
array used in this experiment was the "Atlas Human Cancer 1.2 Array Gene" array 
(Clontech, PT3547-3). A total o f 597 genes were examined on this array. A complete 
list of these genes may be obtained from the Clontech website (www. 
atlas.clontech.com). These genes were divided into roughly six classes, although there
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Fig. 3.5.1:_____ Layout ofDNA array
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Dark gray dots represent orientation marks to help you determine the coordinates of hybridization signals.
Fig. 3.5.1: Scanned photograph of layout o f DNA array.
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was a lot o f overlap between Sections, arranged by letters, for the experiment. The six 
classes are outlined in Table 3.5.1:
Table 3.5.1 Groups of genes analysed in BrdU-exposed DLKP RNA
Group Genes/Proteins
A Oncogenes, Tumour suppressors and Cell cycle proteins
B Intracellular kinases and Phosphatases
C Apoptoic regulators and Transcriptional activators and repressors
D Cell adhesion receptors and Surface antigens
E Interleukins, Interferons and Growth factors
F Functionally unclassified proteins and Housekeeping genes
The results for genes observed to be upregulated in expression, as well as the level of 
upregulation, is shown in Table 3.5.2. The genes downregulated in expression, again 
together with the degree o f downregulation, are shown in Table 3.5.3. For the sake of 
simplicity, the level o f  change in expression has been rounded off to the nearest whole 
number, which represents 2-, 3- or 4-fold, etc. change in expression of the gene. Also, 
results o f changes in expression which were less than a two-fold increase or decrease 
following BrdU treatment are not displayed, since these were not considered to be of 
significance. A scan o f the two analysed arrays is provided, for illustration, in Fig. 3.5.2.
This experiment was only carried out once, without duplicates. It is the opinion o f this 
researcher that these results are representative only, and require the repetition o f both 
this array experiment as well as confirmation via RT-PCR o f the mentioned changes in 
gene expression before they may be taken seriously. All lab manipulations were carried 
out by John Cahill and I. All computer analysis was carried out by Dr. Niall Barron.
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Fig. 3.5.2: Scan of DNA array of BrdU-treated DLKP cells
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Fig. 3.5.2: Scanned photograph of DNA array results on BrdU-treated DLKP cells at
Day 0 (DLKP Control) and Day seven (DLKP 7d BrdU).
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Table 3.5.2 Genes upregulated in DLKP after seven days BrdU exposure
Protein/Gene -Fold
         Increase
Early growth response protein 1 (hEGRl); transcription factor ETR103; 11
KROX24; zinc finger protein 225; AT225
p55CDC 8
Inil 8
Nuclease-sensitive element DNA-binding protein (NSEP) 7
EB1 protein 7
40S ribosomal protein S19 (RPS19) 4
Fibronectin receptor beta subunit (FNRB); integrin beta 1 (ITGB1); 3
VLA4 beta subunit; CD29 antigen
DNA-binding protein inhibitor ID -1; Id-1H 2
70-kDa heat shock protein 1 (HSP70.1; HSPA1) 2
Mitogen-activated protein kinase p38 (MAP kinase p38); cytokine 2
suppressive anti-inflammatory drug binding protein (CSAID binding 
protein; CSBP); MAX-interacting protein 2 (MXI2)
Growth arrest and DNA-damage-inducible protein 153 (GADDI53); 2
DNA-damage-inducible transcript 3 (DDIT3); C/EBP homologous 
protein (CHOP)
Glutathione S-transferase pi (GSTP1; GST3) 2
Alphal-catenin (CTNNA1); cadherin-associated protein; alpha E- 2
catenin
27-kDa heat-shock protein (HSP27); stress-responsive protein 27 2
(SRP27); estrogen-regulated 24-kDa protein; HSPB1
Hepatoma-derived growth factor (HDGF) 2
Guanine nucleotide-binding protein G-s alpha subunit (GNAS); 2
adenylate cyclase-stimulating G alpha protein
Table 3.5.2 shows the genes upregulated in the DLKP cells following seven days 
exposure to BrdU. As can be seen, a total o f sixteen genes out of 597 were upregulated 
in response to the differentiating agent. The most significant increase was in the 
transcription factor ETR103, whose expression increased eleven-fold after seven days
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Iexposure to BrdU. Other highly significant increases were observed for p55CDC and 
Ini 1 (both eight-fold) and for the Nuclease-sensitive element DNA-binding protein 
(NSEP) and EB1 protein (both seven-fold).
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Table 3.5.3 Genes downregulated in DLKP after seven days BrdU exposure
Protein/Gene -Fold
___________________________________________________________________________ _Decrease
CAMP-dependent transcription factor ATF-4; DNA-binding protein 7
TAXREB67; cAMP-response element binding protein (CREB2)
c-myc oncogene 7
60S ribosomal protein L6 (RPL6); TAX-responsive enhancer element 5
binding protein 107 (TAXREB107); neoplasm-related protein C l40
Transcription initiation factor IID; TATA-box factor; TATA sequence- 4
binding protein (TBP)
Cellular nucleic acid binding protein (CNBP); sterol regulatory element- 3
binding protein
DNA-binding protein HIP116; ATPase; SNF2/SWI2-related protein 3
GA-binding protein beta-2 subunit (GABP-beta2); transcription factor 3
E4TF1-60
Cytosolic superoxide dismutase 1 (SOD1) 2
Activator 1 37-kDa subunit; replication factor C 37-kDa subunit 2
(RFC37); RFC4
N-ras; transforming p21 protein 2
DNA-dependent protein kinase (DNA-PK) + DNA-PK catalytic subunit 2
(DNA-PKCS)
Octamer-binding transcription factor 2 (oct-2; OTF2); lymphoid- 2
restricted immunoglobulin octamer binding protein NF-A2; POU2F2 
Vascular endothelial growth factor precursor (VEGF); vascular 2
permeability factor (VPF)
CACCC-box DNA-binding protein 2
Signal transducer and activator o f transcription 6 (STAT6); IL-4 ST AT 2
v-erbA related protein (EAR3); COUP transcription factor (COUP-TF) 2
Glutathione S-transferase mul (GSTM1; GST1); HB subunit 4; GTH4 2
Neuroleukin (NLK); glucose-6-phosphate isomerase (GP1); 2
phosphoglucose Isomerase (PGI); phosphohexose isomerase (PHI)
ERBB-3 receptor protein-tyrosine kinase precursor; epidermal growth 2
factor receptor
acyl-CoA-binding protein (ACBP); diazepam binding inhibitor (DBI) 2
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Table 3.5.3 shows the genes downregulated in the DLKP cells following seven days 
exposure to BrdU. As can be seen, twenty genes out o f a total o f 597 were decreased in 
expression in response to the differentiating agent. The most significant decreases were 
in cAMP-response element binding protein (CREB2) and the c-myc oncogene (both 
seven-fold) after seven days exposure to BrdU. Other significant decreases were in the 
60S ribosomal protein L6 (RPL6) (five-fold) and Transcription initiation factor 1ED 
(four-fold).
Only five genes assayed for changes in expression in the BrdU-exposed DLKP using 
RT-PCR (Section 3.1.1) were also analysed using the array. These five genes, along 
with their fold increase (+) or decrease (-) in expression and location within the DNA 
array can be seen in Table 3.5.4.
Table 3.5.4Genes examined in BrdU-DLKP array also examined using RT-PCR
Array Position Protein/Gene -Fold Change
A la c-myc oncogene 7(-)
C2h Apoptosis regulator bax -
C3e Apoptosis regulator bcl-x -
C4b Apoptosis regulator bcl-2 -
E5g alphal catenin (CTNNA1) 2 (+)
Finally, a number o f housekeeping genes were included on the array to standardise the 
amount of RNA analysed on each array, and also to provide a control for those samples 
against which changes in gene expression could be compared. While the majority o f  the 
housekeeping genes remained the same from the first array to the second, two of these 
genes were observed upregulated in expression in the seven-day BrdU-treated DLKP 
RNA sample. These two genes, along with their respective degree of upregulation are 
listed in Table. 3.5.5.
Table. 3.5.5 Housekeeping genes upregulated by BrdU in DLKP cells__________
Housekeeping gene
Ubiquitin (Stress response protein)
Cytoplasmic beta-actin (ACTB) (Cytoskeleton protein)
-Fold
Increase
3
2
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3.6 Analysis of gene expression in human clinical tissue samples
3.6.1 Introduction to the clinical study group
It has been shown from the literature that the expression o f  certain genes may play a 
significant role in tumour growth and progression (e.g. Nooter et al., 1998, etc.). The 
purpose o f this study was twofold:
1. To ascertain if  a reliable method o f RNA isolation from human tumours could be 
achieved and also if  subsequent analysis o f that RNA using RT-PCR and/or other 
methods yielded results which were clear-cut and reproducible.
2. To investigate the clinical importance of the genes examined in the BrdU- and drug- 
exposed DLKP and A549 cells.
The types o f tissue examined were primary lung, breast and oesophageal tumour 
samples with accompanying normal controls. A number o f lymph node samples were 
also investigated, so as to correlate the expression results o f metastasised tissue 
compared to their corresponding unmetastasised primary tumour. To this end, the lymph 
node samples required were those from patients whose primary tumours had already 
been donated. It is important to not at this point that tissue samples were not 
microdissected upon delivery, so the analysed tissues may comprise a mix o f 
tumourigenic and non-tumourigenic material.
A total o f fifty human tissue samples were obtained from St. Vincent’s Hospital, Dublin 
over the months January to M ay 1999. The tissue breakdown was: eighteen single 
tumour samples, two mediastinal lymph node samples and fifteen tumour/normal 
sample pairs. The samples were stored at -80°C until ready for RNA isolation. RNA 
was isolated as described in Section 2.4.6. and the samples subjected to RT-PCR 
analysis. RT-PCR results were visualised using gel electrophoresis and densitometry.
In order that the study be as unbiased as possible, the samples were received without 
any form of clinical information and as such were analysed on agarose electrophoresis 
gels without regard to their origin or tumour type. As a result, the gel photographs 
presented here display the gene expression results o f the different types o f tissue which
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were supplied. There were a number o f different tissue types supplied, which for clarity, 
have been divided here into five distinct classes, in descending order o f importance to 
this survey. These classes o f tissue are:
• Primary lung
• Primary breast
• Primary oesophageal
• Metastasised lung tumour tissue, mediastinal lymph node samples, metastasised 
breast tumour tissue
• Normal non-carcinoma tissue.
A large number o f the tissue samples (seventeen) supplied were from secondary 
(metastasised) tumours. As such, these tumours could not be classified as being of lung, 
breast or oesophageal origin and were classified separately to the primary tissue samples 
obtained. As well, neither o f the mediastinal lymph node samples corresponded to any 
primary tumours supplied and as such, these tissues constitute another group of 
metastasised tissue. Finally, a total o f five tissue samples were classified as non­
carcinoma in origin.
Therefore, the survey group comprises the following five categories:
1. Four single primary lung tumour samples and ten primary lung tumour/normal 
sample pairs.
2. Two single primary breast tumour samples.
3. Two single primary oesophageal tumour samples.
4. Metastasised lung tumour (five single tumour samples, two mediastinal lymph 
nodes, three tumour/normal sample pairs) and metastasised breast tumour (two 
single tumour samples, one tumour/normal sample pair),
5. Tissue o f non-carcinoma origin (one duodenal tissue sample, one empyema strip 
decortication sample, three non-malignant bronchial resection samples from 
pneumonal patients).
As a result, the study group comprised a total of twenty-two separate RT-PCRs carried 
out on fifty tissue samples, which yielded a total of eleven hundred individual results. 
These are broken up into the various categories as illustrated in Table 3.6.1.
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Table 3.6.1 Amounts of PCR results obtained per analysis category
Analysis Category No. of samples RT-PCR results per category
Primary Lung 24 528
Primary Breast 2 44
Primary Oesophageal 2 44
Metastasised tissue 17 374
Non-carcinoma tissue 5 110
Each tissue sample was given a particular nomenclature indicating in what order it was 
received and whether the reference pertains to a single tumour sample (T), a 
tumour/normal sample pair (T/N), oesophageal primary sample (O) or a mediastinal 
lymph node (LN) sample. Other classifications include; ESD - empyema strip 
decortication and D -  Duodenal sample).
Also, the relative expression level o f each gene was determined by densitometry, which 
is unitless (as explained in Section 2.4.2.7). For reasons o f simplicity, the levels o f gene 
expression observed were divided into Low, Medium and High ranges, which reflect the 
densitometric levels measured. Average expression levels for each gene were surveyed 
and these divisions were decided upon arbitrarily. The limits o f these ranges are 
outlined in Table 3.6.2.
The criteria for estimation of mdr-3 expression are not available as no sample was 
observed to express this gene. The gene expression and clinical data for all twenty-two 
genes is included in Tables 7.IB - 7.1 OB in Appendix B. The expression data for the 
normal samples is printed in bold lettering to distinguish these samples from 
tumourigenic tissue. In sample pairs which differ in expression levels but not by a large 
enough margin to exceed the ranges decided here, a “+” will denote which of the two 
tissues was expressed to a higher level.
Also, in Figs. 3.6.1 -  3.6.42, the different classes o f tissue were assigned colours to 
distinguish one from another. Lung primary tissue samples are RED, Breast primary are 
BLUE, Oesophageal primary are ORANGE, Metastasised tissue is GREY and Non­
carcinoma tissue is NAVY.
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Table 3.6.2 Criteria for identifying the different categories of gene expression
LOW M EDIUM  (MED) H IG H
MRP1 <0.15 0.15-0.4 >0.4
M RP2 <0.1 0.1-0.3 >0.3
MRP3 <2 2-4 >4
M RP4 <0.5 0.5-1 >1
M RP5 <0.1 0.1-0.2 >0.2
M RP6 <1 1-2 >2
Mdr-1 <0.2 0.2-0.4 >0.4
BCRP <0.04 0.04-0.1 >0.1
M dr-3 N/A N/A N/A
COX-1 <0.2 0.2-0.4 >0.4
COX-2 <0.2 0.2-1 >1
BAP <1 1-4 >4
BAXa <0.2 0.2-0.6 >0.6
M RIT <1 1-1.5 >1.5
Bcl-xs <0.1 0.1-0.15 >0.15
B c1-xl <1.5 1.5-2 >2
Bcl-2a <0.5 0.5-1 >1
BAG <2 2-4 >4
Survivin <1 1-1.5 >1.5
eIF-4E <2 2-6 >6
eIF-2a <5 5-15 >15
c-myc <0.015 0.015-0.03 >0.03
3.6.2 RT-PCR expression results for Primary Human Lung Tissue samples
This was the most important study group as it was the only sample group of reasonable 
size composed solely of confirmed primary tumour samples. The group comprised o f 
ten lung tumour samples with normal controls, and four lung tumour samples without 
controls. The gene expression data for these samples is included in Table 7.IB in
235
Appendix B. A complete list o f these sample numbers as used in the survey is provided 
in Table 3.6.3.
Table 3.6.3 List of Primary Lung tissue samples
Sample Name Sample Tissue Type
1 T Single Tumour only
2 T Single Tumour only
3 T Single Tumour only
12 T Single Tumour only
16T/N Tumour with Normal tissue control
17T/N Tumour with Normal tissue control
18T/N Tumour with Normal tissue control
19T/N Tumour with Normal tissue control
21 T/N Tumour with Normal tissue control
22T/N Tumour with Normal tissue control
23 T/N Tumour with Normal tissue control
25 T/N Tumour with Normal tissue control
B 5T/N Tumour with Normal tissue control
B 6T/N Tumour with Normal tissue control
3.6.2.1 MRP1
The results o f these RT-PCRs can be seen in Figs. 3.6.1 and 3.6.2. MRP1 expression 
was detected in twenty-two o f the twenty-four primary lung tissue samples assayed 
(>91%). Expression was detected in three o f the four tumour samples without controls. 
In the tumour/normal sample set, MRP1 expression was detected in every sample 
except one. Overall, MRP1 expression was observed to be higher in the tumour sample 
relative to the normal in five o f the ten tumour/normal sample pairs (50%). Another 
sample pair expressed identical amounts o f the gene in both tissues, while the remaining 
four pairs (40%) express higher amounts o f the gene in the normal tissue.
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Fig. 3.6.1: MRP1 RT-PCR on Tumour tissue samples
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Figs. 3.6.1a & b: Gel electrophoresis photographs of MRP1 RT-PCR results on Lung
Primary (RED), Oesophagus Primary (ORANGE), Metastatic (GREY) & Non­
carcinoma (NAVY) tissue samples; Fig. 3.6.1c: Densitometry of RT-PCR results.
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3.6.2.2 MRP2 (cMOAT)
The results o f these RT-PCRs can be seen in Figs. 3.6.3 and 3.6.4. MRP2 expression 
was observed at a mainly low level in nineteen o f the twenty-four samples studied 
(>71%). Three of the four tumour samples without controls were observed to express 
the MRP2 gene at a low level. Expression levels o f the gene were higher in the tumour 
samples relative to their normal controls in four (40%) tumour/normal sample pairs. 
Normals expressed higher amounts o f the gene in three sample pairs (30%), while three 
other sample pairs (30%) expressed identical amounts o f the gene in both tissues.
3.6.2.3 MRP3
The results o f these RT-PCRs can be seen in Figs. 3.6.5 and 3.6.6. MRP3 expression 
was detected in twenty-three of the twenty-four lung tissue samples assayed (96%). 
Expression was generally observed to be o f a low level in most o f these samples. All 
four lung tumour samples without controls expressed the gene at this low level. Four of 
the ten tumour/normal sample pairs (40%) expressed higher amounts o f the gene in the 
tumour sample relative to their corresponding normal equivalent, while three pairs 
(30%) expressed higher amounts in the normal sample. A further three sample pairs 
(30%) expressed identical amounts o f the gene in both tissues.
3.6.2.4 MRP4
The results o f these RT-PCRs can be seen in Figs. 3.6.7 and 3.6.8. MRP4 expression 
was observed in fifteen of the twenty-four (>62%) lung tissue sample specimens. 
Expression o f the gene was observed in all four o f the tumour specimens without 
normals. In the tumour/normal sample pairs, three pairs (30%) did not express the gene 
in either sample. In the seven sample pairs which were observed to express MRP4, 
expression was observed to be higher in the tumour sample in five o f these seven pairs 
(>70%). In only two sample pairs (<30%) was expression o f the gene higher in the 
normal sample relative to the tumour.
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MRP2 RT-PCR on Tumour tissue samplesFig. 3.6.3:
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Figs. 3.6.3a & b: Gel electrophoresis photographs of MRP2 RT-PCR results on Lung
Primary (RED), Oesophagus Primary (ORANGE), Metastatic (GREY) & Non­
carcinoma (NAVY) tissue samples; Fig. 3.6.3c: Densitometry of RT-PCR results.
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Fig. 3.6.4a:
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Figs. 3.6.4a & b: Gel electrophoresis photographs of MRP2 RT-PCR results on Lung
Primary (RED), Breast Primaiy (BLUE), Metastatic (GREY) tissue samples & Non-
carcinoma (NAVY) tissue samples; Fig. 3.6.4c: Densitometry of RT-PCR results.
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Fig. 3.6.5: 
Fig. 3.6.5a:
IX 1 2
T T
MRP3 RT-PCR on Tumour tissjia^amnks
9 10 11 12 13 14
0 T E T 0 LN
(3-actin
Fig. 3.6.5c:
11
10
Bio
1 T 2 T 3 T 4 T 5 T 6 T 7 T 6 T 9 0  10 11 12 13 14 15 15 15 16 16 17 17 10 18 19 19 20
T E T O L N L N T N T N T N T N T N T
Figs. 3.6.5a & b: Gel electrophoresis photographs of MRP3 RT-PCR results on Lung
Primary (RED), Oesophagus Primary (ORANGE), Metastatic (GREY) & Non­
carcinoma (NAVY) tissue samples; Fig. 3.6.5c: Densitometry of RT-PCR results.
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Fig. 3.6.6a:
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Fig. 3.6.6: MRP3 RT-PCR on Tumour tissue samples
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Figs. 3.6.6a & b: Gel electrophoresis photographs of MRP3 RT-PCR results on Lung
Primary (RED), Breast Primary (BLUE), Metastatic (GREY) & Non-carcinoma
(NAVY) tissue samples; Fig. 3.6.6c: Densitometry of RT-PCR results.
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Fig. 3.6.8a:
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Fig. 3.6.8: MRP4 RT-PCR on Tumour tissue samples
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Figs. 3.6.8a & b: Gel electrophoresis photographs of MRP4 RT-PCR results on Lung
Primary (RED), Breast Primary (BLUE), Metastatic (GREY) & Non-carcinoma
(NAVY) tissue samples; Fig. 3.6.8c: Densitometry of RT-PCR results.
245
3.6.2.5 MRP5
The results o f these RT-PCRs can be seen in Figs. 3.6.9 and 3.6.10. Twenty-two of the 
twenty-four (>91%) lung tissue samples were observed to express the MRP5 gene. High 
levels o f expression o f the gene were observed in two o f the four (50%) tumour samples 
without controls as well as lower expression in a third sample. All o f the tumour/normal 
sample pairs expressed the gene in at least one o f the tissues. In these sample pairs, six 
o f the ten pairs (60%) expressed higher amounts o f the gene in the tumour sample 
relative to the normal, while only three pairs (30%) did the opposite. The remaining 
sample pair expressed identical amounts o f the gene in both tissues.
3.6.2.6 MRP6
The results o f these RT-PCRs can be seen in Figs. 3.6.11 and 3.6.12. MRP6 expression 
was observed in twenty-one o f the twenty-four (>87%) lung tissue specimens studied. 
Expression of the gene was observed in all the unpaired tumour samples. All of the 
tumour/normal sample pairs expressed the gene in at least one o f the paired tissues. O f 
these sample pairs, only two (20%) expressed higher amounts o f the gene in the tumour 
sample relative to the normal control. One other sample pair expressed identical 
amounts o f the gene in both tissues, while the remaining seven sample pairs (70%) 
expressed more MRP6 in the normal tissue. However, the quality o f these PCRs is 
questionable and care would need to be taken in relying too much on the results 
obtained for expression of this gene.
3.6.2.7 mdr-1
The results o f these RT-PCRs can be seen in Figs. 3.6.13 and 3.6.14. mdr-1 expression 
was observed in twenty-one of the twenty-four (>87%) lung tissue specimens studied. 
Expression o f the gene was detected in all four o f the tumour samples studied without 
controls. All o f the tumour/normal sample pairs expressed the gene in at least one of the 
tissues. O f these pairs, mdr-1 overexpression in the tumour sample relative to the
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IFig. 3.6.9: MRP5 RT-PCR on Tumour tissue samples
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Figs. 3.6.9a & b: Gel electrophoresis photographs of MRP5 RT-PCR results on Lung
Primary (RED), Oesophagus Primary (ORANGE), Metastatic (GREY) & Non­
carcinoma (NAVY) tissue samples; Fig. 3.6.9c: Densitometry of RT-PCR results.
247
Fig. 3.6.10a:
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Fig. 3.6.10: MRP5 RT-PCR on Tumour tissue samples
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Figs. 3.6.10a & b: Gel electrophoresis photographs of MRP5 RT-PCR results on Lung
Primary (RED), Breast Primary (BLUE), Metastatic (GREY) & Non-carcinoma
(NAVY) tissue samples; Fig. 3.6.10c: Densitometry of RT-PCR results.
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Fig. 3.6.11: MRP6 RT-PCR on Tumour tissue samples
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Figs. 3.6.11a & b: Gel electrophoresis photographs of MRP6 RT-PCR results on Lung
Primary (RED), Oesophagus Primary (ORANGE), Metastatic (GREY) & Non­
carcinoma (NAVY) tissue samples; Fig. 3.6.9c: Densitometry of RT-PCR results.
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Fig. 3.6.12: MRP6 RT-PCR on Tumour tissue samples
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Figs. 3.6.12a & b: Gel electrophoresis photographs of MRP6 RT-PCR results on Lung
Primary (RED), Breast Primary (BLUE), Metastatic (GREY) & Non-carcinoma
(NAVY) tissue samples; Fig. 3.6.12c: Densitometry of RT-PCR results.
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Figs. 3.6.13a & b: Gel electrophoresis photographs of mdr-1 RT-PCR results on Lung
Primary (RED), Oesophagus Primary (ORANGE), Metastatic (GREY) & Non­
carcinoma (NAVY) tissue samples; Fig. 3.6.13c: Densitometry of RT-PCR results.
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Fig. 3.6.14: in dr-1 RT-PCR on Tumour tissue samples
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Figs. 3.6.14a & b: Gel electrophoresis photographs of mdr-1 RT-PCR results on Lung
Primary (RED), Breast Primary (BLUE), Metastatic (GREY) & Non-carcinoma
(NAVY) tissue samples; Fig. 3.6.14c: Densitometry of RT-PCR results.
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normal was only observed in three (30%) sets. A total o f five (50%) sample pairs 
expressed higher amounts of the gene in the normal sample relative to the tumour, while 
a further two pairs (20%) expressed similar amounts o f mdr-1 in both tissues.
3.6.2.8 BCRP
The results o f these RT-PCRs can be seen in Figs. 3.6.15 and 3.6.16. Twenty o f the 
twenty-four lung tissue samples (>83%) assayed for BCRP expression were observed to 
be positive for the gene. Medium to high levels o f expression were observed for the 
unpaired tumour samples. Nine o f the ten tumour/normal sample pairs were observed to 
express the gene in at least one o f the tissue samples. O f these nine sample pairs, only 
three (33%) expressed higher amounts o f the gene in the tumour sample relative to its 
normal control. Two other sample pairs expressed similar amounts o f the gene, while 
four (>44%) o f the pairs expressed higher amounts in the normal tissue sample.
3.6.2.9 mdr-3
mdr-3 was not expressed in any o f the lung tissue samples assayed for expression. A 
positive level o f expression was observed for the PCR positive control, which indicated 
that the PCR had been carried out correctly. This result indicated that, in these samples 
at least, mdr-3 is not a factor to be considered in the prognosis o f this disease (data not 
shown).
3.6.2.10 COX-1
The results o f these RT-PCRs can be seen in Figs. 3.6.17 and 3.6.18. COX-1 was 
expressed in nine (37.5%) of the twenty-four lung tissue samples assayed. Expression 
was detected in two (50%) o f the four unpaired tumour samples. Five (50%) of the 
following ten tumour/normal sample pairs were observed to express the gene in at least 
one of the tissue samples. Of these samples, COX-1 expression was observed
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Fig. 3.6.15: BCRP RT-PCR on Tumour tissue samples
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Figs. 3.6.15a & b: Gel electrophoresis photographs of BCRP RT-PCR results on Lung
Primary (RED), Oesophagus Primary (ORANGE), Metastatic (GREY) & Non­
carcinoma (NAVY) tissue samples; Fig. 3.6.15c: Densitometry of RT-PCR results.
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Figs. 3.6.16a & b: Gel electrophoresis photographs o f BCRP RT-PCR results on Lung 
Primary (RED), Breast Primary (BLUE), Metastatic (GREY) & Non-carcinoma 
(NAVY) tissue samples; Fig. 3.6.16c: Densitometry o f RT-PCR results.
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Fig. 3.6.17: COX-1 RT-PCR on Tumour tissue samples
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Figs. 3.6.17a & b: Gel electrophoresis photographs of COX-1 RT-PCR results on Lung
Primary (RED), Oesophagus Primary (ORANGE), Metastatic (GREY) & Non­
carcinoma (NAVY) tissue samples; Fig. 3.6.17c: Densitometry of RT-PCR results.
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Fig. 3.6.18: COX-1 RT-PCR on Tumour tissue samples
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Figs. 3.6.18a& b: Gel electrophoresis photographs of COX-1 RT-PCR results on Lung
Primary (RED), Breast Primary (BLUE), Metastatic (GREY& Non-carcinoma (NAVY)
tissue samples; Fig. 3.6.18c: Densitometry of RT-PCR results.
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overexpressed in the tumour sample relative to the normal control in three (60%) 
sample pairs. Also, the highest expression levels observed for these tissues was 
recorded in the tumour samples. As with MRP6, however, the quality o f the RT-PCRs is 
poor, and the results questionable.
3.6.2.11 COX-2
The results o f these RT-PCRs can be seen in Figs. 3.6.19 and 3.6.20. Expression of the 
COX-2 gene was observed in fourteen (>58%) o f the twenty-four lung tissue specimens 
inspected. Expression was detected in only one o f the four unpaired tumour samples. 
Two tumour/normal sample pairs did not express the gene in either tissue. O f the 
remaining eight sample pairs that did express the gene, six (75%) expressed higher 
amounts of COX-2 in the tumour sample relative to the normal tissue.
3.6.2.12 BAP
The results of these RT-PCRs for the pro-apoptotic BAP gene can be seen in Figs. 
3.6.21 and 3.6.22. BAP expression was observed in all twenty-four lung tissue samples 
studied, the first gene studied here to do so. However, only four (40%) o f the ten 
tumour/normal sample pairs overexpress the gene in the normal tissue, while five (50%) 
pairs overexpress the gene in the tumour sample. The remaining sample pair expresses 
identical amounts o f BAP in both tissues while the gene is expressed in all four 
unpaired tumour samples.
3.6.2.13 BAXa
The results o f these RT-PCRs can be seen in Figs. 3.6.23 and 3.6.24. BAXa is also a 
pro-apoptotic gene and, like BAP, is observed expressed in all twenty-four o f the lung 
samples assayed. Expression of the gene is also observed to be high in most o f these 
samples. In the paired tumour/normal samples, expression o f the gene is observed to be
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Fig. 3.6.19a:
IX 1 2 3 4 5 6 7 8 9 10 11 12 13 14
T T T T T T T T O T E T O L N
Fig. 3.6.19: COX-2 RT-PCR on Tumour tissue samples
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Figs. 3.6.19a & b: Gel electrophoresis photographs of COX-2 RT-PCR results on Lung
Primary (RED), Oesophagus Primary (ORANGE), Metastatic (GREY) & Non­
carcinoma (NAVY) tissue samples; Fig. 3.6.19c: Densitometry of RT-PCR results.
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Figs. 3.6.20a & b: Gel electrophoresis photographs of COX-2 RT-PCR results on Lung
Primary (RED), Breast Primary (BLUE), Metastatic (GREY) & Non-carcinoma
(NAVY) tissue samples; Fig. 3.6.20c: Densitometry of RT-PCR results.
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Fig. 3.6.21: BAP RT-PCR on Tumour tissue samples
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Figs. 3.6.21a & b: Gel electrophoresis photographs of BAP RT-PCR results on Lung
Primary (RED), Oesophagus Primary (ORANGE), Metastatic (GREY) & Non­
carcinoma (NAVY) tissue samples; Fig. 3.6.21c: Densitometry of RT-PCR results.
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Fig. 3.6.22: BAP RT-PCR on Tumour tissue samples
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Figs. 3.6.22a & b: Gel electrophoresis photographs of BAP RT-PCR results on Lung
Primary (RED), Breast Primary (BLUE), Metastatic (GREY) & Non-carcinoma
(NAVY) tissue samples; Fig. 3.6.22c: Densitometry of RT-PCR results.
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higher in the normal sample o f only four pairs (40%). The remaining six pairs all 
express higher amounts o f the gene in the tumour sample.
3.6.2.14 MRIT
The results o f these RT-PCRs for the pro-apoptotic MRIT gene can be seen in Figs. 
3.6.25 and 3.6.26. MRIT was found to be expressed in twenty-three o f the twenty-four 
lung samples studied (>95%). Eight (80%) o f the paired tumour/normal tissue samples 
expressed higher amounts o f the gene in the normal sample relative to the tumour 
sample. Although expression o f the gene was also observed in the four unpaired 
samples, it was felt that the former result was o f significance.
3 .6 .2 .15  B c l-x s /B c1-x l
The results o f these RT-PCRs can be seen in Figs. 3.6.27 to 3.6.30. Bcl-xs, also a pro-
apoptotic gene, was found to be expressed in nineteen (>70%) out o f the twenty-four
tissue samples. Overall, expression was generally in the medium to high range. All four 
unpaired tumour samples were observed to express the gene. Also, eight o f the 
tumour/normal sample pairs (80%) expressed the gene to some degree in at least one of 
the tissue samples. O f these eight sample pairs, only two (25%) expressed higher 
amounts o f the gene in the normal tissue, while another sample pair expressed identical 
amounts of the gene in both tissues. The remaining five sample pairs (62.5%) expressed 
higher amounts o f the gene in the tumour tissue.
The anti-apoptotic B c1-Xl gene was expressed in twenty out o f twenty-four lung tissue 
samples (>80%) studied. High levels o f expression were detected in the four unpaired 
tumour samples. O f the ten tumour/normal sample pairs, eight were observed to express 
the gene in both tissues, while the remaining two pairs did not express B c1-Xl at all. Of 
these eight, B c1-xl was observed overexpressed in the tumour sample in five (62 .5% ) 
pairs. Another pair expressed identical amounts o f the gene in both tissues, while the
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Fig. 3.6.25: MRIT RT-PCR on Tumour tissue samples
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Figs. 3.6.25a & b: Gel electrophoresis photographs of MRIT RT-PCR results on Lung
Primary (RED), Oesophagus Primary (ORANGE), Metastatic (GREY) & Non­
carcinoma (NAVY) tissue samples; Fig. 3.6.25c: Densitometry of RT-PCR results.
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Fig. 3.6.26a:
IX 21 22 23 24 25 26 27
T N T N T N T N T N T N T N
Fig. 3.6.26: MR IT RT-PCR on Tumour tissue samples
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Figs. 3.6.26a & b: Gel electrophoresis photographs of MRIT RT-PCR results on Lung
Primary (RED), Breast Primary (BLUE), Metastatic (GREY) & Non-carcinoma
(NAVY) tissue samples; Fig. 3.6.26c: Densitometry of RT-PCR results.
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Fig. 3.6.27a: Gel electrophoresis photograph o f B c1-xl/s RT-PCR results on Lung 
Primary (RED), Oesophagus Primary (ORANGE), Metastatic (GREY) & Non­
carcinoma (NAVY) tissue samples; Fig. 3.6.27b: Densitometrie analysis o f B c1-xl 
RT-PCR results; Fig. 3.6.27c: Densitometrie analysis o f Bcl-xs RT-PCR results.
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Fig. 3.6.28c:
Fig. 3.6.28a: Gel electrophoresis photograph o f B c1-xl/s RT-PCR results on Lung 
Primary (RED), Oesophagus Primary (ORANGE), Metastatic (GREY) & Non­
carcinoma (NAVY) tissue samples; Fig. 3.6.28b: Densitometrie analysis o f Bcl-xL 
RT-PCR results; Fig. 3.6.28c: Densitometrie analysis o f Bcl-xs RT-PCR results.
269
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Fig. 3.6.29: Bcl-Xc/t RT-PCR on Tumour tissue samples
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Fig. 3.6.29a: Gel electrophoresis photograph o f  B c I-xl/s RT-PCR results on Lung 
Primary (RED), Oesophagus Primary (ORANGE), Metastatic (GREY) & Non­
carcinoma (NAVY) tissue samples; Fig. 3.6.29b: Densitometrie analysis o f B c1-xl 
RT-PCR results; Fig. 3.6.29c: Densitometrie analysis o f Bcl-xs RT-PCR results.
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Fig. 3.6.30a: Gel electrophoresis photograph o f B c1-xl/s RT-PCR results on Lung 
Primary (RED), Oesophagus Primary (ORANGE), Metastatic (GREY) & Non- 
carcinoma (NAVY) tissue samples; Fig. 3.6.30b: Densitometrie analysis o f Bcl-xL 
RT-PCR results; Fig. 3.6.27c: Densitometrie analysis o f Bcl-xs RT-PCR results.
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remaining two sample pairs (25%) expressed higher amounts in the normal tissue 
relative to its tumour equivalent.
3.6.2.16 Bcl-2a
The results o f the anti-apoptotic Bcl-2a RT-PCRs can be seen in Figs. 3.6.31 and 
3.6.32. All twenty-four lung tissue samples assayed for Bcl-2a expression were 
observed to express the gene to some degree. Two o f the unpaired tumour samples 
expressed the gene at a low level, while the other two expressed much higher amounts 
o f the gene. O f the ten tumour/normal sample pairs which expressed the gene, six (60%) 
expressed higher amounts o f the anti-apoptotic Bcl-2a in the tumour sample relative to 
its normal equivalent. A further three sample pairs expressed equal amounts o f the gene 
in either tissue, while only one sample pair expressed relatively higher levels in the 
normal tissue sample.
3.6.2.17 BAG
The results o f these RT-PCRs can be seen in Figs. 3.6.33 and 3.6.34. Expression of the 
anti-apoptotic BAG gene was observed in twenty-three o f the twenty-four lung tissue 
samples assayed (>95%). Expression was also observed to be quite high in most 
samples. All four unpaired tumour samples expressed the gene. O f the ten 
tumour/normal sample pairs, only three (30%) were observed to express higher amounts 
of the gene in the tumour sample relative to the normal. Six (60%) sample pairs 
expressed higher amounts of the gene in the normal sample. The remaining sample pair 
expressed similar amounts of the gene in both tissue samples.
3.6.2.18 Survivin
The results o f these RT-PCRs can be seen in Figs. 3.6.35 and 3.6.36. The anti-apoptotic 
Survivin gene was observed expressed in twenty-one o f the twenty-four (>87%) lung
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Fig. 3.6.31: Bcl-2a RT-PCR on Tumour tissue samples
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Figs. 3.6.31a & b: Gel electrophoresis photographs of Bcl-2a RT-PCR results on Lung
Primary (RED), Oesophagus Primary (ORANGE), Metastatic (GREY) & Non­
carcinoma (NAVY) tissue samples; Fig. 3.6.31c: Densitometry of RT-PCR results.
273
Fig, 3.6.32a:
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Fig. 3.6,32: Bcl-2a RT-PCR on Tumour tissue samples
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Figs. 3.6.32a & b: Gel electrophoresis photographs of Bcl-2a RT-PCR results on Lung
Primary (RED), Breast Primary (BLUE), Metastatic (GREY) & Non-carcinoma
(NAVY) tissue samples; Fig. 3.6.32c: Densitometry of RT-PCR results.
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Fig. 3.6.33: BAG RT-PCR on Tumour tissue samples
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Figs. 3.6.33a & b: Gel electrophoresis photographs of BAG RT-PCR results on Lung
Primary (RED), Oesophagus Primary (ORANGE), Metastatic (GREY) & Non­
carcinoma (NAVY) tissue samples; Fig. 3.6.33c: Densitometry of RT-PCR results.
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Fig. 3.6.34: BAG RT-PCR on Tumour tissue samples
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Figs. 3.6.34a & b: Gel electrophoresis photographs of BAG RT-PCR results on Lung
Primary (RED), Breast Primary (BLUE), Metastatic (GREY) & Non-carcinoma
(NAVY) tissue samples; Fig. 3.6.34c: Densitometry of RT-PCR results.
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Survivin RT-PCR on Tumour tissue samplesFig. 3.6.35:
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Fig. 3.6.33c:
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Figs. 3.6.35a & b: Gel electrophoresis photographs o f Survivin RT-PCR results on Lung 
Primary (RED), Oesophagus Primary (ORANGE), Metastatic (GREY) & Non­
carcinoma (NAVY) tissue samples; Fig. 3.6.35c: Densitometry o f RT-PCR results.
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Survivin RT-PCR on Tumour tissue .samplesFig. 3.6.36:_
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Figs. 3.6.36a & b: Gel electrophoresis photographs of Survivin RT-PCR results on Lung
Primary (RED), Breast Primary (BLUE), Metastatic (GREY) & Non-carcinoma
(NAVY) tissue samples; Fig. 3.6.36c: Densitometry of RT-PCR results.
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tissue samples studied. Expression was detected in at least one tissue sample in each of 
the ten tumour/normal sample pairs. All four impaired tumour samples were observed to 
express the gene. However, only five (50%) o f the paired sample sets expressed higher 
levels o f Survivin in the tumour, relative to the normal, tissue. One sample pair 
expressed similar amounts o f the gene, while the remaining four (40%) sample pairs 
expressed more Survivin in the normal tissue. This result indicates that Survivin 
expression is divided roughly equally between tumour and normal tissue in human lung 
cancer.
3.6.2.19 eIF-4E
The results o f these RT-PCRs can be seen in Figs. 3.6.37 and 3.6.38. As with Survivin, 
eIF-4E expression was detected in twenty-one of twenty-four lung tissue samples 
studied. Expression was observed in all four unpaired tumour samples assayed and in 
nine out o f ten (90%) tumour/normal sample pairs. O f these nine pairs, only two (22%) 
expressed higher levels o f eIF-4E in the tumour sample relative to the normal. A total o f 
six (>66%) sample pairs expressed more eIF-4E in the normal sample relative to the 
corresponding tumour sample. The remaining sample pair expressed identical amounts 
o f the gene in both tissues.
3.6.2.20 eIF-2a
The results of these RT-PCRs can be seen in Figs. 3.6.39 and 3.6.40. All twenty-four 
lung tissue samples assayed for eIF-2a expression were observed to express the gene. 
Expression levels in the unpaired tumour samples was generally at a medium level, 
while much greater variance was observed in the tumour/normal sample pairs. O f the 
ten paired sample sets, seven (70%) expressed higher amounts o f the gene in the tumour 
sample relative to the normal equivalent. The remaining three sample sets expressed 
higher amounts o f eIF-2a in the normal tissue sample relative to the tumour.
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Fig. 3.6.37: elF-4E RT-PCR on Tumour tissue samples
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Figs. 3.6.37a & b: Gel electrophoresis photographs of eIF-4E RT-PCR results on Lung
Primary (RED), Oesophagus Primary (ORANGE), Metastatic (GREY) & Non­
carcinoma (NAVY) tissue samples; Fig. 3.6.37c: Densitometry of RT-PCR results.
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Fig. 3.6.38: eIF-4E RT-PCR on Tumour tissue samples
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Figs. 3.6.38a & b: Gel electrophoresis photographs of eIF-4E RT-PCR results on Lung
Primary (RED), Breast Primary (BLUE), Metastatic (GREY) & Non-carcinoma
(NAVY) tissue samples; Fig. 3.6.38c: Densitometry of RT-PCR results.
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Fig. 3.6.39a:
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Fig. 3.6 .39: eIF-2a RT-PCR on Tumour tissue samples
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Figs. 3.6.39a & b: Gel electrophoresis photographs of eIF-2a RT-PCR results on Lung
Primary (RED), Oesophagus Primary (ORANGE), Metastatic (GREY) & Non­
carcinoma (NAVY) tissue samples; Fig. 3.6.39c: Densitometry of RT-PCR results.
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Fig. 3.6.40a:
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Fig. 3.6.40: eIF-2a RT-PCR on Tumour tissue samples
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Figs. 3.6.40a & b: Gel electrophoresis photographs of eIF-2a RT-PCR results on Lung
Primary (RED), Breast Primary (BLUE), Metastatic (GREY) & Non-carcinoma
(NAVY) tissue samples; Fig. 3.6.40c: Densitometry of RT-PCR results.
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3.6.2.21 c-myc
The results o f these RT-PCRs can be seen in Figs. 3.6.41 and 3.6.42. c-myc expression 
was observed in only eleven (46%) o f the twenty-four lung tissue samples studied. Most 
of these samples also expressed only quite low levels o f the gene. Expression was 
detected in two o f the unpaired tumour samples, while six o f the ten tumour/normal 
sample pairs (60%) expressed the gene in at least one o f the supplied tissue samples. O f 
these six pairs, only two expressed higher amounts o f c-myc in the tumour sample. 
Three others expressed higher amounts in the normal sample, while another sample 
expressed equal amounts o f the gene.
3.6.3 Correlation o f Primary lung RT-PCR expression data with clinical data
The largest obstacle to meaningful interpretation o f the primary lung cancer gene 
expression results with regard to their clinical diagnosis is the limited clinical 
information available on the tumours. Data was sought on a total o f twenty-two distinct 
clinical parameters which are summarised in the clinical data information form 
(Clinical Data Questionnaire) included in Appendix B. This form was supplied to the 
clinicians at St. Vincent’s for completion on each sample sent. Age, Gender and 
Tumour size were the only parameters where 100% availability o f information was 
obtained. The other parameters obtained a compliance rate o f between 7% and 78%. 
The clinical information relating to the primary lung samples only is displayed in Table 
7.2B. All information was obtained from patient medical files and the tables presented 
in this Section reflect the totality o f information obtained. As can be seen from a 
comparison o f the Clinical Data Questionnaire with the aforementioned tables, 
information was not available for all parameters sought.
3.6.3.1 Age
Age was one of the most easily obtained o f all the clinical parameters and was readily 
available for all primary tumour and normal samples supplied. The average age o f the
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Figs. 3.6.41a & b: Gel electrophoresis photographs o f c-myc RT-PCR results on Lung
Primary (RED), Oesophagus Primary (ORANGE), Metastatic (GREY) & Non­
carcinoma (NAVY) tissue samples; Fig. 3.6.41c: Densitometry o f RT-PCR results.
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Fig. 3.6.42a:
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Fig. 3.6.42: c-mvc RT-PCR on Tumour tissue samples
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Figs. 3.6.42a & b: Gel electrophoresis photographs o f c-myc RT-PCR results on Lung
Primary (RED), Breast Primary (BLUE), Metastatic (GREY) & Non-carcinoma
(NAVY) tissue samples; Fig. 3.6.42c: Densitometry o f RT-PCR results.
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male patients at time of surgery was 62.6 years. Average age for the female patients was 
eight years younger, at 54.6 years.
Although the study group involved was too small to divide up the samples into 
categories o f patient age, several inferences may be drawn from the data. For instance, it 
was noted that the older the patient at the time of surgery, the larger the removed 
tumour size. Also, despite the fact that a number o f the treated patients had expired at 
the time o f writing (November 2001; two years after surgery), these were not the oldest 
patients to undergo surgery. None of the genes examined revealed a particular 
preponderance for the age of the patient, although expression of the MRP-related genes 
were notably absent from tumours removed from younger patients.
3.6.3.2 Gender
As has been previously explained, samples were taken from a total o f fourteen patients 
undergoing surgery for removal of primary lung carcinomas. Seven patients were male, 
seven were female. Two o f the unpaired tumour samples were obtained from male 
patients, two from female. Also, there were five tumour/normal sample pairs for each 
gender, yielding an identically divided study group along gender lines. A list o f the 
sample numbers divided along gender lines is provided in Table 3.6.4.
Table 3.6.4 Primary lung tumour patient nos, listed by gender
Male Female
1 T 2 T
12 T 3 T
16T/N 19 T/N
17T/N 21 T/N
18 T/N 23 T/N
22T/N B5 T/N
25 T/N B6 T/N
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When the samples are divided up by gender, an analysis o f expression o f the various 
genes reveals a number o f interesting correlations. Firstly, MRP1 is predominantly 
expressed in tumours isolated from male patients. MRP1 overexpression was observed 
in six o f the seven tumour samples (>85%) taken from males. Four o f the five (80%) 
tumour/normal sample pairs expressed higher MRP1 in the tumour sample relative to 
the normal. For the female patients, MRP1 overexpression is largely confined to the 
normal samples, with four o f the five normals expressing higher MRP1.
The expression o f MRP5 also appeared to be slightly sex-linked. The gene was also 
expressed in higher amounts in the tumour sample in four o f the five (80%) 
tumour/normal sample pairs taken from male patients. Other interesting results observed 
when the tumours were segregated according to gender o f donor were those seen for 
COX-1, MRIT, Bcl-2a and eIF-2a. Bcl-2a and eIF-2oc were both observed to be 
overexpressed in the majority o f tumours extracted from male patients with an incidence 
rate o f six out o f seven samples. In tumours donated from female patients, COX-1 was 
observed to be expressed in only one unpaired tissue sample, and then only at a very 
low level. By contrast, MRIT was overexpressed in all seven female tumour tissue 
samples, the highest rate o f expression seen on a gender basis.
Comparison o f the other clinical parameters by gender also reveals another interesting 
anomaly. The average tumour size for specimens isolated from male patients is 2.0cm. 
By contrast, the average tumour size from female patients is almost triple this at an 
average o f 5.4cm. This is the only clinical parameter which appeared to be affected by 
gender classification.
3.6 .3.3 Tumour size
Tumour size was the third and last clinical parameter for which data was received on all 
tissue samples supplied. As has been already outlined (Section 3.3.3.2), tumours from 
female patients were generally larger than those obtaind from male donors. None o f the 
other clinical parameters revealed any significant correlation with tumour size. Also, no 
significant correlation with any o f the gene expression data was noted, although it was
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noted that expression of BAXa was largely confined to smaller tumour sizes, while 
MRP1 tended to be overexpressed slightly in the larger tumours.
3.6.3.4 All other clinical parameters
None o f the other clinical parameters mentioned as relevant to the primary lung tissue 
group contained enough information to make any rational observation about their 
relevance to any other parameter within the group or to any gene expression results. For 
this reason, data from these parameters will not be discussed further in relation to this 
tissue study group.
3.6.4 RT-PCR gene expression results for Primary Human Breast Tissue samples
After analysis o f the clinical data, the group was reduced to just two unpaired primary 
specimens. As this small group is not statistically significant, the general trends will be 
discussed here. The complete RT-PCR results, as well as clinical data, for each o f these 
samples is presented on Table 7.3B in Appendix B. A list o f the clinical data for these 
samples is displayed in Table 7.4B in Appendix B. The two primary breast tumour 
samples are listed in Table 3.6.5.
Table 3.6.5 List of Primary Breast tumour samples
Sample Name Sample Tissue Type
B1 T Single Tumour only
B 2T Single Tumour only
The PCR results for both tumour tissue specimens were observed to be largely similar. 
Both tissue samples expressed low amounts o f the MRP genes 1, 2, 3, 5 and 6 . No 
expression for MRP4 was observed in either tissue. Mdr-1 and BCRP were also 
expressed in these samples to a low degree, although expression o f mdr-3 was not seen. 
Expression of the pro-apoptotic genes BAP, BAX a  and MRIT was observed to be quite 
high in these tissues, although no expression o f the Bcl-xs gene was observed.
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Similarly, Bcl-xL expression was not detected in these samples although the other anti- 
apoptotic genes surveyed, Survivin, BAG and Bcl-2a were all expressed at medium to 
high levels. Finally, high levels o f expression of the eIF-4E and eIF-2a genes was also 
observed, along with high expression of the c-myc gene.
3.6.5 RT-PCR gene expression results for Primary Oesophageal tissue samples
Two unpaired oesophageal tumour samples were received and analysed in the course of 
this study. Due to the small sample size, no significant correlations may be drawn 
between gene expression and clinical data. However, the results obtained for these two 
samples will be outlined here. All gene expression data on these samples are included in 
Table 7.5B, while the clinical information is displayed in Table 7.6B, both of which are 
located in Appendix B. The two primary oesophageal tumour samples are listed in 
Table 3.6.6.
Table 3.6.6 List of Primary Oesophageal tumour samples
Sample Name Sample Tissue Type
9 0 Single Tumour only
13 0 Single Tumour only
RT-PCR analysis of the oesophageal tumour samples reveal high expression o f Bcl-xs 
and medium expression levels of the genes BAXa, B c1-x l , BAG and eIF-4E. Low 
expression levels was observed for MRPs 1, 4, 5 and 6, as well as for COX-1, COX-2, 
and c-myc. Variable expression levels were observed for all other genes studied. The 
clinical data available on these samples was especially sparse, with only four criteria 
completed. Overall, there was little correlation to be made from such a small group; 
both donors were male, in their mid-to-late 70s and both tumours appeared poorly 
differentiated.
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3.6.6 RT-PCR gene expression results for Metastasised tumour samples
The metastasised tissue group was the second largest group in the study, comprising a 
total o f seventeen tissue samples, yielding a total o f 374 individual gene expression 
results. As the origin o f these tumours is unknown, it is impossible to group these 
tissues under any category resembling tumour type and so these samples will therefore 
be analysed in one distinct grouping. All expression data are included in Table 7.7B, 
while the clinical information on these samples is shown in Table 7.8B, both o f which 
are in Appendix B. A list o f the seventeen metastasised tissue sample numbers is given 
in Table 3.6.7.
Table 3.6.7 List of Metastsised human tissue samples
Sample Name Sample Tissue Type
4 T Single Tumour only
5 T Single Tumour only
6 T Single Tumour only
7 T Single Tumour only
8 T Single Tumour only
10 T Single Tumour only
B 4T Single Tumour only
14 LN Mediastinal Lymph Node tissue
15 LN Mediastinal Lymph Node tissue
15T/N Tumour with Normal tissue control
24T/N Tumour with Normal tissue control
27T/N Tumour with Normal tissue control
B 7T/N Tumour with Normal tissue control
As outlined already, the metastasised tissue sample group was made up o f five single 
tumour samples from lung, three tumour/normal sample pairs from lung and two 
mediastinal lymph nodes as well as two single tumour samples from breast and one 
tumour/normal sample pair from breast. An analysis o f the clinical details for this group 
reveals a number o f details which may be o f potentially relevance to the clinical 
profiling of metastasised tumour tissue.
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From the clinical results that were available, the lung samples were excised from five 
male and two female patients. There was an even distribution o f ages over the samples 
included, and only one patient was deceased at the time o f writing. An analysis o f the 
RT-PCR gene expression results revealed a very different expression profile to that 
obtained from primary tumours o f the lung, breast or oesophagus. Most o f the twenty- 
two genes assayed were expressed at widely varying levels over the samples studied. 
Only MRP2, COX-1 and eIF-2a which were generally expressed at low to medium 
levels in these tissues showed any pattern o f expression at all. The expression levels of 
the other genes varied too widely for general classification. Overall, only expression of 
the MRP1 gene in these tissues was deemed significant. MRP1 was strongly 
overexpressed in the tumour sample o f all the tumour/normal sample pairs analysed as 
well as being significantly expressed in every unpaired tumour specimen.
3.6.7 Expression results for non-carcinoma tissue samples
The non-carcinoma tissue group was made up o f five tissue samples as already outlined 
(see Section 3.6.1). The complete RT-PCR results are presented in Table 7.9B in 
Appendix B, along with the clinical data in Table 7.1 OB. The five non-carcinoma tissue 
sample nos. are listed in Table 3.6.8.
Table 3.6.8 List of non-carcinoma human tissue samples
Sample Name Sample Tissue Type
11 E Empyema strip decortication
20 T Non-malignant bronchial reSection
B 3D Duodenal tissue sample
26T/N Non-malignant bronchial reSections
As this sample group is taken from non-malignant tissue, the information obtained is of 
relevance only so far as it may indicate expression levels o f the various genes for 
normal human tissue.
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3.7 Identification o f a cell system for further research into MRP 1 inhibition
As shown in Sections 3.1-3.4, expression o f the MRP1 gene appears to be an important 
factor in the study o f cell responses to outside stimuli. It was found that MRP1 gene 
expression increased following exposure to the differentiating agent BrdU in the DLKP 
and A549 cell lines (Section 3.1), in response to short-term exposure to cisplatin and 
taxol (Section 3.2), also in DLKP and as well after long-term selection into drug- 
resistant DLKP-variant cell lines (Section 3.3). Promoter analysis o f the MRP1 gene has 
indicated that it may be transcriptionally controlled by the action o f at least some of 
these agents (Section 3.5). Expression of MRP1 was also shown to be expresed in 
tumour biopsies (Section 3.7).
It was felt that this gene may prove to be an important target for gene therapy. The twin 
gene therapy techniques o f Antisense and Ribozyme technology were chosen in an 
attempt to modify or eliminate the expression o f the MRP1 gene and its protein product 
in the cell system of choice. Before using these technologies, it was firstly considered 
necessary to identify a cell system in which expression of the MRP1 gene has already 
been identified and which would be amenable to treatment with gene therapy. It was 
then essential to demonstrate the basal level o f activity o f  the MRP1 gene product in 
this system. If  the normal, functioning, activity o f the MRP1 protein was interrupted 
following treatment with either antisense or ribozymes, the doenregulation could then 
be considered to have been achieved.
Significant increases in MRP1 gene expression in response to BrdU and certain 
chemotherapeutic drugs were observed in the DLKP cell line. Therefore, it was decided 
to continue the research into the activity of MRP 1 using this cell system. As outlined in 
Section 1.3.4, DLKP is a poorly differentiated human lung carcinoma cell line, which 
was established in the NCTCC (Law et al., 1992) and is found to be composed o f three 
clonal cell lines, DLKP-I, -M and -SQ. It has been found to express low levels o f MRP 1 
at both the mRNA and protein level.
In order to properly examine the effect o f gene therapy on expression and function of 
MRP1, it was felt that examination o f the role o f the protein in one o f the clonal cell 
lines would be more advantageous. While treating the uncloned DLKP cell line with
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antisense oligonucleotides and monitoring the effect on the gene and protein expression 
o f MRP 1 would be feasible, effective ribozyme treatment required the establishment of 
stable ribozyme-expressing clones to accurately ascertain the effect o f this particular 
gene therapy technique. As DLKP is a composite o f three separate clonal cell lines, it 
would not be apparent which o f the three cell lines was being examined.
For this reason, it was decided that one o f the clonal variants o f DLKP would be chosen 
for further study o f MRP1. The squamous cell line variant o f DLKP, DLKP-SQ, (see 
Section 2.2.2) was chosen as the cell line for further research. This cell line was chosen 
as it had already been characterised in this laboratory as expressing the same level o f 
MRP1 RNA as the parent DLKP. This low level of gene expression was considered 
ideal for use in gene therapy experiments that would attempt to reduce or knock-out the 
effect o f the MRP1 gene, as any observed reduction in the expression o f the gene at 
either the mRNA or protein level should have a significant knock-on impact on the 
toxicological profile o f the cell line.
The proceeding sub-sections will refer to the characterisation o f the DLKP-SQ cell line, 
repeated in order to confirm the expression o f the MRP1 gene in the cell line. A number 
o f other cell lines were also utilised during these characterisations; these are outlined in 
Section 2.2.2. These cell lines were chosen for a number o f reasons; these are outlined 
in Table 3.7.1.
Table 3.7.1 Selected cell lines examined in study
Cell Line Reason for inclusion in study
COR L23R Expresses high levels o f MRP 1; use as a Positive control
COR L23S Expresses very low levels o f  MRP 1; use as a Negative control
A549 Included to give an indication o f the difference between a
A549 C9 clonal and parent cell line response to gene therapy
While reference will be made in the following Sections to results obtained for the 
inhibition o f MRP 1 in DLKP from other studies, all results shown from here on will 
refer exclusively to those obtained for the DLKP-SQ cell line.
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3.7.1 Characterisation o f the DLKP-SQ cell line using RT-PCR
MRP1 RT-PCRs were carried out on the DLKP-SQ cell line as outlined in Section 
2.4.2.5. This was done, firstly to confirm the earlier characterisation data; that the cell 
line expressed MRP1 at a low level, and secondly to compare this expression level with 
other cell lines, including its parental DLKP cell line.
The results o f the PCRs can be seen in Figs. 3.7.1 and 3.7.2. As can be seen, expression 
o f MRP 1 in the DLKP-SQ cell line is generally low, although slightly higher than that 
obtained for the A549 cell line. This is surprising as previous work in this laboratory 
had identified higher MRP1 gene expression levels in the A549 cell line, than for 
DLKP-SQ (M. Heenan, Personal communication). MRP1 gene expression was highest 
for COR L23R (positive control) and almost non-existent for COR L23S (negative 
control). In Fig. 3.72, the relative expression levels o f MRP1 in both the DLKP cell line 
and its clonal variant, DLKP-SQ, were compared. As can be seen from the figure, 
expression levels for the gene were almost identical for both cell lines.
3.7.2 Characterisation of the DLKP-SQ cell line using Northern blotting
Northern blotting o f the selected cell lines was also carried out to examine the level of 
MRP1 gene expression using this method. The probe was prepared and the procedure 
carried out as outlined in Section 2.4.3.3. A GAPDH Northern blot was also carried out 
to standardise the MRP1 expression levels detected. The results o f this blot can be seen 
in Fig. 3.7.3. As can be seen, the COR L23R RNA sample expressed the highest levels 
o f the gene, at almost double that o f the A549, A549 C9 and DLKP-SQ samples. 
Expression levels were generally high also for the DLKP-SQ cell line and for the 
negative COR L23S control.
It was decided that RT-PCR would be commonly used in future to measure changes in 
MRP1 gene expression as it was a more convenient method o f analysis. Northern 
blotting could be used as a secondary method, to back up any RT-PCR results which 
proved promising.
295
Fig. 3.7.1: MRP1 RT-PCR on selected cell lines
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Fig. 3.7.1a: Gel electrophoresis photograph o f MRP1 RT-PCR results selected cell
lines; Fig. 3.7.1b: Densitometrie analysis o f  RT-PCR results.
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Fig.3.7.2: MRP1 expression in DLKP & DLKP-SQ cells
Fig. 3.7.2a:
IX DLKP DLKP-
SQ
Neg. Pos.
MRP1
ß-actin
Fig. 3.7.2a:
DLKP DLKP-SQ Neg Pos.
Fig. 3.7.2a: Gel electrophoresis photograph o f MRP1 RT-PCR results on DLKP &
DLKP-SQ cells; Fig. 3.7.2b: Densitometrie analysis o f RT-PCR results.
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Fig. 3.7.3a:
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Fig. 3.7.3: MRP1 Northern blot of selected cell lines
Fig. 3.7.3b:
M R  P I
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Fig. 3.7.3c:
A549 A549 C9 COR L23R DLKP-SQ COR L23S
Autoradiogram showing the relative expression o f MRP 1 (Fig. 3.7.3a) and GAPDH 
(Fig. 3.7.3b) in the selected cell lines using Northern blotting; Fig. 3.7.3c: 
Densitometrie analysis of autoradiogram results.
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MRP1 protein (see Section 1.7.1.2.4). All five selected cell lines were again assayed in 
this study. The in-vitro toxicity results presented in Figs. 3.7.5 and 3.7.6 are the results 
obtained for one assay o f each type which was successfully repeated twice.
As can be seen in Fig. 3.7.5, COR L23R, which expresses the highest levels o f MRP1 
protein, exhibits the highest level o f resistance to vincristine, while its MRP 1-negative 
parent, COR L23S exhibits the lowest level o f resistance. Both A549 and its C9 clone 
express identical resistance levels to the drug, while DLKP-SQ reveals the second 
lowest level o f resistance to vincristine o f the five cell lines tested. Fig. 3.7.6 examines 
the relative resistance levels o f the five cell lines to the non-MRP 1 substrate vinblastine. 
Resistance levels (jo.g/ml) are much lowered for this drug, although a relatively similar 
pattern o f resistance is observed for the cell lines. One significant difference is for A549 
C9, which expresses a resistance to the drug o f roughly half that o f its parent cell line, 
A549.
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Fig. 3.7.5: Relative IC50 Vincristine (VNC) values of selected cell lines
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3.8 Assessment o f the functionality o f the MRP1 gene product in DLKP-SQ cells
Two techniques were employed to examine the role played by MRP1 in conferring 
multidrug resistance in this cell line; Indomethacin-mediated Combination assays and 
Inside-Out Vesicle (IOV) assays.
3.8.1 Examination o f MRP 1 expression using Combination assays
Several nonsteroidal anti-inflammatory drugs (NSAIDs), have been reported (Duffy et 
ah, 1998; Draper et ah, 1997; Kobayashi et ah, 1997) to have the ability to enhance the 
cytotoxicity o f anti-cancer drugs in-vitro when co-administered to a multidrug-resistant 
cell line which overexpresses MRP1. Indomethacin is a compound which has been 
shown to be very active as an MRP1 inhibitor (Duffy et ah, 1998). The structure o f 
Indomethacin, which was subsequently chosen to inhibit MRP1 activity in DLKP-SQ 
cells here, is shown in Fig. 3.8.1.
Research carried out in this laboratory (Duffy et ah, 1998; S. Touhey, PhD. Thesis, 
2000), indicated the ability o f Indomethacin to potentiate the toxicity o f adriamycin in 
DLKP cells using the miniaturised in-vitro toxicity assay as described in Section 2.3.1. 
It was postulated that indomethacin potentiated the toxicity o f adriamycin in the cancer 
cells by inhibiting the action o f the MRP1 pump in those cells, and in so doing, 
decreasing the level o f chemotherapeutic drug being pumped out o f the cell. An 
enhancement o f chemotherapeutic drug toxicity, caused as a direct result o f the presence 
o f the NSAID, was regarded as significant if  the level o f cell kill achieved by the 
combination was significantly greater than that obtained by either the toxicity of the 
drug or NSAID individually.
Two anticancer drugs were chosen for this assay; Vinblastine (VNB), which has been 
shown to be poorly transported by MRP1 and Vincristine (VNC), which is a substrate 
for the MRP1 pump protein (see Section 1.7.1.2.4). Both o f these are widely used 
chemotherapeutic agents and are detailed in Sections 1.5 and 2.3.1. Two concentrations 
o f both drugs were used in the combination assay experiment, and given the monikers 
MED and HIGH. The “HIGH” drug concentration was the IC50 concentration o f drug
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Fig. 3.8.1: Structure of Indomethacin
Fig. 3.8.1: Schematic structure o f the NSAID Indomethacin
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for the DLKP-SQ cell line, which was calculated from triplicate in-vitro toxicity assays 
(data not shown). The “MED” drug concentration was this concentration divided by 
two. The concentrations for these two drugs are outlined in Table 3.8.1. The 
concentration o f indomethacin used was also varied, in order to determine if  the level o f 
inhibition was concentration-dependant. Three concentrations were chosen for inclusion 
in the combination assay and were given the monikers LOW, MED and HIGH. The 
“HIGH” concentration of the NSAID was that determined to be the highest 
concentration which constituted a non-toxic dose on the DLKP cell line. The “MED” 
and “LOW” concentrations were this concentration divided by two and four, 
respectively.
It was thought that for the indomethacin to exert the effect as expected, a significant 
decrease in the level o f cell survival would be seen when vincristine and indomethacin 
were combined in the assay. It was hypothesised that this would be as a result o f the 
indomethacin inhibiting the transport o f vincristine by the MRP1 protein. Also, a 
variable level o f this inhibition would be seen when varying amounts o f both the drug 
and the NSAID were used on the DLKP-SQ cell line, i.e. the combination of the highest 
concentrations o f both indomethacin and vincristine would result in the greatest amount 
o f cell kill. To ensure that the method o f action of indomethacin was via inhibition o f 
the pumping action of MRP 1 and not through another unrelated method of inhibition, 
duplication o f the combination assay using vinblastine was carried out. In order to 
verify that the method of inhibition was MRP 1-related, it was hypothesised that no 
significant alteration in cell survival would be observed following combination of 
vinblastine and indomethacin at any concentration o f either drug or NSAID. Finally, as 
a further control, the different concentrations o f indomethacin were also added to the 
cells in the absence o f drug, to ascertain cell survival following exposure to the NSAID 
alone. An untreated plate was also included in the experiment against which all 
treatments, combination or otherwise, could be compared.
All assays were carried out in triplicate and all results shown here are representative o f 
those triplicates. The amount of indomethacin required to provide a non-toxic dose in 
DLKP cells which inhibited MRP1 function had already been determined using data 
from three separate experiments (Touhey, Samantha, PhD. Thesis, 2000) and these
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concentrations are listed in Table 3.8.1. These concentrations were also used in the 
combination assays carried out here on the DLKP-SQ cell line.
Table 3.8.1 Highest non-toxic concentration of Indomethacin, Vincristine and
Vinblastine used in combination assay experiments in DLKP-SQ
Compound rig/ml Molar Cone. 
(nM)
Vincristine High 1.25 -
Vincristine Med 0.625 -
Vinblastine High 0.6 -
Vinblastine Med 0.3 -
Indomethacin High 2500 7
Indomethacin Med. 1250 3.5
Indomethacin Low 625 1.75
The combination assays were carried out as outlined in Section 2.3.1.2 and cell survival 
was assayed using the acid-phosphatase assay (Section 2.3.1.4). The results o f the 
assays are outlined in Figs. 3.8.2 -  3.8.6.
3.8.1.1 Effect o f indomethacin on drug toxicity o f Vincristine in DLKP-SQ cells
Fig. 3.8.2 shows the results o f the combination o f the NSAID and vincristine at half the 
IC50 concentration for the cell line (VNC MED). As can be seen, roughly 20% o f the 
cells were killed by the action o f the drug alone at this concentration. Following 
inclusion o f the NSAID, the level o f toxicity o f the drug rose sharply, yielding a cell kill 
o f over 60% at low indomethacin concentration, finally rising to over 90% at the highest 
concentration o f the NSAID. Concomitant exposure o f these concentrations o f NSAID 
to the cells without drug revealed only a slight decrease in cell survival o f roughly 5%. 
Fig. 3.8.3 shows the results for the same concentrations o f indomethacin on the DLKP- 
SQ cells at the higher concentration of vincristine (VNC HIGH). In this plot, the initial 
level o f cell kill without NSAID is far greater, at over 60%. However, the toxicity of the 
drug is again increased following inclusion o f the NSAID, increasing the amount o f cell 
kill to 90% at all concentrations o f the NSAID. Again, exposure o f the cell line to the 
NSAID only revealed a slight decrease in cell survival (<5%).
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Fig. 3.8.2: Effect of Indomethacin on Vincristine (Med.) resistance in DLKP-SQ
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Fig. 3.8.3: Effect of Indomethacin on Vincristine (High) resistance in DLKP-SQ
SCONTROL ■VNC(HIGH) DINDO(LOW) □ INDO (LOW)+VNC
■ INDO(MED) M  INDO (MED)+VNC ■  INDO(HIGH) □ INDO (HIGH)+VNC
Cell Treatments
3.8.1.2 Effect o f indomethacin on drug toxicity o f Vinblastine in DLKP-SQ cells
Figs. 3.8.4 and 3.8.5 show the effect o f exposure to indomethacin on the toxicity o f 
vinblastine in the DLKP-SQ cell line. It is clear from both plots that the combination of 
the NSAID with the drug does not produce any significant effect. In Fig. 3.8.4, the 
combination o f both MED drug concentration and NSAID produces a barely perceptible 
(1-2%) decrease in cell survival at any NSAID concentration. At the higher 
concentration o f vinblastine (Fig. 3.8.5), the amount o f initial cell kill without NSAID 
(roughly 60%) is augmented a further 10% following combination with the NSAID. 
However, a roughly 10% level o f cell kill is seen in this plot following exposure to the 
NSAID without drug, so it can be concluded that this increase in toxicity is non-MRP 1- 
related. Table 3.8.2 shows the actual levels of cell survival obtained for each of the 
different treatments as well as the standard deviation (S.D.) o f those results.
310
Ce
ll 
Su
rv
iv
al
 (
%
)
Fig. 3.8.4: Effect of Indomethacin on Vinblastine (Med.) resistance in DLKP-SQ
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Fig. 3.8.5: Effect of Indomethacin on Vinblastine (High) resistance in DLKP-SQ
■  CONTROL ■VNB(HIGH) niNDO(LOW) □ INDO (LOW)+VNB
■  INDO(MED) INDO (MED)+VNB ■INDO(HIGH) DINDO (HIGH)+VNB
Cell Treatments
Table 3.8.2 Results of effects of NSAID concentrations on drug  toxicity in 
_____________ DLKP-SQ cells________________________________________________
Treatm ent % Cell survival S.D.
DLKP-SQ
C ontrol
Untreated 100 0
VNB MED VNB (MED) 91.394 3.054
INDO (LOW) 94.812 3.281
INDO (LOW) + VNB 85.033 5.929
INDO (MED) 96.591 1.021
INDO (MED) + VNB 82.04 6.059
INDO (HIGH) 96.166 4.341
INDO (HIGH) + VNB 82.486 5.994
VNB H IG H VNB (HIGH) 36.224 3.606
INDO (LOW) 95.248 2.342
INDO (LOW) + VNB 27.927 1.826
INDO (MED) 97.383 5.287
INDO (MED) + VNB 23.351 2.629
INDO (HIGH) 92.605 3.964
INDO (HIGH) + VNB 25.125 1.166
VNC MED VNC (HIGH) 86.809 3.968
INDO (LOW) 95.615 6.04
INDO (LOW) + VNC 36.674 3.143
INDO (MED) 90.306 10.508
INDO (MED) + VNC 20.969 2.115
INDO (HIGH) 87.268 10.306
INDO (HIGH) + VNC 14.452 0.306
VNC H IG H VNC (HIGH) 40.114 2.141
INDO (LOW) 99.123 2.738
INDO (LOW) + VNC 10.488 0.872
INDO (MED) 92.323 1.838
INDO (MED) + VNC 8.584 0.688
INDO (HIGH) 92.97 2.002
INDO (HIGH) + VNC 8.27 0.195
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3.8.2 Examination o f MRP 1 expression using Inside-Out Vesicle (10 V) assays
Western blotting analysis studies failed to show the existence of MRP1 protein in 
whole-cell extracts o f DLKP, although MRP1 protein expression was detected in 
whole-cell preparations from DLKP-SQ (Section 3.7.4). It had been demonstrated that 
all other cell lines, in which the toxicity enhancement effect had been found to occur, 
expressed MRP1 (Duffy et al., 1998). The drug profile, for which the NSAID-mediated 
toxicity enhancement effect was found to occur, was exactly similar to the range of 
drugs believed to be transported by MRP1. This suggested that co-treatment o f MRP 1- 
expressing cells with an MRP 1-substrate drug and an NSALD with the ability to 
interfere with the drug pumping ability o f MRP1 may have resulted in an increased 
retention o f drug within the cell. This would ultimately cause an enhancement of 
cytotoxic drug-induced cell kill. This toxicity enhancement effect which had been found 
to occur in DLKP (S. Touhey, PhD. Thesis, 2000), was also found to occur in DLKP- 
SQ in this study. It was suggested that DLKP expressed MRP 1 at levels undetectable by 
Western blotting in whole cell extracts. In order to isolate the plasma membrane from 
these cells and specifically target Western blotting analysis to the area in which the 
MRP1 protein may have localised, Inside-out Vesicles were prepared from the DLKP 
cells as outlined in Section 2.3.2. It was found that MRP1 was detected in IOVs isolated 
from DLKP (S. Touhey, PhD. Thesis, 2000).
Duffy et al. (1998), also determined that Indomethacin inhibited the transport of the 
MRP1 substrate, LTC4 in IOV (Inside-Out Vesicle) assays prepared from DLKP cells. 
The glutathione conjugate, LTC4, was found to be transported into vesicles in an ATP- 
dependent manner (Jedlitschly et al., 1994; Leir et al., 1994). Duffy et al. (1998), 
demonstrated the influence of various NSAIDs on MRP1 activity in HL60/ADR (a 
strongly MRP 1-overexpressing cell line) IOVs by measuring the ability o f the 
compounds to inhibit the transport o f LTC4. The authors reported that the positive 
NSAIDs, especially sulindac and indomethacin, exhibit strong MRP1 pump inhibitory 
activity on the IOV preparations.
Although the combination assay results had already indicated a functioning MRP1 
protein in the DLKP-SQ cell line and demonstrated that the action of the protein could 
be inhibited by exposure to indomethacin, it was decided to carry out an inside-out
314
vesicle assay on the DLKP-SQ cells. This was carried out to demonstrate the pumping 
ability o f the MRP1 protein in the DLKP-SQ cell line. MRP1 has been localised to the 
membrane vesicles of certain cell types (Leier et al., 1994) and this was investigated in 
the DLKP-SQ cell line with this experiment. Also, MRP1 has been reported to be a 
GST pump (see Section 1.7.1.2.4) and it was considered necessary to investigate i f  this 
was a potential mode o f action o f the protein in this cell line.
A pure preparation o f MRP1 IOVs (see Section 2.3.2) was used in a standard IOV assay 
along with the radiolabelled MRP1 substrate, LTC4. This pure preparation o f MRP1 
was contained within vesicles, prepared from actively growing DLKP-SQ cells, which 
were subsequently turned inside out. This procedure was carried out to allow 
measurement o f the transport o f LTC4 -  instead of the MRP1 protein pumping the 
radiolabelled substrate out o f the vesicle, it now pumped it into the vesicle using ATP as 
an energy source. A repeat o f the procedure was also carried out in the presence of 
AMP to provide a negative control for the experiment. The results o f the IOV assay on 
the DLKP-SQ cell line is shown in Fig. 3.8.6.
From the results presented in Fig. 3.8.6, it is evident that the level of radiolabelled LTC4 
transported into the DLKP-SQ vesicle preparation increases over time. It was also 
demonstrated that this transport was an ATP-dependent mechanism. This result proves 
that MRP1 is functioning in the DLKP-SQ cell line and that its mode o f action (i.e. 
ATP-dependent glutathione-conjugate, vesicle-localised pump) is as described in the 
literature previously mentioned.
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Fig. 3.8.6 Time course of LTC4 transport into DLKP-SQ lOVs
POS (+ATP) NEG (+AMP)
Time (s)
3.9 Analysis o f the use o f MRP 1 ribozyme to downregulate expression of the gene
In order to more accurately examine the effect o f transfection o f the MRP1 ribozyme on 
MRP 1-expressing cells, stable transfections were carried out to establish banks of 
MRP1 ribozyme-expressing clonal cell lines which could be used for further study. The 
DLKP-SQ cell line was transfected with a pHp (pH(3Apr-l-neo) plasmid containing the 
MRP1 ribozyme which was a generous gift from Prof. Kevin Scanlon. This plasmid 
expresses the neomycin phosphotransferase gene under a Simian-Virus (SV) promoter 
(SV-neo) which enables mammalian cells expressing the plasmid to grow in the 
presence o f Geneticin (Promega, G418). Expression o f the MRP1 ribozyme was 
regulated by a p-actin promoter. A BLAST™ homology search 
fhttp://www.ncbi.nlm.iuh.gov/blast/Blast.cgi) revealed that the MRP1 ribozyme shared 100% 
complementarity only with the MRP1 coding sequence. The ribozyme was, however, 
>85% complementary to a number o f additional genes in humans. These genes are 
summarised in Table 3.9.1.
Table 3.9.1 List of human gene sequences which share over 85% 
_____________ complementarity with the MRP1 ribozyme_________________________
Gene
Faciogenital dysplasia (Aarskog-Scott syndrome) (FGD1)
Heparan sulfate (glucosamine) 3-O-sulfotransferase 2 
Ubiquitin associated and SH3 domain containing gene 
Cadherin-associated protein-related (CTNNA2) 
a-catenin
The pH(3 construct is shown in Fig. 3.9.1. A schematic o f  the MRP1 ribozyme and 
target is illustrated in Fig. 3.9.2. The cells were transfected with the ribozyme- 
containing plasmid and stable geneticin-resistant clonal cell lines were isolated from the 
parent cell line as outlined in Section 2.4.5.3. A total o f fifteen clonal cell lines were 
isolated from this transfection and these were subjected to further analysis to examine 
the effect o f MRP 1 ribozyme expression on expression o f the MRP1 gene. A list of the 
fifteen isolated clones are shown in Table. 3.9.2. This analysis will comprise of RT-
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Fig. 3.9.1: Schematic map of pH|3-Apr-l-neo plasmid
SV-neo
B-actin
P1 Ribozyme
ind III 4704
Fig. 3.9.1: Schematic map of pHp plasmid, showing location of cloning site 
and ampicillin & neomycin resistance genes
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Fig. 3.9.2: Schematic of MRP 1 Ribozyme and RNA Target
611 623
s - T G C T T C  G T C A G T G G C - 3' cDNA
5' - U G C U U C G U  C A G U G G C - 3' mRNA
3'
STEM I
A C G A A G C A  U C A C C G -51 Ribozyme
C
uA
A ° A
G A p U 
C G G
STEM III
A U
G C 
G C 
A G 
G U
STEM II
Fig. 3.9.2: Schematic o f MRP1 ribozyme and RNA target sequence, 
showing the location o f Stems I, II & III, as well as the cleavage site 
immediately 3 ’ to the GUC site (RED ARROW)
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PCR, Western blotting and in-vitro toxicity assays to determine the effect, if  any of 
transfection and expression o f the MRP1 ribozyme in the DLKP-SQ cell line.
Table 3.9.2 List of successfully isolated clones from DLKP-SQ________________
Clone Name
DLKP-SQ R1 
DLKP-SQ R2 
DLKP-SQ R3 
DLKP-SQ R4 
DLKP-SQ R 6 
DLKP-SQ R7 
DLKP-SQ R9 
DLKP-SQ R 11 
DLKP-SQ R16 
DLKP-SQ 2R1 
DLKP-SQ 2R3 
DLKP-SQ 2R4 
DLKP-SQ 2R5 
DLKP-SQ 2R9 
DLKP-SQ 2R10
3.9.1 RT-PCR analysis o f DLKP-SQ cells transfected with MRP1 ribozyme
RT-PCR analysis of the clonal cell lines isolated from the transfection o f the MRP1 
ribozyme into the DLKP-SQ cells was divided up into two distinct segments. It was 
considered necessary to firstly identify which of the clones expressed the pHp-M RPl 
ribozyme expression plasmid at the RNA level. pHP expression primers were designed 
to detect expression o f the plasmid from total RNA isolated from the clonal cell lines. 
Once expression of the plasmid had been detected in a cell line, it was considered 
reasonable to assume that clonal cell line was also expressing the MRP1 ribozyme. The 
sequences o f these primers are included in Appendix A (Table 7.1A).
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The second part o f the RT-PCR analysis was to investigate if  the expression o f the 
MRP1 gene was affected by expression o f the MRP1 ribozyme in a ribozyme- 
expressing clone. This was also achieved by the use o f MRP1 expression primers used 
to examine MRP1 expression in the ribozyme-expressing clones.
Also, it was considered important to examine the expression o f the MRP1 homologues 
(Section 1.7.1.2) in the ribozyme-expressing cells relative to the normal DLKP-SQ cell 
line, in case o f non-specific activity o f the MRP1 ribozyme.
3.9.1.1 pHp plasmid expression in the MRP1 ribozyme-transfected clones
pHP RT-PCR analysis o f the untransfected DLKP-SQ control and the geneticin-selected 
clonal cell lines was carried out as outlined in Section 2.4.2.5. The results from the 
expression PCR are shown in the gel electrophoresis photograph as outlined in Fig.
3.9.3. From the results shown, it was apparent that expression o f the pHp plasmid was 
observed in ten o f the fifteen (66.7%) isolated cell lines. A list o f these ribozyme- 
expressing clones is given in Table 3.9.3. The level o f expression o f the plasmid was 
also observed to vary between the different clones. As expected, pHP plasmid 
expression was not observed for the negative (untransfected DLKP-SQ) control. A 
strong positive was observed for the pHp cDNA positive control. From the RT-PCR 
analysis, the ten ribozyme-expressing clones were selected for further study, along with 
two non-ribozyme-expressing cell lines DLKP-SQ R1 and DLKP-SQ 2R10, which were 
included as negative controls.
Table 3.9.3 List of MRP1 ribozyme-expressing clones
Clone Name
DLKP-SQ R2 DLKP-SQ R16
DLKP-SQ R3 DLKP-SQ 2R1
DLKP-SQ R6 DLKP-SQ 2R4
DLKP-SQ R7 DLKP-SQ 2R5
DLKP-SQ R9 DLKP-SQ 2R9
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Fig 3.9.3: pH(3 expression RT-PCR on DLKP-SQ clones
IX R1 R2 R3 R4 R6 R7 R9 R ll  R16
M0  JMHA M O T
I  w
■—  mm m I P
p-actin
IpHp
IX 2R1 2R3 2R4 2R5 2R9 2R10
P-actin
IX POS NEG. NEG.
P-actin
Fig. 3.9.3: Gel electrophoresis photographs o f pHP expression RT-PCR on all MRP1
ribozyme-transfected DLKP-SQ clones.
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3.9.1.2 Analysis o f MRP1 gene expression in the MRP1 ribozyme-transfected clones
MRP1 RT-PCR analysis o f the ribozyme-transfected clones was carried out as outlined 
in Section 2.4.2.5. The results for the PCR are shown in Fig. 3.9.4. As can be seen from 
the plot and accompanying densitometry, no significant decrease in MRP1 gene 
expression was observed in any of the clones, whether they were ribozyme-expressing 
or not. On the contrary, expression o f the MRP1 gene was increased in almost all RNA 
samples assayed. The PCR results displayed are an average o f three separate RT-PCRs 
carried out on these samples.
3.9.1.3 Expression of MRP homologues in MRP1 ribozyme-transfected DLKP-SQ
The sequence similarity o f MRP 1 and its homologues has already been elucidated (see 
Section 1.7.1.2). It was considered that the M RPl-targetted ribozyme might also 
downregulate the expression of the other MRP1 homologues in a non-sequence-specific 
manner. A number o f additional RT-PCRs for the MRP homologues 2 to 6 were carried 
out to examine the expression of these genes in the ribozyme-expressing cells relative to 
the normal DLKP-SQ cell line. These PCRs were carried out in duplicate to confirm the 
results displayed in Figs. 3.9.5 to 3.9.8. As can be seen from these plots, expression o f 
the MRP1 homologues MRP2 and MRP4 only were detected in the DLKP-SQ cell line.
From the MRP2 RT-PCR results (Figs. 3.9.5 and 3.9.6), it was observed that cMOAT 
expression levels varied widely in the clonal cell lines relative to the parent. Expression 
for the most part was decreased in the clones, with 70% of the ribozyme-expressing 
samples showing decreased expression, with one clone retaining identical expression 
levels. Only two o f the MRP1 ribozyme-expressing clones exhibited higher expression 
levels of the gene. The expression pattern for the non-ribozyme-expressing clones was 
quite different, with the majority o f the clones (60%) expressing higher levels o f the 
cMOAT gene than did the parent. The most dramatic increase in expression was 
observed in DLKP-SQ clones 2R3 and 2R10 where expression was increased by more 
than 50% when compared to the parent cell line. Only two o f the five clones not 
expressing the ribozyme showed decreased expression levels o f cMOAT.
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IFig. 1.9.4: MRP1 RT-PCR analysis of DLKP-SO clones
Fig. 3.9.4a:
IX DLKP- LIP 
SO O
R1 R2 R3 R4 R6 R7 R9 R16
MRP1
ß-actin
Fig. 3.9.4b:
IX DLKP- 
SQ
LIPO 2R1 2R4 2R5 2R9 2R10
MRP1
ß-actin
Fig. 3.9.4c:
1.6
1 . 4
1.2
1
0.8
0.6
0 . 4
0.2
results.
Figs. 3.9.4a & b: Gel electrophoresis photographs o f MRP1 RT-PCR results on
ribozyme-transfected DLKP-SQ clones; Fig. 3.9.4c: Densitometrie analysis o f RT-PCR
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Fig. 3.9.5: MRP2 RT-PCR analysis of DLKP-SQ clones
Fig. 3.9.5a:
IX DLKP-SQ CLONAL CELL LINES
SQ RI R2 R3 R4 R6 R7 R9 R ll R16
NEC POS
cMOAT
ß-actin
U  R9 R11 R16
Fig. 3.9.5a: Gel electrophoresis photograph o f cMOAT RT-PCR expression levels o f
MRP Ribozyme-transfected DLKP-SQ clones; Fig. 3.9.5a: Densitometrie analysis o f
RT-PCR results.
Fig. 3.9.6: MRP2 RT-PCR analysis of DLKP-SQ clones
Fig. 3.9.6a:
IX DLKP-SQ CLONAL CELL LINES NEG POS
SQ 2R1 2R3 2R4 2R5 2R9 2R10
cMOAT
ß-actin
Fig. 3.9.6b:
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SQ 2R1 2R3 2R4 2R5 2R9 2R10
Fig. 3.9.6a: Gel electrophoresis photograph of cMOAT RT-PCR expression levels of
MRP Ribozyme-transfected DLKP-SQ clones; Fig. 3.9.6b: Densitometrie analysis of
RT-PCR results.
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In contrast to the MRP2 PCR results for the MRP1 ribozyme-transfected clones, all of 
the clones generated showed decreased levels o f MRP4 gene expression (Figs. 3.9.7 and 
3.9.8). The transfection was repeated transiently, to investigate i f  the downregulation of 
the gene was time-dependant. However, the result was not transiently repeatable.
From the pHp and MRP1 expression RT-PCRs detailed above, a number o f non- 
ribozyme-expressing clones were discarded to make subsequent analysis easier. The 
discarded clones were DLKP-SQ R4, R l l  and 2R3. All analysis from here on will just 
involve the remaining twelve clones.
3.9.2 Western blotting analysis o f MRP 1 ribozyme-transfected DLKP-SQ clones
The results from the Western blotting analyses are shown in Figs. 3.9.9 and 3.9.10. Fig. 
3.9.9 shows the results for the DLKP-SQ clones R1 -  R16. Three o f the ribozyme- 
transfected clones expressed significantly lower levels o f the MRP1 protein than either 
the DLKP-SQ parent or the untransfected DLKP-SQ R1 control. In all other samples, 
MRP1 protein expression had either increased or decreased slightly after transfection. In 
Fig. 3.9.10, there was no decrease in MRP1 protein expression observed for either the 
ribozyme-expressing or non-ribozyme-expressing clones. One clone, DLKP-SQ 2R3, 
expressed almost twice as much MRP1 protein than the parental DLKP-SQ control.
3.9.3 In-vitro toxicity analysis o f MRP1 ribozyme-transfected DLKP-SQ clones
From the results already presented, it was apparent that while no effect had been 
observed at the RNA level, it was possible that the MRP1 ribozyme was exerting an 
effect at the protein level of expression. In order to test whether this effect had any 
influence on the drug resistance profiles o f the ribozyme-expressing clones, a series of 
in-vitro toxicity assays were set up as outlined in Section 2.3.1. Each toxicity assay was 
carried out in triplicate; the results presented here are an average o f those three separate 
assays. Fig. 3.9.11 shows the Vincristine (VNC) resistance profile o f the DLKP-SQ cell 
line as well as the profiles for the ribozyme-expressing and non-ribozyme-expressing
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Fig. 3.9.7: MRP4 RT-PCR analysis of DLKP-SQ clones
Fig. 3.9.7a:
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Fig. 3.9.7a: Gel electrophoresis photograph o f MRP4 RT-PCR expression levels of
MRP1 Ribozyme-transfected DLKP-SQ clones; Fig. 3.9.7b: Densitometrie analysis of
RT-PCR results.
9.7b:
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Fig. 3.9.8: MRP4 RT-PCR analysis of DLKP-SQ clones
Fig. 3.9.8a:
IX DLKP-SQ CLONAL CELL LINES NEG POS
SQ 2R1 2R3 2R4 2R5 2R9 2R10
Fig. 3.9.8b:
SQ 2R1 2R3 2R4 2R5 2R9 2R10
Fig. 3.9.8a: Gel electrophoresis photograph of MRP 4 RT-PCR expression levels of
MRP Ribozyme-transfected DLKP-SQ clones; Fig. 3.9.8b: Densitometrie analysis of
RT-PCR results.
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Fig. 3.9.9: MRP1 Western on transfected DLKP-SQ clones
Fig. 3.9.9a:
DLKP- R l R2 R3 R6 R7 R9 RI 6
SQ ___________________
MRP1 
(190 kDa)
Fig. 3.9.9b:
Fig. 3.9.9a: Western blot o f MRP 1 results on ribozyme-expressing and non-expressing
clones; Fig. 3.9.9b: Densitometrie analysis o f Western blot results.
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Fig. 3.9.10: MRP1 Western on transfected DLKP-SQ clones
Fig. 3.9.10a:
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Fig. 3.9.10b:
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Fig. 3.9.10a: MRP1 Western blot analysis o f ribozyme-expressing and non-expressing
DLKP-SQ clones; Fig. 3.9.10b: Densitometrie analysis o f Western blotting results.
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Fig. 3.9.11: Relative Vincristine (VNC) IC50 values for the MRP1 ribozyme-
transfected DLKP-SQ clones
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clones. If the ribozyme was exerting the specified effect in downregulating expression 
o f the MRP1 protein, as was seen in the DLKP-SQ R2, R6 and R7 clones, an attendant 
effect o f a decrease in resistance to vincristine, an MRP1 substrate, would be expected, 
particularly for these cell lines. As can be seen from Fig. 3.9.11, resistance to vincristine 
increased slightly in most o f the ribozyme-expressing clones, although not significantly 
so. Slight decreases in resistance to the drug were observed in clones DLKP-SQ R6 and 
R9, although neither o f these were felt to be o f significance. The three non-ribozyme- 
expressing clones did not display any significant change in resistance to vincristine. The 
clones were also analysed for any change in resistance to the drug, Vinblastine (VNB). 
The results o f these in-vitro toxicity assays are shown in Fig. 3.9.12. As expected, the 
resistance o f the DLKP-SQ cells, ribozyme-expressing or otherwise, to vinblastine was 
not altered following transfection with the ribozyme.
3.9.4 In-vitro cleavage (IVC) analysis o f the MRP1 ribozyme
From the results presented in the previous sub-Sections, it was apparent that while no 
reduction in MRP1 RNA was observed in the ribozyme-transfected DLKP-SQ cells, a 
reduced level o f expression o f MRP1 protein was observed which, however, did not 
affect significantly the drug resistance profiles o f those cells. It was therefore 
considered necessary to investigate whether the ribozyme was actually capable of 
cleaving the MRP1 mRNA. If the ribozyme was observed not to be involved in the 
downregulation o f the RNA, and hence, the protein product o f the MRP1 gene, the 
decreases would have to attributed to some other factor. As already outlined, one o f the 
non-ribozyme-expressing clones, DLKP-SQ R4, exhibited slightly decreased levels of 
the MRP1 RNA; a phemonenon attributable possibly to the selection process o f the 
clonal cell lines from the parent. The IVC assay was carried out to investigate if  this 
was also a potential cause for the decreases in MRP1 protein expression in the 
ribozyme-expressing cell lines.
As outlined already in Section 2.4.8, the IVC protocol involved a lengthy process which 
had previously been demonstrated by Kashani-Sabet et al. (1992). To manufacture the 
radiolabelled ribozyme, two PCR primers were designed which would anneal to one 
another and amplify a forty base-pair fragment with a T7 RNA polymerase promoter
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Fig. 3.9.12: Relative Vinblastine (VNB) IC50 values for the MRP1 ribozyme-
transfected DLKP-SQ clones
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and leader sequence. This PCR product was used in a T7 polymerase Riboprobe™ kit to 
produce the radiolabelled ribozyme. To manufacture the target sequence, the procedure 
was altered and the protocol as outlined by Kashani-Sabet et al. (1992) was not used. 
Instead, a second pair o f RT-PCR primers were chosen which amplified across the 
cleavage site o f the MRP1 ribozyme. The PCR product was purified and sub-cloned 
into the expression vector pTarget™, which also contains a T7 RNA polymerase 
promoter sequence. This cloned DNA was then transformed into JM109 bacteria and 
from single transformed colonies a number o f “miniprep” purifications were isolated. 
These were analysed using restriction digestion to ascertain the orientation of the insert 
in a particular isolate. Once the correct orientation was confirmed and a particular 
colony identified as desirable, a “maxiprep” isolation o f the bacteria was sequenced to 
confirm correct orientation as well as the inclusion o f the target sequence. Once this was 
confirmed, the plasmid DNA was digested with a single-cutting site enzyme and 
subjected to the same riboprobe™ procedure to generate the radio labelled target RNA. 
Both the radiolabelled ribozyme and target RNA were then combined in the in-vitro 
cleavage (IVC) reaction and the products eluted on a polyacrylamide gel. The results for 
each Section will be illustrated here. The technical details o f these experiments are 
outlined in Section 2.4.8.
3.9.4.1 Selection and amplification o f PCR primers encoding the MRP1 ribozyme
The PCR primers selected to amplify the DNA template for production o f the MRP1 
ribozyme are listed in Appendix A (Table 7.3A). The PCR and subsequent transcription 
labelling o f the ribozyme were carried out as outlined in Section 2.4.8. Once 
transcription and purification was complete, the ribozyme was eluted on a 12% 
polyacrylamide gel to ensure that the fragment was o f the correct size. Fig. 3.9.13 
shows the forty-two base radioactively labelled ribozyme. The ribozyme was sized 
using the migrating dye front as a marker, as outlined by Sambrook et al. (1982).
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Fig. 3.9.13: In-vitro transcription of MRP 1 ribozyme
— -  3 o j,n  / a t
&
MRPl 
Ribozyme 
(42 bases)
Fig. 3.9.13: Autoradiogram showing presence o f the in-vitro transcribed M RPl 
ribozyme
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3.9.4.2 Restriction digestion o f cloned pTarget™ plasmids
The pTarget™ Mammalian Expression Vector System (Promega, A1410) was the 
mammalian expression system chosen for the radioactive-labelling o f the M RPltarget 
fragment as the plasmid can be expressed in both in bacterial as well as mammalian 
cells, and also contains a T7 polymerase promoter immediately 5’ to the cloning site. A 
map of the pTarget™ vector, expressing the MRP1 cleavage target sequence, is shown 
in Fig. 3.9.14.
The RT-PCR primers selected to amplify the MRP1 fragment containing the ribozyme 
cleavage site are listed in Appendix A (Table 7.3A). These primers amplified a 477-bp 
fragment from the cDNA of any MRP 1-expressing cell line. A standard RT-PCR was 
carried out on a COR L23R RNA sample and the PCR product was purified and cloned 
into pTarget™ as outlined in Section 2.4.4.2.I. Restriction enzyme analysis o f the insert 
sequence using the DNA Strider™  1.3 computer package revealed a number of single- 
cutting enzymes which could be used for digestion. Upon further consultation with the 
pTarget™ Mammalian Expression Vector System Technical Manual (Promega, 
TM044), Pstl was the enzyme chosen for digestion, as it cuts twice in the pTarget™ 
plasmid and once in the insert. Depending on the presence and orientation o f the insert, 
the banding pattern obtained for the digest would be different for each ligation. An 
illustration o f the plasmid containing inserts and the resultant banding pattern expected 
from either orientation o f insert is shown in Figs. 3.9.15 to 3.9.17. As can be seen, the 
banding pattern observed for each isolate will reveal the presence and orientation of the 
MRP1 insert in the pTarget plasmid.
The digestion with Pstl (Sigma, R7023) o f the miniprep plasmid DNA isolated from 
JM109 bacteria transformed with this cloned DNA and selected as outlined in Section
2.4.3, is shown in Fig. 3.9.18. As can be seen, DNA isolated from a total o f fifteen 
colonies were selected for digestion. The selection o f transformed colonies was made on 
the basis o f the colour of those colonies. The pTarget™ plasmid contains a sequence 
coding for the lacZ  a-peptide, interrupted by a multiple cloning site. Non-recombinant 
plasmids produce a functional a-peptide, which, by complementing the product of the 
host cell /acZM15 gene, leads to a production o f functional (3-galactosidase. Bacterial
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Fig. 3.9.14: Schematic map of pTarget™ Vector
Fig. 3.9.14: Schematic map o f pTarget™ Vector, showing location o f promoter &
insert, polyadenylation site and neomycin- & ampicillin-resistant genes
Fig. 3.9.15: MRPl-pTarget™ (FWD.) plasmid banding
pattern following Pstl digestion
Fig. 3.9.15a:
Fig. 3.9.15b:
Fig. 3.9.15a: Schematic map o f pTarget™ plasmid containing MRP1 target sequence
insert in the Forward (FWD.) orientation. Location of Pstl sites are included.
Fig. 3.9.15b: Banding pattern o f plasmid obtained when digested with Pstl.
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Fig. 3.9.16: MRPl-pTarget™ (REV.) plasmid banding
pattern following Pstl digestion
Fig. 3.9.16a:
Fig. 3.9.15b:
Fig. 3.9.16a: Schematic map o f pTarget™ plasmid containing MRP1 target sequence
insert in the Reverse (REV.) orientation. Location o f Pstl sites are included.
Fig. 3.9.16b: Banding pattern o f plasmid obtained when digested with Pstl.
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Fig. 3.9.17: pTarget™ plasmid banding pattern following
Pstl digestion
Fig. 3.9.17a:
Fig. 3.9.17b:
3652 bases 
2018 bases
Fig. 3.9.17a: Schematic map o f naked pTarget™ plasmid. Location of Pstl sites are
included. Fig. 3.9.15b: Banding pattern o f plasmid obtained when digested with Pstl.
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Fig. 3.9.18: Pstl digest of pTarget™ plasmid DNA
Fig. 3.9.18a:
III 1 2 3
Banding pattern for Samples 1, 3, 4, 9-13 & 15
4 5 6 7 8 9 10 11 12 13 14 15 IX
Fig. 3.9.18b:
III 1 2 3
Banding pattern for Samples 2, 5 & 14
4 5 6 7 8 9 10 11 12 13 14
Fig. 3.9.18c:
m  l  2 3
Banding pattern for Samples 6, 7 & 8
4 5 6 7 8 9 10 11 12 13 14
Fig. 3.9.18a: Banding pattern obtained for plasmids expressing MRP1 insert in the 
forward orientation. Fig. 3.9.18b: Banding pattern obtained for plasmids expressing 
MRP1 insert in the reverse orientation. Fig. 3.9.18c: Banding pattern obtained for naked 
pTarget™ plasmids.
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colonies harbouring the naked recircularised pTarget™ vector are blue in colour when 
plated on indicator plates containing IPTG and X-Gal as outlined in Section 2.4.4.4. 
However, when the lacZ  a-peptide is disrupted by cloning into the pTarget™ vector 
multiple cloning region, complementation does not occur and no P-galactosidase 
activity is produced. Colonies harbouring recombinant pTarget™ vector constructs are 
therefore coloured white. Twelve o f the selected colonies were white in colour, and 
three, samples 6-8, were blue. These last three colonies instead contained the 
recircularised plasmid, and were chosen to act as negative controls for the insert in the 
digestion. Nine o f the twelve white transformed colonies (samples 1, 3, 4, 9-13 and 15) 
contained the insert in the correct (forward) orientation. Three colonies (samples 2, 5 
and 14) contained the insert in the reverse orientation, while the remaining three 
colonies (samples 6-8) were observed not to contain the insert, as expected.
3.9.4.3 Sequence analysis o f cloned fragment
Colony samples 1 and 14 were chosen for further cultivation o f the expression plasmids 
containing the insert in the correct orientation (sample 1) and in the reverse orientation 
(sample 14). A plasmid maxiprep was carried out on these samples to provide DNA for 
sequence analysis to confirm both the orientation o f the insert in both samples and also, 
in the case o f sample 1 , to confirm that the ribozyme cleavage site was contained within 
the insert. The isolated DNA from both samples was subjected to sequence analysis as 
outlined in Section 2.4.4.6 and the products were eluted on a polyacrylamide gel. Fig. 
3.9.19 shows the relevant Section o f sequence from sample 1 containing the ribozyme 
cleavage site, which was also obtained in the correct orientation for transcriptional
production of the mRNA product. Sequence analysis o f sample no. 14 also confirmed
that the insert was reverse-oriented in the pTarget™ plasmid (data not shown).
3.9.4.4 Riboprobe™ production o f Target sequence
Once orientation and presence o f ribozyme cleavage site had been confirmed, the 
transcribed target mRNA was then generated from the isolated plasmid DNA along with
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Fig. 3.9.19: Sequence analysis of MRP 1 target
Fig. 3.9.19a:
Fig. 3.9.19b:
AGT TGC TCA TCA AGT TCG TGA ATG ACC GAA 
GGC CCC AGA CTG GCA GGG CTA CTT CTC TAC 
ACC GTG CTG CTG CTG TTT GTC ACT GCC TGC 
CTG CAG ACC CTC GTG CTG CAC CAG TAC TTC
CAC ATC TGC TTC GTC AGT GGC A
Fig. 3.9.19a: Autoradiogram showing sequence o f  the MRP1 target from sample 1 
containing ribozyme cleavage site (Bases 1236 -  1373). Fig. 3.9.19b: Sequence data 
showing transcribed sequence (Black) including PstI site (Green) and ribozyme 
cleavage site (Red). An unreadable compression section is listed in Blue.
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an in-vitro transcribed pGem positive control. In Fig. 3.9.20, the transcribed MRP1 
target sequence can be seen, sized against a human apoptosis hAPO-2c multi-probe 
RNA marker (Promega, 45609P) (Fig. 3.9.20). It can be observed from this figure that 
the transcribed fragment was o f the correct size (477 bases). In Fig. 3.9.21, the 
radioactively-labelled MRP1 target RNA fragment was placed beside the 1,065 base 
pGem RNA product. As can be seen in both figures, the in-vitro transcribed MRP1 
target fragment did not suffer any non-specific degradation in its stability. Thus, this 
presentation will serve as the untreated control for all subsequent cleavage experiments 
involving the MRP1 ribozyme.
3.9.4.5 In-vitro cleavage o f Ribozyme and Target
The radioactively-labelled MRP1 ribozyme and target sequence were combined in an 
in-vitro cleavage assay as outlined in Section 2.4.8.5. Cleavage reactions were 
incubated at 37°C and samples were removed for analysis at 30mins, 60mins, 3 hours 
and overnight. There are five expected cleavage reaction products;
1. 519 bases -  the size o f the bound MRP 1 target sequence and ribozyme
2. 477 bases -  unbound and uncleaved MRP1 target sequence
3. 348 bases - 1st and larger cleavage product
4. 129 bases -  2nd and smaller cleavage product
5. 42 bases -  unbound MRP 1 ribozyme
The reactions were eluted on a 12% polyacrylamide gel, the results o f which are shown 
on Fig. 3.9.22. At the higher fragment sizes, it was difficult to discern the bound and 
unbound radioactively-labelled fragments. As a result, these two fragments will be 
analysed together here as one fragment. As can be seen from the autoradiogram and 
densitometric analysis in Fig. 3.9.22, the amount o f the bound MRP1 target sequence 
decreases over time, while those o f both cleavage products increase with time. This is 
entirely consistent with a time-dependent cleavage o f the MRP1 target sequence by the 
MRP1 ribozyme. The radioactively-labelled MRP1 ribozyme was either run off the gel 
or remains bound to the remaining MRP1 target sequence.
345
Fig. 3.9.20: In-vitro transcription of MRP 1 target
Human Apoptosis In-vitro transcribed 
(hAPO-2c) Multi-probe MRP1 target sequence 
RNA Marker (477 bases)
□
i>
ILÜ
MRP1 Target 
sequence 
(477 bases)
Fig. 3.9.20: Autoradiogram showing the in-vitro transcription of the MRP1 target RNA
sequence sized against a commercially prepared marker (hAPO-2c)
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Fig. 3.9.21: In-vitro transcription of MRP1 target
In-vitro transcribed pGEM In-vitro transcribed MRP 1
Positive (1065 bases) target sequence (477 bases)
PGEM Positive 
(1065 bases)
MRP1 Target 
sequence 
(477 bases)
Fig. 3.9.21: Autoradiogram showing the in-vitro transcription o f the pGEM positive 
control and the MRP1 target RNA sequence
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Fig. 3.9.22: In-vitro cleavage of MRP1 target
Fig. 3.9.22a:
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Fig. 3.9.22a: In-vitro cleavage o f the MRP1 target sequence over time using the in-vitro
transcribed MRP1 ribozyme; Fig. 3.9.22b: Densitometrie analysis o f autoradiogram
results.
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3.9.4.6 Cleavage of the MRP1 target sequence using cell extract
As outlined by Kashani-Sabet et al. (1992), a further test of the activity of the ribozyme 
was the cleavage of the MRP1 target sequence using cell extract taken from ribozyme- 
expressing clones. The protocol for isolating the cell extract from these clones is as 
outlined in Section 2.4.8.2. The radioactively labelled MRP1 target sequence was 
incubated in the standard in-vitro cleavage reaction (see Section 2.4.8.5) with solutions 
of cell extract taken from three ribozyme-expressing clones (DLKP-SQ 2R1, R7 and 
R9), one non-ribozyme-expressing clone (DLKP-SQ R l) and from the control DLKP- 
SQ cell line. The cleavage reaction was allowed to run overnight and the products 
eluted on a 12% polyacrylamide gel. The results of this reaction can be seen in Fig. 
3.9.23. As can be seen, cleavage of the target sequence occurs in all three ribozyme- 
expressing clones, the highest level of cleavage occurring in the cell extract from the 
DLKP-SQ R9 sample. No cleavage was observed in the DLKP-SQ control cell line, 
although it must be noted that less MRP1 target sequence was incubated in this reaction. 
Slight cleavage was observed in the ribozyme-negative DLKP-SQ R l control, although 
this was more likely due to non-specific RNA degradation due to the samples being 
incubated at 37°C overnight as no clear cleavage banding pattern was observed for this 
sample.
It was also considered interesting to investigate if  the cleavage recorded for the cell 
extract was also time-dependant, as was observed for the in-vitro transcribed MRP1 
ribozyme. Cell extract from one of the ribozyme-expressing clones examined in the 
previous cell extract cleavage experiment, DLKP-SQ R7, was incubated in a cleavage 
reaction with the radioactively-labelled MRP1 target sequence. The cleavage reaction 
was carried out as usual (see Section 2.4.8.5), and samples were removed from the 
reaction at Ohrs, 30 mins, lhr, 3hrs and overnight (O/N). The samples were eluted on a 
12% polyacrylamide gel, the autoradiogram and attendant densitometry of which is 
shown in Fig. 3.9.24. As can be seen, the large target sequence is degraded over time 
into the distinct smaller cleavage fragments characteristic of the action of the MRP1 
ribozyme. However, significant cleavage of the target sequence is only obtained after 
the reaction has proceeded overnight, which indicates that the process from cell extract 
is slower than that observed for the purified MRP1 ribozyme.
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Fig. 3.9.24: In-vitro cleavage with Clone No.7 Cell Extract
Fig. 3.9.24a:
In-vitro cleavage over time (mins)
R7 R7 R7 R7 R7 
0 30 60 180 O/N
477 base 
fragment
348 base 
fragment
129 base 
fragment
Fig. 3.9.24b:
0477b B348b D129b
R7 0 R7 30 R7 60 R7 180 R7 O/N
Fig. 3.9.24a: In-vitro cleavage of the MRP1 target sequence over time using cell extract
from the ribozyme-expressing clone DLKP-SQ R7; Fig. 3.9.24a: Densitometrie analysis
of autoradiogram results.
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3.10 Analysis of MRP 1 downregulation using MRP1 antisense oligonucleotides
A decrease in MRP1 mRNA or protein expression was sought also through using 
antisense oligonucleotides targetted to the mRNA of the MRP1 gene. The analysis was 
begun by utilising an MRP1 antisense which had already been proven to downregulate 
expression of both the MRP1 mRNA and protein in HeLa cells. This antisense was 
transfected into DLKP-SQ cells and its effect on expression of both the MRP1 mRNA 
and protein, as well as the in vitro toxicity profile of the cell line was examined.
This was then followed up by the identification of nineteen novel potential MRP1 
antisense oligonucleotides. These oligos were selected on the basis of inhibition studies 
carried out on the MRP1 mRNA and protein (see Section 1.7.1.2.2). These oligos were 
also transfected into DLKP-SQ and their effect on MRP1 mRNA expression and drug- 
resistance profile in the cell line was investigated. An RNaseH assay was also 
developed and optimised to investigate if the selected antisense were capable of 
cleaving the MRP 1 sequence.
3.10.1 Use of MRP1 antisense oligonucleotide ISIS 7597 to downregulate MRP1 
expression
From the relevant literature (Stewart et al., 1996; Canitrot et al., 1996), a 
phosphorothioate antisense oligonucleotide, ISIS 7597, was chosen to be used to 
downregulate expression of the MRP1 gene in the DLKP-SQ cell line. From these 
previous studies, the oligo had been successful in decreasing MRP1 gene expression by 
90% and protein expression by 49% in the HeLa cell line. Unfortunately, several 
transfections of the antisense including a sense control oligonucleotide into the DLKP- 
SQ cell line failed to induce any significant decrease in expression of either the MRP1 
gene or protein (data not shown). Also, in-vitro toxicity assays carried out on the 
transfected cells with the MRP1 substrate chemotherapeutic drug, vincristine, failed to 
detect any effect on the resistance profile o f the transfected cell line relative to the 
normal (data not shown). Subsequent discussion on the subject of this oligonucleotide 
with external colleagues revealed that the molecule was not as efficient at cleaving the
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MRP1 mRNA as had been previously assumed (Dr. Finbarr Cotter, Personal 
communication).
3.10.2 Selection of novel MRP1 antisense oligonucleotides to downregulate gene 
expression
The decision was taken to design a number of novel antisense oligonucleotides to target 
and hopefully inhibit the action of the MRP1 gene. A total of nineteen potential oligos 
were designed from inhibition studies carried out in previous studies (see Section 
1.7.1.2.2). Ten of these nineteen oligonucleotides were chosen for further use in 
downregulating the MRP1 gene in DLKP-SQ cells. These ten oligos, along with their 
sequence and the position on the MRP1 coding mRNA strand relative to the 
translational start are outlined in Table 3.10.1. The oligos are given the prefix MA, 
which stands for MRP 1 ^nti sense.
Table 3.10.1 List of novel antisense targetted to the MRP1 gene
Name Target position Antisense sequence
MAI 315-334 CCCACGGAACAAAAATGGAG
MA3 854-873 TGG AAG ACC ACCT AGT GTCC
MA5 2366-2385 CTTTTGTAGGAAAAACCTAC
MAS 3690-3709 CAGTGCGAAGCTCGGAAGCTCCTCGTCCGCACTG
MA9 569-588 GTCGACCTCTCCTCCTTCCC
MAIO 1436-1455 CGGTCTTTT AGG AGGT GCC A
MA12 1775-1794 TTCCACGACCGGTAGTCCGT
MAÌ3 4533-4552 CCTTCTGCTTCTAGGAACAC
MA\A 2246-2265 TTCAACAGGGACGAGAGTCG
M A\9 5’ UTR ACCCCGCCCCGG AGGCGT AG
All of the above oligos except MA 19 were targetted to the coding mRNA strand of the 
MRP1 gene. MA19 was targetted to the gene itself. The oligos were selected for the 
reasons outlined below, although Section 1.7.1.2.2 contains the background to the 
studies which identified those areas of the MRP1 gene and protein which were more 
likely to have a significant effect on the functioning protein if  successfully disrupted. 
BLAST™ homology searches revealed that none on the designed oligos shared 100% 
complementarity with any other known human genes (data not shown).
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3.10.2.1 Reasons for selection of novel MRP1 antisense oligonucleotides
MAX is targetted to the first transmembrane helix in the MSD1 region of the MRP1 
gene, corresponding to the amino acid positions 41 -  46. Previous studies had already 
determined that removal or inhibition of this area of the gene (Stewart et ah, 1996) or 
protein (Gao et ah, 1998) resulted in disruption of MRP1 function.
MA3 is targetted to the L0 linker region of the MRP1 gene, identified as essential for 
activity in several previous studies (Bakos et ah, 1998; Gao et ah, 1998).
MA5 targets the NBD1 Section of the gene, at a position indicated by studies involving 
deletion mutations in the Yeast Cadmium Factor (YCF1) as being potentially important 
for MRP 1 activity.
Deletion mutant studies involving YCF1 (Falcon-Perez et ah, 1999) were also the 
source of identification of the next antisense, MA8, which is targetted to the MSD3 area 
of the gene, also deemed a necessary part of the protein to ensure proper function 
(Stride et ah, 1999). This structure of this oligonucleotide was designed to act as a 
circular antisense (Niewiarowski et ah, Paper submitted).
Epitope insertion studies which inactivated the MRP1 protein (Kast et ah, 1997) 
identified sensitive sites for MRP1 function which are targetted by the following three 
antisense oligos; MA9, MA\Q and M/i 12. MA9 is targetted to the MSD1 region of the 
gene, while the other two target MSD2.
Studies in the murine mrp gene (Lorico et al., 1997) identified a deletion which 
disrupted the activity of the protein. M413 was designed to target the equivalent region 
in the human MRP1 gene.
The identification of shared homology between the various MRP genes (MRPs 1 - 6 )  
allowed for the selection of antisense which may target functionally important 
sequences. MA14 was designed with this in mind as it targets the Walker A motif in the 
NBD1 region of the MRP1 gene.
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Finally, an attempt was made to design an effective “antigene”, or antisense targetted to 
the MRP1 DNA sequence. Such antigenes bind to the DNA, forming stable triple­
stranded structures and are sometimes effective in downregulating expression of the 
targetted gene. From the promoter analysis already carried out (Section 3.4.6.1), it has 
been determined that most MRP1 promoter activity in the DLKP cell line occurs in the 
-91 to +103 base Section of the promoter sequence (relative to the transcriptional start). 
It was considered that this Section of the promoter might also be the most utilised in the 
DLKP-SQ cell line. To this end, M AI9 was designed to target the transcriptional start 
site of MRP1 and the promoter region immediately 5’ to it. The antisense was designed 
to bind to the Spl transcription recognition sequence which is the most prevalent motif 
in this Section of the MRP1 promoter.
Overall, three antisense were designed to target the first Membrane-spanning Domain 
(MSD1), two to target both MSD2 and Nucleotide-binding Domain 1 (NBD1) and one 
each against MSD3, NBD2 and the 5’ Untranslated region (UTR).
3.10.2.2 Transfection of novel antisense into DLKP-SQ
The type of oligos used for all the antisense except MAS were Second-generation 
chimera™ antisense, rather than the simple phosphorothioates which had been 
previously used. A description of these chimeric oligos is included in Section 2.4.4.1. 
Two concentrations of each oligo were set up for transfection into the DLKP-SQ cell 
line, which were denoted by letters A and B. The concentrations used (in pm/ml) were 
1.0 (A) and 1.5 (B) of oligonucleotide. Transient antisense transfections using the novel 
designed oligos into DLKP-SQ were set up as outlined in Section 2.4.5, and the cells 
were analysed for effects on MRP1 mRNA and toxicological response.
3.10.2.3 Analysis of antisense-transfected DLKP-SQ cells by MRP1 RT-PCR
The DLKP-SQ cells were taken down 24hrs after transfection with the antisense oligos 
and assayed by RT-PCR to examine any possible effect on the MRP1 gene expression
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levels in the transfected cells. The results of these RT-PCRs can be seen in Figs. 3.10.1 
and 3.10.2. As can be seen from these figures, none of the designed oligos were 
observed to reduce expression of the MRP1 gene in the transfected DLKP-SQ cells. In 
the main, MRP1 gene expression was increased in most of the transfected cells, the 
most significant increases observed for MA 13 (Cone. A), at eighteen-fold, and for MA 
10 (Cone. A), at twelve-fold. Overall, expression of the MRP1 gene was observed 
increased in ten of the twenty (50%) transfections carried out, while no significant 
decreases in expression were observed.
3.10.2.4 In vitro toxicity analysis of antisense-transfected DLKP-SQ cells
In-vitro toxicity assays with the designed MRP1 antisense oligos were carried to 
examine if transfection with the oligos affected the drug resistance profile of the DLKP- 
SQ cells. DLKP-SQ cells were set up for transfection with the oligos and the results 
analysed as outlined in Section 2.4.5. The results of these toxicity assays are shown in 
Figs. 3.10.3 (1.0 jj.ni/ml conc. antisense) and 3.10.4 (1.5 fim/ml conc. antisense). As can 
be seen, none of the designed oligos were effective in significantly decreasing the 
resistance of the DLKP-SQ cells to the MRP 1-substrate vincristine. Transfection with 
the oligos was observed to adversely affect the ability of the cells to survive, although 
this lowered cell survival was also observed at zero vincristine concentration, so the 
toxic effect is not specifically MRP 1-related. The most promising result was that 
obtained for MA 3 (at 1.0 (im/ml conc.) for which a negligible 13% non-specific rate of 
cell death was observed at zero vincristine concentration. This had increased to a cell 
death rate of almost 40% at 1 fog/ml vincristine conc., at which the untreated DLKP-SQ 
control registers almost no cell death due to the action of the drug alone (Fig. 3.10.3). 
However, further transfections at the higher oligo conc. of 1.5 pm/ml (Fig. 3.10.4) 
revealed no significant effect of the oligo. The oligos which exhibited the most toxic 
non-specific effect were MAs 1 and 14. These oligos were targetted to the first 
transmembrane helix and the Walker A motif in nucleotide-binding domain 1 (NBD1), 
respectively.
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Fig. 3.10.1a:
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Fig. 3.10.1:MRP1 RT-PCR on Antisense-transfected DLKP-SQ
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Fig. 3.10.1a: Gel electrophoresis photograph of MRP 1 RT-PCR results on antisense-
transfected DLKP-SQ cells; Fig. 3.10.1b: Densitometrie analysis of RT-PCR results.
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Fig. 3.10.2:MRP 1 RT-PCR on Antisense-transfected DLKP-SQ
Fig. 3.10.2a:
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Fig. 3.10.2a: Gel electrophoresis photograph of MRP1 RT-PCR results on antisense-
transfected DLKP-SQ cells; Fig. 3.10.2b: Densitometrie analysis of RT-PCR results.
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Fig. 3.10.3: Effect of MRP1 Antisense (1.0 um/ml) on Vincristine (VNC) resistance in DLKP-SQ
cells
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Fig. 3.10.4: Effect of MRP1 Antisense (1.5 um/ml) on Vincristine (VNC) resistance in DLKP-SQ
cells
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The effects of the antisense (at 1.5jim concentration) on the vinblastine resistance of the 
DLKP-SQ cells can be seen in Fig. 3.10.5. As can be seen, no significant MRPl-related 
effect was observed in the transfected DLKP-SQ cells. Again, MAs 14 and 19 exerted 
the most non-specific toxic effect of all the oligos tested.
3.10.3 Use of the RNaseH assay to examine MRP1 antisense cleavage
In Section 3.9.4.5, the ribozyme in-vitro cleavage assay had demonstrated the ability of 
the MRP1 ribozyme to cleave its target fragment and thereby indicated that the failure 
of the ribozyme to successfully affect the expression and/or activity of the gene in-vivo 
was due to some other factor. It was considered useful to develop a similar assay to 
examine whether the designed MRP1 antisense oligonucleotides were capable of 
cleaving their target fragments. To this end, an RNaseH assay was designed to 
investigate the cleavage properties of the antisense oligonucleotides examined here.
3.10.3.1 Optimisation of the RNaseH assay using an mdr-1 antisense oligonucleotide
In order to standardise the assay, and also to detect the desired cleavage, an antisense 
oligo which had been comprehensively proven to downregulate expression of its target 
gene was required. It was also necessary that this oligo recruited RnaseH for cleavage of 
the target mRNA. An mdr-1 antisense which targets the AUG codon (Alahari et al.,
1996) was chosen for this purpose, the sequence of which is listed in Appendix A 
(Table 7.5A). The type of chemical modification chosen for optimisation of the assay 
was phosphorothioate, as this type of antisense has been shown to recruit RNaseH to 
cleave DNA:RNA hybrids (Nakamura et al., 1991; Peng Ho et al., 1996; Milner et al.,
1997).
The RNaseH assay was carried out much the same way as for the ribozyme in-vitro 
cleavage assay. Two PCR primers were designed which would anneal to each other 
during a PCR cycle, amplifying a DNA fragment with a T7 RNA polymerase promoter 
attached. Once this fragment was purified, a radioactively-labelled RNA product would
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Fig. 3.10.5: Effect of MRP1 Antisense (1.5 um/ml) on Vinblastine (VNB) resistance in DLKP-SQ
cells
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be generated from the DNA template using the Riboprobe™ kit. This radioactively- 
labelled target RNA could then be cleaved by the addition of the selected antisense 
oligo in a specifically-controlled RNaseH cleavage assay (see Section 2.4.7), the 
conditions for which were obtained from previous studies (Nakamura et al., 1991; Peng 
Ho et al., 1996). The fragments were eluted and sized in a similar fashion to the 
radioactively-labelled MRP1 ribozyme (see Section 3.9.4.5). A schematic of the 
expected cleavage and desired products is shown in Fig. 3.10.6.
3.10.3.2 Results of the mdr-1 RNaseH assay
The assay was carried out as outlined in Section 2.4.7. The results of the assay are 
shown in Fig. 3.10.7. As can be seen, the 38-base fragment of uncleaved target 
sequence becomes cleaved over time into the smaller 20-, 11- and 7-base fragments, 
which are observed to accumulate with time. RNaseH-mediated cleavage was observed 
to occur at a much faster rate than for the ribozyme, with all of the target sequence 
cleaved after one hour. After this hour, all of the larger fragments (38-base, 20-base) 
had been broken down into the smallest fragments (7-bases).
3.10.3.3 Use of the Second Generation Chimera™ antisense in the RNaseH assay
The designed MRP1 antisense oligos were used in the same way as the mdr-1 antisense 
in the RNaseH assay. Each oligo had its own particular target sequence designed and 
manufactured and each was subjected to analysis using the assay. The sequences for 
these target primers are listed in Appendix A (Table 7.6A). The procedure was again 
carried out as outlined in Section 2.4.7.
None of the Second Generation Chimera™ antisense were observed to effectively 
cleave their target RNA sequences. A typical result from the RNaseH assay is shown in 
Fig. 3.10.8. As can be seen, a similar-looking banding pattern of cleavage products is 
obtained. However, a much larger number of labelled bands were observed, most of 
which could not be sized accurately to those expected cleavage products.
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Fig. 3.10.6: Schematic of RNaseH cleavage of mdr-1 target
Fig. 3.10.6a:
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Fig. 3.10.6b:
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Fig. 3.10.6a: Schematic of binding of mdr-1 antisense (RED) to transcribed 
radiolabelled target sequence (BLACK) and the cleavage fragments generated by the 
recruitment of RNaseH; Fig. 3.10.6b: List o f expected cleavage fragments.
Fig. 3.10.8: RnaseH cleavage using 2nd Generation Antisense
RNaseH cleavage over time 
30s 60s lhour Overnight
Fig. 3.10.8: Example o f RNaseH-mediated cleavage using Second Generation™ 
antisense oligonucleotides.
